chembl_id,compound_name,SMILES,linked_proteins,num_linked_proteins,num_druggable_proteins,linked_pathways,num_linked_pathways,num_key_pathways,linked_MoAs,approval_phase_max,status_evidence,in_known_drugs,in_moa_kg,source_files,prelim_mechanistic_score,CYP3A4_p_value_0,CYP3A4_p_value_1,CYP3A4_CYP3A4_inhibition,CYP2D6_p_value_0,CYP2D6_p_value_1,CYP2D6_CYP2D6_inhibition,CYP2C9_p_value_0,CYP2C9_p_value_1,CYP2C9_CYP2C9_inhibition,CYP2C19_p_value_0,CYP2C19_p_value_1,CYP2C19_CYP2C19_inhibition,CYP1A2_p_value_0,CYP1A2_p_value_1,CYP1A2_CYP1A2_inhibition,hERG_p_value_0,hERG_p_value_1,hERG_hERG_inhibition,AMES_p_value_0,AMES_p_value_1,AMES_AMES_mutagenic,PGP_p_value_0,PGP_p_value_1,PGP_PGP_inhibition,Solubility_logS,Solubility_logS_lower_bound,Solubility_logS_upper_bound,Solubility_Capped_logS_lower_bound,Solubility_Capped_logS_upper_bound,Lipophilicity_logP,PAMPA_p_value_0,PAMPA_p_value_1,PAMPA_PAMPA_permeability,BBB_p_value_0,BBB_p_value_1,BBB_BBB_penetration,hERG_flag,CYP3A4_inhib_flag,CYP2D6_inhib_flag,CYP2C9_inhib_flag,CYP2C19_inhib_flag,CYP1A2_inhib_flag,PGP_inhib_flag,AMES_flag,poor_solubility_flag,good_solubility_bonus,high_logP_flag,low_logP_flag,good_logP_bonus,low_perm_flag,good_perm_bonus,bbb_penetrant_info,multi_cyp_inhib_count,cyp3a4_inhibitor_flag,DDI_flag,composite_score,confidence
CHEMBL1000,CETIRIZINE,O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,1,0,known_drugs;pathway_drug_candidates,5.5,0.714,0.0559,0.0,0.356,0.215,0.5,0.785,0.0352,0.0,0.802,0.0245,0.0,0.887,0.00734,0.0,0.166,0.263,1,0.884,0.0157,0.0,0.998,0.0175,0,-2.9,-3.55,-2.24,-3.55,-2.24,3.148200000000002,0.732,0.0566,0.0,0.729,0.0156,0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-0.5,L
CHEMBL1004,DOXYLAMINE,CN(C)CCOC(C)(c1ccccc1)c1ccccn1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.448,0.13,0.0,0.114,0.446,1.0,0.879,0.00992,0.0,0.483,0.097,0.0,0.629,0.0336,0.0,0.685,0.0625,0,0.578,0.0533,0.0,0.898,0.00426,0,-2.4,-3.74,-1.07,-3.74,-1.07,2.923300000000001,0.295,0.302,0.5,0.0314,0.884,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.5,L
CHEMBL1005,REMIFENTANIL,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,3.0,Completed,0,0,pathway_drug_candidates,5.0,0.797,0.027,0.0,0.212,0.339,0.5,0.859,0.014,0.0,0.895,0.0109,0.0,0.188,0.221,0.5,0.0371,0.5,1,0.989,0.00179,0.0,0.119,0.218,1,-2.3,-3.51,-1.1,-3.51,-1.1,2.0002999999999997,0.0625,0.9,1.0,0.104,0.527,1,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,0.0,1.0,-2.0,L
CHEMBL101,PHENYLBUTAZONE,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.59,0.0656,0.0,0.592,0.0957,0.0,0.0548,0.642,1.0,0.0307,0.819,1.0,0.0663,0.43,1.0,0.688,0.0539,0,0.56,0.0568,0.0,0.236,0.167,0,-4.38,-5.56,-3.19,-5.56,-3.19,3.7878000000000025,0.118,0.685,1.0,0.714,0.015,0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,0.0,1.0,6.0,L
CHEMBL101253,VATALANIB,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.126,0.419,1.0,0.0523,0.556,1.0,0.0177,0.849,1.0,0.00349,0.956,1.0,0.0183,0.697,1.0,0.003,0.909,1,0.73,0.0332,0.0,0.127,0.215,1,-4.27,-4.98,-3.56,-4.98,-3.56,5.012600000000003,0.282,0.423,0.5,0.213,0.194,0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,5.0,1.0,1.0,-12.5,L
CHEMBL1014,CANDESARTAN CILEXETIL,CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,Type-1 angiotensin II receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.134,0.412,1.0,0.855,0.0318,0.0,0.849,0.0136,0.0,0.847,0.018,0.0,0.3,0.145,0.0,0.455,0.129,0,0.977,0.00452,0.0,0.868,0.0362,0,-7.69,-9.06,-6.32,-9.06,-6.32,6.319100000000007,0.637,0.0744,0.0,0.229,0.149,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,-2.5,L
CHEMBL1016,CANDESARTAN,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,AGTR1,1,1,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,Type-1 angiotensin II receptor antagonist,3.0,Unknown status,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,6.5,0.647,0.0529,0.0,0.909,0.0157,0.0,0.673,0.0437,0.0,0.875,0.0143,0.0,0.331,0.118,0.0,0.676,0.0615,0,0.968,0.00376,0.0,0.855,0.00339,0,-6.17,-7.43,-4.91,-7.43,-4.91,4.028600000000002,0.947,0.00128,0.0,0.364,0.0458,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,L
CHEMBL1017,TELMISARTAN,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,AGTR1,1,1,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,Type-1 angiotensin II receptor antagonist,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.784,0.0383,0.0,0.958,0.00594,0.0,0.841,0.0145,0.0,0.937,0.009,0.0,0.182,0.251,0.5,0.893,0.0193,0,0.985,0.000644,0.0,0.639,0.0321,0,-3.93,-4.69,-3.17,-4.69,-3.17,7.2644200000000065,0.477,0.14,0.0,0.321,0.0704,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,5.5,L
CHEMBL1020,TOLMETIN,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.769,0.0386,0.0,0.674,0.0735,0.0,0.795,0.0257,0.0,0.582,0.0715,0.0,0.307,0.142,0.0,0.544,0.101,0,0.8,0.0266,0.0,0.631,0.0631,0,-3.83,-4.87,-2.8,-4.87,-2.8,2.1916200000000003,0.806,0.0274,0.0,0.296,0.113,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,9.5,H
CHEMBL1021,NEPAFENAC,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.623,0.065,0.0,0.44,0.171,0.0,0.363,0.148,0.0,0.0431,0.674,1.0,0.153,0.263,1.0,0.843,0.0278,0,0.215,0.144,0.0,0.788,0.0403,0,-3.68,-5.1,-2.27,-5.1,-2.27,1.5276,0.27,0.351,0.5,0.206,0.192,0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,7.5,M
CHEMBL10316,IDAZOXAN,c1ccc2c(c1)OCC(C1=NCCN1)O2,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,3.0,Withdrawn,0,0,pathway_drug_candidates,3.0,0.528,0.1,0.0,0.0319,0.68,1.0,0.865,0.00819,0.0,0.238,0.251,0.5,0.188,0.226,0.5,0.361,0.158,0,0.23,0.157,0.0,0.251,0.135,0,-2.27,-3.14,-1.4,-3.14,-1.4,0.8280999999999994,0.506,0.133,0.0,0.245,0.171,0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,0.0,1.0,-1.0,L
CHEMBL1034,DICLOFENAC SODIUM,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+],PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.244,0.259,0.5,0.966,0.0141,0.0,0.0936,0.5,1.0,0.522,0.0876,0.0,0.366,0.096,0.0,0.84,0.0285,0,0.651,0.0377,0.0,0.758,0.0538,0,-2.41,-5.32,0.497,-5.32,0.497,0.033399999999999,0.647,0.0632,0.0,0.212,0.237,0.5,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.5,2.0,1.0,1.0,5.0,L
CHEMBL1040,CALCIFEDIOL ANHYDROUS,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.659,0.057,0.0,0.633,0.0958,0.0,0.535,0.103,0.0,0.724,0.0447,0.0,0.544,0.0542,0.0,0.877,0.0226,0,0.41,0.0983,0.0,0.171,0.195,0.5,-4.52,-4.99,-4.05,-4.99,-4.05,6.733900000000008,0.274,0.417,0.5,0.148,0.529,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,-1.5,L
CHEMBL1042,CHOLECALCIFEROL,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12,VDR,1,1,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Vitamin D receptor agonist,4.0,Recruiting,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.709,0.0451,0.0,0.495,0.148,0.0,0.421,0.145,0.0,0.454,0.105,0.0,0.438,0.0728,0.0,0.779,0.0373,0,0.706,0.035,0.0,0.13,0.207,1,-6.01,-6.95,-5.07,-6.95,-5.07,7.619000000000008,0.264,0.457,0.5,0.126,0.423,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,4.0,L
CHEMBL1046,AMINOCAPROIC ACID,NCCCCCC(=O)O,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4,1,Plasminogen inhibitor,4.0,Unknown status,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.923,0.00813,0.0,0.827,0.0437,0.0,0.644,0.0488,0.0,0.944,0.00928,0.0,0.714,0.0211,0.0,0.949,0.00848,0,0.909,0.0122,0.0,0.659,0.0723,0,-0.72,-2.37,0.932,-2.37,0.932,0.5901000000000001,0.911,0.0131,0.0,0.502,0.031,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.5,L
CHEMBL1064,SIMVASTATIN,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,HMGCR,1,1,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,HMG-CoA reductase inhibitor,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.1,0.464,1.0,0.66,0.0833,0.0,0.586,0.0765,0.0,0.594,0.0639,0.0,0.685,0.0242,0.0,0.33,0.178,0,0.266,0.138,0.0,0.0178,0.563,1,-6.25,-8.54,-3.96,-8.54,-3.96,4.585600000000005,0.278,0.395,0.5,0.135,0.476,1,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,L
CHEMBL1069,VALSARTAN,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,AGTR1,1,1,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,Type-1 angiotensin II receptor antagonist,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.628,0.0668,0.0,0.935,0.0143,0.0,0.832,0.0197,0.0,0.845,0.0191,0.0,0.829,0.0137,0.0,0.768,0.0449,0,0.976,0.00601,0.0,0.708,0.0545,0,-3.58,-5.83,-1.33,-5.83,-1.33,4.161700000000002,0.849,0.0171,0.0,0.174,0.262,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,7.5,M
CHEMBL107,COLCHICINE,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,TUBB4B,1,1,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,Tubulin inhibitor,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,9.5,0.427,0.139,0.0,0.114,0.453,1.0,0.191,0.339,1.0,0.226,0.251,0.5,0.441,0.0715,0.0,0.818,0.034,0,0.594,0.0539,0.0,0.4,0.121,0,-1.12,-1.93,-0.311,-1.93,-0.311,2.871600000000001,0.917,0.0101,0.0,0.0738,0.673,1,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,7.5,M
CHEMBL1070,NABUMETONE,COc1ccc2cc(CCC(C)=O)ccc2c1,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.0947,0.465,1.0,0.362,0.207,0.5,0.4,0.146,0.0,0.439,0.107,0.0,0.0394,0.579,1.0,0.133,0.302,1,0.835,0.0137,0.0,0.0498,0.261,1,-2.35,-3.79,-0.906,-3.79,-0.906,3.370000000000002,0.544,0.106,0.0,0.16,0.371,1,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-2.0,L
CHEMBL1071,OXAPROZIN,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.448,0.141,0.0,0.459,0.171,0.0,0.215,0.291,0.5,0.279,0.2,0.5,0.0851,0.385,1.0,0.764,0.045,0,0.657,0.0382,0.0,0.377,0.132,0,-2.44,-3.35,-1.52,-3.35,-1.52,4.025800000000003,0.674,0.0393,0.0,0.692,0.00817,0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,0.0,1.0,6.0,L
CHEMBL1076903,VARENICLINE,c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1,,0,0,R-HSA-629587|Highly sodium permeable postsynaptic acetylcholine nicotinic receptors;R-HSA-629594|Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;R-HSA-629597|Highly calcium permeable nicotinic acetylcholine receptors,3,0,,4.0,Terminated,0,0,pathway_drug_candidates,4.0,0.526,0.104,0.0,0.121,0.428,1.0,0.31,0.196,0.0,0.117,0.41,1.0,0.127,0.299,1.0,0.647,0.0663,0,0.0805,0.427,1.0,0.304,0.141,0,-0.236,-1.61,1.14,-1.61,1.14,1.8039,0.387,0.243,0.0,0.24,0.142,0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,3.0,0.0,1.0,-1.0,L
CHEMBL1077,BROMFENAC,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.726,0.0464,0.0,0.647,0.0938,0.0,0.194,0.314,1.0,0.0419,0.736,1.0,0.299,0.13,0.0,0.397,0.147,0,0.875,0.0191,0.0,0.649,0.0659,0,-3.66,-4.59,-2.74,-4.59,-2.74,2.889400000000001,0.735,0.0464,0.0,0.175,0.298,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,7.5,M
CHEMBL1078178,MOMELOTINIB,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",27,13,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,3.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,13.0,0.889,0.0131,0.0,0.919,0.0192,0.0,0.537,0.0984,0.0,0.91,0.0115,0.0,0.0783,0.432,1.0,0.718,0.0521,0,0.273,0.143,0.0,0.793,0.0353,0,-4.73,-5.67,-3.79,-5.67,-3.79,2.9771800000000015,0.155,0.672,1.0,0.189,0.222,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,11.5,H
CHEMBL1079,TIZANIDINE,Clc1ccc2nsnc2c1NC1=NCCN1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.624,0.0659,0.0,0.141,0.428,1.0,0.387,0.154,0.0,0.368,0.146,0.0,0.12,0.332,1.0,0.179,0.255,1,0.152,0.239,1.0,0.631,0.0477,0,-2.98,-3.88,-2.08,-3.88,-2.08,1.715799999999999,0.614,0.0642,0.0,0.153,0.276,1,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-6.5,L
CHEMBL1082407,ENZALUTAMIDE,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,AR,1,1,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Androgen Receptor antagonist,4.0,Unknown status,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.276,0.224,0.5,0.953,0.00765,0.0,0.056,0.623,1.0,0.165,0.353,1.0,0.181,0.247,0.5,0.956,0.00959,0,0.898,0.0097,0.0,0.224,0.161,0,-3.26,-3.77,-2.76,-3.77,-2.76,3.992480000000003,0.125,0.679,1.0,0.191,0.203,1,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,4.0,1.0,1.0,3.0,L
CHEMBL1083385,CLOPIDOGREL BISULFATE,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1.O=S(=O)(O)O,,0,0,R-HSA-418594|G alpha (i) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0893,0.475,1.0,0.0913,0.488,1.0,0.279,0.219,0.5,0.253,0.229,0.5,0.159,0.243,1.0,0.428,0.137,0,0.778,0.0211,0.0,0.411,0.125,0,-2.78,-3.38,-2.17,-3.38,-2.17,3.021100000000001,0.27,0.308,0.5,0.17,0.272,1,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,5.0,1.0,1.0,-3.0,L
CHEMBL1088752,LOSMAPIMOD,,,0,0,,0,0,MAP kinase p38 alpha inhibitor;MAP kinase p38 beta inhibitor,,,1,1,known_drugs;mechanism_of_actions,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL1089636,ANG1005,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.743,0.0372,0.0,0.984,0.00363,0.0,0.955,0.00533,0.0,0.945,0.00694,0.0,1.0,0.00157,0.0,1.0,0.000666,0,0.98,0.00393,0.0,0.877,0.0233,0,-11.5,-11.8,-11.2,-11.8,-11.2,1.3761400000000212,0.989,0.00524,0.0,0.442,0.0382,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,L
CHEMBL1091,HYDROCORTISONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.629,0.0672,0.0,0.609,0.0918,0.0,0.639,0.0633,0.0,0.714,0.0365,0.0,0.687,0.0204,0.0,0.392,0.138,0,0.514,0.0607,0.0,0.341,0.142,0,-4.32,-5.24,-3.4,-5.24,-3.4,2.3524000000000003,0.533,0.0896,0.0,0.189,0.231,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,4.0,L
CHEMBL1094,FELBAMATE,NC(=O)OCC(COC(N)=O)c1ccccc1,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,Glutamate [NMDA] receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.439,0.134,0.0,0.0336,0.673,1.0,0.454,0.123,0.0,0.455,0.104,0.0,0.368,0.0975,0.0,0.377,0.154,0,0.123,0.304,1.0,0.25,0.151,0,-1.3,-2.31,-0.301,-2.31,-0.301,0.9607999999999992,0.654,0.0499,0.0,0.0639,0.801,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.5,L
CHEMBL1095032,LETAXABAN,O=C([C@H](O)CS(=O)(=O)c1ccc2cc(Cl)ccc2c1)N1CCC(N2CCCNC2=O)CC1,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.699,0.0373,0.0,0.273,0.256,0.5,0.375,0.161,0.0,0.762,0.0274,0.0,0.453,0.069,0.0,0.00165,0.948,1,0.405,0.0869,0.0,0.157,0.203,1,-5.57,-6.03,-5.1,-6.03,-5.1,2.0341,0.706,0.0377,0.0,0.0955,0.512,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,-7.0,L
CHEMBL1096,AMLEXANOX,CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,Phosphodiesterase 4 inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.754,0.0319,0.0,0.743,0.0697,0.0,0.442,0.116,0.0,0.362,0.145,0.0,0.383,0.0847,0.0,0.83,0.0328,0,0.595,0.0416,0.0,0.292,0.162,0,-4.59,-5.6,-3.58,-5.6,-3.58,2.745,0.963,0.00409,0.0,0.369,0.053,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,L
CHEMBL1096380,PLINABULIN,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,3.0,Completed,0,0,pathway_drug_candidates,5.0,0.342,0.192,0.0,0.323,0.224,0.5,0.347,0.183,0.0,0.17,0.338,1.0,0.11,0.351,1.0,0.377,0.148,0,0.652,0.0439,0.0,0.382,0.147,0,-5.1,-5.79,-4.42,-5.79,-4.42,0.7413999999999987,0.338,0.248,0.0,0.248,0.136,0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,0.0,1.0,-0.5,L
CHEMBL1097279,CANGRELOR TETRASODIUM,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])OP(=O)([O-])C(Cl)(Cl)P(=O)([O-])[O-])[C@@H](O)[C@H]1O.[Na+].[Na+].[Na+].[Na+],,0,0,R-HSA-418594|G alpha (i) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.312,0.19,0.0,0.996,0.00249,0.0,0.313,0.197,0.0,0.511,0.0878,0.0,0.997,0.00108,0.0,0.998,0.000458,0,0.759,0.0303,0.0,0.903,0.0189,0,1.03,0.609,1.45,0.609,1.45,-11.661500000000013,0.813,0.0179,0.0,0.0253,0.964,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,3.0,L
CHEMBL1106,EPINASTINE,NC1=NCC2c3ccccc3Cc3ccccc3N12,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.315,0.197,0.0,0.122,0.43,1.0,0.214,0.312,0.5,0.154,0.351,1.0,0.309,0.12,0.0,0.652,0.0671,0,0.174,0.216,1.0,0.448,0.129,0,-4.36,-5.4,-3.32,-5.4,-3.32,2.4668,0.613,0.0845,0.0,0.158,0.375,1,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,-3.0,L
CHEMBL1108,DROPERIDOL,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,,0,0,,0,0,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.692,0.0523,0.0,0.0329,0.685,1.0,0.246,0.256,0.5,0.499,0.0932,0.0,0.464,0.0716,0.0,0.00469,0.873,1,0.539,0.0524,0.0,0.0208,0.556,1,-4.92,-6.29,-3.56,-6.29,-3.56,3.6784000000000026,0.158,0.621,1.0,0.1,0.646,1,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-9.0,L
CHEMBL1112,ARIPIPRAZOLE,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.446,0.129,0.0,0.102,0.472,1.0,0.315,0.203,0.5,0.18,0.3,1.0,0.511,0.0626,0.0,0.00101,0.969,1,0.844,0.0232,0.0,0.169,0.175,1,-4.73,-5.98,-3.49,-5.98,-3.49,4.859300000000005,0.0714,0.859,1.0,0.121,0.423,1,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-11.0,L
CHEMBL112,ACETAMINOPHEN,CC(=O)Nc1ccc(O)cc1,FAAH;PTGS2;TRPV1,3,3,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-3295583|TRP channels;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,11,2,Anandamide amidohydrolase inhibitor;Anandamide amidohydrolase inhibitor | Cyclooxygenase inhibitor | Vanilloid receptor opener;Cyclooxygenase inhibitor;Vanilloid receptor opener,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,15.5,0.391,0.153,0.0,0.609,0.0964,0.0,0.555,0.0831,0.0,0.466,0.0975,0.0,0.0721,0.444,1.0,0.81,0.0336,0,0.745,0.0383,0.0,0.826,0.0287,0,-1.28,-2.18,-0.388,-2.18,-0.388,1.3505999999999998,0.715,0.0358,0.0,0.114,0.439,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,15.5,H
CHEMBL1120,BISMUTH SUBSALICYLATE,,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.0,H
CHEMBL1131,ACITRETIN,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,,0,0,R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-5362517|Signaling by Retinoic Acid;R-HSA-5617472|Activation of anterior HOX genes in hindbrain development during early embryogenesis,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.681,0.0416,0.0,0.0106,0.818,1.0,0.752,0.0464,0.0,0.539,0.0804,0.0,0.559,0.0419,0.0,0.232,0.215,0,0.363,0.105,0.0,0.41,0.133,0,-3.98,-4.65,-3.3,-4.65,-3.3,5.167060000000005,0.336,0.325,0.5,0.305,0.114,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,L
CHEMBL1136,TELITHROMYCIN,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.12,0.422,1.0,0.878,0.0264,0.0,0.482,0.113,0.0,0.954,0.0029,0.0,0.671,0.0232,0.0,0.923,0.0144,0,0.85,0.0139,0.0,0.481,0.11,0,-1.87,-2.26,-1.49,-2.26,-1.49,4.929200000000005,0.157,0.617,1.0,0.287,0.0919,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,-3.0,L
CHEMBL114,SAQUINAVIR,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,,0,0,,0,0,Human immunodeficiency virus type 1 protease inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.0416,0.637,1.0,0.0648,0.582,1.0,0.185,0.325,1.0,0.138,0.374,1.0,0.385,0.09,0.0,0.0736,0.39,1,0.91,0.013,0.0,0.0338,0.426,1,-3.73,-4.4,-3.05,-4.4,-3.05,3.092400000000003,0.207,0.511,1.0,0.369,0.0489,0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,1.0,1.0,-11.5,L
CHEMBL1144,PRAVASTATIN,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,,0,0,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,,4.0,Completed,0,0,pathway_drug_candidates,4.0,0.729,0.0408,0.0,0.784,0.0479,0.0,0.129,0.42,1.0,0.765,0.0294,0.0,0.8,0.0133,0.0,0.698,0.0579,0,0.674,0.0325,0.0,0.787,0.0226,0,-1.98,-2.57,-1.38,-2.57,-1.38,2.4404000000000003,0.728,0.0264,0.0,0.701,0.00969,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,3.0,L
CHEMBL1152,PREDNISOLONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.592,0.0705,0.0,0.52,0.123,0.0,0.618,0.0627,0.0,0.725,0.0372,0.0,0.532,0.0489,0.0,0.363,0.154,0,0.569,0.0537,0.0,0.255,0.158,0,-4.24,-4.85,-3.62,-4.85,-3.62,2.1284,0.484,0.145,0.0,0.0349,0.866,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,4.0,L
CHEMBL1159650,CLOBETASOL PROPIONATE,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.0983,0.467,1.0,0.184,0.338,1.0,0.492,0.107,0.0,0.62,0.0521,0.0,0.498,0.0542,0.0,0.311,0.182,0,0.72,0.0345,0.0,0.909,0.0156,0,-4.62,-5.33,-3.91,-5.33,-3.91,4.103100000000003,0.305,0.302,0.5,0.0725,0.749,1,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-0.5,L
CHEMBL116,AMPRENAVIR,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,,0,0,,0,0,Human immunodeficiency virus type 1 protease inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.734,0.0377,0.0,0.0835,0.468,1.0,0.96,0.00455,0.0,0.12,0.396,1.0,0.338,0.11,0.0,0.11,0.332,1,0.946,0.0111,0.0,0.913,0.00901,0,-3.35,-3.88,-2.83,-3.88,-2.83,2.4028,0.119,0.636,1.0,0.217,0.158,0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,2.0,0.0,1.0,-6.0,L
CHEMBL1161,MOMETASONE FUROATE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.0967,0.461,1.0,0.0322,0.683,1.0,0.4,0.158,0.0,0.518,0.0877,0.0,0.129,0.305,1.0,0.477,0.113,0,0.715,0.0426,0.0,0.0302,0.413,1,-4.09,-4.54,-3.65,-4.54,-3.65,4.869200000000005,0.376,0.235,0.0,0.00998,0.975,1,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-1.0,L
CHEMBL1162175,REGRELOR,CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21,,0,0,R-HSA-418594|G alpha (i) signalling events,1,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.836,0.0257,0.0,0.4,0.171,0.0,0.891,0.00784,0.0,0.669,0.0472,0.0,0.439,0.075,0.0,0.996,0.000945,0,0.943,0.00968,0.0,0.915,0.0196,0,-4.33,-4.96,-3.7,-4.96,-3.7,1.7978999999999998,0.902,0.011,0.0,0.078,0.698,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,L
CHEMBL1165,MOEXIPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.445,0.14,0.0,0.351,0.225,0.5,0.324,0.203,0.5,0.563,0.0686,0.0,0.317,0.13,0.0,0.817,0.0286,0,0.761,0.0302,0.0,0.182,0.188,0.5,-2.19,-2.71,-1.67,-2.71,-1.67,2.5843,0.624,0.0782,0.0,0.177,0.324,1,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,2.5,L
CHEMBL1168,RAMIPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,Angiotensin-converting enzyme inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.755,0.0379,0.0,0.48,0.168,0.0,0.419,0.133,0.0,0.459,0.0997,0.0,0.55,0.045,0.0,0.739,0.0464,0,0.854,0.0192,0.0,0.506,0.0949,0,-2.14,-2.57,-1.72,-2.57,-1.72,2.3831999999999995,0.661,0.0465,0.0,0.178,0.274,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,5.5,L
CHEMBL1170,TESTOSTERONE PROPIONATE,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,1.0,Suspended,0,0,pathway_drug_candidates,1.0,0.447,0.133,0.0,0.616,0.081,0.0,0.849,0.015,0.0,0.288,0.188,0.0,0.839,0.00936,0.0,0.366,0.148,0,0.673,0.0378,0.0,0.0833,0.252,1,-5.04,-6.99,-3.09,-6.99,-3.09,4.840100000000005,0.435,0.21,0.0,0.51,0.0233,0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,-3.5,L
CHEMBL1171837,PONATINIB,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,3.0,Recruiting,0,0,pathway_drug_candidates,3.0,0.949,0.00571,0.0,0.123,0.44,1.0,0.509,0.092,0.0,0.821,0.0211,0.0,0.943,0.00393,0.0,0.816,0.0357,0,0.792,0.0266,0.0,0.0826,0.252,1,-3.02,-3.43,-2.62,-3.43,-2.62,4.456020000000003,0.0951,0.824,1.0,0.15,0.418,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.5,L
CHEMBL1172,DESLORATADINE,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,Terminated,0,0,pathway_drug_candidates,4.0,0.422,0.147,0.0,0.236,0.292,0.5,0.27,0.244,0.5,0.454,0.103,0.0,0.249,0.185,0.5,0.389,0.145,0,0.643,0.0437,0.0,0.0374,0.353,1,-3.39,-4.23,-2.55,-4.23,-2.55,4.018900000000002,0.269,0.455,0.5,0.429,0.0422,0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,0.0,1.0,-1.0,L
CHEMBL118,CELECOXIB,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.54,0.093,0.0,0.633,0.0822,0.0,0.0281,0.749,1.0,0.377,0.139,0.0,0.805,0.0121,0.0,0.132,0.3,1,0.773,0.0291,0.0,0.0674,0.248,1,-4.48,-5.44,-3.52,-5.44,-3.52,3.5139200000000006,0.297,0.244,0.0,0.0288,0.908,1,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.5,L
CHEMBL1186579,METHYLNALTREXONE,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,3.0,Withdrawn,0,0,pathway_drug_candidates,5.0,0.726,0.0388,0.0,0.3,0.235,0.5,0.416,0.13,0.0,0.678,0.0502,0.0,0.722,0.0201,0.0,0.419,0.137,0,0.764,0.0252,0.0,0.719,0.0454,0,-1.99,-3.05,-0.923,-3.05,-0.923,1.6699999999999997,0.282,0.324,0.5,0.175,0.229,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,4.0,L
CHEMBL1189432,OLOPATADINE,CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.98,0.00414,0.0,0.186,0.345,1.0,0.632,0.0699,0.0,0.757,0.0347,0.0,0.305,0.124,0.0,0.684,0.0606,0,0.77,0.0309,0.0,0.0579,0.296,1,-3.55,-4.5,-2.6,-4.5,-2.6,3.589500000000002,0.783,0.0228,0.0,0.131,0.421,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,L
CHEMBL1193,PHENIRAMINE,CN(C)CCC(c1ccccc1)c1ccccn1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.769,0.0302,0.0,0.0605,0.559,1.0,0.849,0.0181,0.0,0.644,0.0631,0.0,0.316,0.124,0.0,0.418,0.133,0,0.648,0.041,0.0,0.836,0.0261,0,-1.5,-3.05,0.0508,-3.05,0.0508,3.1652000000000013,0.412,0.228,0.0,0.664,0.0193,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,2.5,L
CHEMBL1197051,ISOXSUPRINE,CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,2.0,,0,0,pathway_drug_candidates,2.0,0.641,0.0636,0.0,0.0295,0.682,1.0,0.626,0.0649,0.0,0.241,0.228,0.5,0.0593,0.455,1.0,0.479,0.113,0,0.55,0.091,0.0,0.882,0.0295,0,-1.68,-2.48,-0.883,-2.48,-0.883,2.871200000000001,0.683,0.0469,0.0,0.527,0.0247,0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,3.0,0.0,1.0,-1.0,L
CHEMBL12,DIAZEPAM,CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.36,0.17,0.0,0.255,0.262,0.5,0.461,0.116,0.0,0.112,0.435,1.0,0.0215,0.703,1.0,0.24,0.218,0,0.745,0.0243,0.0,0.82,0.0212,0,-3.63,-4.3,-2.95,-4.3,-2.95,3.153800000000002,0.145,0.569,1.0,0.0544,0.843,1,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-2.5,L
CHEMBL1200323,LABETALOL HYDROCHLORIDE,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.722,0.0404,0.0,0.0165,0.753,1.0,0.259,0.231,0.5,0.172,0.313,1.0,0.448,0.0665,0.0,0.136,0.287,1,0.935,0.00971,0.0,0.818,0.0198,0,-2.58,-3.4,-1.75,-3.4,-1.75,2.5572000000000004,0.794,0.0075,0.0,0.168,0.226,1,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,-4.5,L
CHEMBL1200329,TIZANIDINE HYDROCHLORIDE,Cl.Clc1ccc2nsnc2c1NC1=NCCN1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.671,0.0515,0.0,0.223,0.303,0.5,0.465,0.117,0.0,0.362,0.145,0.0,0.128,0.305,1.0,0.16,0.272,1,0.152,0.239,1.0,0.633,0.0493,0,-2.27,-3.22,-1.32,-3.22,-1.32,2.1376,0.637,0.0508,0.0,0.00291,0.956,1,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-5.5,L
CHEMBL1200335,TESTOSTERONE ENANTHATE,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.583,0.0847,0.0,0.897,0.0158,0.0,0.766,0.0252,0.0,0.23,0.263,0.5,0.772,0.0143,0.0,0.273,0.199,0,0.855,0.0149,0.0,0.0364,0.353,1,-7.46,-10.4,-4.47,-10.4,-4.47,6.400500000000007,0.237,0.38,1.0,0.338,0.0785,0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,L
CHEMBL1200339,PHENYLEPHRINE HYDROCHLORIDE,CNC[C@H](O)c1cccc(O)c1.Cl,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.681,0.051,0.0,0.795,0.0488,0.0,0.637,0.0675,0.0,0.749,0.0352,0.0,0.711,0.0211,0.0,0.824,0.0331,0,0.778,0.0219,0.0,0.0302,0.347,1,-1.17,-2.4,0.0494,-2.4,0.0494,1.0668,0.736,0.0277,0.0,0.124,0.4,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,3.0,L
CHEMBL1200342,PARAMETHASONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,,0,0,,0,0,Glucocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.578,0.0826,0.0,0.603,0.111,0.0,0.686,0.0565,0.0,0.772,0.0287,0.0,0.635,0.0307,0.0,0.53,0.102,0,0.608,0.0473,0.0,0.0188,0.535,1,-4.47,-5.23,-3.7,-5.23,-3.7,2.3224,0.464,0.195,0.0,0.0222,0.987,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,-3.0,L
CHEMBL1200343,PERINDOPRIL ERBUMINE,CC(C)(C)N.CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,Angiotensin-converting enzyme inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.637,0.0573,0.0,0.799,0.0421,0.0,0.791,0.0262,0.0,0.684,0.0472,0.0,0.885,0.00644,0.0,0.897,0.0205,0,0.737,0.0175,0.0,0.761,0.0473,0,-0.0531,-0.625,0.518,-0.625,0.518,2.6842000000000015,0.5,0.1,0.0,0.152,0.352,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,6.0,L
CHEMBL1200376,BETAMETHASONE BENZOATE,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccccc1)C(=O)CO,,0,0,,0,0,Glucocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.205,0.292,1.0,0.0932,0.494,1.0,0.329,0.184,0.0,0.233,0.232,0.5,0.329,0.119,0.0,0.629,0.0679,0,0.79,0.0246,0.0,0.703,0.0323,0,-5.19,-5.84,-4.53,-5.84,-4.53,3.760400000000003,0.217,0.448,1.0,0.106,0.451,1,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-6.0,L
CHEMBL1200384,BETAMETHASONE DIPROPIONATE,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.17,0.314,1.0,0.472,0.151,0.0,0.586,0.0757,0.0,0.435,0.108,0.0,0.666,0.0237,0.0,0.232,0.219,0,0.76,0.0274,0.0,0.755,0.0205,0,-4.09,-5.13,-3.05,-5.13,-3.05,3.8175000000000026,0.204,0.501,1.0,0.0535,0.734,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,2.0,L
CHEMBL1200386,PREDNICARBATE,CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.287,0.223,0.5,0.629,0.0964,0.0,0.699,0.0445,0.0,0.44,0.106,0.0,0.463,0.0694,0.0,0.297,0.186,0,0.846,0.0206,0.0,0.923,0.0276,0,-4.74,-5.58,-3.89,-5.58,-3.89,3.6993000000000023,0.279,0.357,0.5,0.0247,0.955,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.5,L
CHEMBL1200392,DOXYLAMINE SUCCINATE,CN(C)CCOC(C)(c1ccccc1)c1ccccn1.O=C(O)CCC(=O)O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.966,0.00293,0.0,0.654,0.0951,0.0,0.948,0.0037,0.0,0.918,0.00793,0.0,0.925,0.00257,0.0,0.964,0.00563,0,0.886,0.0102,0.0,0.961,0.00379,0,-1.54,-3.1,0.0299,-3.1,0.0299,2.8591000000000006,0.808,0.0157,0.0,0.0304,0.884,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,3.0,L
CHEMBL1200395,ORPHENADRINE CITRATE,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-416476|G alpha (q) signalling events;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",10,0,Glutamate [NMDA] receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.961,0.00411,0.0,0.0296,0.672,1.0,0.782,0.0222,0.0,0.74,0.0282,0.0,0.882,0.00682,0.0,0.0363,0.514,1,0.872,0.0133,0.0,0.982,0.00351,0,-1.82,-2.44,-1.2,-2.44,-1.2,2.4141199999999996,0.887,0.00133,0.0,0.03,0.897,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-2.0,L
CHEMBL1200406,DIMENHYDRINATE,CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.697,0.0536,0.0,0.165,0.346,1.0,0.829,0.0154,0.0,0.541,0.0889,0.0,0.533,0.0525,0.0,0.773,0.0395,0,0.812,0.0223,0.0,0.979,0.00937,0,-3.32,-3.95,-2.7,-3.95,-2.7,2.967900000000001,0.653,0.0605,0.0,0.0379,0.927,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,2.5,L
CHEMBL1200413,TETRAHYDROZOLINE HYDROCHLORIDE,Cl.c1ccc2c(c1)CCCC2C1=NCCN1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,3.0,Unknown status,0,0,pathway_drug_candidates,3.0,0.49,0.114,0.0,0.0579,0.6,1.0,0.626,0.0655,0.0,0.441,0.107,0.0,0.449,0.0679,0.0,0.418,0.134,0,0.15,0.259,1.0,0.79,0.0231,0,-2.54,-3.47,-1.61,-3.47,-1.61,2.53,0.601,0.0909,0.0,0.0306,0.925,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-0.5,L
CHEMBL1200419,MOLINDONE HYDROCHLORIDE,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2.Cl,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.128,0.417,1.0,0.309,0.242,0.5,0.64,0.0687,0.0,0.0261,0.797,1.0,0.403,0.0831,0.0,0.198,0.239,1,0.32,0.0869,0.0,0.91,0.00559,0,-0.837,-1.67,-0.00309,-1.67,-0.00309,2.3846200000000013,0.583,0.0878,0.0,0.0076,0.994,1,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,1.0,1.0,-10.0,L
CHEMBL1200420,MIDAZOLAM HYDROCHLORIDE,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2.Cl,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.365,0.177,0.0,0.265,0.282,0.5,0.464,0.11,0.0,0.498,0.0909,0.0,0.0432,0.566,1.0,0.0312,0.561,1,0.226,0.175,0.0,0.0406,0.394,1,-4.68,-5.38,-3.98,-5.38,-3.98,4.746020000000003,0.302,0.324,0.5,0.0228,0.999,1,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-11.5,L
CHEMBL1200434,OXTRIPHYLLINE,C[N+](C)(C)CCO.Cn1c(=O)c2[n-]cnc2n(C)c1=O,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,Phosphodiesterase 4 inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.825,0.0262,0.0,0.873,0.0284,0.0,0.916,0.00691,0.0,0.956,0.00481,0.0,0.791,0.0112,0.0,0.857,0.0257,0,0.797,0.0263,0.0,0.844,0.0329,0,0.963,0.484,1.44,0.484,1.44,-1.725699999999997,0.785,0.0196,0.0,0.133,0.393,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,3.0,L
CHEMBL1200436,OXANDROLONE,C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,3.0,Withdrawn,0,0,pathway_drug_candidates,3.0,0.585,0.0736,0.0,0.481,0.147,0.0,0.591,0.079,0.0,0.235,0.248,0.5,0.775,0.0143,0.0,0.0879,0.368,1,0.327,0.112,0.0,0.184,0.173,0.5,-4.6,-5.17,-4.04,-5.17,-4.04,3.543100000000003,0.476,0.147,0.0,0.688,0.0094,0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,-6.5,L
CHEMBL1200449,TRIAMCINOLONE DIACETATE,CC(=O)OCC(=O)[C@@]1(O)[C@H](OC(C)=O)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,,0,0,,0,0,Glucocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.576,0.0795,0.0,0.571,0.104,0.0,0.505,0.0988,0.0,0.838,0.014,0.0,0.712,0.0204,0.0,0.298,0.192,0,0.466,0.0671,0.0,0.13,0.171,1,-4.11,-4.58,-3.64,-4.58,-3.64,1.7620999999999991,0.44,0.168,0.0,0.0528,0.815,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,-3.0,L
CHEMBL1200461,MIDODRINE HYDROCHLORIDE,COc1ccc(OC)c(C(O)CNC(=O)CN)c1.Cl,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,3.0,Terminated,0,0,pathway_drug_candidates,3.0,0.0742,0.531,1.0,0.494,0.148,0.0,0.528,0.092,0.0,0.463,0.102,0.0,0.0635,0.438,1.0,0.329,0.163,0,0.145,0.261,1.0,0.345,0.12,0,-0.862,-1.9,0.178,-1.9,0.178,0.2339000000000002,0.628,0.0669,0.0,0.0351,0.882,1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-3.5,L
CHEMBL1200463,OXAPROZIN POTASSIUM,O=C([O-])CCc1nc(-c2ccccc2)c(-c2ccccc2)o1.[K+],,0,0,,0,0,Cyclooxygenase inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.422,0.147,0.0,0.487,0.152,0.0,0.215,0.291,0.5,0.291,0.197,0.0,0.0855,0.385,1.0,0.809,0.037,0,0.658,0.0389,0.0,0.381,0.136,0,-1.46,-2.55,-0.379,-2.55,-0.379,-0.3048999999999999,0.681,0.0407,0.0,0.697,0.00975,0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,-3.0,L
CHEMBL1200467,HYDROXYZINE PAMOATE,O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O.OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.956,0.00569,0.0,0.455,0.16,0.0,0.789,0.0257,0.0,0.891,0.0125,0.0,0.908,0.00606,0.0,0.00468,0.872,1,0.474,0.0823,0.0,0.276,0.167,0,-3.37,-4.24,-2.49,-4.24,-2.49,7.447300000000008,0.789,0.0344,0.0,0.188,0.321,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-3.0,L
CHEMBL1200469,PROMAZINE HYDROCHLORIDE,CN(C)CCCN1c2ccccc2Sc2ccccc21.Cl,,0,0,,0,0,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.701,0.0495,0.0,0.0256,0.697,1.0,0.691,0.0501,0.0,0.282,0.195,0.0,0.304,0.132,0.0,0.132,0.303,1,0.414,0.0773,0.0,0.158,0.184,1,-3.95,-5.2,-2.7,-5.2,-2.7,4.662800000000004,0.407,0.248,0.0,0.0199,0.978,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,-9.0,L
CHEMBL1200472,QUAZEPAM,Fc1ccccc1C1=NCC(=S)N(CC(F)(F)F)c2ccc(Cl)cc21,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.135,0.389,1.0,0.157,0.389,1.0,0.0685,0.576,1.0,0.29,0.176,0.0,0.0271,0.664,1.0,0.533,0.0982,0,0.311,0.118,0.0,0.111,0.219,1,-6.01,-6.53,-5.49,-6.53,-5.49,5.026200000000003,0.185,0.529,1.0,0.0417,0.864,1,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,4.0,1.0,1.0,-9.0,L
CHEMBL1200474,DEMECLOCYCLINE HYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12.Cl,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.799,0.028,0.0,0.817,0.0445,0.0,0.129,0.465,1.0,0.487,0.0942,0.0,0.404,0.0951,0.0,0.508,0.105,0,0.814,0.0254,0.0,0.752,0.0564,0,-2.77,-3.71,-1.83,-3.71,-1.83,0.6867000000000003,0.833,0.0213,0.0,0.102,0.504,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-2.0,L
CHEMBL1200485,SORAFENIB TOSYLATE,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.335,0.19,0.0,0.526,0.118,0.0,0.803,0.027,0.0,0.299,0.179,0.0,0.67,0.0304,0.0,0.913,0.0184,0,0.989,0.00239,0.0,0.386,0.146,0,-5.09,-5.92,-4.26,-5.92,-4.26,6.791420000000006,0.07,0.884,1.0,0.133,0.49,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,2.0,L
CHEMBL1200491,EPINASTINE HYDROCHLORIDE,Cl.NC1=NCC2c3ccccc3Cc3ccccc3N12,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.362,0.17,0.0,0.19,0.327,1.0,0.274,0.242,0.5,0.137,0.367,1.0,0.324,0.113,0.0,0.622,0.0769,0,0.171,0.214,1.0,0.433,0.116,0,-3.77,-4.92,-2.62,-4.92,-2.62,2.888600000000001,0.619,0.0654,0.0,0.00388,0.969,1,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,-1.5,L
CHEMBL1200492,NEFAZODONE HYDROCHLORIDE,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1.Cl,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.946,0.00706,0.0,0.474,0.165,0.0,0.844,0.0151,0.0,0.14,0.373,1.0,0.126,0.3,1.0,0.00398,0.884,1,0.942,0.00761,0.0,0.0302,0.366,1,-4.55,-5.37,-3.72,-5.37,-3.72,3.973700000000003,0.136,0.672,1.0,0.00998,0.987,1,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-9.0,L
CHEMBL1200494,GUANFACINE HYDROCHLORIDE,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.34,0.187,0.0,0.391,0.194,0.0,0.283,0.212,0.5,0.263,0.22,0.5,0.102,0.381,1.0,0.352,0.164,0,0.235,0.165,0.0,0.445,0.108,0,-2.35,-3.75,-0.956,-3.75,-0.956,1.96737,0.729,0.023,0.0,0.0307,0.917,1,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,0.5,L
CHEMBL1200495,HYDROCORTISONE SODIUM SUCCINATE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+],NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.626,0.0614,0.0,0.99,0.00333,0.0,0.796,0.0205,0.0,0.732,0.04,0.0,0.964,0.00358,0.0,0.791,0.0379,0,0.793,0.0292,0.0,0.844,0.0221,0,-2.82,-4.17,-1.47,-4.17,-1.47,-2.1333999999999937,0.82,0.0191,0.0,0.0942,0.618,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,4.5,L
CHEMBL1200500,BECLOMETHASONE DIPROPIONATE,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.429,0.136,0.0,0.301,0.246,0.5,0.566,0.0807,0.0,0.46,0.103,0.0,0.511,0.0528,0.0,0.259,0.206,0,0.707,0.0388,0.0,0.0904,0.268,1,-3.69,-4.43,-2.95,-4.43,-2.95,4.086800000000004,0.188,0.526,1.0,0.0178,0.998,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,4.5,L
CHEMBL1200506,ERYTHROMYCIN LACTOBIONATE,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.976,0.00382,0.0,0.927,0.0102,0.0,0.934,0.00637,0.0,0.986,0.00122,0.0,0.994,0.00122,0.0,0.971,0.00597,0,0.958,0.00499,0.0,0.925,0.0107,0,0.355,-0.188,0.899,-0.188,0.899,-3.8833,0.962,0.00405,0.0,0.761,0.0127,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,L
CHEMBL1200510,ERYTHROMYCIN STEARATE,CCCCCCCCCCCCCCCCCC(=O)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.961,0.00356,0.0,0.996,0.00227,0.0,0.908,0.00757,0.0,0.979,0.00313,0.0,0.961,0.00312,0.0,0.743,0.0459,0,0.998,0.00146,0.0,0.457,0.0841,0,-5.41,-6.67,-4.14,-6.67,-4.14,8.11810000000001,0.264,0.291,0.5,0.807,0.00775,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.5,L
CHEMBL1200531,ALFENTANIL HYDROCHLORIDE,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1.Cl,,0,0,,0,0,Mu opioid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.858,0.0213,0.0,0.574,0.105,0.0,0.802,0.0238,0.0,0.522,0.0767,0.0,0.175,0.248,0.5,0.0489,0.461,1,0.968,0.00552,0.0,0.801,0.0421,0,-2.01,-2.98,-1.03,-2.98,-1.03,1.8056999999999992,0.281,0.297,0.5,0.0188,0.986,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-6.5,L
CHEMBL1200534,MOEXIPRIL HYDROCHLORIDE,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O.Cl,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,Angiotensin-converting enzyme inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.519,0.105,0.0,0.5,0.176,0.0,0.379,0.158,0.0,0.548,0.0742,0.0,0.329,0.126,0.0,0.805,0.0301,0,0.758,0.0275,0.0,0.164,0.172,1,-1.58,-2.13,-1.04,-2.13,-1.04,3.0061000000000013,0.617,0.0509,0.0,0.00311,0.96,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,4.5,L
CHEMBL1200538,BETAMETHASONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.501,0.108,0.0,0.584,0.121,0.0,0.607,0.0692,0.0,0.729,0.0353,0.0,0.671,0.0278,0.0,0.397,0.141,0,0.594,0.0525,0.0,0.0427,0.49,1,-4.71,-5.6,-3.82,-5.6,-3.82,2.466500000000001,0.458,0.207,0.0,0.102,0.445,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,3.0,L
CHEMBL1200542,DESOXYCORTICOSTERONE ACETATE,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,,0,0,,0,0,Mineralocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.615,0.072,0.0,0.56,0.101,0.0,0.864,0.0169,0.0,0.736,0.0332,0.0,0.8,0.0118,0.0,0.556,0.0895,0,0.383,0.094,0.0,0.0327,0.321,1,-4.83,-5.76,-3.91,-5.76,-3.91,4.266700000000004,0.408,0.218,0.0,0.253,0.0887,0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,-3.5,L
CHEMBL1200543,ANILERIDINE PHOSPHATE,CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1.O=P(O)(O)O,,0,0,,0,0,Mu opioid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.765,0.0318,0.0,0.242,0.29,0.5,0.953,0.00314,0.0,0.849,0.0161,0.0,0.334,0.103,0.0,0.972,0.00774,0,0.401,0.0876,0.0,0.731,0.0381,0,-3.24,-4.21,-2.27,-4.21,-2.27,2.479600000000001,0.204,0.468,1.0,0.0262,0.871,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,L
CHEMBL1200545,DIFLORASONE DIACETATE,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.368,0.169,0.0,0.418,0.182,0.0,0.615,0.0703,0.0,0.84,0.0157,0.0,0.735,0.0199,0.0,0.501,0.113,0,0.731,0.0313,0.0,0.2,0.166,0,-5.35,-6.04,-4.66,-6.04,-4.66,2.9853000000000014,0.279,0.326,0.5,0.00814,0.962,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,4.0,L
CHEMBL1200561,DOXAZOSIN MESYLATE,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC.CS(=O)(=O)O,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0999,0.463,1.0,0.757,0.0507,0.0,0.42,0.136,0.0,0.761,0.036,0.0,0.478,0.0647,0.0,0.133,0.303,1,0.379,0.103,0.0,0.877,0.0333,0,-2.36,-3.37,-1.34,-3.37,-1.34,1.2218000000000009,0.0722,0.784,1.0,0.161,0.415,1,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,-3.0,L
CHEMBL1200562,HYDROCORTISONE VALERATE,CCCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,,0,0,,0,0,Glucocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.535,0.0974,0.0,0.69,0.0806,0.0,0.472,0.113,0.0,0.451,0.105,0.0,0.702,0.0199,0.0,0.584,0.0848,0,0.805,0.028,0.0,0.77,0.0431,0,-5.6,-6.48,-4.71,-6.48,-4.71,3.522700000000002,0.358,0.234,0.0,0.108,0.474,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-2.5,L
CHEMBL1200563,CERIVASTATIN SODIUM,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c1-c1ccc(F)cc1.[Na+],,0,0,,0,0,HMG-CoA reductase inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.57,0.0664,0.0,0.941,0.0135,0.0,0.443,0.135,0.0,0.0716,0.57,1.0,0.864,0.0101,0.0,0.843,0.0302,0,0.878,0.0135,0.0,0.646,0.0798,0,-1.66,-2.1,-1.23,-2.1,-1.23,0.5500000000000004,0.744,0.0408,0.0,0.07,0.747,1,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-1.5,L
CHEMBL1200578,THEOPHYLLINE SODIUM GLYCINATE,Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCC(=O)[O-].[Na+],,0,0,,0,0,Phosphodiesterase 4 inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.435,0.149,0.0,0.988,0.000965,0.0,0.899,0.0083,0.0,0.944,0.00578,0.0,0.898,0.0047,0.0,0.906,0.0174,0,0.815,0.0245,0.0,0.94,0.00368,0,1.74,1.18,2.29,1.18,2.14,-6.340699999999999,0.928,0.00139,0.0,0.258,0.128,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,L
CHEMBL1200588,CLINDAMYCIN HYDROCHLORIDE,CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1.Cl,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.7,0.0435,0.0,0.482,0.143,0.0,0.497,0.101,0.0,0.336,0.169,0.0,0.644,0.0327,0.0,0.134,0.3,1,0.783,0.0265,0.0,0.0394,0.393,1,-0.948,-1.4,-0.494,-1.4,-0.494,0.8112999999999999,0.706,0.0415,0.0,0.236,0.164,0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,-6.5,L
CHEMBL1200592,DESOXYCORTICOSTERONE PIVALATE,CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,,0,0,,0,0,Mineralocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.466,0.126,0.0,0.657,0.0823,0.0,0.868,0.0112,0.0,0.336,0.161,0.0,0.853,0.00775,0.0,0.685,0.0574,0,0.348,0.0927,0.0,0.077,0.266,1,-5.29,-6.17,-4.41,-6.17,-4.41,5.292900000000006,0.413,0.244,0.0,0.477,0.0293,0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,-4.5,L
CHEMBL1200599,DIFENOXIN HYDROCHLORIDE,Cl.N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1,,0,0,,0,0,Mu opioid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.44,0.12,0.0,0.116,0.443,1.0,0.706,0.0477,0.0,0.646,0.0503,0.0,0.493,0.0631,0.0,0.0674,0.4,1,0.858,0.0206,0.0,0.752,0.0464,0,-2.08,-2.91,-1.25,-2.91,-1.25,5.426580000000005,0.478,0.16,0.0,0.0118,0.963,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-8.0,L
CHEMBL1200600,FLUOROMETHOLONE,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.487,0.107,0.0,0.379,0.185,0.0,0.146,0.402,1.0,0.262,0.209,0.5,0.47,0.0552,0.0,0.172,0.269,1,0.715,0.0327,0.0,0.81,0.024,0,-4.77,-5.4,-4.14,-5.4,-4.14,2.923300000000001,0.46,0.159,0.0,0.0322,0.921,1,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-3.0,L
CHEMBL1200613,TOLMETIN SODIUM,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+],PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.386,0.157,0.0,0.973,0.00515,0.0,0.824,0.0171,0.0,0.606,0.0602,0.0,0.414,0.0728,0.0,0.731,0.0523,0,0.797,0.024,0.0,0.614,0.0479,0,-2.83,-3.84,-1.82,-3.84,-1.82,-2.139079999999997,0.773,0.0216,0.0,0.191,0.2,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,8.5,H
CHEMBL1200617,RIMEXOLONE,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.262,0.23,0.5,0.358,0.209,0.5,0.307,0.213,0.5,0.437,0.104,0.0,0.438,0.0667,0.0,0.194,0.251,1,0.714,0.0324,0.0,0.834,0.0224,0,-3.9,-4.65,-3.16,-4.65,-3.16,4.496500000000005,0.341,0.266,0.5,0.0679,0.741,1,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-5.0,L
CHEMBL1200618,FEXOFENADINE HYDROCHLORIDE,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1.Cl,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.566,0.0857,0.0,0.496,0.149,0.0,0.666,0.062,0.0,0.732,0.0345,0.0,0.878,0.00558,0.0,0.133,0.301,1,0.949,0.00831,0.0,0.873,0.0304,0,-4.43,-5.82,-3.05,-5.82,-3.05,5.932300000000009,0.698,0.0436,0.0,0.32,0.0981,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-4.5,L
CHEMBL1200622,PARICALCITOL,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@]12C,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Vitamin D receptor agonist,4.0,Terminated,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.7,0.0491,0.0,0.35,0.211,0.5,0.13,0.421,1.0,0.524,0.0861,0.0,0.538,0.0558,0.0,0.629,0.0805,0,0.478,0.0609,0.0,0.22,0.163,0,-3.66,-4.15,-3.16,-4.15,-3.16,5.560600000000008,0.401,0.23,0.0,0.231,0.122,0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,0.0,L
CHEMBL1200632,CLINDAMYCIN PALMITATE HYDROCHLORIDE,CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H]([C@H](NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](C)Cl)O[C@@H]1SC.Cl,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.857,0.0155,0.0,0.844,0.0339,0.0,0.668,0.0458,0.0,0.565,0.0778,0.0,0.663,0.0296,0.0,0.0894,0.337,1,0.984,0.00272,0.0,0.0403,0.431,1,-5.2,-5.8,-4.6,-5.8,-4.6,6.843500000000008,0.119,0.707,1.0,0.0851,0.569,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,-8.0,L
CHEMBL1200635,HYDROCORTAMATE HYDROCHLORIDE,CCN(CC)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C.Cl,,0,0,,0,0,Glucocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.909,0.00978,0.0,0.793,0.0445,0.0,0.763,0.0354,0.0,0.534,0.089,0.0,0.653,0.03,0.0,0.0619,0.433,1,0.747,0.0287,0.0,0.642,0.0379,0,-2.88,-3.67,-2.09,-3.67,-2.09,3.096100000000001,0.49,0.132,0.0,0.000275,0.972,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-6.0,L
CHEMBL1200636,CYCLOBENZAPRINE HYDROCHLORIDE,CN(C)CCC=C1c2ccccc2C=Cc2ccccc21.Cl,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.4,0.164,0.0,0.0111,0.827,1.0,0.498,0.0939,0.0,0.591,0.0707,0.0,0.143,0.274,1.0,0.315,0.166,0,0.384,0.0907,0.0,0.0314,0.443,1,-2.49,-3.22,-1.77,-3.22,-1.77,4.9756000000000045,0.459,0.164,0.0,0.0248,0.98,1,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-5.0,L
CHEMBL1200638,DEXBROMPHENIRAMINE MALEATE,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.983,0.00385,0.0,0.377,0.186,0.0,0.913,0.0064,0.0,0.925,0.00768,0.0,0.898,0.00552,0.0,0.261,0.206,0,0.962,0.00502,0.0,0.959,0.0109,0,-2.22,-3.43,-1.01,-3.43,-1.01,3.639500000000001,0.615,0.0863,0.0,0.698,0.0168,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,L
CHEMBL1200644,FONDAPARINUX SODIUM,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-8957275|Post-translational protein phosphorylation,4,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.346,0.22,0.5,1.0,0.00473,0.0,0.976,0.00295,0.0,0.985,0.00205,0.0,1.0,0.00204,0.0,0.939,0.00769,0,0.984,0.00463,0.0,0.977,0.018,0,9.24,8.9,9.58,2.14,2.14,-49.12030000000009,0.998,0.00682,0.0,0.499,0.032,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,L
CHEMBL1200649,QUINUPRISTIN,CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2CC(=O)[C@H](CS[C@@H]3CN4CCC3CC4)CN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@@H]2CCCN2C1=O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.499,0.106,0.0,0.891,0.018,0.0,0.979,0.00199,0.0,0.425,0.125,0.0,0.737,0.0164,0.0,0.824,0.0342,0,0.123,0.319,1.0,0.0569,0.276,1,-3.56,-4.09,-3.02,-4.09,-3.02,2.323500000000009,0.618,0.0796,0.0,0.636,0.0174,0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,-3.5,L
CHEMBL1200659,ENALAPRIL MALEATE,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.O=C(O)/C=C\C(=O)O,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,Angiotensin-converting enzyme inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.974,0.00358,0.0,0.899,0.0147,0.0,0.86,0.0138,0.0,0.901,0.00959,0.0,0.883,0.00528,0.0,0.903,0.0154,0,0.952,0.00786,0.0,0.806,0.0371,0,-1.45,-2.14,-0.758,-2.14,-0.758,1.316400000000002,0.815,0.014,0.0,0.204,0.209,0.5,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.5,0.0,0.0,0.0,6.0,L
CHEMBL1200665,DIPHENOXYLATE HYDROCHLORIDE,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1.Cl,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,2.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.172,0.302,1.0,0.0783,0.537,1.0,0.788,0.0325,0.0,0.44,0.108,0.0,0.257,0.156,0.0,0.134,0.295,1,0.902,0.00649,0.0,0.303,0.133,0,-3.32,-4.24,-2.4,-4.24,-2.4,5.905080000000007,0.144,0.6,1.0,0.000997,0.988,1,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,-5.5,L
CHEMBL1200666,CALCIPOTRIENE,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Vitamin D receptor agonist,4.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.815,0.0258,0.0,0.558,0.106,0.0,0.0676,0.57,1.0,0.72,0.043,0.0,0.521,0.0547,0.0,0.444,0.13,0,0.589,0.0511,0.0,0.192,0.161,0,-4.36,-4.89,-3.83,-4.89,-3.83,5.090600000000006,0.41,0.193,0.0,0.28,0.0935,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-0.5,L
CHEMBL1200678,ATAZANAVIR SULFATE,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C.O=S(=O)(O)O,,0,0,,0,0,Human immunodeficiency virus type 1 protease inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.661,0.0489,0.0,0.279,0.264,0.5,0.274,0.223,0.5,0.362,0.143,0.0,0.511,0.0461,0.0,0.00137,0.956,1,0.973,0.00168,0.0,0.721,0.0383,0,-0.789,-1.83,0.252,-1.83,0.252,3.5588000000000024,0.042,0.8,1.0,0.0776,0.436,1,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-6.0,L
CHEMBL1200681,MONTELUKAST SODIUM,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+],,0,0,R-HSA-416476|G alpha (q) signalling events;R-HSA-9679191|Potential therapeutics for SARS,2,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.721,0.0519,0.0,0.988,0.00387,0.0,0.843,0.0132,0.0,0.418,0.122,0.0,0.0949,0.364,1.0,0.787,0.0407,0,0.365,0.0885,0.0,0.436,0.128,0,-6.32,-6.69,-5.95,-6.69,-5.95,4.617300000000005,0.358,0.263,0.5,0.0704,0.696,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-0.5,L
CHEMBL1200688,ERYTHROMYCIN ETHYLSUCCINATE,CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.607,0.0663,0.0,0.86,0.0307,0.0,0.817,0.0175,0.0,0.757,0.0304,0.0,0.875,0.00685,0.0,0.868,0.0238,0,0.867,0.0166,0.0,0.568,0.0887,0,-0.898,-1.58,-0.219,-1.58,-0.219,2.6798000000000073,0.315,0.38,0.5,0.377,0.0382,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,L
CHEMBL1200689,NITRIC OXIDE,[N]=O,GUCY1B1,1,1,R-HSA-445355|Smooth Muscle Contraction,1,0,Soluble guanylate cyclase activator,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-0.4471,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL1200692,OLMESARTAN MEDOXOMIL,CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,Type-1 angiotensin II receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.716,0.0419,0.0,0.931,0.0109,0.0,0.856,0.0114,0.0,0.603,0.0669,0.0,0.13,0.272,1.0,0.714,0.0552,0,0.96,0.00382,0.0,0.8,0.0226,0,-4.72,-5.64,-3.81,-5.64,-3.81,4.170020000000003,0.641,0.0761,0.0,0.364,0.0299,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.5,L
CHEMBL1200694,SEVOFLURANE,FCOC(C(F)(F)F)C(F)(F)F,GABRA1;KCNK10;KCNK18;KCNK3;KCNK9,5,5,R-HSA-112314|Neurotransmitter receptors and postsynaptic signal transmission;R-HSA-1299316|TWIK-releated acid-sensitive K+ channel (TASK);R-HSA-1299503|TWIK related potassium channel (TREK);R-HSA-5576886|Phase 4 - resting membrane potential,4,0,GABA-A receptor; anion channel positive allosteric modulator;GABA-A receptor; anion channel positive allosteric modulator | Glycine receptor (alpha-1/beta) positive modulator | Potassium channel subfamily K member 10 opener | Potassium channel subfamily K member 18 opener | Potassium channel subfamily K member 2 opener | Potassium channel subfamily K member 3 opener | Potassium channel subfamily K member 9 opener;Glycine receptor (alpha-1/beta) positive modulator;Potassium channel subfamily K member 10 opener;Potassium channel subfamily K member 18 opener;Potassium channel subfamily K member 2 opener;Potassium channel subfamily K member 3 opener;Potassium channel subfamily K member 9 opener,3.0,Completed;Not yet recruiting,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,14.5,0.372,0.157,0.0,0.146,0.399,1.0,0.0343,0.754,1.0,0.16,0.354,1.0,0.309,0.122,0.0,0.688,0.0609,0,0.471,0.0703,0.0,0.163,0.18,1,-1.9,-2.85,-0.942,-2.85,-0.942,2.4232000000000005,0.483,0.111,0.0,0.0786,0.535,1,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,10.5,M
CHEMBL1200699,DOXYCYCLINE,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,MMP1;MMP13;MMP7;MMP8,4,4,R-HSA-1442490|Collagen degradation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases;R-HSA-210991|Basigin interactions;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6798695|Neutrophil degranulation,7,1,Bacterial 70S ribosome inhibitor;Bacterial 70S ribosome inhibitor | Matrix metalloproteinase 13 inhibitor | Matrix metalloproteinase 7 inhibitor | Matrix metalloproteinase 8 inhibitor | Matrix metalloproteinase-1 inhibitor;Matrix metalloproteinase 13 inhibitor;Matrix metalloproteinase 7 inhibitor;Matrix metalloproteinase 8 inhibitor;Matrix metalloproteinase-1 inhibitor,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,15.5,0.861,0.0156,0.0,0.486,0.155,0.0,0.0208,0.872,1.0,0.274,0.205,0.5,0.651,0.0276,0.0,0.416,0.137,0,0.199,0.194,0.5,0.53,0.102,0,-3.56,-4.46,-2.66,-4.46,-2.66,-1.172299999999998,0.954,0.00644,0.0,0.382,0.0597,0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,11.0,M
CHEMBL1200703,CHLORDIAZEPOXIDE HYDROCHLORIDE,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1.Cl,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.403,0.154,0.0,0.116,0.453,1.0,0.549,0.0753,0.0,0.1,0.446,1.0,0.0064,0.862,1.0,0.583,0.0895,0,0.467,0.0699,0.0,0.247,0.16,0,-3.59,-4.46,-2.71,-4.46,-2.71,3.372500000000002,0.223,0.435,1.0,0.0119,0.976,1,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-2.5,L
CHEMBL1200729,CHLORAMPHENICOL SODIUM SUCCINATE,O=C([O-])CCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc([N+](=O)[O-])cc1.[Na+],,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.596,0.0721,0.0,0.993,0.00269,0.0,0.777,0.031,0.0,0.642,0.0505,0.0,0.924,0.00331,0.0,0.824,0.0341,0,0.835,0.0177,0.0,0.775,0.0386,0,-1.54,-2.83,-0.245,-2.83,-0.245,-3.0059999999999967,0.782,0.0182,0.0,0.368,0.0447,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,L
CHEMBL1200732,AMCINONIDE,CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,,0,0,,0,0,Glucocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.584,0.0788,0.0,0.663,0.093,0.0,0.771,0.0332,0.0,0.852,0.0167,0.0,0.641,0.0327,0.0,0.33,0.18,0,0.613,0.0471,0.0,0.2,0.166,0,-5.01,-5.83,-4.2,-5.83,-4.2,3.5238000000000023,0.345,0.248,0.0,0.0459,0.893,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-2.5,L
CHEMBL1200733,DESFLURANE,FC(F)OC(F)C(F)(F)F,,0,0,R-HSA-112314|Neurotransmitter receptors and postsynaptic signal transmission;R-HSA-1299316|TWIK-releated acid-sensitive K+ channel (TASK);R-HSA-1299503|TWIK related potassium channel (TREK);R-HSA-5576886|Phase 4 - resting membrane potential,4,0,GABA-A receptor; anion channel positive allosteric modulator | Glycine receptor (alpha-1/beta) positive modulator | Potassium channel subfamily K member 10 opener | Potassium channel subfamily K member 18 opener | Potassium channel subfamily K member 2 opener | Potassium channel subfamily K member 3 opener | Potassium channel subfamily K member 9 opener,2.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,2.0,0.275,0.235,0.5,0.0978,0.486,1.0,0.105,0.474,1.0,0.192,0.29,1.0,0.317,0.127,0.0,0.119,0.318,1,0.421,0.0799,0.0,0.26,0.143,0,-1.82,-2.76,-0.879,-2.76,-0.879,2.0835,0.473,0.151,0.0,0.103,0.472,1,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,4.0,1.0,1.0,-9.0,L
CHEMBL1200734,FOSAMPRENAVIR CALCIUM,CC(C)CN(C[C@@H](OP(=O)([O-])[O-])[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1.[Ca+2],,0,0,,0,0,Human immunodeficiency virus type 1 protease inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.757,0.0338,0.0,0.0821,0.474,1.0,0.991,0.00254,0.0,0.212,0.25,0.5,0.54,0.0531,0.0,0.415,0.143,0,0.967,0.00581,0.0,0.964,0.0155,0,-3.91,-4.51,-3.31,-4.51,-3.31,0.875000000000003,0.238,0.484,1.0,0.226,0.233,0.5,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.5,2.0,0.0,1.0,-1.5,L
CHEMBL1200750,PROMETHAZINE HYDROCHLORIDE,CC(CN1c2ccccc2Sc2ccccc21)N(C)C.Cl,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.367,0.169,0.0,0.0622,0.569,1.0,0.345,0.172,0.0,0.194,0.291,1.0,0.177,0.27,0.5,0.187,0.252,1,0.706,0.0347,0.0,0.552,0.111,0,-3.07,-4.78,-1.35,-4.78,-1.35,4.6612000000000045,0.465,0.159,0.0,0.0231,0.975,1,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,3.0,0.0,1.0,-6.0,L
CHEMBL1200760,BALSALAZIDE DISODIUM,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+],PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.904,0.0101,0.0,0.995,0.000653,0.0,0.853,0.0112,0.0,0.409,0.131,0.0,0.98,0.000283,0.0,0.97,0.00557,0,0.158,0.239,1.0,0.872,0.0119,0,-1.24,-2.22,-0.254,-2.22,-0.254,-5.951099999999998,0.964,0.000943,0.0,0.529,0.0173,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,M
CHEMBL1200762,BETAMETHASONE SODIUM PHOSPHATE,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.0513,0.6,1.0,0.985,0.00313,0.0,0.565,0.0868,0.0,0.533,0.085,0.0,0.973,0.00243,0.0,0.411,0.142,0,0.864,0.0132,0.0,0.315,0.135,0,-2.56,-3.44,-1.69,-3.44,-1.69,-5.243299999999994,0.678,0.0545,0.0,0.221,0.203,0.5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.5,1.0,1.0,1.0,1.5,L
CHEMBL1200774,FLUPREDNISOLONE,C[C@]12C=CC(=O)C=C1[C@@H](F)C[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,,0,0,,0,0,Glucocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.516,0.1,0.0,0.433,0.159,0.0,0.317,0.193,0.0,0.441,0.113,0.0,0.585,0.0399,0.0,0.145,0.288,1,0.665,0.0435,0.0,0.573,0.0783,0,-3.8,-4.49,-3.12,-4.49,-3.12,1.5056,0.577,0.104,0.0,0.0924,0.63,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,-5.5,L
CHEMBL1200787,PHENOXYBENZAMINE HYDROCHLORIDE,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,Adrenergic receptor alpha antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.57,0.086,0.0,0.144,0.39,1.0,0.699,0.0439,0.0,0.219,0.28,0.5,0.305,0.128,0.0,0.511,0.117,0,0.0662,0.494,1.0,0.58,0.0616,0,-3.58,-4.15,-3.01,-4.15,-3.01,4.616700000000005,0.256,0.336,0.5,0.199,0.216,1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-2.0,L
CHEMBL1200790,METHYPRYLON,CCC1(CC)C(=O)NCC(C)C1=O,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.435,0.143,0.0,0.498,0.122,0.0,0.249,0.262,0.5,0.443,0.115,0.0,0.441,0.0709,0.0,0.4,0.143,0,0.269,0.133,0.0,0.325,0.144,0,-0.653,-1.69,0.387,-1.69,0.387,1.1278,0.312,0.265,0.5,0.158,0.24,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-1.0,L
CHEMBL1200791,OXYMETAZOLINE HYDROCHLORIDE,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.6,0.0676,0.0,0.384,0.201,0.5,0.761,0.0421,0.0,0.484,0.0969,0.0,0.404,0.0837,0.0,0.392,0.149,0,0.799,0.0228,0.0,0.0358,0.437,1,-2.71,-3.61,-1.8,-3.61,-1.8,3.2725400000000024,0.569,0.108,0.0,0.0416,0.917,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,L
CHEMBL1200794,OXYMORPHONE HYDROCHLORIDE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.68,0.0577,0.0,0.24,0.293,0.5,0.565,0.0851,0.0,0.363,0.148,0.0,0.573,0.0367,0.0,0.105,0.338,1,0.716,0.0355,0.0,0.818,0.031,0,-1.45,-2.97,0.0707,-2.97,0.0707,1.1669999999999998,0.402,0.19,0.0,0.0164,0.973,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,L
CHEMBL1200795,CLEMASTINE FUMARATE,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1.O=C(O)/C=C/C(=O)O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.896,0.0138,0.0,0.401,0.181,0.0,0.95,0.0051,0.0,0.682,0.0486,0.0,0.405,0.0806,0.0,0.000987,0.965,1,0.905,0.0101,0.0,0.0904,0.22,1,-2.9,-3.52,-2.27,-3.52,-2.27,4.816200000000003,0.426,0.176,0.0,0.179,0.251,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,-4.0,L
CHEMBL1200798,TRAZODONE HYDROCHLORIDE,Cl.O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.773,0.0361,0.0,0.497,0.148,0.0,0.791,0.0317,0.0,0.374,0.149,0.0,0.192,0.212,0.5,0.00931,0.775,1,0.925,0.0105,0.0,0.0817,0.279,1,-2.77,-3.65,-1.89,-3.65,-1.89,2.783500000000001,0.155,0.602,1.0,0.0205,0.978,1,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,-6.0,L
CHEMBL1200802,TALBUTAL,C=CCC1(C(C)CC)C(=O)NC(=O)NC1=O,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.391,0.164,0.0,0.682,0.0831,0.0,0.118,0.46,1.0,0.604,0.0671,0.0,0.513,0.0564,0.0,0.841,0.0244,0,0.765,0.0249,0.0,0.887,0.0343,0,-2.21,-2.9,-1.52,-2.9,-1.52,0.961,0.258,0.417,0.5,0.021,0.986,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-2.0,L
CHEMBL1200804,DICLOFENAC POTASSIUM,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+],PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.613,0.0667,0.0,0.557,0.12,0.0,0.0603,0.596,1.0,0.512,0.093,0.0,0.127,0.315,1.0,0.78,0.0348,0,0.651,0.0377,0.0,0.757,0.0534,0,-2.42,-6.42,1.58,-6.42,1.58,0.033399999999999,0.647,0.0631,0.0,0.287,0.116,0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,7.0,M
CHEMBL1200806,NAPROXEN SODIUM,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+],PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.0868,0.512,1.0,0.945,0.0157,0.0,0.63,0.0652,0.0,0.479,0.103,0.0,0.639,0.0325,0.0,0.608,0.0852,0,0.863,0.0133,0.0,0.917,0.0222,0,-2.95,-4.23,-1.67,-4.23,-1.67,-1.294199999999999,0.864,0.0191,0.0,0.222,0.159,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,5.5,L
CHEMBL1200809,AZELASTINE HYDROCHLORIDE,CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1.Cl,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,Completed,0,0,pathway_drug_candidates,4.0,0.155,0.374,1.0,0.113,0.447,1.0,0.493,0.0997,0.0,0.259,0.209,0.5,0.128,0.295,1.0,0.00481,0.865,1,0.7,0.0409,0.0,0.0936,0.224,1,-4.2,-4.9,-3.5,-4.9,-3.5,4.719300000000006,0.514,0.12,0.0,0.00905,0.954,1,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-11.5,L
CHEMBL1200810,DOXERCALCIFEROL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Vitamin D receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.672,0.0549,0.0,0.451,0.156,0.0,0.262,0.239,0.5,0.524,0.0847,0.0,0.597,0.0375,0.0,0.613,0.0832,0,0.561,0.0558,0.0,0.181,0.161,0,-5.4,-6.08,-4.72,-6.08,-4.72,6.6118000000000094,0.313,0.282,0.5,0.282,0.0808,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-0.5,L
CHEMBL1200817,LEVOMETHADYL ACETATE HYDROCHLORIDE,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1.Cl,,0,0,,0,0,Mu opioid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.146,0.332,1.0,0.0893,0.519,1.0,0.482,0.103,0.0,0.161,0.312,1.0,0.304,0.124,0.0,0.0816,0.374,1,0.896,0.00915,0.0,0.454,0.111,0,-2.21,-3.02,-1.39,-3.02,-1.39,5.076400000000006,0.26,0.374,0.5,0.00958,0.987,1,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-12.0,L
CHEMBL1200825,METHADONE HYDROCHLORIDE,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1.Cl,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.103,0.418,1.0,0.091,0.504,1.0,0.249,0.269,0.5,0.0635,0.622,1.0,0.227,0.176,0.5,0.0686,0.407,1,0.869,0.0121,0.0,0.792,0.0436,0,-1.44,-2.21,-0.663,-2.21,-0.663,4.713800000000005,0.305,0.298,0.5,0.00803,0.994,1,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,5.0,1.0,1.0,-6.5,L
CHEMBL1200826,LITHIUM CARBONATE,O=C([O-])[O-].[Li+].[Li+],,0,0,R-HSA-198323|AKT phosphorylates targets in the cytosol;R-HSA-381038|XBP1(S) activates chaperone genes;R-HSA-5674400|Constitutive Signaling by AKT1 E17K in Cancer;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9635465|Suppression of apoptosis;R-HSA-9683610|Maturation of nucleoprotein,6,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.316,0.215,0.5,0.172,0.352,1.0,0.0793,0.575,1.0,0.251,0.218,0.5,0.244,0.169,0.5,0.0418,0.484,1,0.273,0.132,0.0,0.346,0.134,0,-1.09,-3.97,1.79,-3.97,1.79,-8.439,0.699,0.0436,0.0,0.323,0.0693,0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,5.0,1.0,1.0,-8.0,L
CHEMBL1200831,SPIRAPRIL HYDROCHLORIDE,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2.Cl,,0,0,,0,0,Angiotensin-converting enzyme inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.834,0.0249,0.0,0.664,0.0799,0.0,0.486,0.0913,0.0,0.287,0.191,0.0,0.36,0.105,0.0,0.807,0.0333,0,0.77,0.0276,0.0,0.557,0.0978,0,-2.03,-2.47,-1.59,-2.47,-1.59,2.812600000000001,0.787,0.0263,0.0,0.0298,0.949,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,-0.5,L
CHEMBL1200845,HALCINONIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.226,0.273,0.5,0.591,0.101,0.0,0.464,0.128,0.0,0.727,0.0373,0.0,0.541,0.0501,0.0,0.282,0.197,0,0.348,0.108,0.0,0.954,0.0171,0,-4.03,-4.56,-3.49,-4.56,-3.49,3.889300000000003,0.588,0.0957,0.0,0.0745,0.862,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.5,L
CHEMBL1200865,LOTEPREDNOL ETABONATE,CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.318,0.205,0.0,0.497,0.131,0.0,0.665,0.0521,0.0,0.693,0.0491,0.0,0.394,0.0852,0.0,0.135,0.299,1,0.779,0.0267,0.0,0.922,0.0168,0,-5.01,-5.54,-4.47,-5.54,-4.47,3.916500000000003,0.465,0.159,0.0,0.149,0.475,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-1.5,L
CHEMBL1200873,PHENTOLAMINE MESYLATE,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,Adrenergic receptor alpha antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.701,0.0494,0.0,0.0315,0.678,1.0,0.721,0.044,0.0,0.437,0.106,0.0,0.449,0.0658,0.0,0.0463,0.475,1,0.341,0.0884,0.0,0.0926,0.184,1,-0.379,-1.23,0.472,-1.23,0.472,2.3444199999999995,0.45,0.119,0.0,0.146,0.395,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,-3.0,L
CHEMBL1200875,FLAVOXATE HYDROCHLORIDE,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O.Cl,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,Phosphodiesterase 4 inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.164,0.336,1.0,0.0585,0.603,1.0,0.619,0.0762,0.0,0.345,0.157,0.0,0.185,0.223,0.5,0.0361,0.521,1,0.607,0.0548,0.0,0.0374,0.391,1,-3.31,-4.94,-1.67,-4.94,-1.67,4.832920000000005,0.169,0.584,1.0,0.0185,0.973,1,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-7.5,L
CHEMBL1200877,FLUMETHASONE PIVALATE,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,,0,0,,0,0,Glucocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.3,0.208,0.0,0.643,0.0932,0.0,0.655,0.0595,0.0,0.347,0.15,0.0,0.757,0.02,0.0,0.624,0.0766,0,0.672,0.0393,0.0,0.0824,0.261,1,-6.39,-7.19,-5.6,-7.19,-5.6,3.4407000000000023,0.442,0.213,0.0,0.0469,0.861,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,-3.5,L
CHEMBL1200878,TRIAMCINOLONE HEXACETONIDE,CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,Unknown status,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.302,0.202,0.0,0.772,0.0559,0.0,0.588,0.0747,0.0,0.548,0.0799,0.0,0.563,0.0445,0.0,0.261,0.214,0,0.717,0.0344,0.0,0.813,0.0338,0,-5.34,-6.22,-4.47,-6.22,-4.47,4.405900000000004,0.304,0.327,0.5,0.0203,0.966,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,3.5,L
CHEMBL1200881,MINOCYCLINE HYDROCHLORIDE,CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O.Cl,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.96,0.00537,0.0,0.649,0.0827,0.0,0.775,0.0222,0.0,0.316,0.172,0.0,0.348,0.102,0.0,0.441,0.135,0,0.642,0.0404,0.0,0.624,0.0509,0,-2.98,-3.8,-2.16,-3.8,-2.16,0.6084,0.886,0.005,0.0,0.0564,0.767,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-1.0,L
CHEMBL1200890,OXYCODONE HYDROCHLORIDE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.Cl,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.453,0.119,0.0,0.184,0.348,1.0,0.674,0.0548,0.0,0.316,0.173,0.0,0.483,0.052,0.0,0.061,0.416,1,0.721,0.0328,0.0,0.55,0.081,0,-0.906,-1.47,-0.344,-1.47,-0.344,1.4699999999999998,0.359,0.241,0.0,0.00747,0.986,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,L
CHEMBL1200901,HALOFANTRINE HYDROCHLORIDE,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12.Cl,,0,0,,0,0,Ferriprotoporphyrin IX inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.0967,0.453,1.0,0.0311,0.688,1.0,0.745,0.043,0.0,0.62,0.0566,0.0,0.00632,0.901,1.0,0.00202,0.933,1,0.848,0.0173,0.0,0.181,0.178,0.5,-6.47,-7.78,-5.17,-7.78,-5.17,9.066099999999995,0.205,0.549,1.0,0.0235,0.991,1,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-13.0,L
CHEMBL1200903,SECOBARBITAL SODIUM,C=CCC1(C(C)CCC)C(=O)[N-]C(=O)NC1=O.[Na+],,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.138,0.37,1.0,0.974,0.0079,0.0,0.19,0.338,1.0,0.418,0.115,0.0,0.829,0.00983,0.0,0.829,0.0301,0,0.753,0.0258,0.0,0.893,0.0301,0,-1.51,-2.22,-0.806,-2.22,-0.806,-0.8607999999999985,0.224,0.442,1.0,0.0153,0.976,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,-3.5,L
CHEMBL1200908,HALOBETASOL PROPIONATE,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,Terminated,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.0761,0.521,1.0,0.197,0.325,1.0,0.491,0.107,0.0,0.65,0.0484,0.0,0.53,0.0483,0.0,0.419,0.133,0,0.766,0.0225,0.0,0.958,0.00112,0,-5.86,-6.54,-5.18,-6.54,-5.18,4.0511000000000035,0.315,0.272,0.5,0.00153,0.968,1,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-0.5,L
CHEMBL1200909,PREDNISOLONE TEBUTATE,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,,0,0,,0,0,Glucocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.423,0.133,0.0,0.6,0.101,0.0,0.562,0.0829,0.0,0.331,0.165,0.0,0.457,0.0683,0.0,0.227,0.223,0.5,0.792,0.0299,0.0,0.683,0.0546,0,-5.2,-5.82,-4.57,-5.82,-4.57,3.5447000000000024,0.371,0.26,0.5,0.023,0.959,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-7.5,L
CHEMBL1200914,TAMSULOSIN HYDROCHLORIDE,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1.Cl,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0531,0.596,1.0,0.261,0.295,0.5,0.438,0.15,0.0,0.805,0.024,0.0,0.584,0.0442,0.0,0.0152,0.708,1,0.817,0.0308,0.0,0.886,0.0128,0,-1.21,-1.85,-0.576,-1.85,-0.576,2.762700000000001,0.147,0.706,1.0,0.0174,0.977,1,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,1.0,1.0,-3.5,L
CHEMBL1200916,THIORIDAZINE HYDROCHLORIDE,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2.Cl,,0,0,,0,0,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.76,0.0354,0.0,0.0276,0.703,1.0,0.432,0.132,0.0,0.288,0.191,0.0,0.0999,0.363,1.0,0.0032,0.904,1,0.624,0.0525,0.0,0.172,0.16,0,-4.94,-5.81,-4.07,-5.81,-4.07,6.307400000000006,0.326,0.282,0.5,0.0125,0.98,1,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-10.5,L
CHEMBL1200927,DEXCHLORPHENIRAMINE MALEATE,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.984,0.00357,0.0,0.24,0.297,0.5,0.846,0.0107,0.0,0.959,0.00314,0.0,0.555,0.0438,0.0,0.134,0.299,1,0.96,0.00466,0.0,0.967,0.00876,0,-2.43,-3.39,-1.47,-3.39,-1.47,3.5304,0.53,0.128,0.0,0.72,0.0119,0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-3.0,L
CHEMBL1200937,DALFOPRISTIN,CCN(CC)CCS(=O)(=O)[C@@H]1CCN2C(=O)c3coc(n3)CC(=O)C[C@H](O)/C=C(C)/C=C/CNC(=O)/C=C/[C@@H](C)[C@@H](C(C)C)OC(=O)[C@@H]12,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.98,0.00384,0.0,0.92,0.0177,0.0,0.822,0.0156,0.0,0.788,0.027,0.0,0.851,0.00979,0.0,0.000835,0.973,1,0.46,0.0814,0.0,0.765,0.0486,0,-2.44,-2.78,-2.1,-2.78,-2.1,2.269300000000002,0.17,0.583,1.0,0.293,0.11,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,-4.0,L
CHEMBL1200946,NANDROLONE DECANOATE,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.775,0.0286,0.0,0.894,0.0134,0.0,0.756,0.0345,0.0,0.229,0.257,0.5,0.627,0.0358,0.0,0.25,0.208,0,0.918,0.00705,0.0,0.0264,0.306,1,-7.08,-11.1,-3.07,-11.1,-3.07,7.180700000000009,0.0486,0.873,1.0,0.544,0.0179,0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,-2.0,L
CHEMBL1200948,TRIMIPRAMINE MALEATE,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21.O=C(O)/C=C\C(=O)O,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.856,0.0204,0.0,0.481,0.167,0.0,0.784,0.0228,0.0,0.892,0.0116,0.0,0.906,0.0051,0.0,0.455,0.124,0,0.769,0.0219,0.0,0.824,0.0261,0,-3.96,-5.46,-2.47,-5.46,-2.47,3.8328000000000024,0.424,0.138,0.0,0.0857,0.685,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-1.0,L
CHEMBL1200953,HYDROCORTISONE PROBUTATE,CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.37,0.158,0.0,0.631,0.0889,0.0,0.698,0.0445,0.0,0.363,0.147,0.0,0.704,0.0224,0.0,0.681,0.0645,0,0.808,0.0237,0.0,0.744,0.0558,0,-5.29,-6.26,-4.33,-6.26,-4.33,4.093500000000003,0.366,0.285,0.5,0.0245,0.931,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,3.5,L
CHEMBL1200959,METHDILAZINE,CN1CCC(CN2c3ccccc3Sc3ccccc32)C1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.515,0.105,0.0,0.0237,0.704,1.0,0.419,0.134,0.0,0.457,0.101,0.0,0.289,0.144,0.0,0.0656,0.408,1,0.648,0.0449,0.0,0.0555,0.276,1,-3.9,-5.43,-2.37,-5.43,-2.37,4.241000000000003,0.255,0.332,0.5,0.129,0.357,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,-4.0,L
CHEMBL1200961,BROMPHENIRAMINE MALEATE,CN(C)CCC(c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.982,0.00314,0.0,0.376,0.184,0.0,0.913,0.0055,0.0,0.925,0.00705,0.0,0.897,0.00489,0.0,0.261,0.206,0,0.961,0.0041,0.0,0.952,0.0054,0,-2.22,-3.43,-1.01,-3.43,-1.01,3.639500000000001,0.603,0.0842,0.0,0.691,0.0144,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,L
CHEMBL1200968,HYDROCORTISONE SODIUM PHOSPHATE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],,0,0,,0,0,Glucocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.0935,0.48,1.0,0.988,0.000135,0.0,0.607,0.0694,0.0,0.525,0.0837,0.0,0.969,0.00113,0.0,0.395,0.15,0,0.85,0.0128,0.0,0.87,0.000513,0,-2.03,-2.9,-1.15,-2.9,-1.15,-5.357399999999995,0.741,0.0287,0.0,0.267,0.145,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,-4.5,L
CHEMBL1200974,CARBINOXAMINE MALEATE,CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.976,0.00329,0.0,0.569,0.121,0.0,0.976,0.00107,0.0,0.941,0.00503,0.0,0.906,0.00289,0.0,0.774,0.0408,0,0.882,0.0123,0.0,0.964,0.00656,0,-1.57,-2.6,-0.54,-2.6,-0.54,3.1144000000000007,0.606,0.0701,0.0,0.11,0.586,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,3.5,L
CHEMBL1200975,CLOCORTOLONE PIVALATE,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,,0,0,,0,0,Glucocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.587,0.0852,0.0,0.529,0.114,0.0,0.422,0.168,0.0,0.45,0.108,0.0,0.631,0.0331,0.0,0.538,0.0976,0,0.454,0.0683,0.0,0.0638,0.291,1,-4.92,-5.49,-4.35,-5.49,-4.35,4.595100000000004,0.277,0.378,0.5,0.024,0.983,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,-4.5,L
CHEMBL1200982,BUTABARBITAL SODIUM,CCC(C)C1(CC)C(=O)[N-]C(=O)NC1=O.[Na+],,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.115,0.396,1.0,0.975,0.0081,0.0,0.21,0.304,0.5,0.604,0.0572,0.0,0.836,0.011,0.0,0.892,0.0228,0,0.617,0.0418,0.0,0.799,0.0403,0,-1.29,-1.87,-0.707,-1.87,-0.707,-1.4169999999999978,0.393,0.24,0.0,0.042,0.844,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-5.0,L
CHEMBL1200986,HALOPERIDOL DECANOATE,CCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.529,0.0937,0.0,0.178,0.371,1.0,0.881,0.0106,0.0,0.895,0.0106,0.0,0.204,0.214,0.5,0.00494,0.863,1,0.973,0.00297,0.0,0.00937,0.612,1,-8.7,-9.76,-7.65,-9.76,-7.65,8.11720000000001,0.0172,0.996,1.0,0.0358,0.908,1,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-10.0,L
CHEMBL1200987,EPROSARTAN MESYLATE,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1.CS(=O)(=O)O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,Type-1 angiotensin II receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.963,0.00434,0.0,0.987,0.00138,0.0,0.683,0.0547,0.0,0.908,0.0113,0.0,0.866,0.00595,0.0,0.392,0.148,0,0.974,0.00089,0.0,0.715,0.0336,0,-2.39,-3.08,-1.7,-3.08,-1.7,4.248400000000002,0.542,0.0981,0.0,0.083,0.627,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,3.0,L
CHEMBL1200988,METHANTHELINE BROMIDE,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21.[Br-],,0,0,R-HSA-418555|G alpha (s) signalling events,1,0,Histamine H2 receptor antagonist,1.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,1.0,0.507,0.101,0.0,0.0313,0.694,1.0,0.425,0.134,0.0,0.479,0.0967,0.0,0.116,0.314,1.0,0.824,0.0269,0,0.279,0.126,0.0,0.415,0.134,0,-0.77,-1.26,-0.279,-1.26,-0.279,0.9577999999999997,0.127,0.608,1.0,0.737,0.00893,0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,0.0,L
CHEMBL1200989,ALCLOMETASONE DIPROPIONATE,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.302,0.208,0.0,0.502,0.142,0.0,0.702,0.047,0.0,0.505,0.0875,0.0,0.473,0.0615,0.0,0.268,0.195,0,0.707,0.039,0.0,0.641,0.0521,0,-3.14,-3.83,-2.45,-3.83,-2.45,3.942700000000003,0.19,0.534,1.0,0.044,0.917,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,6.5,L
CHEMBL1201,THIOTHIXENE,CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.0976,0.466,1.0,0.0328,0.679,1.0,0.867,0.00899,0.0,0.546,0.0684,0.0,0.437,0.0715,0.0,0.00447,0.874,1,0.741,0.03,0.0,0.0514,0.281,1,-3.38,-4.11,-2.65,-4.11,-2.65,3.4707000000000026,0.217,0.533,1.0,0.0865,0.588,1,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,-9.5,L
CHEMBL1201006,PYRILAMINE MALEATE,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1.O=C(O)/C=C\C(=O)O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.851,0.023,0.0,0.611,0.0937,0.0,0.836,0.0136,0.0,0.92,0.0095,0.0,0.974,0.00305,0.0,0.0395,0.494,1,0.9,0.00932,0.0,0.966,0.00805,0,-2.1,-3.09,-1.11,-3.09,-1.11,2.3702000000000005,0.222,0.453,1.0,0.72,0.0116,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,L
CHEMBL1201010,FLUDROCORTISONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,,0,0,,0,0,Mineralocorticoid receptor agonist,,,1,1,known_drugs;mechanism_drug_candidate;mechanism_of_actions,1.5,0.631,0.06,0.0,0.527,0.114,0.0,0.426,0.134,0.0,0.7,0.0398,0.0,0.763,0.0141,0.0,0.337,0.175,0,0.51,0.0607,0.0,0.284,0.114,0,-4.3,-4.79,-3.8,-4.79,-3.8,2.444500000000001,0.472,0.147,0.0,0.0649,0.673,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,-0.5,L
CHEMBL1201011,QUINAPRIL HYDROCHLORIDE,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O.Cl,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,Angiotensin-converting enzyme inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.685,0.0503,0.0,0.345,0.206,0.5,0.436,0.13,0.0,0.218,0.248,0.5,0.372,0.0934,0.0,0.832,0.0278,0,0.813,0.0243,0.0,0.22,0.163,0,-2.1,-2.75,-1.45,-2.75,-1.45,2.9889000000000014,0.658,0.0473,0.0,0.016,0.973,1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,3.5,L
CHEMBL1201012,FLURANDRENOLIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.326,0.213,0.5,0.723,0.0678,0.0,0.622,0.0698,0.0,0.769,0.0272,0.0,0.71,0.0197,0.0,0.206,0.238,1,0.41,0.0818,0.0,0.906,0.0226,0,-3.62,-4.62,-2.63,-4.62,-2.63,2.498700000000001,0.641,0.0726,0.0,0.0808,0.664,1,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,-2.5,L
CHEMBL1201013,OLSALAZINE SODIUM,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+],PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.875,0.0168,0.0,0.995,0.00433,0.0,0.507,0.0998,0.0,0.248,0.235,0.5,0.968,0.00294,0.0,0.842,0.0281,0,0.0322,0.681,1.0,0.78,0.0543,0,-2.66,-3.63,-1.7,-3.63,-1.7,-5.751799999999998,0.995,0.00625,0.0,0.651,0.0152,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,5.5,L
CHEMBL1201014,PREDNISOLONE SODIUM PHOSPHATE,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.0867,0.464,1.0,0.984,0.00327,0.0,0.586,0.0745,0.0,0.492,0.0905,0.0,0.951,0.00249,0.0,0.408,0.138,0,0.859,0.0117,0.0,0.844,0.0125,0,-1.96,-2.54,-1.37,-2.54,-1.37,-5.581399999999994,0.686,0.0369,0.0,0.054,0.788,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,2.0,L
CHEMBL1201023,ORPHENADRINE HYDROCHLORIDE,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-416476|G alpha (q) signalling events;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",10,0,Glutamate [NMDA] receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.49,0.108,0.0,0.0283,0.707,1.0,0.705,0.0496,0.0,0.163,0.354,1.0,0.697,0.0205,0.0,0.537,0.0978,0,0.615,0.0433,0.0,0.904,0.00171,0,-1.76,-2.41,-1.11,-2.41,-1.11,4.084420000000004,0.404,0.151,0.0,0.00233,0.993,1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,1.5,L
CHEMBL1201044,DAPIPRAZOLE HYDROCHLORIDE,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1.Cl,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.364,0.178,0.0,0.328,0.232,0.5,0.534,0.107,0.0,0.503,0.0886,0.0,0.707,0.0212,0.0,0.0758,0.369,1,0.372,0.106,0.0,0.0843,0.262,1,-1.99,-3.46,-0.523,-3.46,-0.523,2.7093200000000013,0.307,0.299,0.5,0.0225,0.975,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,-3.0,L
CHEMBL1201047,ANILERIDINE HYDROCHLORIDE,CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1.Cl,,0,0,,0,0,Mu opioid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.634,0.0645,0.0,0.301,0.261,0.5,0.944,0.00598,0.0,0.79,0.0288,0.0,0.213,0.185,0.5,0.964,0.00858,0,0.232,0.156,0.0,0.6,0.0932,0,-2.71,-3.54,-1.88,-3.54,-1.88,3.8300000000000023,0.181,0.55,1.0,0.0241,0.991,1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-1.5,L
CHEMBL1201051,CIMETIDINE HYDROCHLORIDE,CN/C(=N\CCSCc1nc[nH]c1C)NC#N.Cl,,0,0,,0,0,Histamine H2 receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.347,0.181,0.0,0.776,0.0535,0.0,0.607,0.0702,0.0,0.136,0.4,1.0,0.0505,0.49,1.0,0.413,0.129,0,0.443,0.0774,0.0,0.421,0.128,0,-0.946,-1.83,-0.0649,-1.83,-0.0649,1.0192,0.686,0.0629,0.0,0.27,0.152,0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,-2.0,L
CHEMBL1201052,MESORIDAZINE BESYLATE,CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21.O=S(=O)(O)c1ccccc1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.863,0.0163,0.0,0.0049,0.86,1.0,0.682,0.0467,0.0,0.259,0.207,0.5,0.407,0.0827,0.0,0.00144,0.954,1,0.882,0.0133,0.0,0.412,0.107,0,-2.61,-3.61,-1.61,-3.61,-1.61,5.834400000000006,0.353,0.248,0.0,0.142,0.388,1,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-9.0,L
CHEMBL1201060,LOXAPINE HYDROCHLORIDE,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1.Cl,,0,0,,0,0,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.794,0.0281,0.0,0.0536,0.592,1.0,0.802,0.0247,0.0,0.715,0.0419,0.0,0.0703,0.421,1.0,0.0661,0.41,1,0.472,0.0701,0.0,0.000493,0.68,1,-3.87,-4.61,-3.13,-4.61,-3.13,4.1932000000000045,0.205,0.53,1.0,0.000581,0.984,1,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-7.5,L
CHEMBL1201064,FLUOROMETHOLONE ACETATE,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,,0,0,,0,0,Glucocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.541,0.09,0.0,0.412,0.172,0.0,0.333,0.203,0.5,0.706,0.0404,0.0,0.581,0.0382,0.0,0.275,0.196,0,0.779,0.0266,0.0,0.566,0.0916,0,-5.35,-5.9,-4.79,-5.9,-4.79,3.494100000000002,0.306,0.32,0.5,0.0341,0.966,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-3.5,L
CHEMBL1201065,THIAMYLAL SODIUM,C=CCC1(C(C)CCC)C(=O)[N-]C(=S)NC1=O.[Na+],,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.131,0.427,1.0,0.969,0.0121,0.0,0.116,0.457,1.0,0.212,0.26,0.5,0.717,0.0277,0.0,0.7,0.0599,0,0.716,0.038,0.0,0.901,0.0367,0,-2.68,-3.4,-1.96,-3.4,-1.96,-0.6958999999999984,0.14,0.642,1.0,0.0737,0.696,1,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-5.0,L
CHEMBL1201071,TETRACYCLINE PHOSPHATE COMPLEX,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12.O=P(O)(O)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.909,0.0109,0.0,0.702,0.0742,0.0,0.479,0.106,0.0,0.521,0.0825,0.0,0.719,0.0181,0.0,0.671,0.0632,0,0.783,0.0286,0.0,0.771,0.0374,0,-2.73,-3.8,-1.67,-3.8,-1.67,-1.142999999999998,0.916,0.00344,0.0,0.455,0.0361,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.5,L
CHEMBL1201081,METHYLPREDNISOLONE SODIUM SUCCINATE,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[Na+],NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.767,0.0351,0.0,0.988,0.00441,0.0,0.785,0.0243,0.0,0.795,0.0233,0.0,0.923,0.00405,0.0,0.834,0.0281,0,0.816,0.0267,0.0,0.0402,0.413,1,-2.84,-3.57,-2.1,-3.57,-2.1,-2.1113999999999935,0.731,0.0385,0.0,0.0229,0.995,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,6.0,L
CHEMBL1201089,DIPHENHYDRAMINE CITRATE,CN(C)CCOC(c1ccccc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.981,0.00379,0.0,0.0365,0.671,1.0,0.671,0.0542,0.0,0.66,0.0548,0.0,0.894,0.00761,0.0,0.00599,0.836,1,0.872,0.0161,0.0,0.99,0.0104,0,-2.18,-3.06,-1.3,-3.06,-1.3,2.1056999999999997,0.981,0.00395,0.0,0.0888,0.662,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-3.5,L
CHEMBL1201099,CODEINE PHOSPHATE,,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL1201101,TESTOSTERONE CYPIONATE,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.536,0.0953,0.0,0.56,0.107,0.0,0.836,0.0126,0.0,0.236,0.244,0.5,0.891,0.00446,0.0,0.219,0.229,1,0.414,0.0751,0.0,0.0236,0.303,1,-7.16,-8.99,-5.33,-8.99,-5.33,6.400500000000007,0.149,0.543,1.0,0.42,0.0329,0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,-5.0,L
CHEMBL1201103,METHOXAMINE HYDROCHLORIDE,COc1ccc(OC)c(C(O)C(C)N)c1.Cl,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.176,0.346,1.0,0.497,0.15,0.0,0.39,0.146,0.0,0.483,0.104,0.0,0.136,0.277,1.0,0.138,0.292,1,0.631,0.0426,0.0,0.793,0.0354,0,-0.716,-1.42,-0.00922,-1.42,-0.00922,1.5062,0.423,0.171,0.0,0.0994,0.604,1,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,1.0,1.0,-7.0,L
CHEMBL1201109,DESONIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.287,0.226,0.5,0.668,0.0783,0.0,0.706,0.0456,0.0,0.737,0.0372,0.0,0.507,0.0509,0.0,0.195,0.25,1,0.412,0.0838,0.0,0.92,0.0155,0,-3.36,-4.18,-2.53,-4.18,-2.53,2.326700000000001,0.584,0.0987,0.0,0.147,0.436,1,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,-2.5,L
CHEMBL1201120,REMIFENTANIL HYDROCHLORIDE,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1.Cl,,0,0,,0,0,Mu opioid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.828,0.0219,0.0,0.286,0.25,0.5,0.877,0.0123,0.0,0.896,0.0118,0.0,0.195,0.214,0.5,0.0329,0.525,1,0.99,0.00315,0.0,0.129,0.226,1,-1.62,-2.98,-0.27,-2.98,-0.27,2.422100000000001,0.12,0.854,1.0,0.0254,0.984,1,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,0.0,1.0,-6.5,L
CHEMBL1201124,KETOROLAC TROMETHAMINE,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.942,0.00541,0.0,0.551,0.127,0.0,0.557,0.0837,0.0,0.373,0.141,0.0,0.738,0.0176,0.0,0.933,0.0152,0,0.501,0.0676,0.0,0.768,0.0418,0,-1.53,-2.15,-0.914,-2.15,-0.914,-0.0482,0.703,0.0373,0.0,0.664,0.0099,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,H
CHEMBL1201127,DARUNAVIR ETHANOLATE,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1.CCO,,0,0,,0,0,Human immunodeficiency virus type 1 protease inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.624,0.063,0.0,0.101,0.427,1.0,0.961,0.00396,0.0,0.215,0.252,0.5,0.445,0.0724,0.0,0.117,0.323,1,0.949,0.00729,0.0,0.876,0.0243,0,-3.24,-3.74,-2.74,-3.74,-2.74,2.3739000000000012,0.0715,0.834,1.0,0.213,0.156,0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,2.0,0.0,1.0,-6.0,L
CHEMBL1201132,NALBUPHINE HYDROCHLORIDE,Cl.Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.497,0.103,0.0,0.257,0.283,0.5,0.496,0.0994,0.0,0.434,0.114,0.0,0.648,0.0294,0.0,0.136,0.3,1,0.577,0.0406,0.0,0.919,0.00461,0,-2.32,-4.3,-0.328,-4.3,-0.328,2.1290999999999993,0.5,0.109,0.0,0.00627,0.974,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-0.5,L
CHEMBL1201141,IBUPROFEN LYSINE,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.889,0.0129,0.0,0.882,0.0212,0.0,0.763,0.0317,0.0,0.827,0.0178,0.0,0.973,0.000618,0.0,0.966,0.00481,0,0.201,0.181,0.0,0.963,0.00544,0,-2.12,-2.85,-1.4,-2.85,-1.4,2.6005,0.971,0.00206,0.0,0.678,0.0145,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,9.5,H
CHEMBL1201148,MEPREDNISONE,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,4.0,0.625,0.0706,0.0,0.632,0.0914,0.0,0.777,0.0215,0.0,0.483,0.0932,0.0,0.652,0.0299,0.0,0.503,0.113,0,0.475,0.0684,0.0,0.333,0.15,0,-3.44,-4.18,-2.71,-4.18,-2.71,2.0118000000000005,0.488,0.149,0.0,0.832,0.00376,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,3.5,L
CHEMBL1201149,NALTREXONE HYDROCHLORIDE,Cl.O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,Terminated,0,0,pathway_drug_candidates,6.0,0.441,0.13,0.0,0.166,0.392,1.0,0.354,0.174,0.0,0.507,0.0937,0.0,0.786,0.0143,0.0,0.131,0.301,1,0.742,0.0293,0.0,0.819,0.0319,0,-3.02,-4.41,-1.63,-4.41,-1.63,1.9472,0.294,0.291,0.5,0.0177,0.977,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-0.5,L
CHEMBL1201155,LOXAPINE SUCCINATE,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1.O=C(O)CCC(=O)O,,0,0,,0,0,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.986,0.00302,0.0,0.379,0.217,0.5,0.91,0.00843,0.0,0.956,0.00373,0.0,0.392,0.084,0.0,0.746,0.0429,0,0.853,0.0167,0.0,0.0052,0.542,1,-3.67,-4.46,-2.88,-4.46,-2.88,3.707200000000002,0.69,0.0374,0.0,0.0574,0.704,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,-3.0,L
CHEMBL1201159,FENTANYL HYDROCHLORIDE,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.Cl,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,3.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,5.0,0.954,0.00694,0.0,0.157,0.361,1.0,0.755,0.0411,0.0,0.741,0.0329,0.0,0.447,0.0628,0.0,0.00705,0.814,1,0.996,0.00109,0.0,0.0291,0.384,1,-3.34,-4.7,-1.97,-4.7,-1.97,4.558500000000005,0.264,0.327,0.5,0.00874,0.987,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,-4.0,L
CHEMBL1201163,SUFENTANIL CITRATE,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.986,0.00422,0.0,0.0885,0.49,1.0,0.94,0.00533,0.0,0.963,0.00586,0.0,0.288,0.148,0.0,0.00116,0.956,1,0.993,0.00233,0.0,0.186,0.165,0,-3.12,-3.92,-2.31,-3.92,-2.31,2.9663000000000004,0.709,0.0445,0.0,0.0444,0.8,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-0.5,L
CHEMBL1201167,CARVEDILOL PHOSPHATE,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12.O=P(O)(O)O,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.13,0.414,1.0,0.0773,0.511,1.0,0.796,0.0252,0.0,0.249,0.219,0.5,0.0956,0.419,1.0,0.00529,0.841,1,0.803,0.0149,0.0,0.95,0.00333,0,-4.11,-4.95,-3.27,-4.95,-3.27,2.8094000000000015,0.0072,0.955,1.0,0.197,0.22,1,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,4.0,1.0,1.0,-7.5,L
CHEMBL1201173,MEDRYSONE,CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.394,0.161,0.0,0.47,0.144,0.0,0.439,0.125,0.0,0.719,0.041,0.0,0.445,0.0633,0.0,0.413,0.134,0,0.664,0.037,0.0,0.0561,0.323,1,-3.62,-4.42,-2.81,-4.42,-2.81,3.9403000000000032,0.392,0.197,0.0,0.104,0.438,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,4.0,L
CHEMBL1201174,SITAGLIPTIN PHOSPHATE,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O.O=P(O)(O)O,,0,0,,0,0,Dipeptidyl peptidase IV inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.453,0.122,0.0,0.144,0.42,1.0,0.0137,0.899,1.0,0.63,0.0543,0.0,0.61,0.036,0.0,0.709,0.0507,0,0.563,0.0487,0.0,0.437,0.11,0,-1.51,-2.45,-0.564,-2.45,-0.564,0.2631999999999995,0.388,0.205,0.0,0.0827,0.638,1,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-2.5,L
CHEMBL1201180,DICLOFENAC EPOLAMINE,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.888,0.0137,0.0,0.665,0.092,0.0,0.46,0.12,0.0,0.925,0.00994,0.0,0.363,0.0976,0.0,0.969,0.00738,0,0.807,0.0243,0.0,0.833,0.0308,0,-2.23,-4.71,0.256,-4.71,0.256,4.438600000000004,0.745,0.0259,0.0,0.144,0.367,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,9.0,H
CHEMBL1201187,MARAVIROC,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,,0,0,R-HSA-173107|Binding and entry of HIV virion;R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,4,2,,4.0,Completed,0,0,pathway_drug_candidates,8.0,0.571,0.0707,0.0,0.113,0.453,1.0,0.576,0.0783,0.0,0.646,0.0535,0.0,0.974,0.00204,0.0,0.732,0.0495,0,0.743,0.0301,0.0,0.26,0.169,0,-3.44,-3.94,-2.93,-3.94,-2.93,5.950920000000006,0.238,0.485,1.0,0.151,0.379,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,6.5,L
CHEMBL1201190,LEVOCETIRIZINE DIHYDROCHLORIDE,Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.76,0.0402,0.0,0.556,0.134,0.0,0.836,0.0184,0.0,0.796,0.0278,0.0,0.894,0.00745,0.0,0.137,0.296,1,0.885,0.0159,0.0,0.999,0.0185,0,-1.86,-2.58,-1.13,-2.58,-1.13,3.991800000000003,0.759,0.0426,0.0,0.0764,0.726,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-1.5,L
CHEMBL1201191,LEVOCETIRIZINE,O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.714,0.0559,0.0,0.356,0.215,0.5,0.785,0.0352,0.0,0.802,0.0245,0.0,0.887,0.00735,0.0,0.166,0.263,1,0.884,0.0157,0.0,0.998,0.0176,0,-2.9,-3.55,-2.24,-3.55,-2.24,3.148200000000002,0.732,0.0567,0.0,0.729,0.0157,0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-3.0,L
CHEMBL1201202,FONDAPARINUX,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-8957275|Post-translational protein phosphorylation,4,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.998,0.000356,0.0,0.948,0.00567,0.0,0.954,0.00353,0.0,0.978,0.00245,0.0,0.997,0.000313,0.0,0.173,0.263,1,0.981,0.00206,0.0,0.96,0.00276,0,3.59,3.2,3.97,2.14,2.14,-13.750099999999994,0.966,0.00104,0.0,0.904,0.00118,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.0,L
CHEMBL1201207,BETAMETHASONE PHOSPHORIC ACID,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,3.0,Terminated,0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.432,0.13,0.0,0.471,0.155,0.0,0.441,0.129,0.0,0.463,0.0982,0.0,0.778,0.0147,0.0,0.14,0.287,1,0.863,0.0123,0.0,0.309,0.13,0,-4.05,-5.01,-3.08,-5.01,-3.08,2.0127000000000006,0.668,0.0562,0.0,0.343,0.0635,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.0,L
CHEMBL1201212,MIDODRINE,COc1ccc(OC)c(C(O)CNC(=O)CN)c1,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0562,0.571,1.0,0.357,0.209,0.5,0.436,0.125,0.0,0.47,0.102,0.0,0.06,0.453,1.0,0.355,0.155,0,0.146,0.261,1.0,0.347,0.122,0,-1.61,-2.54,-0.683,-2.54,-0.683,-0.1878999999999994,0.55,0.0962,0.0,0.332,0.0726,0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,3.0,1.0,1.0,-4.0,L
CHEMBL1201216,DAPIPRAZOLE,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.3,0.208,0.0,0.228,0.307,0.5,0.458,0.137,0.0,0.546,0.0781,0.0,0.691,0.0214,0.0,0.0875,0.346,1,0.37,0.105,0.0,0.0757,0.254,1,-2.68,-4.01,-1.35,-4.01,-1.35,2.2875200000000007,0.244,0.389,1.0,0.15,0.356,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,-2.0,L
CHEMBL1201231,PREDNISOLONE PHOSPHORIC ACID,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,3.0,Unknown status,0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.564,0.0888,0.0,0.421,0.173,0.0,0.46,0.118,0.0,0.437,0.111,0.0,0.669,0.0277,0.0,0.133,0.3,1,0.862,0.0141,0.0,0.86,0.0267,0,-3.46,-4.1,-2.83,-4.1,-2.83,1.6746,0.717,0.0423,0.0,0.188,0.333,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,-0.5,L
CHEMBL1201234,MEPHENTERMINE,CNC(C)(C)Cc1ccccc1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.424,0.139,0.0,0.0681,0.576,1.0,0.418,0.144,0.0,0.451,0.105,0.0,0.433,0.0724,0.0,0.368,0.157,0,0.955,0.0107,0.0,0.535,0.101,0,-1.79,-3.14,-0.444,-3.14,-0.444,2.2271,0.434,0.185,0.0,0.199,0.254,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,3.0,L
CHEMBL1201245,BROMODIPHENHYDRAMINE,CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.679,0.0528,0.0,0.0196,0.751,1.0,0.28,0.217,0.5,0.0596,0.573,1.0,0.705,0.0228,0.0,0.0785,0.369,1,0.96,0.00531,0.0,0.873,0.022,0,-3.42,-4.2,-2.64,-4.2,-2.64,4.116700000000003,0.487,0.123,0.0,0.0299,0.876,1,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,0.0,1.0,-5.0,L
CHEMBL1201262,DIPIVEFRIN,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.863,0.0184,0.0,0.956,0.00761,0.0,0.794,0.0278,0.0,0.791,0.0279,0.0,0.908,0.00436,0.0,0.862,0.0255,0,0.743,0.0256,0.0,0.0117,0.595,1,-3.62,-4.36,-2.89,-4.36,-2.89,2.842400000000002,0.562,0.1,0.0,0.735,0.0125,0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,2.5,L
CHEMBL1201264,METHANTHELINE,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21,,0,0,R-HSA-418555|G alpha (s) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.423,0.151,0.0,0.0369,0.681,1.0,0.42,0.137,0.0,0.459,0.103,0.0,0.127,0.301,1.0,0.84,0.0235,0,0.282,0.129,0.0,0.432,0.148,0,-1.65,-2.22,-1.09,-2.22,-1.09,3.953800000000003,0.155,0.674,1.0,0.706,0.0151,0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,3.0,L
CHEMBL1201265,METHYLPREDNISOLONE HEMISUCCINATE,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,3.0,Terminated,1,0,known_drugs;protein_drug_candidates;pathway_drug_candidates,6.5,0.934,0.00763,0.0,0.855,0.0328,0.0,0.757,0.0296,0.0,0.768,0.0249,0.0,0.768,0.0163,0.0,0.683,0.0564,0,0.813,0.0243,0.0,0.024,0.399,1,-3.82,-4.6,-3.03,-4.6,-3.03,2.2193000000000005,0.699,0.0331,0.0,0.00328,0.977,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,5.0,L
CHEMBL1201271,BUCLIZINE,CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.429,0.13,0.0,0.345,0.224,0.5,0.415,0.138,0.0,0.454,0.105,0.0,0.58,0.0402,0.0,0.0386,0.488,1,0.988,0.000977,0.0,0.0719,0.27,1,-6.06,-6.68,-5.44,-6.68,-5.44,6.544700000000008,0.196,0.527,1.0,0.109,0.432,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,-5.0,L
CHEMBL1201287,DEXBROMPHENIRAMINE,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.763,0.0317,0.0,0.0535,0.591,1.0,0.759,0.0446,0.0,0.555,0.0857,0.0,0.42,0.0781,0.0,0.342,0.168,0,0.881,0.0142,0.0,0.784,0.0467,0,-2.67,-3.76,-1.57,-3.76,-1.57,3.9277000000000024,0.366,0.278,0.5,0.708,0.02,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,2.0,L
CHEMBL1201293,ACAMPROSATE,CC(=O)NCCCS(=O)(=O)O,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,4.0,Completed,0,0,pathway_drug_candidates,4.0,0.917,0.00683,0.0,0.889,0.0237,0.0,0.878,0.0117,0.0,0.925,0.0092,0.0,0.431,0.0745,0.0,0.919,0.0139,0,0.445,0.0742,0.0,0.856,0.0339,0,-0.829,-2.42,0.759,-2.42,0.759,-0.5995999999999997,0.625,0.07,0.0,0.476,0.0348,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,L
CHEMBL1201294,DIPHENOXYLATE,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.133,0.352,1.0,0.0483,0.624,1.0,0.742,0.045,0.0,0.448,0.104,0.0,0.244,0.166,0.5,0.152,0.272,1,0.904,0.00825,0.0,0.315,0.143,0,-4.0,-4.84,-3.17,-4.84,-3.17,5.483280000000006,0.126,0.708,1.0,0.0528,0.876,1,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-6.5,L
CHEMBL1201302,DEXAMETHASONE PHOSPHORIC ACID,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,3.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.433,0.132,0.0,0.472,0.158,0.0,0.442,0.131,0.0,0.464,0.0995,0.0,0.779,0.0159,0.0,0.14,0.288,1,0.866,0.0142,0.0,0.322,0.14,0,-4.05,-5.01,-3.08,-5.01,-3.08,2.0127000000000006,0.691,0.0603,0.0,0.358,0.0681,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.0,L
CHEMBL1201319,METARAMINOL,C[C@H](N)[C@H](O)c1cccc(O)c1,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.507,0.096,0.0,0.764,0.0637,0.0,0.319,0.201,0.5,0.589,0.0683,0.0,0.307,0.13,0.0,0.446,0.128,0,0.373,0.0967,0.0,0.834,0.0542,0,-1.07,-1.77,-0.37,-1.77,-0.37,0.7728000000000002,0.71,0.0455,0.0,0.715,0.0152,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,2.5,L
CHEMBL1201346,BALSALAZIDE,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,3.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,9.0,0.984,0.00258,0.0,0.888,0.0226,0.0,0.814,0.0156,0.0,0.337,0.159,0.0,0.893,0.0044,0.0,0.921,0.015,0,0.158,0.239,1.0,0.871,0.0105,0,-2.8,-3.86,-1.73,-3.86,-1.73,2.7103,0.961,0.00041,0.0,0.672,0.00856,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,6.5,L
CHEMBL1201353,DEXCHLORPHENIRAMINE,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,3.0,Unknown status,0,0,pathway_drug_candidates,3.0,0.763,0.0326,0.0,0.0334,0.681,1.0,0.502,0.103,0.0,0.759,0.0383,0.0,0.096,0.361,1.0,0.205,0.235,1,0.873,0.0154,0.0,0.823,0.0349,0,-2.89,-3.71,-2.06,-3.71,-2.06,3.818600000000002,0.274,0.395,0.5,0.756,0.015,0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,-5.0,L
CHEMBL1201414,TINZAPARIN SODIUM,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-8957275|Post-translational protein phosphorylation,4,0,,4.0,Completed,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL1201421,PEGAPTANIB SODIUM,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1234158|Regulation of gene expression by Hypoxia-inducible Factor;R-HSA-194138|Signaling by VEGF;R-HSA-194313|VEGF ligand-receptor interactions;R-HSA-195399|VEGF binds to VEGFR leading to receptor dimerization;R-HSA-4420097|VEGFA-VEGFR2 Pathway;R-HSA-5218921|VEGFR2 mediated cell proliferation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9679191|Potential therapeutics for SARS,10,2,,4.0,,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL1201438,ALDESLEUKIN,,,0,0,,0,0,Interleukin-2 receptor agonist,,,1,1,known_drugs;mechanism_of_actions,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL1201460,DALTEPARIN SODIUM,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-8957275|Post-translational protein phosphorylation,4,0,,4.0,,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL1201476,ENOXAPARIN SODIUM,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-8957275|Post-translational protein phosphorylation,4,0,,4.0,,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL1201513,HEPARIN CALCIUM,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-8957275|Post-translational protein phosphorylation,4,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL1201534,DANAPAROID SODIUM,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-8957275|Post-translational protein phosphorylation,4,0,,4.0,,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL1201536,NICOTINE POLACRILEX,,,0,0,R-HSA-629587|Highly sodium permeable postsynaptic acetylcholine nicotinic receptors;R-HSA-629594|Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;R-HSA-629597|Highly calcium permeable nicotinic acetylcholine receptors,3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL1201554,ANTITHROMBIN ALFA,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,,4.0,,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL1201556,BECAPLERMIN,,,0,0,R-HSA-5673001|RAF/MAP kinase cascade,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL1201557,INTERFERON ALFACON-1,,,0,0,R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,5,2,,4.0,,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL1201558,INTERFERON ALFA-2B,,,0,0,R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,5,2,,4.0,,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL1201560,PEGINTERFERON ALFA-2A,,,0,0,R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,5,2,,4.0,,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL1201561,PEGINTERFERON ALFA-2B,,,0,0,R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,5,2,,4.0,,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL1201562,INTERFERON BETA-1A,,IFNAR1,1,0,R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,5,2,Interferon alpha/beta receptor agonist,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,11.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,12.5,H
CHEMBL1201563,INTERFERON BETA-1B,,,0,0,R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,5,2,,4.0,,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL1201570,ANAKINRA,,IL1R1,1,0,R-HSA-6783783|Interleukin-10 signaling;R-HSA-9020702|Interleukin-1 signaling;R-HSA-9679191|Potential therapeutics for SARS,3,2,Interleukin-1 receptor antagonist,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,11.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,12.5,H
CHEMBL1201572,ETANERCEPT,,TNF,1,1,R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,4,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.0,H
CHEMBL1201580,ADALIMUMAB,,TNF,1,1,R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,4,2,TNF-alpha inhibitor,4.0,Completed,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_of_actions,11.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,12.5,H
CHEMBL1201581,INFLIXIMAB,,TNF,1,1,R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,4,2,TNF-alpha inhibitor,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_of_actions,11.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,12.5,H
CHEMBL1201583,BEVACIZUMAB,,VEGFA,1,0,R-HSA-114608|Platelet degranulation;R-HSA-1234158|Regulation of gene expression by Hypoxia-inducible Factor;R-HSA-194138|Signaling by VEGF;R-HSA-194313|VEGF ligand-receptor interactions;R-HSA-195399|VEGF binds to VEGFR leading to receptor dimerization;R-HSA-4420097|VEGFA-VEGFR2 Pathway;R-HSA-5218921|VEGFR2 mediated cell proliferation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9679191|Potential therapeutics for SARS,10,2,Vascular endothelial growth factor A inhibitor,4.0,Completed,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,11.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,12.5,H
CHEMBL1201619,APROTININ,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4,1,,4.0,Completed,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL1201657,HEPARIN SODIUM,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-8957275|Post-translational protein phosphorylation,4,0,,4.0,,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.585,0.0929,0.0,0.825,0.0401,0.0,0.685,0.0526,0.0,0.642,0.057,0.0,0.429,0.0708,0.0,0.564,0.096,0,0.361,0.0959,0.0,0.546,0.0869,0,-2.0,-2.71,-1.29,-2.71,-1.29,3.560840000000001,0.144,0.633,1.0,0.0155,0.968,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,4.5,L
CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0237,0.71,1.0,0.404,0.187,0.0,0.0422,0.681,1.0,0.949,0.00259,0.0,0.172,0.253,0.5,0.821,0.0275,0,0.627,0.0516,0.0,0.153,0.23,1,-3.36,-4.15,-2.57,-4.15,-2.57,5.952940000000006,0.188,0.514,1.0,0.00534,0.969,1,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-2.5,L
CHEMBL1201743,SAXAGLIPTIN HYDROCHLORIDE,Cl.N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,,0,0,,0,0,Dipeptidyl peptidase IV inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.556,0.0862,0.0,0.649,0.073,0.0,0.361,0.189,0.0,0.33,0.172,0.0,0.0653,0.402,1.0,0.248,0.209,0,0.638,0.0519,0.0,0.256,0.156,0,-0.947,-1.68,-0.213,-1.68,-0.213,1.5797799999999995,0.563,0.105,0.0,0.0447,0.929,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-1.0,L
CHEMBL1201747,ALCAFTADINE,CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.539,0.1,0.0,0.132,0.401,1.0,0.43,0.129,0.0,0.265,0.212,0.5,0.597,0.0385,0.0,0.528,0.107,0,0.524,0.0573,0.0,0.0752,0.274,1,-2.78,-3.42,-2.13,-3.42,-2.13,2.7792000000000012,0.368,0.229,0.0,0.179,0.222,1,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,0.5,L
CHEMBL1201748,CABAZITAXEL,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,Tubulin inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.615,0.076,0.0,0.108,0.469,1.0,0.802,0.0206,0.0,0.825,0.0186,0.0,0.369,0.106,0.0,0.877,0.0238,0,0.344,0.114,0.0,0.165,0.202,1,-6.01,-7.26,-4.77,-7.26,-4.77,4.5678000000000045,0.0886,0.808,1.0,0.612,0.0216,0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,2.0,L
CHEMBL1201749,DIFLUPREDNATE,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.563,0.085,0.0,0.452,0.157,0.0,0.55,0.0932,0.0,0.737,0.0339,0.0,0.71,0.0241,0.0,0.727,0.0534,0,0.815,0.0248,0.0,0.447,0.119,0,-7.53,-8.07,-6.99,-8.07,-6.99,3.5195000000000025,0.242,0.427,1.0,0.0206,0.998,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,5.0,L
CHEMBL1201752,IXABEPILONE,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,Tubulin inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.533,0.113,0.0,0.523,0.128,0.0,0.0882,0.509,1.0,0.161,0.324,1.0,0.489,0.0542,0.0,0.712,0.0507,0,0.633,0.0376,0.0,0.29,0.138,0,-3.06,-3.45,-2.68,-3.45,-2.68,4.050520000000002,0.493,0.124,0.0,0.413,0.039,0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,3.0,L
CHEMBL1201753,PITAVASTATIN,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,,0,0,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.893,0.0131,0.0,0.61,0.0935,0.0,0.0417,0.69,1.0,0.672,0.048,0.0,0.603,0.0383,0.0,0.387,0.138,0,0.796,0.0251,0.0,0.481,0.12,0,-3.86,-4.33,-3.39,-4.33,-3.39,4.518100000000003,0.641,0.0561,0.0,0.124,0.397,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,L
CHEMBL1201758,BEPOTASTINE,O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.932,0.00693,0.0,0.452,0.172,0.0,0.954,0.00413,0.0,0.981,0.0018,0.0,0.539,0.0521,0.0,0.487,0.121,0,0.835,0.0202,0.0,0.986,0.0159,0,-1.86,-2.75,-0.976,-2.75,-0.976,4.170200000000004,0.714,0.0453,0.0,0.477,0.039,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.5,L
CHEMBL1201759,BEPOTASTINE BESYLATE,O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.972,0.00244,0.0,0.0488,0.617,1.0,0.961,5.52e-07,0.0,0.975,0.00107,0.0,0.703,0.0161,0.0,0.162,0.268,1,0.946,0.00637,0.0,0.978,3.38e-06,0,-0.11,-1.12,0.901,-1.12,0.901,5.103500000000005,0.673,0.0536,0.0,0.519,0.0242,0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-3.5,L
CHEMBL1201770,METHYLNALTREXONE BROMIDE,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-],,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.77,0.0288,0.0,0.259,0.274,0.5,0.425,0.13,0.0,0.697,0.0393,0.0,0.691,0.021,0.0,0.349,0.163,0,0.763,0.0249,0.0,0.717,0.0436,0,-1.17,-2.04,-0.296,-2.04,-0.296,-1.3259999999999974,0.298,0.274,0.5,0.208,0.189,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,4.0,L
CHEMBL1201772,PRASUGREL,CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2,,0,0,R-HSA-418594|G alpha (i) signalling events,1,0,,3.0,Completed,1,0,known_drugs;pathway_drug_candidates,4.5,0.148,0.34,1.0,0.122,0.457,1.0,0.26,0.24,0.5,0.735,0.036,0.0,0.191,0.223,0.5,0.752,0.047,0,0.206,0.194,0.5,0.0712,0.25,1,-4.3,-4.92,-3.67,-4.92,-3.67,3.891000000000003,0.399,0.219,0.0,0.121,0.405,1,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-7.0,L
CHEMBL1201773,PRASUGREL HYDROCHLORIDE,CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2.Cl,,0,0,R-HSA-418594|G alpha (i) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.187,0.311,1.0,0.158,0.349,1.0,0.309,0.189,0.0,0.742,0.0396,0.0,0.204,0.213,0.5,0.732,0.0518,0,0.209,0.196,0.5,0.0866,0.264,1,-3.62,-4.27,-2.97,-4.27,-2.97,4.312800000000005,0.509,0.15,0.0,0.0252,0.976,1,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-5.0,L
CHEMBL1201776,TAPENTADOL,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.422,0.16,0.0,0.177,0.333,1.0,0.447,0.117,0.0,0.564,0.0833,0.0,0.367,0.104,0.0,0.364,0.155,0,0.654,0.0426,0.0,0.551,0.0824,0,-1.99,-3.22,-0.756,-3.22,-0.756,3.0835000000000017,0.382,0.253,0.5,0.189,0.245,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,4.5,L
CHEMBL1201777,TAPENTADOL HYDROCHLORIDE,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C.Cl,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.475,0.126,0.0,0.278,0.271,0.5,0.521,0.09,0.0,0.547,0.0882,0.0,0.378,0.0925,0.0,0.331,0.17,0,0.655,0.0437,0.0,0.559,0.0888,0,-1.41,-2.73,-0.094,-2.73,-0.094,3.505300000000003,0.428,0.204,0.0,0.0182,0.957,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,4.5,L
CHEMBL1201782,FOSAPREPITANT DIMEGLUMINE,CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,,0,0,,0,0,Neurokinin 1 receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.939,0.00605,0.0,0.955,0.00974,0.0,0.46,0.109,0.0,0.837,0.0171,0.0,0.992,0.00101,0.0,0.95,0.00861,0,0.986,0.00151,0.0,0.293,0.16,0,-1.23,-1.6,-0.867,-1.6,-0.867,-2.3502999999999874,0.686,0.0391,0.0,0.088,0.625,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-1.0,L
CHEMBL1201823,ABATACEPT,,,0,0,,0,0,T-lymphocyte activation antigen CD80 inhibitor;T-lymphocyte activation antigen CD86 inhibitor,,,1,1,known_drugs;mechanism_of_actions,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL1201825,RANIBIZUMAB,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1234158|Regulation of gene expression by Hypoxia-inducible Factor;R-HSA-194138|Signaling by VEGF;R-HSA-194313|VEGF ligand-receptor interactions;R-HSA-195399|VEGF binds to VEGFR leading to receptor dimerization;R-HSA-4420097|VEGFA-VEGFR2 Pathway;R-HSA-5218921|VEGFR2 mediated cell proliferation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9679191|Potential therapeutics for SARS,10,2,,4.0,,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL1201828,ECULIZUMAB,,C5,1,0,R-HSA-166665|Terminal pathway of complement;R-HSA-174577|Activation of C3 and C5;R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-977606|Regulation of Complement cascade,5,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.0,H
CHEMBL1201830,RILONACEPT,,,0,0,R-HSA-448706|Interleukin-1 processing;R-HSA-5620971|Pyroptosis;R-HSA-5660668|CLEC7A/inflammasome pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9020702|Interleukin-1 signaling;R-HSA-9660826|Purinergic signaling in leishmaniasis infection,7,4,,4.0,,0,0,pathway_drug_candidates,12.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,12.0,H
CHEMBL1201831,CERTOLIZUMAB PEGOL,,TNF,1,1,R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,4,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.0,H
CHEMBL1201833,GOLIMUMAB,,TNF,1,1,R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,4,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.0,H
CHEMBL1201834,CANAKINUMAB,,IL1B,1,0,R-HSA-448706|Interleukin-1 processing;R-HSA-5620971|Pyroptosis;R-HSA-5660668|CLEC7A/inflammasome pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9020702|Interleukin-1 signaling;R-HSA-9660826|Purinergic signaling in leishmaniasis infection,7,4,Interleukin-1 beta inhibitor,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,15.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,16.5,H
CHEMBL1201891,DEFLAZACORT,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.599,0.0722,0.0,0.514,0.124,0.0,0.653,0.0617,0.0,0.7,0.044,0.0,0.499,0.0589,0.0,0.507,0.109,0,0.462,0.067,0.0,0.27,0.171,0.5,-3.96,-4.58,-3.34,-4.58,-3.34,2.5632,0.491,0.15,0.0,0.0397,0.738,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,4.5,L
CHEMBL1205,NELFINAVIR MESYLATE,CS(=O)(=O)O.Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,,0,0,,0,0,Human immunodeficiency virus type 1 protease inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.448,0.126,0.0,0.896,0.0234,0.0,0.22,0.286,0.5,0.296,0.182,0.0,0.688,0.0283,0.0,0.133,0.301,1,0.939,0.0103,0.0,0.0477,0.297,1,-1.6,-2.16,-1.04,-2.16,-1.04,4.251620000000003,0.429,0.159,0.0,0.449,0.0341,0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,-7.5,L
CHEMBL1206232,FOSBRETABULIN,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,3.0,Withdrawn,0,0,pathway_drug_candidates,5.0,0.148,0.353,1.0,0.553,0.118,0.0,0.49,0.112,0.0,0.632,0.0555,0.0,0.428,0.0715,0.0,0.69,0.0585,0,0.873,0.0139,0.0,0.771,0.0353,0,-4.47,-5.85,-3.09,-5.85,-3.09,3.3629000000000033,0.495,0.138,0.0,0.112,0.598,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,-0.5,L
CHEMBL1206690,PARECOXIB,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.509,0.111,0.0,0.628,0.0912,0.0,0.4,0.157,0.0,0.351,0.149,0.0,0.42,0.076,0.0,0.175,0.255,1,0.908,0.0127,0.0,0.634,0.0561,0,-4.19,-5.19,-3.19,-5.19,-3.19,3.531920000000002,0.591,0.103,0.0,0.316,0.109,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.5,L
CHEMBL1207366,GW468816,O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.453,0.147,0.0,0.315,0.23,0.5,0.282,0.224,0.5,0.235,0.257,0.5,0.0358,0.628,1.0,0.536,0.104,0,0.957,0.00761,0.0,0.267,0.168,0,-4.6,-5.34,-3.86,-5.34,-3.86,3.7993000000000023,0.465,0.192,0.0,0.136,0.398,1,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,4.0,0.0,1.0,-3.5,L
CHEMBL1213351,PROPOXYPHENE,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.108,0.473,1.0,0.0278,0.69,1.0,0.464,0.113,0.0,0.55,0.0894,0.0,0.395,0.086,0.0,0.349,0.164,0,0.972,0.00683,0.0,0.843,0.031,0,-4.7,-5.8,-3.6,-5.8,-3.6,4.275500000000004,0.226,0.46,1.0,0.0422,0.868,1,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,1.0,L
CHEMBL1215,PHENYLEPHRINE,CNC[C@H](O)c1cccc(O)c1,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.634,0.0624,0.0,0.739,0.0648,0.0,0.542,0.0866,0.0,0.755,0.0345,0.0,0.703,0.0237,0.0,0.84,0.0287,0,0.777,0.021,0.0,0.0238,0.341,1,-1.86,-3.0,-0.726,-3.0,-0.726,0.645,0.678,0.0364,0.0,0.567,0.0169,0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,2.5,L
CHEMBL122,ROFECOXIB,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.244,0.254,0.5,0.231,0.312,0.5,0.42,0.132,0.0,0.399,0.127,0.0,0.153,0.251,1.0,0.949,0.00857,0,0.713,0.0396,0.0,0.558,0.0648,0,-4.92,-6.22,-3.62,-6.22,-3.62,2.5577000000000005,0.437,0.196,0.0,0.0616,0.765,1,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,1.0,1.0,3.0,L
CHEMBL1224,ACRIVASTINE,Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.618,0.0533,0.0,0.474,0.147,0.0,0.751,0.038,0.0,0.0999,0.469,1.0,0.652,0.0275,0.0,0.0411,0.479,1,0.833,0.017,0.0,0.943,0.00654,0,-2.4,-3.4,-1.4,-3.4,-1.4,4.015320000000003,0.806,0.0168,0.0,0.0602,0.792,1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-3.0,L
CHEMBL1230609,FORETINIB,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.756,0.0275,0.0,0.497,0.135,0.0,0.8,0.0315,0.0,0.827,0.0198,0.0,0.911,0.00372,0.0,0.0969,0.344,1,0.0875,0.472,1.0,0.324,0.137,0,-5.35,-5.81,-4.89,-5.81,-4.89,5.772400000000005,0.25,0.502,1.0,0.0189,0.974,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,-7.0,L
CHEMBL1231124,AZD-1480,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;RMTs methylate histone arginines",21,9,,1.0,Terminated,0,0,pathway_drug_candidates,11.0,0.0972,0.467,1.0,0.109,0.446,1.0,0.183,0.37,1.0,0.353,0.159,0.0,0.328,0.129,0.0,0.915,0.0152,0,0.428,0.077,0.0,0.259,0.145,0,-3.48,-4.07,-2.89,-4.07,-2.89,3.00732,0.19,0.485,1.0,0.235,0.127,0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,1.0,1.0,6.5,L
CHEMBL1236936,CINACIGUAT,O=C(O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(C(=O)O)cc1,,0,0,R-HSA-445355|Smooth Muscle Contraction,1,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.935,0.00779,0.0,0.853,0.0257,0.0,0.199,0.294,1.0,0.556,0.0743,0.0,0.616,0.0368,0.0,0.653,0.0651,0,0.953,0.00538,0.0,0.917,0.00355,0,-4.56,-8.65,-0.467,-8.65,-0.467,7.0486000000000075,0.908,0.00134,0.0,0.182,0.265,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-2.5,L
CHEMBL1237,LISINOPRIL ANHYDROUS,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,,3.0,Withdrawn,0,0,pathway_drug_candidates,5.0,0.926,0.00839,0.0,0.786,0.0467,0.0,0.828,0.026,0.0,0.762,0.032,0.0,0.855,0.00843,0.0,0.994,0.00131,0,0.94,0.0141,0.0,0.618,0.0931,0,-0.218,-0.87,0.433,-0.87,0.433,1.2352000000000007,0.957,0.00669,0.0,0.306,0.108,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,L
CHEMBL1237022,TOCILIZUMAB,,IL6R,1,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9616222|Transcriptional regulation of granulopoiesis;R-HSA-9679191|Potential therapeutics for SARS,6,2,Interleukin-6 receptor alpha subunit inhibitor,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_of_actions,11.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,12.5,H
CHEMBL1237044,TRAMADOL,COc1cccc(C2(O)CCCCC2CN(C)C)c1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,Recruiting,0,0,pathway_drug_candidates,6.0,0.408,0.151,0.0,0.088,0.505,1.0,0.752,0.0318,0.0,0.472,0.101,0.0,0.776,0.02,0.0,0.542,0.11,0,0.379,0.0855,0.0,0.17,0.186,1,-2.67,-3.4,-1.94,-3.4,-1.94,2.6346000000000007,0.198,0.617,1.0,0.16,0.418,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,5.0,L
CHEMBL1237055,HYDROMORPHONE HYDROCHLORIDE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5.Cl,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.745,0.0356,0.0,0.222,0.315,0.5,0.351,0.181,0.0,0.245,0.245,0.5,0.49,0.0462,0.0,0.0985,0.356,1,0.736,0.029,0.0,0.916,0.00191,0,-1.61,-2.74,-0.477,-2.74,-0.477,2.0521,0.275,0.301,0.5,0.0026,0.969,1,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-1.0,L
CHEMBL1237061,PITAVASTATIN CALCIUM,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Ca+2],,0,0,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,HMG-CoA reductase inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.966,0.00358,0.0,0.812,0.0443,0.0,0.0186,0.853,1.0,0.853,0.016,0.0,0.8,0.0149,0.0,0.562,0.084,0,0.906,0.00945,0.0,0.575,0.0937,0,-5.38,-5.74,-5.03,-5.74,-5.03,5.986000000000008,0.645,0.0638,0.0,0.0617,0.813,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-0.5,L
CHEMBL1237065,TRAMADOL HYDROCHLORIDE,COc1cccc(C2(O)CCCCC2CN(C)C)c1.Cl,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.462,0.121,0.0,0.124,0.422,1.0,0.806,0.0224,0.0,0.446,0.109,0.0,0.783,0.0166,0.0,0.511,0.118,0,0.376,0.0836,0.0,0.158,0.175,1,-1.95,-2.73,-1.16,-2.73,-1.16,3.0564000000000022,0.215,0.477,1.0,0.00672,0.966,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,5.0,L
CHEMBL1237072,DIRITHROMYCIN,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.848,0.0208,0.0,0.622,0.104,0.0,0.912,0.0108,0.0,0.818,0.0215,0.0,0.876,0.00644,0.0,0.49,0.115,0,0.853,0.0112,0.0,0.555,0.0662,0,-0.86,-1.41,-0.305,-1.41,-0.305,2.201700000000009,0.45,0.179,0.0,0.757,0.0122,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,L
CHEMBL1237102,LEVOCABASTINE HYDROCHLORIDE,C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1.Cl,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.593,0.0889,0.0,0.146,0.408,1.0,0.534,0.0845,0.0,0.455,0.103,0.0,0.458,0.0674,0.0,0.134,0.301,1,0.865,0.0142,0.0,0.375,0.113,0,-3.27,-3.92,-2.61,-3.92,-2.61,5.315880000000006,0.448,0.189,0.0,0.0248,0.971,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-5.0,L
CHEMBL1237104,PROPOXYPHENE HYDROCHLORIDE,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.Cl,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.131,0.408,1.0,0.044,0.633,1.0,0.539,0.0858,0.0,0.536,0.0941,0.0,0.415,0.0822,0.0,0.321,0.177,0,0.973,0.00758,0.0,0.849,0.0355,0,-4.03,-5.21,-2.85,-5.21,-2.85,4.697300000000006,0.275,0.374,0.5,0.0226,0.999,1,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-1.5,L
CHEMBL1241,TRIPELENNAMINE,CN(C)CCN(Cc1ccccc1)c1ccccn1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.552,0.0902,0.0,0.0482,0.611,1.0,0.578,0.0707,0.0,0.259,0.206,0.5,0.57,0.0395,0.0,0.0914,0.356,1,0.803,0.0222,0.0,0.912,0.0278,0,-2.5,-3.31,-1.68,-3.31,-1.68,2.649800000000001,0.162,0.665,1.0,0.493,0.0362,0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,2.0,0.0,1.0,-2.0,L
CHEMBL124660,TANDUTINIB,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.246,0.248,0.5,0.0654,0.503,1.0,0.805,0.0234,0.0,0.837,0.0152,0.0,0.404,0.0805,0.0,0.00107,0.965,1,0.983,0.00196,0.0,0.252,0.153,0,-4.54,-5.35,-3.73,-5.35,-3.73,5.034500000000005,0.13,0.594,1.0,0.0789,0.658,1,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,-9.0,L
CHEMBL1255582,FIPAMEZOLE,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.0745,0.536,1.0,0.161,0.386,1.0,0.293,0.208,0.5,0.519,0.0879,0.0,0.147,0.24,1.0,0.366,0.155,0,0.687,0.0384,0.0,0.0993,0.218,1,-2.97,-3.79,-2.14,-3.79,-2.14,2.995400000000002,0.463,0.154,0.0,0.141,0.276,1,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,4.0,1.0,1.0,-5.5,L
CHEMBL1255794,APLAVIROC,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2,,0,0,R-HSA-173107|Binding and entry of HIV virion;R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,4,2,,3.0,Terminated,0,0,pathway_drug_candidates,7.0,0.138,0.407,1.0,0.792,0.0431,0.0,0.297,0.206,0.5,0.896,0.00797,0.0,0.995,0.000461,0.0,0.0411,0.495,1,0.874,0.0118,0.0,0.424,0.108,0,-6.15,-6.67,-5.63,-6.67,-5.63,4.580000000000004,0.729,0.023,0.0,0.0824,0.658,1,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-5.5,L
CHEMBL1256,ISOFLURANE,FC(F)OC(Cl)C(F)(F)F,GABRA1;KCNK10;KCNK18;KCNK3;KCNK9,5,5,R-HSA-112314|Neurotransmitter receptors and postsynaptic signal transmission;R-HSA-1299316|TWIK-releated acid-sensitive K+ channel (TASK);R-HSA-1299503|TWIK related potassium channel (TREK);R-HSA-5576886|Phase 4 - resting membrane potential,4,0,GABA-A receptor; anion channel positive allosteric modulator;GABA-A receptor; anion channel positive allosteric modulator | Glycine receptor (alpha-1/beta) positive modulator | Potassium channel subfamily K member 10 opener | Potassium channel subfamily K member 18 opener | Potassium channel subfamily K member 2 opener | Potassium channel subfamily K member 3 opener | Potassium channel subfamily K member 9 opener;Glycine receptor (alpha-1/beta) positive modulator;Potassium channel subfamily K member 10 opener;Potassium channel subfamily K member 18 opener;Potassium channel subfamily K member 2 opener;Potassium channel subfamily K member 3 opener;Potassium channel subfamily K member 9 opener,3.0,Recruiting;Terminated;Withdrawn,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,14.5,0.282,0.235,0.5,0.101,0.484,1.0,0.138,0.43,1.0,0.218,0.25,0.5,0.232,0.175,0.5,0.0815,0.375,1,0.362,0.0966,0.0,0.287,0.148,0,-1.79,-2.61,-0.958,-2.61,-0.958,2.3528,0.434,0.174,0.0,0.0972,0.503,1,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,5.0,1.0,1.0,3.5,L
CHEMBL1256958,EPINEPHRINE BITARTRATE,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.811,0.0259,0.0,0.744,0.0599,0.0,0.916,0.00341,0.0,0.992,0.000231,0.0,0.861,0.00558,0.0,0.84,0.0296,0,0.752,0.0242,0.0,0.285,0.125,0,-0.293,-1.55,0.965,-1.55,0.965,-1.7719999999999998,0.859,0.00791,0.0,0.798,0.00491,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,L
CHEMBL1257,ENFLURANE,FC(F)OC(F)(F)C(F)Cl,,0,0,,0,0,Glycine receptor (alpha-1/beta) positive modulator | Potassium channel subfamily K member 10 opener | Potassium channel subfamily K member 18 opener | Potassium channel subfamily K member 2 opener | Potassium channel subfamily K member 3 opener | Potassium channel subfamily K member 9 opener,,,0,0,mechanism_drug_candidate,0.0,0.301,0.211,0.5,0.0998,0.489,1.0,0.117,0.469,1.0,0.247,0.228,0.5,0.28,0.144,0.0,0.0656,0.405,1,0.586,0.0536,0.0,0.297,0.157,0,-1.7,-2.5,-0.899,-2.5,-0.899,2.3528,0.524,0.113,0.0,0.122,0.452,1,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,4.0,1.0,1.0,-11.0,L
CHEMBL1257040,TRIFLUOPERAZINE HYDROCHLORIDE,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1.Cl.Cl,,0,0,,0,0,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.148,0.366,1.0,0.0372,0.654,1.0,0.93,0.00508,0.0,0.0841,0.551,1.0,0.387,0.0869,0.0,0.124,0.311,1,0.876,0.0132,0.0,0.014,0.481,1,-2.92,-4.37,-1.47,-4.37,-1.47,5.7892000000000055,0.251,0.465,0.5,0.0166,0.997,1,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-13.0,L
CHEMBL1259059,SOFOSBUVIR,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,,0,0,,0,0,RNA-directed RNA polymerase inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.595,0.0766,0.0,0.198,0.329,1.0,0.0185,0.881,1.0,0.142,0.36,1.0,0.702,0.0245,0.0,0.511,0.0998,0,0.673,0.0412,0.0,0.697,0.0552,0,-1.63,-2.01,-1.26,-2.01,-1.26,1.6565000000000003,0.732,0.0423,0.0,0.203,0.233,0.5,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.5,3.0,0.0,1.0,-3.0,L
CHEMBL126,LINEZOLID,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.929,0.00734,0.0,0.798,0.0446,0.0,0.837,0.0169,0.0,0.934,0.00752,0.0,0.839,0.00965,0.0,0.927,0.0114,0,0.319,0.0924,0.0,0.817,0.0284,0,-3.27,-4.25,-2.28,-4.25,-2.28,1.1235999999999997,0.34,0.288,0.5,0.0771,0.563,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,-0.5,L
CHEMBL12610,BENZYDAMINE,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.764,0.0324,0.0,0.0321,0.684,1.0,0.44,0.126,0.0,0.498,0.0927,0.0,0.323,0.112,0.0,0.95,0.013,0,0.35,0.0964,0.0,0.038,0.43,1,-3.35,-4.54,-2.16,-4.54,-2.16,3.4151000000000016,0.449,0.169,0.0,0.0453,0.893,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,7.0,M
CHEMBL1265,ADAPALENE,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2,,0,0,R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-5362517|Signaling by Retinoic Acid;R-HSA-5617472|Activation of anterior HOX genes in hindbrain development during early embryogenesis,3,0,Retinoic acid receptor agonist,4.0,Terminated,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.456,0.125,0.0,0.0435,0.612,1.0,0.682,0.0445,0.0,0.729,0.0341,0.0,0.0841,0.41,1.0,0.87,0.0245,0,0.8,0.0253,0.0,0.616,0.0649,0,-8.3,-9.47,-7.12,-9.47,-7.12,6.681400000000005,0.753,0.0246,0.0,0.14,0.392,1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-1.5,L
CHEMBL1266,TETRAHYDROZOLINE,c1ccc2c(c1)CCCC2C1=NCCN1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.43,0.146,0.0,0.034,0.683,1.0,0.54,0.0952,0.0,0.46,0.102,0.0,0.433,0.0758,0.0,0.447,0.128,0,0.153,0.261,1.0,0.804,0.0359,0,-3.18,-4.01,-2.35,-4.01,-2.35,2.1082,0.559,0.117,0.0,0.248,0.149,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.5,L
CHEMBL1269025,EDOXABAN,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,,4.0,,1,0,known_drugs;pathway_drug_candidates,5.5,0.742,0.0355,0.0,0.591,0.0919,0.0,0.844,0.014,0.0,0.142,0.357,1.0,0.779,0.013,0.0,0.197,0.241,1,0.86,0.0113,0.0,0.751,0.0577,0,-2.89,-3.37,-2.42,-3.37,-2.42,1.2896000000000014,0.0423,0.868,1.0,0.166,0.246,1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.5,L
CHEMBL127071,POZANICLINE,Cc1ncccc1OC[C@@H]1CCCN1,,0,0,R-HSA-629587|Highly sodium permeable postsynaptic acetylcholine nicotinic receptors;R-HSA-629594|Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;R-HSA-629597|Highly calcium permeable nicotinic acetylcholine receptors,3,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.593,0.0684,0.0,0.125,0.446,1.0,0.862,0.0125,0.0,0.187,0.283,1.0,0.154,0.267,1.0,0.434,0.13,0,0.365,0.102,0.0,0.582,0.0766,0,-0.412,-1.61,0.79,-1.61,0.79,1.5208199999999998,0.512,0.107,0.0,0.361,0.0612,0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,3.0,0.0,1.0,-1.0,L
CHEMBL12713,SERTINDOLE,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.445,0.137,0.0,0.482,0.155,0.0,0.42,0.118,0.0,0.66,0.0522,0.0,0.0645,0.466,1.0,0.684,0.0517,0,0.746,0.0298,0.0,0.0722,0.261,1,-4.76,-5.67,-3.86,-5.67,-3.86,4.627600000000004,0.219,0.451,1.0,0.0975,0.543,1,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,L
CHEMBL1274,NILUTAMIDE,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Androgen Receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.368,0.158,0.0,0.619,0.091,0.0,0.4,0.144,0.0,0.189,0.285,1.0,0.341,0.105,0.0,0.897,0.0226,0,0.7,0.0346,0.0,0.47,0.13,0,-3.29,-4.03,-2.55,-4.03,-2.55,2.4484000000000004,0.137,0.685,1.0,0.247,0.168,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,4.0,L
CHEMBL1276308,MIFEPRISTONE,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,6.0,0.0977,0.466,1.0,0.0341,0.679,1.0,0.19,0.337,1.0,0.0528,0.639,1.0,0.111,0.329,1.0,0.798,0.0327,0,0.511,0.054,0.0,0.0316,0.405,1,-6.26,-7.06,-5.47,-7.06,-5.47,5.406500000000006,0.57,0.0924,0.0,0.354,0.0524,0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,5.0,1.0,1.0,-4.5,L
CHEMBL1278146,FAMITINIB,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.467,0.139,0.0,0.555,0.113,0.0,0.349,0.166,0.0,0.15,0.353,1.0,0.23,0.193,0.5,0.606,0.0798,0,0.351,0.101,0.0,0.179,0.186,0.5,-3.45,-4.19,-2.72,-4.19,-2.72,3.295020000000001,0.0738,0.895,1.0,0.0729,0.781,1,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,0.5,L
CHEMBL1282,IMIQUIMOD,CC(C)Cn1cnc2c(N)nc3ccccc3c21,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-168181|Toll Like Receptor 7/8 (TLR7/8) Cascade;R-HSA-5686938|Regulation of TLR by endogenous ligand;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9692916|SARS-CoV-1 activates/modulates innate immune responses;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome;R-HSA-9824856|Defective regulation of TLR7 by endogenous ligand;R-HSA-9833110|RSV-host interactions,11,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.16,0.382,1.0,0.158,0.379,1.0,0.122,0.459,1.0,0.164,0.335,1.0,0.172,0.237,0.5,0.411,0.132,0,0.249,0.146,0.0,0.742,0.0564,0,-2.76,-3.51,-2.01,-3.51,-2.01,2.8227,0.489,0.178,0.0,0.253,0.15,0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,5.0,1.0,1.0,-2.5,L
CHEMBL128748,DIMETHYLCURCUMIN,COc1ccc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(OC)c(OC)c2)cc1OC,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.483,0.107,0.0,0.339,0.232,0.5,0.24,0.283,0.5,0.71,0.048,0.0,0.163,0.227,0.5,0.612,0.0812,0,0.75,0.0267,0.0,0.604,0.092,0,-3.83,-4.42,-3.24,-4.42,-3.24,4.458600000000003,0.24,0.438,1.0,0.247,0.173,0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,0.0,1.0,-0.5,L
CHEMBL1287853,FEDRATINIB,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;RMTs methylate histone arginines",21,9,Tyrosine-protein kinase JAK2 inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,14.0,0.159,0.322,1.0,0.668,0.0924,0.0,0.254,0.257,0.5,0.917,0.00892,0.0,0.517,0.0453,0.0,0.25,0.208,0,0.74,0.0276,0.0,0.743,0.0408,0,-3.65,-4.32,-2.99,-4.32,-2.99,4.823620000000004,0.211,0.398,1.0,0.156,0.333,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,9.5,M
CHEMBL1289494,TIVOZANIB,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,3.0,,0,0,pathway_drug_candidates,3.0,0.547,0.0842,0.0,0.902,0.0147,0.0,0.81,0.0199,0.0,0.557,0.075,0.0,0.036,0.583,1.0,0.629,0.0736,0,0.163,0.239,1.0,0.451,0.103,0,-6.16,-6.8,-5.52,-6.8,-5.52,5.6381200000000025,0.08,0.832,1.0,0.0505,0.846,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,-2.0,L
CHEMBL1297,FENOPROFEN,CC(C(=O)O)c1cccc(Oc2ccccc2)c1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.386,0.159,0.0,0.474,0.166,0.0,0.602,0.0692,0.0,0.318,0.168,0.0,0.737,0.0246,0.0,0.516,0.109,0,0.72,0.0287,0.0,0.815,0.0378,0,-4.0,-4.62,-3.37,-4.62,-3.37,3.6670000000000016,0.673,0.0465,0.0,0.253,0.161,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,H
CHEMBL130,CHLORAMPHENICOL,O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.425,0.13,0.0,0.731,0.0553,0.0,0.46,0.114,0.0,0.236,0.249,0.5,0.456,0.0645,0.0,0.144,0.293,1,0.744,0.0276,0.0,0.627,0.0788,0,-2.18,-3.15,-1.21,-3.15,-1.21,0.9089999999999998,0.599,0.0691,0.0,0.684,0.0135,0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-7.0,L
CHEMBL1305,ANTAZOLINE,c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,3.0,Unknown status,0,0,pathway_drug_candidates,3.0,0.773,0.0327,0.0,0.0311,0.695,1.0,0.532,0.0937,0.0,0.304,0.183,0.0,0.443,0.0704,0.0,0.389,0.147,0,0.942,0.0108,0.0,0.0408,0.394,1,-2.83,-3.81,-1.86,-3.81,-1.86,2.6949000000000014,0.527,0.135,0.0,0.149,0.318,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.5,L
CHEMBL131,PREDNISOLONE,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.434,0.135,0.0,0.452,0.154,0.0,0.423,0.129,0.0,0.422,0.111,0.0,0.502,0.054,0.0,0.136,0.299,1,0.602,0.0533,0.0,0.812,0.0234,0,-3.32,-3.99,-2.66,-3.99,-2.66,1.5576,0.581,0.0767,0.0,0.378,0.0544,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,L
CHEMBL1311,ISOSORBIDE MONONITRATE,O=[N+]([O-])O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O,,0,0,R-HSA-445355|Smooth Muscle Contraction,1,0,Soluble guanylate cyclase activator,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.601,0.0691,0.0,0.367,0.207,0.5,0.969,0.00416,0.0,0.477,0.0984,0.0,0.397,0.0853,0.0,0.143,0.291,1,0.604,0.0505,0.0,0.728,0.0444,0,-0.706,-1.62,0.21,-1.62,0.21,-1.2782000000000004,0.606,0.0772,0.0,0.3,0.0879,0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-3.0,L
CHEMBL1323,DARUNAVIR,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1,,0,0,,0,0,Human immunodeficiency virus type 1 protease inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.616,0.0662,0.0,0.0937,0.468,1.0,0.96,0.00343,0.0,0.212,0.252,0.5,0.425,0.0773,0.0,0.0918,0.355,1,0.947,0.00674,0.0,0.861,0.0211,0,-4.13,-4.71,-3.54,-4.71,-3.54,2.3753,0.0656,0.822,1.0,0.228,0.138,0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,2.0,0.0,1.0,-7.5,L
CHEMBL13280,FLUNITRAZEPAM,CN1C(=O)CN=C(c2ccccc2F)c2cc([N+](=O)[O-])ccc21,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.183,0.317,1.0,0.576,0.12,0.0,0.0689,0.595,1.0,0.439,0.12,0.0,0.51,0.0467,0.0,0.346,0.163,0,0.0588,0.531,1.0,0.276,0.139,0,-3.95,-4.52,-3.39,-4.52,-3.39,2.5477000000000007,0.454,0.17,0.0,0.0718,0.648,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,1.0,1.0,-6.5,L
CHEMBL1336,SORAFENIB,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,3.0,Completed;Not yet recruiting,0,0,pathway_drug_candidates,3.0,0.211,0.298,0.5,0.66,0.0831,0.0,0.667,0.0657,0.0,0.195,0.276,1.0,0.501,0.0594,0.0,0.708,0.0566,0,0.982,0.00249,0.0,0.213,0.203,0.5,-6.43,-7.35,-5.5,-7.35,-5.5,5.549700000000003,0.114,0.781,1.0,0.0946,0.706,1,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,-4.0,L
CHEMBL13376,CLOMETACIN,COc1ccc2c(C(=O)c3ccc(Cl)cc3)c(C)n(CC(=O)O)c2c1,,0,0,,0,0,Cyclooxygenase inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.418,0.148,0.0,0.622,0.0925,0.0,0.829,0.0175,0.0,0.108,0.446,1.0,0.103,0.375,1.0,0.136,0.303,1,0.635,0.0499,0.0,0.122,0.211,1,-5.42,-6.28,-4.56,-6.28,-4.56,3.9273200000000026,0.279,0.344,0.5,0.144,0.443,1,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-10.5,L
CHEMBL1339,VARDENAFIL HYDROCHLORIDE,CCCc1nc(C)c2c(O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)nn12.Cl,,0,0,R-HSA-418457|cGMP effects;R-HSA-445355|Smooth Muscle Contraction;R-HSA-9013422|RHOBTB1 GTPase cycle,3,0,Phosphodiesterase 5A inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.774,0.0327,0.0,0.708,0.0738,0.0,0.84,0.0151,0.0,0.258,0.231,0.5,0.139,0.284,1.0,0.69,0.0599,0,0.79,0.0252,0.0,0.568,0.0737,0,-3.24,-3.93,-2.54,-3.93,-2.54,2.904520000000002,0.363,0.267,0.5,0.0105,0.959,1,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,1.5,L
CHEMBL134,CLONIDINE,Clc1cccc(Cl)c1NC1=NCCN1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.41,0.139,0.0,0.0613,0.567,1.0,0.175,0.347,1.0,0.523,0.0828,0.0,0.238,0.179,0.5,0.423,0.146,0,0.587,0.0546,0.0,0.788,0.0308,0,-3.17,-4.63,-1.71,-4.63,-1.71,2.3644999999999996,0.638,0.0686,0.0,0.143,0.433,1,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,0.5,L
CHEMBL1341,METHOXYFLURANE,COC(F)(F)C(Cl)Cl,,0,0,R-HSA-112314|Neurotransmitter receptors and postsynaptic signal transmission,1,0,,4.0,Unknown status,0,0,pathway_drug_candidates,4.0,0.337,0.182,0.0,0.0723,0.53,1.0,0.333,0.171,0.0,0.441,0.114,0.0,0.192,0.219,0.5,0.136,0.299,1,0.576,0.0573,0.0,0.245,0.17,0,-2.03,-2.87,-1.18,-2.87,-1.18,2.0293,0.551,0.107,0.0,0.126,0.441,1,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-3.5,L
CHEMBL1357648,AMODIAQUINE HYDROCHLORIDE,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl.Cl.O.O,,0,0,,0,0,Ferriprotoporphyrin IX inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.827,0.0233,0.0,0.0295,0.693,1.0,0.803,0.0232,0.0,0.943,0.00759,0.0,0.108,0.328,1.0,0.173,0.262,1,0.159,0.244,1.0,0.0332,0.444,1,-5.13,-7.03,-3.22,-7.03,-3.22,4.373400000000007,0.39,0.249,0.0,0.0139,0.996,1,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-12.5,L
CHEMBL1364144,METHYLPREDNISOLONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.736,0.0382,0.0,0.53,0.122,0.0,0.631,0.0637,0.0,0.799,0.026,0.0,0.479,0.058,0.0,0.444,0.119,0,0.627,0.0466,0.0,0.0138,0.795,1,-4.32,-4.89,-3.75,-4.89,-3.75,2.3744000000000005,0.393,0.24,0.0,0.0163,0.977,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,3.0,L
CHEMBL136478,SODIUM NITROPRUSSIDE,,,0,0,R-HSA-445355|Smooth Muscle Contraction,1,0,Soluble guanylate cyclase activator,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL1366933,ESMIRTAZAPINE,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",7,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.423,0.15,0.0,0.0336,0.679,1.0,0.0598,0.618,1.0,0.0886,0.525,1.0,0.273,0.148,0.0,0.282,0.193,0,0.749,0.0305,0.0,0.367,0.143,0,-2.88,-3.79,-1.97,-3.79,-1.97,2.4789000000000003,0.295,0.333,0.5,0.152,0.405,1,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,-0.5,L
CHEMBL1370,BUDESONIDE,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.1,0.463,1.0,0.636,0.0931,0.0,0.796,0.0271,0.0,0.554,0.0843,0.0,0.522,0.0488,0.0,0.2,0.245,1,0.618,0.0567,0.0,0.824,0.0341,0,-4.12,-4.65,-3.59,-4.65,-3.59,2.7168000000000014,0.584,0.0951,0.0,0.0965,0.598,1,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,-1.5,L
CHEMBL1370561,AMINOPHYLLINE,Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.439,0.133,0.0,0.932,0.0101,0.0,0.929,0.00472,0.0,0.971,0.00222,0.0,0.629,0.029,0.0,0.918,0.0164,0,0.862,0.0128,0.0,0.958,0.00064,0,-0.282,-0.859,0.294,-0.859,0.294,-3.1755999999999975,0.921,0.000242,0.0,0.693,0.00841,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,L
CHEMBL1375743,ZIPRASIDONE HYDROCHLORIDE,Cl.O.O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.673,0.0696,0.0,0.139,0.441,1.0,0.0279,0.802,1.0,0.0492,0.665,1.0,0.113,0.34,1.0,0.0107,0.747,1,0.654,0.0446,0.0,0.215,0.16,0,-5.24,-6.19,-4.3,-6.19,-4.3,3.4061000000000012,0.244,0.443,1.0,0.0126,0.972,1,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,4.0,0.0,1.0,-9.0,L
CHEMBL13828,OXATOMIDE,O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.554,0.0912,0.0,0.0134,0.794,1.0,0.244,0.274,0.5,0.492,0.0908,0.0,0.889,0.00614,0.0,0.266,0.196,0,0.376,0.103,0.0,0.051,0.328,1,-4.58,-5.83,-3.33,-5.83,-3.33,4.126900000000004,0.599,0.0988,0.0,0.263,0.133,0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,-1.5,L
CHEMBL139,DICLOFENAC,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.629,0.0628,0.0,0.528,0.122,0.0,0.0593,0.594,1.0,0.485,0.0938,0.0,0.126,0.314,1.0,0.731,0.0452,0,0.648,0.0358,0.0,0.744,0.0423,0,-3.4,-6.6,-0.207,-6.6,-0.207,4.364100000000001,0.622,0.0589,0.0,0.272,0.111,0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,7.0,M
CHEMBL1395,METHYLTESTOSTERONE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.439,0.128,0.0,0.421,0.168,0.0,0.754,0.0402,0.0,0.275,0.201,0.5,0.873,0.00659,0.0,0.114,0.323,1,0.62,0.0432,0.0,0.163,0.171,1,-4.1,-4.84,-3.36,-4.84,-3.36,4.269300000000005,0.595,0.0646,0.0,0.521,0.0168,0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,-5.5,L
CHEMBL139835,CYPROTERONE ACETATE,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,3.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.673,0.0588,0.0,0.505,0.132,0.0,0.618,0.0681,0.0,0.474,0.0955,0.0,0.345,0.104,0.0,0.3,0.19,0,0.582,0.0513,0.0,0.325,0.134,0,-6.59,-7.12,-6.06,-7.12,-6.06,4.607600000000004,0.317,0.261,0.5,0.0152,0.952,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.5,L
CHEMBL1411979,METHAPYRILENE,CN(C)CCN(Cc1cccs1)c1ccccn1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.475,0.124,0.0,0.0635,0.564,1.0,0.456,0.122,0.0,0.15,0.408,1.0,0.224,0.186,0.5,0.00528,0.854,1,0.781,0.0237,0.0,0.956,0.00838,0,-2.45,-3.17,-1.73,-3.17,-1.73,2.7113000000000005,0.0998,0.743,1.0,0.0883,0.674,1,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,3.0,0.0,1.0,-3.0,L
CHEMBL1421,DASATINIB,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,,0,0,"R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",4,0,,4.0,Unknown status,0,0,pathway_drug_candidates,4.0,0.211,0.309,0.5,0.655,0.0778,0.0,0.0384,0.689,1.0,0.825,0.0208,0.0,0.324,0.123,0.0,0.639,0.0738,0,0.409,0.0724,0.0,0.2,0.164,0,-2.73,-3.23,-2.22,-3.23,-2.22,3.3135400000000015,0.151,0.53,1.0,0.0953,0.554,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,0.5,L
CHEMBL1422,SITAGLIPTIN,,,0,0,,0,0,,,,1,0,known_drugs,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL1423,PIMOZIDE,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.592,0.0795,0.0,0.00774,0.864,1.0,0.18,0.342,1.0,0.77,0.0302,0.0,0.78,0.013,0.0,0.00277,0.919,1,0.895,0.0114,0.0,0.034,0.388,1,-5.42,-6.03,-4.8,-6.03,-4.8,5.8570000000000055,0.17,0.601,1.0,0.0653,0.795,1,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-10.0,L
CHEMBL142703,VILDAGLIPTIN,N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,,0,0,,0,0,Dipeptidyl peptidase IV inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.416,0.157,0.0,0.263,0.266,0.5,0.29,0.218,0.5,0.34,0.155,0.0,0.181,0.231,0.5,0.725,0.0492,0,0.552,0.0532,0.0,0.52,0.0791,0,-1.98,-2.61,-1.36,-2.61,-1.36,1.1742799999999989,0.368,0.241,0.0,0.23,0.151,0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,3.0,0.0,1.0,-3.0,L
CHEMBL1431,METFORMIN,,,0,0,,0,0,,,,1,0,known_drugs,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL1433,DOXYCYCLINE ANHYDROUS,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,,0,0,R-HSA-1442490|Collagen degradation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases;R-HSA-210991|Basigin interactions;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6798695|Neutrophil degranulation,7,1,,3.0,Completed;Unknown status,1,0,known_drugs;pathway_drug_candidates,6.5,0.846,0.0169,0.0,0.682,0.0788,0.0,0.0729,0.64,1.0,0.247,0.243,0.5,0.616,0.0319,0.0,0.358,0.166,0,0.199,0.194,0.5,0.53,0.102,0,-3.03,-3.79,-2.27,-3.79,-2.27,-0.3475999999999985,0.955,0.00661,0.0,0.429,0.0439,0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,1.0,L
CHEMBL1434513,NOREPINEPHRINE BITARTRATE,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.662,0.0581,0.0,0.429,0.17,0.0,0.765,0.0394,0.0,0.984,0.000608,0.0,0.63,0.0295,0.0,0.862,0.0225,0,0.136,0.303,1.0,0.854,0.0148,0,-0.375,-2.32,1.57,-2.32,1.57,-2.8574000000000006,0.889,0.00917,0.0,0.828,0.00231,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,L
CHEMBL1437,NOREPINEPHRINE,NC[C@H](O)c1ccc(O)c(O)c1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.227,0.268,0.5,0.726,0.0632,0.0,0.329,0.168,0.0,0.472,0.0993,0.0,0.338,0.113,0.0,0.777,0.0434,0,0.0375,0.673,1.0,0.756,0.0332,0,-0.309,-1.45,0.834,-1.45,0.834,0.0898999999999999,0.73,0.0269,0.0,0.882,0.00212,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,-1.5,L
CHEMBL14376,ILOPERIDONE,COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.534,0.0942,0.0,0.0242,0.699,1.0,0.272,0.237,0.5,0.856,0.0163,0.0,0.111,0.316,1.0,0.00267,0.913,1,0.954,0.00353,0.0,0.587,0.0492,0,-3.82,-4.65,-2.99,-4.65,-2.99,4.826600000000004,0.351,0.219,0.0,0.00274,0.929,1,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,3.0,0.0,1.0,-10.0,L
CHEMBL1440,TETRACYCLINE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.795,0.0256,0.0,0.685,0.0743,0.0,0.328,0.199,0.0,0.373,0.145,0.0,0.567,0.0332,0.0,0.646,0.0673,0,0.59,0.0526,0.0,0.598,0.0472,0,-2.83,-3.64,-2.02,-3.64,-2.02,-0.2143999999999983,0.813,0.0107,0.0,0.481,0.0203,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.5,L
CHEMBL1442422,DIBENZEPIN,CN(C)CCN1C(=O)c2ccccc2N(C)c2ccccc21,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.593,0.0793,0.0,0.632,0.0889,0.0,0.0963,0.485,1.0,0.0721,0.597,1.0,0.372,0.0898,0.0,0.375,0.153,0,0.32,0.113,0.0,0.413,0.132,0,-3.84,-4.51,-3.18,-4.51,-3.18,2.976300000000001,0.388,0.229,0.0,0.077,0.577,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,1.5,L
CHEMBL1445,FLUOXYMESTERONE,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.345,0.189,0.0,0.316,0.214,0.5,0.303,0.212,0.5,0.403,0.122,0.0,0.813,0.0145,0.0,0.0715,0.405,1,0.652,0.0439,0.0,0.691,0.0429,0,-3.72,-4.15,-3.28,-4.15,-3.28,3.332200000000002,0.542,0.109,0.0,0.514,0.0304,0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,-4.0,L
CHEMBL1446,KANAMYCIN SULFATE,NC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@@H]2N)[C@H](O)[C@@H](O)[C@@H]1O.O=S(=O)(O)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.966,0.0057,0.0,0.795,0.0486,0.0,0.887,0.0118,0.0,0.903,0.0104,0.0,0.949,0.00287,0.0,0.908,0.0203,0,0.732,0.0329,0.0,0.943,0.0158,0,0.103,-1.43,1.64,-1.43,1.64,-7.944200000000013,0.954,0.00599,0.0,0.781,0.0108,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,L
CHEMBL1447,LINCOMYCIN,CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@@H](C)O)N(C)C1,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.605,0.064,0.0,0.401,0.177,0.0,0.0678,0.576,1.0,0.458,0.101,0.0,0.714,0.0186,0.0,0.293,0.19,0,0.847,0.0134,0.0,0.0583,0.259,1,-0.529,-0.988,-0.071,-0.988,-0.071,-0.856999999999998,0.682,0.0371,0.0,0.685,0.0139,0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,-3.0,L
CHEMBL1451,TRIAMCINOLONE,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.428,0.129,0.0,0.443,0.158,0.0,0.128,0.429,1.0,0.414,0.12,0.0,0.649,0.0247,0.0,0.135,0.299,1,0.425,0.0797,0.0,0.775,0.0195,0,-3.49,-4.25,-2.73,-4.25,-2.73,0.6204999999999998,0.614,0.0607,0.0,0.229,0.137,0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-1.0,L
CHEMBL1457,HYDROCODONE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.457,0.116,0.0,0.102,0.468,1.0,0.484,0.0974,0.0,0.213,0.269,0.5,0.389,0.0836,0.0,0.0875,0.369,1,0.724,0.0322,0.0,0.776,0.0207,0,-2.19,-2.66,-1.72,-2.66,-1.72,1.9333,0.167,0.501,1.0,0.0657,0.686,1,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,0.0,1.0,0.0,L
CHEMBL146095,GLAFENINE,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.0986,0.465,1.0,0.492,0.138,0.0,0.937,0.00607,0.0,0.575,0.0695,0.0,0.0314,0.616,1.0,0.913,0.015,0,0.238,0.153,0.0,0.173,0.207,0.5,-6.55,-9.04,-4.06,-9.04,-4.06,3.141800000000001,0.159,0.636,1.0,0.192,0.27,1,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,4.0,L
CHEMBL1471,APREPITANT,C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,,0,0,,0,0,Neurokinin 1 receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.116,0.411,1.0,0.284,0.229,0.5,0.528,0.103,0.0,0.147,0.378,1.0,0.673,0.0295,0.0,0.591,0.083,0,0.932,0.00896,0.0,0.0605,0.289,1,-5.18,-5.68,-4.67,-5.68,-4.67,4.952100000000003,0.233,0.509,1.0,0.0978,0.561,1,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-8.0,L
CHEMBL1473,FLUTICASONE PROPIONATE,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.107,0.451,1.0,0.4,0.163,0.0,0.441,0.128,0.0,0.556,0.0728,0.0,0.701,0.0204,0.0,0.329,0.179,0,0.814,0.0207,0.0,0.892,0.000279,0,-7.3,-8.05,-6.55,-8.05,-6.55,4.430000000000004,0.271,0.336,0.5,0.0257,0.891,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.5,L
CHEMBL1477,CERIVASTATIN,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,,0,0,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.832,0.0225,0.0,0.321,0.229,0.5,0.36,0.175,0.0,0.0661,0.611,1.0,0.667,0.0283,0.0,0.726,0.0511,0,0.878,0.0135,0.0,0.646,0.0797,0,-2.7,-3.15,-2.26,-3.15,-2.26,4.8807000000000045,0.744,0.0407,0.0,0.108,0.449,1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,0.0,L
CHEMBL1479,DANAZOL,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0969,0.461,1.0,0.114,0.421,1.0,0.189,0.323,1.0,0.218,0.262,0.5,0.0592,0.451,1.0,0.154,0.27,1,0.731,0.0319,0.0,0.915,0.00047,0,-5.68,-6.42,-4.93,-6.42,-4.93,4.221000000000004,0.634,0.0502,0.0,0.308,0.106,0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,1.0,1.0,-9.5,L
CHEMBL1483,ALBENDAZOLE,CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1,,0,0,,0,0,Tubulin inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.722,0.0393,0.0,0.392,0.178,0.0,0.843,0.0188,0.0,0.842,0.0184,0.0,0.0528,0.469,1.0,0.531,0.104,0,0.599,0.0433,0.0,0.741,0.0583,0,-4.53,-5.73,-3.32,-5.73,-3.32,3.2433000000000005,0.106,0.758,1.0,0.116,0.44,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,-2.0,L
CHEMBL1487,ATORVASTATIN,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,,0,0,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,,4.0,,1,0,known_drugs;pathway_drug_candidates,5.5,0.344,0.19,0.0,0.308,0.222,0.5,0.0423,0.697,1.0,0.463,0.105,0.0,0.509,0.0466,0.0,0.614,0.0784,0,0.959,0.00568,0.0,0.78,0.0337,0,-4.78,-5.21,-4.35,-5.21,-4.35,6.313600000000008,0.767,0.0199,0.0,0.0586,0.708,1,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,1.0,L
CHEMBL1489,AZACITIDINE,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,,0,0,,0,0,RNA inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.907,0.00861,0.0,0.783,0.047,0.0,0.323,0.187,0.0,0.525,0.0868,0.0,0.909,0.00327,0.0,0.898,0.0141,0,0.071,0.473,1.0,0.689,0.0476,0,-1.04,-1.85,-0.222,-1.85,-0.222,-3.1679999999999997,0.98,0.00375,0.0,0.27,0.125,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.0,L
CHEMBL1492,DIPHENYLPYRALINE,CN1CCC(OC(c2ccccc2)c2ccccc2)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.492,0.0932,0.0,0.0285,0.682,1.0,0.421,0.135,0.0,0.457,0.102,0.0,0.521,0.0582,0.0,0.0883,0.364,1,0.64,0.0389,0.0,0.877,0.0133,0,-2.52,-3.25,-1.8,-3.25,-1.8,3.8868000000000023,0.488,0.13,0.0,0.335,0.0907,0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-3.0,L
CHEMBL1493,FLAVOXATE,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,2.0,,0,0,pathway_drug_candidates,2.0,0.132,0.393,1.0,0.0317,0.679,1.0,0.538,0.105,0.0,0.344,0.149,0.0,0.186,0.224,0.5,0.0409,0.489,1,0.605,0.0539,0.0,0.031,0.385,1,-3.88,-5.35,-2.4,-5.35,-2.4,4.411120000000004,0.0971,0.71,1.0,0.101,0.489,1,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-8.5,L
CHEMBL1496,ROSUVASTATIN,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,,0,0,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,,4.0,,1,0,known_drugs;pathway_drug_candidates,5.5,0.953,0.00514,0.0,0.638,0.0822,0.0,0.0662,0.587,1.0,0.323,0.163,0.0,0.789,0.012,0.0,0.901,0.0174,0,0.831,0.0163,0.0,0.731,0.0492,0,-2.53,-3.0,-2.06,-3.0,-2.06,2.4017,0.604,0.0722,0.0,0.18,0.227,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,5.0,L
CHEMBL1497,BETAMETHASONE VALERATE,CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.405,0.144,0.0,0.489,0.153,0.0,0.312,0.193,0.0,0.446,0.11,0.0,0.66,0.0275,0.0,0.578,0.0875,0,0.817,0.025,0.0,0.599,0.0538,0,-4.85,-5.63,-4.06,-5.63,-4.06,3.6368000000000023,0.239,0.428,1.0,0.15,0.387,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,5.0,L
CHEMBL1501,FLUOCINONIDE,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.422,0.138,0.0,0.715,0.072,0.0,0.64,0.0634,0.0,0.849,0.0162,0.0,0.632,0.0312,0.0,0.429,0.131,0,0.512,0.0607,0.0,0.817,0.0297,0,-5.66,-6.6,-4.72,-6.6,-4.72,2.9376000000000015,0.461,0.172,0.0,0.0147,0.98,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,4.0,L
CHEMBL1504,TRIAMCINOLONE ACETONIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.328,0.179,0.0,0.645,0.0877,0.0,0.521,0.0869,0.0,0.714,0.038,0.0,0.608,0.0357,0.0,0.134,0.301,1,0.443,0.0803,0.0,0.907,0.0134,0,-4.09,-5.02,-3.16,-5.02,-3.16,2.4188000000000005,0.54,0.112,0.0,0.182,0.236,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,-1.0,L
CHEMBL1512,FLUNISOLIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.334,0.187,0.0,0.656,0.084,0.0,0.624,0.0662,0.0,0.738,0.0364,0.0,0.568,0.0374,0.0,0.214,0.235,1,0.444,0.0732,0.0,0.847,0.0277,0,-3.73,-4.51,-2.95,-4.51,-2.95,2.2747000000000006,0.57,0.0962,0.0,0.0244,0.951,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.5,L
CHEMBL1513,IRBESARTAN,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,AGTR1,1,1,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,Type-1 angiotensin II receptor antagonist,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.537,0.0897,0.0,0.901,0.0236,0.0,0.861,0.0116,0.0,0.868,0.0177,0.0,0.415,0.0775,0.0,0.518,0.0997,0,0.97,0.0056,0.0,0.887,0.0237,0,-4.43,-5.74,-3.12,-5.74,-3.12,4.777400000000004,0.848,0.0126,0.0,0.133,0.379,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,5.0,L
CHEMBL1514,LEVOMETHADYL ACETATE,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.115,0.384,1.0,0.0692,0.566,1.0,0.409,0.138,0.0,0.17,0.301,1.0,0.291,0.132,0.0,0.0971,0.347,1,0.897,0.0105,0.0,0.463,0.119,0,-2.88,-3.63,-2.14,-3.63,-2.14,4.654600000000005,0.232,0.473,1.0,0.0715,0.837,1,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-4.5,L
CHEMBL1516,OLMESARTAN,CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,AGTR1,1,1,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,Type-1 angiotensin II receptor antagonist,3.0,Completed,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,6.5,0.797,0.036,0.0,0.919,0.016,0.0,0.9,0.00994,0.0,0.819,0.0262,0.0,0.369,0.0969,0.0,0.872,0.0216,0,0.962,0.00551,0.0,0.865,0.0138,0,-3.88,-5.34,-2.43,-5.34,-2.43,3.656600000000002,0.909,0.00879,0.0,0.326,0.0623,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.5,L
CHEMBL1517,OXYTETRACYCLINE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.794,0.0313,0.0,0.735,0.0659,0.0,0.0393,0.745,1.0,0.297,0.195,0.0,0.601,0.0328,0.0,0.513,0.115,0,0.594,0.0551,0.0,0.598,0.0625,0,-2.97,-3.72,-2.21,-3.72,-2.21,-1.2435999999999974,0.953,0.00581,0.0,0.502,0.0268,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-2.5,L
CHEMBL1519,TRANDOLAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,Angiotensin-converting enzyme inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.761,0.0366,0.0,0.465,0.168,0.0,0.523,0.0892,0.0,0.422,0.108,0.0,0.568,0.0428,0.0,0.778,0.0409,0,0.867,0.0128,0.0,0.495,0.0945,0,-2.49,-2.96,-2.01,-2.96,-2.01,2.7733000000000008,0.633,0.05,0.0,0.154,0.286,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,5.5,L
CHEMBL1520,VARDENAFIL,CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12,,0,0,R-HSA-418457|cGMP effects;R-HSA-445355|Smooth Muscle Contraction;R-HSA-9013422|RHOBTB1 GTPase cycle,3,0,,4.0,Completed,0,0,pathway_drug_candidates,4.0,0.667,0.0514,0.0,0.652,0.077,0.0,0.827,0.0141,0.0,0.307,0.178,0.0,0.24,0.161,0.5,0.776,0.0428,0,0.766,0.0242,0.0,0.744,0.0299,0,-4.74,-5.33,-4.14,-5.33,-4.14,2.07042,0.283,0.317,0.5,0.182,0.247,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,L
CHEMBL1522,ESZOPICLONE,CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.792,0.0308,0.0,0.178,0.357,1.0,0.888,0.0096,0.0,0.0896,0.52,1.0,0.559,0.0515,0.0,0.863,0.026,0,0.836,0.0179,0.0,0.422,0.125,0,-1.39,-1.83,-0.945,-1.83,-0.945,1.5679999999999998,0.27,0.365,0.5,0.106,0.608,1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-2.0,L
CHEMBL1523964,EPHEDRINE SULFATE,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.693,0.0524,0.0,0.00881,0.851,1.0,0.762,0.0338,0.0,0.204,0.251,0.5,0.098,0.409,1.0,0.0882,0.379,1,0.879,0.0111,0.0,0.978,0.0187,0,0.214,-1.29,1.72,-1.29,1.72,2.003,0.666,0.0711,0.0,0.329,0.0927,0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,3.0,0.0,1.0,-4.0,L
CHEMBL1528134,BENZYDAMINE HYDROCHLORIDE,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,3.0,Not yet recruiting,0,0,protein_drug_candidates;pathway_drug_candidates,9.0,0.795,0.028,0.0,0.0488,0.611,1.0,0.536,0.0954,0.0,0.48,0.103,0.0,0.339,0.107,0.0,0.947,0.0136,0,0.351,0.097,0.0,0.0424,0.433,1,-2.68,-3.94,-1.42,-3.94,-1.42,3.836900000000003,0.53,0.124,0.0,0.0249,1.0,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,6.0,L
CHEMBL1530428,DEXAMETHASONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,3.0,Unknown status,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,5.0,0.501,0.108,0.0,0.583,0.121,0.0,0.607,0.069,0.0,0.729,0.0352,0.0,0.671,0.0276,0.0,0.397,0.141,0,0.594,0.0523,0.0,0.0413,0.489,1,-4.71,-5.6,-3.82,-5.6,-3.82,2.466500000000001,0.455,0.207,0.0,0.101,0.445,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,2.0,L
CHEMBL1535,HYDROXYCHLOROQUINE,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-168181|Toll Like Receptor 7/8 (TLR7/8) Cascade;R-HSA-5686938|Regulation of TLR by endogenous ligand;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9692916|SARS-CoV-1 activates/modulates innate immune responses;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome;R-HSA-9824856|Defective regulation of TLR7 by endogenous ligand;R-HSA-9833110|RSV-host interactions,11,0,,4.0,,1,0,known_drugs;pathway_drug_candidates,5.5,0.861,0.0142,0.0,0.163,0.398,1.0,0.97,0.000998,0.0,0.97,0.00391,0.0,0.138,0.25,1.0,0.0769,0.383,1,0.0743,0.479,1.0,0.0288,0.327,1,-2.67,-3.35,-2.0,-3.35,-2.0,3.783000000000002,0.213,0.506,1.0,0.0724,0.521,1,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-3.0,L
CHEMBL1536,ERGOCALCIFEROL,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]12,VDR,1,1,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Vitamin D receptor agonist,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.673,0.0563,0.0,0.365,0.211,0.5,0.485,0.108,0.0,0.567,0.0806,0.0,0.528,0.0537,0.0,0.627,0.076,0,0.526,0.0592,0.0,0.206,0.162,0,-6.11,-6.79,-5.44,-6.79,-5.44,7.641000000000008,0.263,0.408,0.5,0.297,0.0773,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,4.0,L
CHEMBL154,NAPROXEN,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,11.5,0.338,0.197,0.0,0.37,0.191,0.0,0.571,0.0762,0.0,0.424,0.124,0.0,0.261,0.172,0.5,0.431,0.122,0,0.861,0.012,0.0,0.908,0.0146,0,-3.97,-5.39,-2.55,-5.39,-2.55,3.036500000000001,0.848,0.0163,0.0,0.315,0.0912,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,10.5,H
CHEMBL1549,HYDROCORTISONE CYPIONATE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,4.0,0.42,0.141,0.0,0.73,0.0633,0.0,0.474,0.116,0.0,0.235,0.232,0.5,0.729,0.0188,0.0,0.26,0.208,0,0.493,0.0598,0.0,0.77,0.0525,0,-6.47,-7.42,-5.52,-7.42,-5.52,4.302900000000004,0.215,0.502,1.0,0.134,0.379,1,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,2.0,L
CHEMBL1558,PRAZOSIN HYDROCHLORIDE,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC.Cl,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.588,0.0837,0.0,0.425,0.162,0.0,0.65,0.061,0.0,0.774,0.0275,0.0,0.655,0.0242,0.0,0.556,0.0985,0,0.158,0.243,1.0,0.824,0.0339,0,-4.09,-5.3,-2.87,-5.3,-2.87,2.2064,0.7,0.0414,0.0,0.0205,0.954,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,L
CHEMBL1560,CAPTOPRIL,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,ACE,1,1,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,Angiotensin-converting enzyme inhibitor,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,9.5,0.771,0.0287,0.0,0.814,0.0407,0.0,0.663,0.0592,0.0,0.721,0.0402,0.0,0.673,0.0272,0.0,0.873,0.0225,0,0.231,0.144,0.0,0.457,0.108,0,-1.65,-2.49,-0.822,-2.49,-0.822,0.6279000000000001,0.703,0.0301,0.0,0.301,0.0785,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,M
CHEMBL1562610,MECLOFENAMATE SODIUM,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+],PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.171,0.324,1.0,0.916,0.0179,0.0,0.0235,0.856,1.0,0.774,0.0302,0.0,0.0871,0.384,1.0,0.93,0.0142,0,0.429,0.0736,0.0,0.894,0.0212,0,-4.32,-5.74,-2.9,-5.74,-2.9,-0.411779999999999,0.745,0.0259,0.0,0.542,0.0172,0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,3.0,1.0,1.0,2.0,L
CHEMBL1565476,APAZONE,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.862,0.0157,0.0,0.513,0.146,0.0,0.423,0.132,0.0,0.117,0.445,1.0,0.543,0.0491,0.0,0.491,0.109,0,0.0898,0.438,1.0,0.26,0.169,0,-3.43,-4.06,-2.79,-4.06,-2.79,2.0642199999999997,0.467,0.188,0.0,0.409,0.0519,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,6.5,L
CHEMBL1567,SUNITINIB MALATE,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,4.0,Completed,0,0,pathway_drug_candidates,4.0,0.976,0.00341,0.0,0.742,0.0688,0.0,0.795,0.0367,0.0,0.37,0.133,0.0,0.882,0.00835,0.0,0.337,0.168,0,0.603,0.0506,0.0,0.378,0.13,0,-0.594,-1.09,-0.0959,-1.09,-0.0959,2.24154,0.588,0.0743,0.0,0.0615,0.7,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,4.0,L
CHEMBL15677,FENCLOFENAC,O=C(O)Cc1ccccc1Oc1ccc(Cl)cc1Cl,,0,0,,0,0,Cyclooxygenase inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.462,0.131,0.0,0.638,0.0864,0.0,0.234,0.279,0.5,0.334,0.158,0.0,0.0601,0.472,1.0,0.667,0.0654,0,0.544,0.0637,0.0,0.559,0.104,0,-4.59,-5.59,-3.6,-5.59,-3.6,4.4128000000000025,0.632,0.0785,0.0,0.262,0.138,0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,-4.5,L
CHEMBL1568698,GANAXOLONE,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.431,0.138,0.0,0.465,0.161,0.0,0.405,0.139,0.0,0.391,0.131,0.0,0.568,0.0471,0.0,0.347,0.163,0,0.5,0.0669,0.0,0.0868,0.292,1,-4.59,-5.3,-3.87,-5.3,-3.87,4.985300000000005,0.449,0.203,0.0,0.45,0.0445,0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,-4.5,L
CHEMBL1569,AMANTADINE HYDROCHLORIDE,Cl.NC12CC3CC(CC(C3)C1)C2,GRIN1,1,1,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,Glutamate [NMDA] receptor antagonist;Glutamate [NMDA] receptor antagonist | Matrix protein 2 inhibitor;Matrix protein 2 inhibitor,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.394,0.15,0.0,0.496,0.149,0.0,0.497,0.1,0.0,0.442,0.107,0.0,0.537,0.0439,0.0,0.314,0.183,0,0.655,0.0415,0.0,0.82,0.0386,0,-1.36,-2.33,-0.382,-2.33,-0.382,2.3357,0.422,0.2,0.0,0.0396,0.891,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,8.5,M
CHEMBL1569487,LORNOXICAM,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.757,0.041,0.0,0.66,0.0781,0.0,0.0773,0.61,1.0,0.349,0.153,0.0,0.328,0.12,0.0,0.499,0.112,0,0.752,0.0328,0.0,0.792,0.0247,0,-4.66,-5.21,-4.11,-5.21,-4.11,2.2958999999999996,0.192,0.52,1.0,0.457,0.0308,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,8.5,H
CHEMBL15770,SULINDAC,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.624,0.0631,0.0,0.514,0.128,0.0,0.253,0.247,0.5,0.772,0.0286,0.0,0.0616,0.456,1.0,0.483,0.107,0,0.794,0.0265,0.0,0.214,0.167,0,-4.57,-5.28,-3.87,-5.28,-3.87,4.365500000000003,0.826,0.0202,0.0,0.296,0.136,0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,5.5,L
CHEMBL1581,PERINDOPRIL,CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.65,0.049,0.0,0.777,0.045,0.0,0.707,0.0419,0.0,0.611,0.0613,0.0,0.802,0.0109,0.0,0.817,0.0346,0,0.374,0.0767,0.0,0.545,0.0866,0,-1.38,-1.92,-0.843,-1.92,-0.843,1.940599999999999,0.636,0.0507,0.0,0.141,0.384,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,6.0,L
CHEMBL15870,INDOPROFEN,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.42,0.138,0.0,0.572,0.104,0.0,0.215,0.288,0.5,0.542,0.0761,0.0,0.627,0.0331,0.0,0.688,0.064,0,0.904,0.0127,0.0,0.815,0.0468,0,-4.28,-5.57,-2.98,-5.57,-2.98,3.0351000000000017,0.775,0.0213,0.0,0.354,0.105,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,6.5,H
CHEMBL159,VINBLASTINE,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.263,0.243,0.5,0.0221,0.752,1.0,0.72,0.0502,0.0,0.619,0.0574,0.0,0.661,0.0284,0.0,0.387,0.143,0,0.848,0.0153,0.0,0.166,0.185,1,-4.61,-5.06,-4.15,-5.06,-4.15,3.990900000000003,0.0333,0.938,1.0,0.0974,0.474,1,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,0.0,L
CHEMBL1592,QUINAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.638,0.0632,0.0,0.259,0.287,0.5,0.372,0.174,0.0,0.229,0.249,0.5,0.354,0.0993,0.0,0.843,0.0258,0,0.812,0.0236,0.0,0.216,0.159,0,-2.75,-3.36,-2.15,-3.36,-2.15,2.5671,0.617,0.0635,0.0,0.137,0.386,1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,3.5,L
CHEMBL159226,MOXISYLYTE,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,Adrenergic receptor alpha antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.775,0.0395,0.0,0.0497,0.603,1.0,0.443,0.135,0.0,0.668,0.0476,0.0,0.488,0.0561,0.0,0.426,0.136,0,0.428,0.0851,0.0,0.157,0.212,1,-2.41,-2.99,-1.82,-2.99,-1.82,2.9841200000000017,0.295,0.332,0.5,0.233,0.144,0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.5,L
CHEMBL1595,DIHYDROCODEINE,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,Completed,0,0,pathway_drug_candidates,6.0,0.443,0.12,0.0,0.128,0.449,1.0,0.24,0.273,0.5,0.322,0.171,0.0,0.403,0.0841,0.0,0.0571,0.433,1,0.605,0.0391,0.0,0.745,0.0429,0,-1.25,-2.05,-0.456,-2.05,-0.456,1.7251,0.379,0.245,0.0,0.0839,0.529,1,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-1.0,L
CHEMBL1601669,ALFACALCIDOL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.704,0.0445,0.0,0.544,0.12,0.0,0.211,0.311,0.5,0.392,0.138,0.0,0.519,0.053,0.0,0.75,0.0438,0,0.721,0.0342,0.0,0.103,0.203,1,-5.34,-6.21,-4.47,-6.21,-4.47,6.589800000000009,0.281,0.359,0.5,0.12,0.421,1,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,-2.5,L
CHEMBL1607273,CETIRIZINE HYDROCHLORIDE,Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.76,0.0398,0.0,0.556,0.133,0.0,0.836,0.0179,0.0,0.795,0.0274,0.0,0.893,0.00707,0.0,0.137,0.296,1,0.884,0.0153,0.0,0.994,0.0152,0,-1.86,-2.58,-1.13,-2.58,-1.13,3.991800000000003,0.752,0.0413,0.0,0.0719,0.724,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-1.5,L
CHEMBL1607480,OXYTETRACYCLINE HYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12.Cl,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.825,0.0231,0.0,0.808,0.0469,0.0,0.0558,0.673,1.0,0.278,0.2,0.5,0.598,0.032,0.0,0.485,0.121,0,0.593,0.054,0.0,0.591,0.056,0,-2.27,-3.08,-1.45,-3.08,-1.45,-0.8217999999999985,0.939,0.00336,0.0,0.089,0.55,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-3.5,L
CHEMBL1614710,OSI-930,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,1.0,Completed,0,0,pathway_drug_candidates,1.0,0.332,0.174,0.0,0.261,0.26,0.5,0.0966,0.508,1.0,0.0943,0.496,1.0,0.0401,0.567,1.0,0.858,0.0238,0,0.0505,0.714,1.0,0.0911,0.239,1,-4.78,-5.48,-4.08,-5.48,-4.08,6.059300000000004,0.216,0.357,1.0,0.0306,0.876,1,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,4.0,0.0,1.0,-7.0,L
CHEMBL1615372,LURASIDONE HYDROCHLORIDE,Cl.O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.0782,0.518,1.0,0.567,0.105,0.0,0.364,0.171,0.0,0.262,0.199,0.0,0.401,0.0807,0.0,0.0659,0.419,1,0.776,0.0261,0.0,0.0796,0.249,1,-5.44,-6.01,-4.87,-6.01,-4.87,4.677600000000004,0.217,0.419,1.0,0.00526,0.973,1,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,-11.0,L
CHEMBL1615438,LEVOCABASTINE,C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.545,0.103,0.0,0.109,0.432,1.0,0.469,0.11,0.0,0.463,0.102,0.0,0.442,0.0711,0.0,0.154,0.281,1,0.862,0.0119,0.0,0.359,0.0986,0,-3.95,-4.56,-3.34,-4.56,-3.34,4.894080000000004,0.377,0.241,0.0,0.183,0.285,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-4.0,L
CHEMBL1620,DIPHENHYDRAMINE HYDROCHLORIDE,CN(C)CCOC(c1ccccc1)c1ccccc1.Cl,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.696,0.0491,0.0,0.0284,0.704,1.0,0.516,0.0896,0.0,0.0851,0.501,1.0,0.723,0.0163,0.0,0.255,0.203,0,0.577,0.053,0.0,0.906,0.00241,0,-2.07,-3.05,-1.1,-3.05,-1.1,3.776000000000004,0.597,0.0721,0.0,0.00327,0.989,1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,1.0,L
CHEMBL1621,PALIPERIDONE,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.662,0.0526,0.0,0.138,0.409,1.0,0.124,0.445,1.0,0.601,0.0569,0.0,0.672,0.03,0.0,0.00258,0.921,1,0.396,0.0734,0.0,0.414,0.123,0,-2.39,-3.12,-1.66,-3.12,-1.66,3.081320000000002,0.402,0.214,0.0,0.0909,0.549,1,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-8.0,L
CHEMBL1623,MECLIZINE,Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0885,0.472,1.0,0.0155,0.773,1.0,0.779,0.0345,0.0,0.8,0.024,0.0,0.544,0.0497,0.0,0.0364,0.519,1,0.774,0.0245,0.0,0.854,0.0321,0,-4.43,-5.43,-3.42,-5.43,-3.42,5.555620000000006,0.457,0.162,0.0,0.00514,0.945,1,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-8.5,L
CHEMBL1626,CLEMASTINE,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.269,0.245,0.5,0.0755,0.553,1.0,0.867,0.0112,0.0,0.152,0.366,1.0,0.0594,0.447,1.0,0.00173,0.941,1,0.563,0.0562,0.0,0.0351,0.446,1,-3.38,-3.94,-2.83,-3.94,-2.83,5.104400000000005,0.194,0.505,1.0,0.166,0.247,1,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,4.0,1.0,1.0,-8.5,L
CHEMBL163,RITONAVIR,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,CYP3A4,1,1,R-HSA-211981|Xenobiotics;R-HSA-5423646|Aflatoxin activation and detoxification,2,0,Cytochrome P450 3A inhibitor;Cytochrome P450 3A inhibitor | Human immunodeficiency virus type 1 protease inhibitor;Human immunodeficiency virus type 1 protease inhibitor,4.0,Completed,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.305,0.21,0.5,0.0261,0.694,1.0,0.0329,0.778,1.0,0.087,0.563,1.0,0.625,0.0282,0.0,0.993,0.00108,0,0.968,0.00698,0.0,0.51,0.0979,0,-3.72,-4.31,-3.14,-4.31,-3.14,5.905200000000005,0.228,0.509,1.0,0.714,0.0137,0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,4.0,1.0,1.0,2.0,L
CHEMBL1633,KETOTIFEN FUMARATE,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1.O=C(O)/C=C/C(=O)O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,3.0,"Active, not recruiting",0,0,pathway_drug_candidates,3.0,0.899,0.0109,0.0,0.286,0.245,0.5,0.727,0.0539,0.0,0.84,0.016,0.0,0.908,0.0053,0.0,0.482,0.125,0,0.919,0.00788,0.0,0.945,0.00894,0,-3.22,-3.75,-2.68,-3.75,-2.68,3.7262000000000017,0.679,0.0496,0.0,0.0891,0.572,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,L
CHEMBL1642,IMATINIB MESYLATE,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,,0,0,"R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",4,0,,4.0,Completed,0,0,pathway_drug_candidates,4.0,0.707,0.0406,0.0,0.839,0.0376,0.0,0.754,0.025,0.0,0.995,0.00134,0.0,0.65,0.0291,0.0,0.232,0.22,0.5,0.954,0.00835,0.0,0.322,0.153,0,1.52,0.82,2.22,0.82,2.14,4.094320000000002,0.145,0.694,1.0,0.0661,0.727,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,L
CHEMBL1643,RIBAVIRIN,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,,0,0,,0,0,Inosine-5'-monophosphate dehydrogenase 1 inhibitor;Inosine-5'-monophosphate dehydrogenase 1 inhibitor | RNA inhibitor | RNA-directed RNA polymerase inhibitor;RNA inhibitor;RNA-directed RNA polymerase inhibitor,,,1,1,known_drugs;mechanism_drug_candidate;mechanism_of_actions,1.5,0.78,0.0263,0.0,0.754,0.0557,0.0,0.424,0.135,0.0,0.472,0.1,0.0,0.732,0.0198,0.0,0.917,0.0121,0,0.609,0.0486,0.0,0.539,0.0806,0,-0.156,-0.851,0.539,-0.851,0.539,-3.0114999999999994,0.931,0.00194,0.0,0.686,0.0143,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.5,L
CHEMBL1649931,PF-232798,CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3c1CCN(C(=O)C(C)C)C3)C2)c1cccc(F)c1,,0,0,R-HSA-173107|Binding and entry of HIV virion;R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,4,2,,2.0,Completed,0,0,pathway_drug_candidates,6.0,0.863,0.0164,0.0,0.586,0.112,0.0,0.345,0.187,0.0,0.411,0.126,0.0,0.855,0.00904,0.0,0.866,0.0216,0,0.132,0.273,1.0,0.273,0.108,0,-3.13,-3.66,-2.6,-3.66,-2.6,4.306720000000003,0.649,0.0516,0.0,0.0826,0.589,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,3.0,L
CHEMBL1650,CORTISONE ACETATE,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.802,0.0272,0.0,0.696,0.0652,0.0,0.811,0.0236,0.0,0.73,0.0368,0.0,0.813,0.0143,0.0,0.67,0.0633,0,0.421,0.0785,0.0,0.326,0.154,0,-4.14,-4.73,-3.56,-4.73,-3.56,2.560600000000001,0.476,0.158,0.0,0.242,0.143,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,L
CHEMBL1653,PHENIRAMINE MALEATE,CN(C)CCC(c1ccccc1)c1ccccn1.O=C(O)/C=C\C(=O)O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.982,0.00337,0.0,0.406,0.172,0.0,0.947,0.00426,0.0,0.941,0.00725,0.0,0.861,0.00723,0.0,0.317,0.17,0,0.915,0.00759,0.0,0.965,0.00721,0,-0.994,-2.61,0.619,-2.61,0.619,2.877,0.628,0.067,0.0,0.668,0.0152,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,L
CHEMBL1657,TAZAROTENE,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1,,0,0,R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-5362517|Signaling by Retinoic Acid;R-HSA-5617472|Activation of anterior HOX genes in hindbrain development during early embryogenesis,3,0,Retinoic acid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.563,0.12,0.0,0.335,0.23,0.5,0.387,0.131,0.0,0.198,0.304,1.0,0.0426,0.534,1.0,0.659,0.0675,0,0.85,0.0176,0.0,0.388,0.142,0,-6.17,-6.87,-5.47,-6.87,-5.47,4.431500000000004,0.189,0.559,1.0,0.0906,0.589,1,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,0.0,L
CHEMBL1659,CHLORPHENIRAMINE MALEATE,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.984,0.00322,0.0,0.24,0.296,0.5,0.846,0.0102,0.0,0.959,0.00283,0.0,0.555,0.0435,0.0,0.134,0.299,1,0.959,0.00421,0.0,0.963,0.00605,0,-2.43,-3.39,-1.47,-3.39,-1.47,3.5304,0.524,0.127,0.0,0.717,0.0107,0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-3.0,L
CHEMBL1668019,APLAVIROC HYDROCHLORIDE,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl,,0,0,R-HSA-173107|Binding and entry of HIV virion;R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,4,2,,3.0,Terminated,0,0,pathway_drug_candidates,7.0,0.176,0.349,1.0,0.83,0.0399,0.0,0.387,0.168,0.0,0.891,0.00872,0.0,0.995,0.000147,0.0,0.0339,0.526,1,0.874,0.0114,0.0,0.421,0.105,0,-5.54,-6.08,-5.0,-6.08,-5.0,5.001800000000005,0.799,0.0183,0.0,0.00176,0.98,1,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,-4.5,L
CHEMBL166863,POLMACOXIB,CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,3.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,9.0,0.434,0.139,0.0,0.293,0.251,0.5,0.183,0.337,1.0,0.496,0.0946,0.0,0.906,0.00459,0.0,0.829,0.0306,0,0.371,0.0976,0.0,0.057,0.267,1,-3.95,-4.63,-3.27,-4.63,-3.27,2.7193000000000014,0.7,0.0473,0.0,0.105,0.614,1,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,5.5,L
CHEMBL1676,FLUTICASONE FUROATE,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.0353,0.636,1.0,0.143,0.383,1.0,0.339,0.177,0.0,0.416,0.123,0.0,0.318,0.107,0.0,0.44,0.128,0,0.815,0.0187,0.0,0.546,0.0826,0,-7.12,-7.64,-6.6,-7.64,-6.6,4.9268000000000045,0.342,0.227,0.0,0.0844,0.648,1,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-1.5,L
CHEMBL1683,HYDROCORTISONE BUTYRATE,CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.531,0.0942,0.0,0.555,0.102,0.0,0.642,0.0604,0.0,0.53,0.0818,0.0,0.734,0.0195,0.0,0.545,0.102,0,0.716,0.0323,0.0,0.799,0.0213,0,-5.14,-5.88,-4.4,-5.88,-4.4,3.132600000000002,0.445,0.14,0.0,0.104,0.434,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,3.5,L
CHEMBL1683544,ERIBULIN MESYLATE,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,Tubulin inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.913,0.00989,0.0,0.949,0.0101,0.0,0.921,0.00479,0.0,0.965,0.00333,0.0,0.806,0.0151,0.0,0.784,0.0391,0,0.826,0.0145,0.0,0.615,0.0576,0,-0.189,-0.96,0.582,-0.96,0.582,2.9420000000000055,0.655,0.0647,0.0,0.565,0.0166,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,L
CHEMBL1683590,ERIBULIN,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.814,0.0224,0.0,0.706,0.0774,0.0,0.885,0.0098,0.0,0.849,0.0122,0.0,0.745,0.0186,0.0,0.934,0.0111,0,0.642,0.0356,0.0,0.349,0.136,0,-2.15,-3.03,-1.26,-3.03,-1.26,3.438000000000005,0.66,0.0656,0.0,0.492,0.0258,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,L
CHEMBL1685,DEZOCINE,C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.231,0.254,0.5,0.158,0.396,1.0,0.554,0.0912,0.0,0.408,0.122,0.0,0.262,0.161,0.5,0.474,0.124,0,0.87,0.013,0.0,0.346,0.124,0,-2.99,-3.79,-2.19,-3.79,-2.19,3.113600000000001,0.424,0.183,0.0,0.131,0.426,1,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,0.0,L
CHEMBL1688243,INCB-9471,CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,,0,0,R-HSA-173107|Binding and entry of HIV virion;R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,4,2,,2.0,Completed,0,0,pathway_drug_candidates,6.0,0.153,0.363,1.0,0.255,0.275,0.5,0.577,0.0745,0.0,0.304,0.182,0.0,0.621,0.0325,0.0,0.237,0.227,0.5,0.828,0.0181,0.0,0.546,0.0788,0,-2.45,-3.19,-1.7,-3.19,-1.7,4.815540000000005,0.067,0.862,1.0,0.0942,0.58,1,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,-3.5,L
CHEMBL1689,TOLAZOLINE HYDROCHLORIDE,Cl.c1ccc(CC2=NCCN2)cc1,,0,0,,0,0,Adrenergic receptor alpha antagonist,,,0,0,mechanism_drug_candidate,0.0,0.668,0.0611,0.0,0.0612,0.552,1.0,0.498,0.094,0.0,0.491,0.0998,0.0,0.395,0.091,0.0,0.227,0.226,0.5,0.939,0.0129,0.0,0.442,0.114,0,-1.45,-2.3,-0.601,-2.3,-0.601,1.6525999999999996,0.757,0.0253,0.0,0.0385,0.936,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-6.0,L
CHEMBL1690,HYDROXYCHLOROQUINE SULFATE,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O,TLR7;TLR9,2,2,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-168181|Toll Like Receptor 7/8 (TLR7/8) Cascade;R-HSA-5686938|Regulation of TLR by endogenous ligand;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9692916|SARS-CoV-1 activates/modulates innate immune responses;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome;R-HSA-9824856|Defective regulation of TLR7 by endogenous ligand;R-HSA-9833110|RSV-host interactions,11,0,Ferriprotoporphyrin IX inhibitor;Ferriprotoporphyrin IX inhibitor | Toll-like receptor 7 antagonist | Toll-like receptor 9 antagonist;Toll-like receptor 7 antagonist;Toll-like receptor 9 antagonist,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,9.5,0.919,0.00527,0.0,0.315,0.253,0.5,0.981,0.00049,0.0,0.98,0.00141,0.0,0.271,0.151,0.0,0.0133,0.714,1,0.2,0.179,0.0,0.0361,0.286,1,-1.8,-2.62,-0.989,-2.62,-0.989,3.1302000000000003,0.206,0.473,1.0,0.118,0.447,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,4.5,L
CHEMBL1694,BENAZEPRIL HYDROCHLORIDE,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O.Cl,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,Angiotensin-converting enzyme inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.609,0.0736,0.0,0.621,0.114,0.0,0.22,0.307,0.5,0.168,0.325,1.0,0.298,0.143,0.0,0.948,0.00969,0,0.722,0.0308,0.0,0.589,0.0691,0,-2.3,-2.8,-1.8,-2.8,-1.8,2.9949000000000017,0.659,0.0547,0.0,0.00423,0.977,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,3.5,L
CHEMBL1699,MEMANTINE HYDROCHLORIDE,CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.391,0.155,0.0,0.346,0.215,0.5,0.585,0.0768,0.0,0.453,0.104,0.0,0.454,0.0663,0.0,0.136,0.297,1,0.695,0.0397,0.0,0.548,0.0936,0,-1.1,-2.5,0.305,-2.5,0.305,3.1159000000000012,0.499,0.132,0.0,0.0119,0.971,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-2.5,L
CHEMBL1701,MEPERIDINE HYDROCHLORIDE,CCOC(=O)C1(c2ccccc2)CCN(C)CC1.Cl,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,Unknown status,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.623,0.0589,0.0,0.413,0.181,0.0,0.76,0.0282,0.0,0.206,0.282,0.5,0.251,0.172,0.5,0.913,0.0151,0,0.843,0.0132,0.0,0.152,0.172,1,-1.26,-2.02,-0.495,-2.02,-0.495,2.634900000000002,0.352,0.233,0.0,0.00347,0.985,1,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,3.0,L
CHEMBL1705,CLONIDINE HYDROCHLORIDE,Cl.Clc1cccc(Cl)c1NC1=NCCN1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.471,0.112,0.0,0.0915,0.493,1.0,0.236,0.274,0.5,0.505,0.0863,0.0,0.251,0.162,0.5,0.386,0.156,0,0.588,0.055,0.0,0.791,0.0335,0,-2.55,-4.19,-0.916,-4.19,-0.916,2.7863000000000007,0.711,0.052,0.0,0.02,0.974,1,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,0.5,L
CHEMBL1706,NAPHAZOLINE HYDROCHLORIDE,Cl.c1ccc2c(CC3=NCCN3)cccc2c1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.519,0.0976,0.0,0.352,0.215,0.5,0.626,0.0647,0.0,0.442,0.107,0.0,0.451,0.0675,0.0,0.397,0.146,0,0.142,0.295,1.0,0.28,0.151,0,-2.28,-3.14,-1.42,-3.14,-1.42,2.8058000000000005,0.573,0.0894,0.0,0.0379,0.919,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.5,L
CHEMBL1707,LOPERAMIDE HYDROCHLORIDE,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1.Cl,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.409,0.146,0.0,0.134,0.441,1.0,0.928,0.00346,0.0,0.143,0.373,1.0,0.517,0.0506,0.0,0.00472,0.865,1,0.939,0.00357,0.0,0.0133,0.408,1,-2.37,-2.91,-1.84,-2.91,-1.84,5.5098000000000065,0.0658,0.808,1.0,0.0288,0.86,1,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-2.5,L
CHEMBL1713,CHLORPROMAZINE HYDROCHLORIDE,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21.Cl,,0,0,,0,0,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.605,0.073,0.0,0.0117,0.822,1.0,0.828,0.0182,0.0,0.0856,0.528,1.0,0.0424,0.578,1.0,0.0261,0.591,1,0.518,0.0587,0.0,0.0417,0.451,1,-4.63,-5.44,-3.83,-5.44,-3.83,5.316200000000005,0.221,0.535,1.0,0.0235,0.991,1,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-11.0,L
CHEMBL1714,KETAMINE HYDROCHLORIDE,CNC1(c2ccccc2Cl)CCCCC1=O.Cl,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,3.0,"Active, not recruiting",0,0,pathway_drug_candidates,3.0,0.421,0.14,0.0,0.467,0.158,0.0,0.344,0.157,0.0,0.314,0.161,0.0,0.38,0.0906,0.0,0.278,0.195,0,0.653,0.0411,0.0,0.783,0.0267,0,-0.189,-1.09,0.715,-1.09,0.715,3.3196000000000025,0.384,0.232,0.0,0.0106,0.971,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,2.5,L
CHEMBL17157,TERFENADINE,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.29,0.222,0.5,0.032,0.677,1.0,0.406,0.142,0.0,0.487,0.0904,0.0,0.71,0.0185,0.0,0.00463,0.874,1,0.983,0.000535,0.0,0.0254,0.418,1,-6.11,-7.69,-4.52,-7.69,-4.52,6.445800000000008,0.299,0.301,0.5,0.688,0.0095,0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,2.0,1.0,1.0,-9.5,L
CHEMBL1716,CYPROHEPTADINE HYDROCHLORIDE,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.28,0.235,0.5,0.0172,0.761,1.0,0.349,0.176,0.0,0.454,0.104,0.0,0.425,0.073,0.0,0.239,0.209,0,0.574,0.053,0.0,0.0136,0.446,1,-2.33,-2.95,-1.71,-2.95,-1.71,5.119700000000004,0.455,0.136,0.0,0.00355,0.969,1,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-3.0,L
CHEMBL1717,TICLOPIDINE HYDROCHLORIDE,Cl.Clc1ccccc1CN1CCc2sccc2C1,,0,0,R-HSA-418594|G alpha (i) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.059,0.567,1.0,0.0295,0.677,1.0,0.101,0.492,1.0,0.0166,0.855,1.0,0.0621,0.453,1.0,0.723,0.0523,0,0.482,0.0672,0.0,0.486,0.115,0,-2.67,-3.22,-2.12,-3.22,-2.12,4.381600000000003,0.629,0.0577,0.0,0.00276,0.969,1,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,5.0,1.0,1.0,-3.0,L
CHEMBL1718,NALOXONE HYDROCHLORIDE,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.608,0.0696,0.0,0.137,0.436,1.0,0.673,0.0569,0.0,0.564,0.0707,0.0,0.527,0.0491,0.0,0.227,0.229,0.5,0.778,0.027,0.0,0.86,0.0374,0,-2.47,-3.64,-1.29,-3.64,-1.29,1.7231999999999998,0.285,0.364,0.5,0.0251,0.992,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-0.5,L
CHEMBL1719,OLOPATADINE HYDROCHLORIDE,CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.984,0.00484,0.0,0.282,0.275,0.5,0.694,0.0508,0.0,0.736,0.0375,0.0,0.323,0.12,0.0,0.655,0.0668,0,0.772,0.0318,0.0,0.0642,0.302,1,-2.89,-3.92,-1.87,-3.92,-1.87,4.011300000000004,0.816,0.0213,0.0,0.0253,0.976,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,L
CHEMBL1721885,SU-014813,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.338,0.168,0.0,0.926,0.0134,0.0,0.197,0.312,1.0,0.0514,0.659,1.0,0.392,0.0892,0.0,0.861,0.0229,0,0.0912,0.364,1.0,0.499,0.0983,0,-1.94,-2.5,-1.38,-2.5,-1.38,1.68624,0.408,0.266,0.5,0.0939,0.617,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-2.0,L
CHEMBL1723,ALFUZOSIN HYDROCHLORIDE,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.492,0.106,0.0,0.115,0.468,1.0,0.859,0.0108,0.0,0.738,0.0429,0.0,0.452,0.0674,0.0,0.946,0.0109,0,0.273,0.11,0.0,0.892,0.00029,0,-1.86,-2.99,-0.734,-2.99,-0.734,1.7724999999999995,0.409,0.21,0.0,0.000394,0.968,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,3.0,L
CHEMBL1735,INDINAVIR SULFATE,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O.O=S(=O)(O)O,,0,0,,0,0,Human immunodeficiency virus type 1 protease inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.0609,0.537,1.0,0.272,0.261,0.5,0.236,0.271,0.5,0.576,0.068,0.0,0.751,0.0176,0.0,0.657,0.0647,0,0.995,0.00229,0.0,0.994,0.0135,0,-0.156,-0.679,0.366,-0.679,0.366,2.2141000000000024,0.469,0.13,0.0,0.168,0.377,1,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,1.0,1.0,-5.0,L
CHEMBL17350,TRAXOPRODIL,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.349,0.18,0.0,0.109,0.44,1.0,0.743,0.0426,0.0,0.138,0.416,1.0,0.272,0.146,0.0,0.00662,0.831,1,0.771,0.0265,0.0,0.409,0.129,0,-2.59,-3.22,-1.96,-3.22,-1.96,2.7977000000000007,0.733,0.0345,0.0,0.283,0.108,0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,-5.5,L
CHEMBL1737,SILDENAFIL CITRATE,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,PDE5A,1,1,R-HSA-418457|cGMP effects;R-HSA-445355|Smooth Muscle Contraction;R-HSA-9013422|RHOBTB1 GTPase cycle,3,0,Phosphodiesterase 5A inhibitor,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.973,0.00463,0.0,0.621,0.0985,0.0,0.879,0.012,0.0,0.887,0.018,0.0,0.887,0.00727,0.0,0.0374,0.516,1,0.921,0.00922,0.0,0.933,0.0169,0,-3.77,-4.44,-3.1,-4.44,-3.1,0.362400000000005,0.956,0.0064,0.0,0.202,0.222,0.5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.5,0.0,0.0,0.0,2.5,L
CHEMBL1738757,REBASTINIB,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,1.0,Terminated,0,0,pathway_drug_candidates,1.0,0.653,0.0568,0.0,0.982,0.00143,0.0,0.433,0.132,0.0,0.884,0.0113,0.0,0.0976,0.342,1.0,0.706,0.053,0,0.823,0.02,0.0,0.124,0.204,1,-6.37,-6.89,-5.84,-6.89,-5.84,6.048000000000005,0.0318,0.866,1.0,0.17,0.29,1,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,-3.0,L
CHEMBL1738889,ENOBOSARM,C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.694,0.0442,0.0,0.925,0.0104,0.0,0.0949,0.534,1.0,0.0567,0.615,1.0,0.23,0.181,0.5,0.769,0.0428,0,0.116,0.357,1.0,0.174,0.181,0.5,-2.59,-3.25,-1.94,-3.25,-1.94,3.2172600000000013,0.269,0.39,0.5,0.471,0.0451,0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,0.0,1.0,-4.0,L
CHEMBL1741,CLARITHROMYCIN,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.518,0.0953,0.0,0.66,0.0744,0.0,0.75,0.0264,0.0,0.857,0.0195,0.0,0.837,0.0119,0.0,0.359,0.154,0,0.862,0.0145,0.0,0.431,0.0956,0,-1.99,-2.77,-1.22,-2.77,-1.22,2.439700000000004,0.513,0.118,0.0,0.761,0.0127,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,L
CHEMBL1742423,BILASTINE,CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.614,0.0658,0.0,0.782,0.0519,0.0,0.0791,0.582,1.0,0.248,0.209,0.5,0.367,0.0899,0.0,0.669,0.0645,0,0.752,0.0366,0.0,0.989,0.00928,0,-3.91,-4.58,-3.23,-4.58,-3.23,4.857100000000004,0.46,0.15,0.0,0.474,0.0362,0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,0.0,L
CHEMBL1742461,LAFUTIDINE,O=C(C[S+]([O-])Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1,,0,0,R-HSA-418555|G alpha (s) signalling events,1,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.713,0.0556,0.0,0.185,0.355,1.0,0.81,0.0193,0.0,0.628,0.0595,0.0,0.557,0.0488,0.0,0.394,0.148,0,0.634,0.0455,0.0,0.419,0.137,0,0.05,-0.9,1.0,-0.9,1.0,2.6606000000000014,0.449,0.187,0.0,0.366,0.0627,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,2.0,L
CHEMBL1742471,EBROTIDINE,NC(N)=Nc1nc(CSCCN/C=N/S(=O)(=O)c2ccc(Br)cc2)cs1,,0,0,,0,0,Histamine H2 receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.0893,0.478,1.0,0.0225,0.718,1.0,0.394,0.148,0.0,0.167,0.329,1.0,0.249,0.184,0.5,0.663,0.0678,0,0.605,0.0482,0.0,0.626,0.0589,0,-4.13,-4.86,-3.4,-4.86,-3.4,2.0505,0.693,0.0473,0.0,0.0672,0.572,1,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,4.0,1.0,1.0,-8.0,L
CHEMBL1742982,AFLIBERCEPT,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1234158|Regulation of gene expression by Hypoxia-inducible Factor;R-HSA-194138|Signaling by VEGF;R-HSA-194313|VEGF ligand-receptor interactions;R-HSA-195399|VEGF binds to VEGFR leading to receptor dimerization;R-HSA-4420097|VEGFA-VEGFR2 Pathway;R-HSA-5218921|VEGFR2 mediated cell proliferation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9679191|Potential therapeutics for SARS,10,2,,4.0,,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL1742994,BRENTUXIMAB VEDOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,4.0,,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL1743026,GEVOKIZUMAB,,,0,0,R-HSA-448706|Interleukin-1 processing;R-HSA-5620971|Pyroptosis;R-HSA-5660668|CLEC7A/inflammasome pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9020702|Interleukin-1 signaling;R-HSA-9660826|Purinergic signaling in leishmaniasis infection,7,4,,3.0,Terminated,0,0,pathway_drug_candidates,11.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,11.0,H
CHEMBL1743028,GLEMBATUMUMAB VEDOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL1743033,ITOLIZUMAB,,,0,0,,0,0,T-cell differentiation antigen CD6 inhibitor,,,1,1,known_drugs;mechanism_of_actions,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL1743034,IXEKIZUMAB,,IL17A,1,0,R-HSA-448424|Interleukin-17 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses,3,2,Interleukin 17A inhibitor,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,11.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,12.5,H
CHEMBL1743037,LORVOTUZUMAB MERTANSINE,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL1743044,NAMILUMAB,,,0,0,"R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling",3,2,,2.0,Terminated,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL1743050,OLOKIZUMAB,,IL6,1,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8957275|Post-translational protein phosphorylation,7,3,Interleukin-6 inhibitor,3.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,12.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,12.5,H
CHEMBL1743054,OZORALIZUMAB,,TNF,1,1,R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,4,2,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL1743057,PEGSUNERCEPT,,TNF,1,1,R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,4,2,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL1743068,SECUKINUMAB,,,0,0,R-HSA-448424|Interleukin-17 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses,3,2,,4.0,,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL1743070,SILTUXIMAB,,IL6,1,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8957275|Post-translational protein phosphorylation,7,3,Interleukin-6 antagonist,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,13.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,14.5,H
CHEMBL1743071,SIRUKUMAB,,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8957275|Post-translational protein phosphorylation,7,3,,3.0,,0,0,pathway_drug_candidates,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,9.0,M
CHEMBL1743082,TRASTUZUMAB EMTANSINE,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,4.0,,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL1744447,ROSUVASTATIN CALCIUM,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2],,0,0,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,HMG-CoA reductase inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.993,0.000517,0.0,0.843,0.0356,0.0,0.0283,0.773,1.0,0.374,0.151,0.0,0.934,0.00259,0.0,0.982,0.00201,0,0.93,0.00864,0.0,0.886,0.0229,0,-3.28,-3.64,-2.92,-3.64,-2.92,1.7532000000000014,0.608,0.0765,0.0,0.119,0.445,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,2.5,L
CHEMBL175,DEXIBUPROFEN,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.658,0.0575,0.0,0.608,0.0895,0.0,0.245,0.271,0.5,0.542,0.0806,0.0,0.77,0.013,0.0,0.563,0.0987,0,0.565,0.0528,0.0,0.808,0.03,0,-3.87,-4.74,-2.99,-4.74,-2.99,3.073200000000001,0.924,0.0042,0.0,0.643,0.0168,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,8.0,H
CHEMBL1752,DYPHYLLINE,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,Phosphodiesterase 4 inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.595,0.0681,0.0,0.766,0.0589,0.0,0.407,0.144,0.0,0.75,0.0395,0.0,0.531,0.047,0.0,0.919,0.014,0,0.506,0.0603,0.0,0.955,0.0175,0,-0.0639,-0.658,0.53,-0.658,0.53,-2.213099999999999,0.793,0.0209,0.0,0.163,0.294,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,3.0,L
CHEMBL1754,DOXAPRAM,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O,,0,0,R-HSA-1299316|TWIK-releated acid-sensitive K+ channel (TASK);R-HSA-5576886|Phase 4 - resting membrane potential,2,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.129,0.389,1.0,0.339,0.225,0.5,0.59,0.0766,0.0,0.178,0.33,1.0,0.596,0.0393,0.0,0.449,0.128,0,0.445,0.0649,0.0,0.737,0.0543,0,-1.85,-3.15,-0.554,-3.15,-0.554,3.173300000000001,0.275,0.435,0.5,0.0601,0.841,1,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-1.5,L
CHEMBL1762621,BARDOXOLONE METHYL,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,,0,0,"R-HSA-112409|MAP3K8 (TPL2)-dependent MAPK1/3 activation;R-HSA-1169091|Activation of NF-kappaB in B cells;R-HSA-1236974|ER-Phagosome pathway;R-HSA-168638|NOD1/2 Signaling Pathway;R-HSA-168927|TICAM1, RIP1-mediated IKK complex recruitment;R-HSA-1810476|RIP-mediated NFkB activation via ZBP1;R-HSA-202424|Downstream TCR signaling;R-HSA-209543|p75NTR recruits signalling complexes;R-HSA-209560|NF-kB is activated and signals survival;R-HSA-2871837|FCERI mediated NF-kB activation;R-HSA-2871837|NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10;R-HSA-445989|TAK1-dependent IKK and NF-kappa-B activation;R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-5602636|IKBKB deficiency causes SCID;R-HSA-5603027|IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR);R-HSA-5603029|IkBA variant leads to EDA-ID;R-HSA-5607764|CLEC7A (Dectin-1) signaling;R-HSA-9020702|Interleukin-1 signaling;R-HSA-933542|TRAF6 mediated NF-kB activation;R-HSA-937039|IRAK1 recruits IKK complex;R-HSA-937041|IKK complex recruitment mediated by RIP1;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-975144|IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation;R-HSA-9758274|Regulation of NF-kappa B signaling;R-HSA-9833482|PKR-mediated signaling;R-HSA-9860276|SLC15A4:TASL-dependent IRF5 activation;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells;R-HSA-9909505|Modulation of host responses by IFN-stimulated genes",29,5,,3.0,Terminated,0,0,pathway_drug_candidates,13.0,0.409,0.148,0.0,0.621,0.0897,0.0,0.833,0.0204,0.0,0.687,0.0474,0.0,0.0622,0.464,1.0,0.42,0.136,0,0.462,0.0657,0.0,0.121,0.248,1,-6.03,-6.97,-5.08,-6.97,-5.08,6.378980000000007,0.265,0.35,0.5,0.206,0.178,0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,7.5,M
CHEMBL1764,LEVOMEPROMAZINE,COc1ccc2c(c1)N(C[C@H](C)CN(C)C)c1ccccc1S2,,0,0,,0,0,D2-like dopamine receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.295,0.209,0.0,0.0108,0.815,1.0,0.609,0.0652,0.0,0.588,0.0668,0.0,0.318,0.122,0.0,0.139,0.286,1,0.437,0.0691,0.0,0.0257,0.4,1,-4.67,-5.96,-3.39,-5.96,-3.39,4.495600000000004,0.131,0.634,1.0,0.0681,0.663,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,-8.0,L
CHEMBL1766,DESOXIMETASONE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.344,0.167,0.0,0.41,0.168,0.0,0.225,0.305,0.5,0.429,0.116,0.0,0.636,0.028,0.0,0.136,0.298,1,0.527,0.0576,0.0,0.486,0.096,0,-3.73,-4.56,-2.9,-4.56,-2.9,2.7808000000000015,0.412,0.179,0.0,0.103,0.424,1,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-0.5,L
CHEMBL1767164,GSK-1004723,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.0473,0.661,1.0,0.00449,0.905,1.0,0.374,0.146,0.0,0.669,0.0468,0.0,0.033,0.646,1.0,0.125,0.305,1,0.134,0.269,1.0,0.125,0.223,1,-7.89,-8.49,-7.3,-8.49,-7.3,7.772900000000009,0.359,0.32,0.5,0.124,0.539,1,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-14.5,L
CHEMBL1770248,ERTUGLIFLOZIN,CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1,,0,0,,0,0,Sodium/glucose cotransporter 2 inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.741,0.0367,0.0,0.881,0.0274,0.0,0.00314,0.975,1.0,0.35,0.152,0.0,0.143,0.26,1.0,0.189,0.244,1,0.155,0.266,1.0,0.28,0.133,0,-5.47,-5.93,-5.0,-5.93,-5.0,1.3564999999999994,0.654,0.0571,0.0,0.254,0.138,0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,-11.0,L
CHEMBL1771,CLOPIDOGREL,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,,0,0,R-HSA-418594|G alpha (i) signalling events,1,0,,4.0,,1,0,known_drugs;pathway_drug_candidates,5.5,0.044,0.608,1.0,0.0387,0.626,1.0,0.103,0.484,1.0,0.155,0.37,1.0,0.0784,0.411,1.0,0.678,0.0613,0,0.461,0.073,0.0,0.325,0.14,0,-3.66,-4.17,-3.14,-4.17,-3.14,3.6739000000000024,0.268,0.33,0.5,0.15,0.396,1,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,5.0,1.0,1.0,-0.5,L
CHEMBL1773,CAPECITABINE,CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,,0,0,,0,0,RNA inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.665,0.0552,0.0,0.603,0.0972,0.0,0.513,0.1,0.0,0.882,0.011,0.0,0.845,0.00994,0.0,0.635,0.0765,0,0.72,0.0339,0.0,0.503,0.0876,0,-4.01,-4.95,-3.07,-4.95,-3.07,0.7601999999999995,0.659,0.0546,0.0,0.0669,0.828,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-2.5,L
CHEMBL1779710,EVOGLIPTIN,CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,,0,0,,0,0,Dipeptidyl peptidase IV inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.463,0.122,0.0,0.406,0.183,0.0,0.247,0.258,0.5,0.572,0.0683,0.0,0.88,0.00722,0.0,0.893,0.0212,0,0.0993,0.382,1.0,0.169,0.186,1,-0.731,-1.47,0.00665,-1.47,0.00665,1.5058999999999998,0.341,0.23,0.0,0.125,0.367,1,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,-4.0,L
CHEMBL17860,LOFEXIDINE,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.293,0.22,0.5,0.102,0.464,1.0,0.431,0.157,0.0,0.401,0.135,0.0,0.0368,0.585,1.0,0.441,0.127,0,0.323,0.122,0.0,0.364,0.14,0,-2.81,-3.29,-2.33,-3.29,-2.33,2.7624000000000004,0.67,0.0709,0.0,0.264,0.12,0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,3.0,1.0,1.0,-1.5,L
CHEMBL178803,BLONANSERIN,CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.664,0.0539,0.0,0.972,0.00286,0.0,0.676,0.0573,0.0,0.669,0.0441,0.0,0.167,0.247,0.5,0.386,0.149,0,0.966,0.00663,0.0,0.0778,0.219,1,-3.94,-4.65,-3.24,-4.65,-3.24,4.6886000000000045,0.0641,0.811,1.0,0.0662,0.529,1,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,-2.5,L
CHEMBL1788132,LOFEXIDINE HYDROCHLORIDE,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.343,0.178,0.0,0.145,0.417,1.0,0.498,0.126,0.0,0.407,0.131,0.0,0.0397,0.571,1.0,0.412,0.139,0,0.323,0.122,0.0,0.364,0.141,0,-2.18,-2.69,-1.66,-2.69,-1.66,3.184200000000002,0.734,0.0569,0.0,0.0497,0.915,1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,1.0,L
CHEMBL1789941,RUXOLITINIB,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",27,13,,4.0,,1,0,known_drugs;pathway_drug_candidates,15.5,0.372,0.162,0.0,0.274,0.293,0.5,0.799,0.0284,0.0,0.596,0.0606,0.0,0.0244,0.672,1.0,0.839,0.0302,0,0.419,0.0708,0.0,0.403,0.127,0,-3.09,-3.72,-2.46,-3.72,-2.46,3.466380000000001,0.129,0.702,1.0,0.185,0.22,1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,15.0,M
CHEMBL1790041,RANITIDINE,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,,0,0,R-HSA-418555|G alpha (s) signalling events,1,0,Histamine H2 receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.597,0.0813,0.0,0.0974,0.484,1.0,0.217,0.298,0.5,0.257,0.226,0.5,0.718,0.0242,0.0,0.441,0.121,0,0.601,0.0536,0.0,0.92,0.0157,0,-2.28,-3.19,-1.36,-3.19,-1.36,1.459,0.153,0.72,1.0,0.865,0.00672,0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,3.0,0.0,1.0,2.0,L
CHEMBL1795071,RUXOLITINIB PHOSPHATE,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",27,13,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,14.0,0.578,0.069,0.0,0.301,0.256,0.5,0.855,0.0162,0.0,0.733,0.0349,0.0,0.0449,0.566,1.0,0.847,0.0271,0,0.682,0.0359,0.0,0.565,0.109,0,-2.99,-3.78,-2.2,-3.78,-2.2,2.537780000000001,0.24,0.484,1.0,0.173,0.264,1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,0.0,1.0,13.0,M
CHEMBL17976,RESINIFERATOXIN,C=C(C)[C@]12C[C@@H](C)[C@@]34O[C@](Cc5ccccc5)(O[C@@H]1[C@@H]3C=C(COC(=O)Cc1ccc(O)c(OC)c1)C[C@]1(O)C(=O)C(C)=C[C@@H]41)O2,,0,0,R-HSA-3295583|TRP channels,1,0,,1.0,Completed,0,0,pathway_drug_candidates,1.0,0.834,0.0193,0.0,0.158,0.401,1.0,0.747,0.049,0.0,0.177,0.327,1.0,0.204,0.208,0.5,0.67,0.0617,0,0.892,0.0156,0.0,0.482,0.121,0,-5.43,-5.8,-5.06,-5.8,-5.06,4.744700000000005,0.116,0.743,1.0,0.289,0.117,0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,3.0,0.0,1.0,-4.0,L
CHEMBL1808388,BEXAGLIFLOZIN,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,,0,0,,0,0,Sodium/glucose cotransporter 2 inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.943,0.00914,0.0,0.847,0.0383,0.0,0.026,0.788,1.0,0.331,0.168,0.0,0.214,0.198,0.5,0.757,0.0452,0,0.162,0.249,1.0,0.0705,0.297,1,-4.31,-4.9,-3.71,-4.9,-3.71,2.0034999999999994,0.785,0.0266,0.0,0.365,0.0705,0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,-7.0,L
CHEMBL182066,RADIPRODIL,O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.735,0.0379,0.0,0.0882,0.495,1.0,0.103,0.45,1.0,0.658,0.0514,0.0,0.749,0.0224,0.0,0.539,0.104,0,0.952,0.0127,0.0,0.0866,0.254,1,-3.91,-4.78,-3.04,-4.78,-3.04,3.0923000000000016,0.264,0.421,0.5,0.102,0.595,1,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-2.0,L
CHEMBL1835207,APRICOXIB,CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,8.0,0.813,0.0223,0.0,0.809,0.0426,0.0,0.375,0.167,0.0,0.828,0.0207,0.0,0.794,0.0153,0.0,0.241,0.219,0,0.148,0.246,1.0,0.164,0.172,1,-3.79,-4.52,-3.07,-4.52,-3.07,3.498820000000001,0.618,0.0724,0.0,0.104,0.662,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,4.0,L
CHEMBL185,FLUOROURACIL,O=c1[nH]cc(F)c(=O)[nH]1,,0,0,,0,0,RNA inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.308,0.191,0.0,0.482,0.148,0.0,0.203,0.308,0.5,0.743,0.0365,0.0,0.483,0.0578,0.0,0.783,0.0373,0,0.428,0.086,0.0,0.312,0.16,0,-1.41,-2.14,-0.668,-2.14,-0.668,-0.7977000000000001,0.714,0.0535,0.0,0.709,0.0201,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-2.0,L
CHEMBL1873475,IBRUTINIB,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,Tyrosine-protein kinase BTK inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.57,0.0814,0.0,0.88,0.0191,0.0,0.615,0.0782,0.0,0.111,0.441,1.0,0.283,0.138,0.0,0.375,0.156,0,0.222,0.167,0.0,0.53,0.0917,0,-4.83,-5.54,-4.12,-5.54,-4.12,4.2173000000000025,0.114,0.835,1.0,0.084,0.813,1,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,4.0,L
CHEMBL187927,DIANICLINE,c1cnc2c(c1)O[C@H]1CCN3CC[C@@]1(C2)C3,,0,0,R-HSA-629587|Highly sodium permeable postsynaptic acetylcholine nicotinic receptors;R-HSA-629594|Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;R-HSA-629597|Highly calcium permeable nicotinic acetylcholine receptors,3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.458,0.122,0.0,0.189,0.364,1.0,0.799,0.0246,0.0,0.54,0.0782,0.0,0.281,0.14,0.0,0.0121,0.736,1,0.482,0.062,0.0,0.462,0.122,0,-2.39,-3.75,-1.02,-3.75,-1.02,1.4809,0.449,0.186,0.0,0.291,0.097,0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,-3.5,L
CHEMBL188462,ISPRONICLINE,CN[C@@H](C)C/C=C/c1cncc(OC(C)C)c1,,0,0,R-HSA-629587|Highly sodium permeable postsynaptic acetylcholine nicotinic receptors;R-HSA-629594|Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;R-HSA-629597|Highly calcium permeable nicotinic acetylcholine receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.215,0.296,0.5,0.0207,0.755,1.0,0.1,0.48,1.0,0.138,0.374,1.0,0.365,0.0986,0.0,0.251,0.207,0,0.726,0.0272,0.0,0.539,0.0671,0,-1.25,-1.83,-0.666,-1.83,-0.666,2.8800000000000017,0.342,0.235,0.0,0.204,0.206,0.5,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.5,4.0,1.0,1.0,-4.0,L
CHEMBL188952,PIRPROFEN,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.866,0.0165,0.0,0.309,0.217,0.5,0.21,0.333,0.5,0.512,0.0906,0.0,0.384,0.0862,0.0,0.31,0.183,0,0.671,0.0438,0.0,0.951,0.00471,0,-3.25,-4.22,-2.28,-4.22,-2.28,2.904300000000001,0.71,0.0338,0.0,0.272,0.119,0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,7.5,M
CHEMBL189171,ACEMETACIN,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.425,0.128,0.0,0.715,0.0685,0.0,0.418,0.132,0.0,0.653,0.0522,0.0,0.43,0.0715,0.0,0.887,0.0212,0,0.838,0.0187,0.0,0.976,0.00705,0,-4.6,-5.06,-4.14,-5.06,-4.14,3.4705200000000014,0.215,0.46,1.0,0.326,0.0635,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,H
CHEMBL190,THEOPHYLLINE,Cn1c(=O)c2[nH]cnc2n(C)c1=O,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.426,0.137,0.0,0.689,0.0677,0.0,0.747,0.0375,0.0,0.828,0.0218,0.0,0.413,0.0753,0.0,0.416,0.134,0,0.638,0.0436,0.0,0.844,0.0223,0,-1.58,-2.53,-0.623,-2.53,-0.623,-1.0397000000000003,0.845,0.0156,0.0,0.364,0.0501,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,L
CHEMBL19019,NALTREXONE,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,Completed,0,0,pathway_drug_candidates,6.0,0.399,0.149,0.0,0.106,0.428,1.0,0.285,0.219,0.5,0.519,0.09,0.0,0.772,0.0129,0.0,0.152,0.284,1,0.739,0.0271,0.0,0.805,0.0192,0,-3.69,-4.96,-2.43,-4.96,-2.43,1.5254,0.246,0.368,1.0,0.0755,0.565,1,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,0.0,1.0,0.0,L
CHEMBL1908376,SEOCALCITOL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/C=C/C(O)(CC)CC)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,3.0,Terminated,0,0,pathway_drug_candidates,3.0,0.823,0.0292,0.0,0.517,0.128,0.0,0.308,0.194,0.0,0.597,0.0557,0.0,0.603,0.0427,0.0,0.667,0.0654,0,0.677,0.0413,0.0,0.171,0.188,0.5,-5.04,-5.46,-4.61,-5.46,-4.61,6.42700000000001,0.418,0.25,0.0,0.201,0.206,0.5,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.5,0.0,0.0,1.0,-1.5,L
CHEMBL1908391,MASITINIB,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.207,0.31,1.0,0.016,0.797,1.0,0.215,0.309,0.5,0.982,0.0023,0.0,0.638,0.0344,0.0,0.846,0.0269,0,0.927,0.00819,0.0,0.163,0.218,1,-0.884,-1.79,0.0163,-1.79,0.0163,5.256820000000005,0.143,0.627,1.0,0.0275,0.907,1,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-2.0,L
CHEMBL1908397,KW-2449,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,1.0,Terminated,0,0,pathway_drug_candidates,1.0,0.638,0.0602,0.0,0.598,0.0851,0.0,0.147,0.426,1.0,0.395,0.128,0.0,0.234,0.173,0.5,0.659,0.0647,0,0.586,0.0659,0.0,0.585,0.0981,0,-3.04,-3.64,-2.44,-3.64,-2.44,2.7787000000000006,0.568,0.0764,0.0,0.142,0.35,1,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-1.5,L
CHEMBL191,LOSARTAN,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,,4.0,,1,0,known_drugs;pathway_drug_candidates,5.5,0.697,0.0479,0.0,0.936,0.0106,0.0,0.878,0.0081,0.0,0.758,0.0335,0.0,0.443,0.0697,0.0,0.855,0.0274,0,0.968,0.00361,0.0,0.769,0.0402,0,-4.67,-5.84,-3.5,-5.84,-3.5,4.2668000000000035,0.705,0.033,0.0,0.657,0.0132,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,L
CHEMBL191413,REPARIXIN,,,0,0,,0,0,Interleukin-8 receptor A modulator;Interleukin-8 receptor B modulator,,,1,1,known_drugs;mechanism_of_actions,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL192,SILDENAFIL,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,,0,0,R-HSA-418457|cGMP effects;R-HSA-445355|Smooth Muscle Contraction;R-HSA-9013422|RHOBTB1 GTPase cycle,3,0,,4.0,Unknown status,1,0,known_drugs;pathway_drug_candidates,5.5,0.532,0.0843,0.0,0.545,0.124,0.0,0.795,0.02,0.0,0.325,0.157,0.0,0.692,0.0203,0.0,0.638,0.0731,0,0.803,0.0223,0.0,0.533,0.104,0,-4.14,-4.8,-3.49,-4.8,-3.49,1.6109,0.511,0.125,0.0,0.14,0.36,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,4.5,L
CHEMBL1922235,DAREXABAN,COc1ccc(C(=O)Nc2cccc(O)c2NC(=O)c2ccc(N3CCCN(C)CC3)cc2)cc1,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.624,0.0618,0.0,0.107,0.467,1.0,0.39,0.158,0.0,0.756,0.0296,0.0,0.596,0.035,0.0,0.556,0.0975,0,0.687,0.0281,0.0,0.0177,0.468,1,-3.32,-4.49,-2.15,-4.49,-2.15,4.047300000000003,0.0742,0.795,1.0,0.233,0.196,0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.5,L
CHEMBL1928262,GISADENAFIL,CCOc1ncc(S(=O)(=O)N2CCN(CC)CC2)cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1,,0,0,R-HSA-418457|cGMP effects;R-HSA-445355|Smooth Muscle Contraction;R-HSA-9013422|RHOBTB1 GTPase cycle,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.65,0.0671,0.0,0.628,0.0836,0.0,0.447,0.111,0.0,0.651,0.0524,0.0,0.642,0.0287,0.0,0.799,0.0363,0,0.802,0.0252,0.0,0.605,0.0741,0,-2.37,-2.82,-1.92,-2.82,-1.92,1.1153000000000004,0.289,0.36,0.5,0.251,0.173,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.5,L
CHEMBL1929396,ANAGLIPTIN,Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1,,0,0,,0,0,Dipeptidyl peptidase IV inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.341,0.185,0.0,0.293,0.264,0.5,0.537,0.0918,0.0,0.723,0.0414,0.0,0.161,0.247,0.5,0.873,0.0248,0,0.613,0.0471,0.0,0.581,0.0435,0,-1.3,-1.94,-0.661,-1.94,-0.661,0.6503000000000008,0.135,0.695,1.0,0.172,0.253,1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-1.0,L
CHEMBL19299,LOXOPROFEN,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,3.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,9.0,0.832,0.0199,0.0,0.701,0.0626,0.0,0.423,0.136,0.0,0.717,0.041,0.0,0.855,0.0078,0.0,0.515,0.108,0,0.225,0.179,0.0,0.788,0.0499,0,-3.29,-3.99,-2.59,-3.99,-2.59,2.7864000000000013,0.902,0.0117,0.0,0.581,0.0295,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,8.5,M
CHEMBL193240,ROFLUMILAST,O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,Phosphodiesterase 4 inhibitor,4.0,Completed;Recruiting,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.0306,0.672,1.0,0.0149,0.796,1.0,0.0205,0.882,1.0,0.0907,0.53,1.0,0.316,0.128,0.0,0.408,0.138,0,0.811,0.0229,0.0,0.176,0.192,0.5,-5.55,-6.17,-4.93,-6.17,-4.93,5.030900000000003,0.112,0.726,1.0,0.155,0.348,1,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,4.0,1.0,1.0,-5.0,L
CHEMBL1944698,ZOTIRACICLIB,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;RMTs methylate histone arginines",21,9,,1.0,Completed,0,0,pathway_drug_candidates,11.0,0.426,0.164,0.0,0.18,0.346,1.0,0.171,0.372,1.0,0.0362,0.772,1.0,0.254,0.175,0.5,0.433,0.141,0,0.141,0.286,1.0,0.276,0.158,0,-3.14,-3.97,-2.31,-3.97,-2.31,4.657700000000004,0.161,0.653,1.0,0.304,0.112,0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,4.0,0.0,1.0,5.5,L
CHEMBL19449,IBUDILAST,CC(C)C(=O)c1c(C(C)C)nn2ccccc12,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418457|cGMP effects;R-HSA-418555|G alpha (s) signalling events;R-HSA-445355|Smooth Muscle Contraction;R-HSA-9013422|RHOBTB1 GTPase cycle;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",6,0,Phosphodiesterase 4 inhibitor | Phosphodiesterase 5A inhibitor,3.0,Recruiting,0,0,pathway_drug_candidates;mechanism_drug_candidate,3.0,0.0951,0.466,1.0,0.0329,0.683,1.0,0.114,0.478,1.0,0.201,0.283,0.5,0.0637,0.443,1.0,0.309,0.183,0,0.359,0.102,0.0,0.203,0.169,0,-2.06,-2.94,-1.17,-2.94,-1.17,3.296400000000002,0.518,0.153,0.0,0.214,0.185,0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,1.0,1.0,-4.0,L
CHEMBL1946170,REGORAFENIB,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,,0,0,"R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",4,0,MAP kinase p38 beta inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.473,0.122,0.0,0.863,0.0294,0.0,0.793,0.0337,0.0,0.596,0.0782,0.0,0.188,0.225,0.5,0.471,0.131,0,0.915,0.0126,0.0,0.184,0.197,0.5,-6.84,-7.6,-6.08,-7.6,-6.08,5.688800000000002,0.123,0.722,1.0,0.161,0.372,1,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,L
CHEMBL1951095,ERAVACYCLINE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.944,0.00604,0.0,0.771,0.0543,0.0,0.223,0.31,0.5,0.768,0.0332,0.0,0.548,0.047,0.0,0.932,0.0127,0,0.831,0.0206,0.0,0.946,0.009,0,-3.32,-3.95,-2.69,-3.95,-2.69,0.2940000000000011,0.939,0.00341,0.0,0.227,0.169,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-2.0,L
CHEMBL1951143,FIMASARTAN,CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,,3.0,,0,0,pathway_drug_candidates,3.0,0.862,0.0202,0.0,0.953,0.00642,0.0,0.833,0.0163,0.0,0.486,0.096,0.0,0.758,0.0178,0.0,0.815,0.0385,0,0.978,0.00414,0.0,0.868,0.034,0,-4.19,-5.13,-3.25,-5.13,-3.25,4.221220000000003,0.679,0.0697,0.0,0.187,0.228,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.5,L
CHEMBL1951914,AZD5672,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1,,0,0,R-HSA-173107|Binding and entry of HIV virion;R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,4,2,,2.0,Completed,0,0,pathway_drug_candidates,6.0,0.958,0.00604,0.0,0.352,0.24,0.5,0.774,0.023,0.0,0.952,0.00638,0.0,0.998,0.00209,0.0,0.774,0.0386,0,0.866,0.0158,0.0,0.565,0.075,0,-3.12,-3.65,-2.59,-3.65,-2.59,4.069200000000003,0.101,0.725,1.0,0.0878,0.685,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,5.5,L
CHEMBL1963681,AVANAFIL,COc1ccc(CNc2nc(N3CCC[C@H]3CO)ncc2C(=O)NCc2ncccn2)cc1Cl,,0,0,R-HSA-418457|cGMP effects;R-HSA-445355|Smooth Muscle Contraction;R-HSA-9013422|RHOBTB1 GTPase cycle,3,0,Phosphodiesterase 5A inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.0476,0.609,1.0,0.0247,0.713,1.0,0.738,0.0447,0.0,0.803,0.0236,0.0,0.0647,0.442,1.0,0.874,0.0218,0,0.46,0.0764,0.0,0.538,0.113,0,-2.8,-3.42,-2.17,-3.42,-2.17,2.4318,0.102,0.786,1.0,0.19,0.263,1,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,3.0,1.0,1.0,0.0,L
CHEMBL1980297,ILORASERTIB,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12,,0,0,R-HSA-5673001|RAF/MAP kinase cascade,1,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.636,0.0541,0.0,0.271,0.283,0.5,0.0126,0.894,1.0,0.127,0.389,1.0,0.214,0.197,0.5,0.936,0.011,0,0.78,0.0243,0.0,0.369,0.125,0,-4.64,-5.23,-4.05,-5.23,-4.05,5.184400000000003,0.606,0.0653,0.0,0.0795,0.658,1,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,4.0,0.0,1.0,-4.5,L
CHEMBL1980391,RG-1530,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2,,0,0,R-HSA-5673001|RAF/MAP kinase cascade,1,0,,1.0,Completed,0,0,pathway_drug_candidates,1.0,0.11,0.452,1.0,0.116,0.412,1.0,0.03,0.79,1.0,0.0926,0.526,1.0,0.108,0.333,1.0,0.268,0.204,0,0.439,0.0742,0.0,0.179,0.157,0,-4.69,-5.36,-4.01,-5.36,-4.01,4.745320000000002,0.346,0.231,0.0,0.0839,0.606,1,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,5.0,1.0,1.0,-8.5,L
CHEMBL1981592,AVIPTADIL,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O,ADRA1A,1,1,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,Adrenergic receptor alpha antagonist,3.0,Withdrawn,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,6.5,0.546,0.0996,0.0,0.999,0.00172,0.0,0.939,0.00415,0.0,0.996,0.000744,0.0,0.999,0.000743,0.0,1.0,0.000316,0,0.588,0.0648,0.0,0.986,0.00655,0,0.405,0.044,0.767,0.044,0.767,-14.616860000000129,0.974,0.00248,0.0,0.909,0.00281,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.5,L
CHEMBL198362,RIVAROXABAN,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,F10,1,1,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,Coagulation factor X inhibitor,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.759,0.0354,0.0,0.646,0.0792,0.0,0.105,0.507,1.0,0.0949,0.559,1.0,0.113,0.365,1.0,0.302,0.182,0,0.384,0.103,0.0,0.554,0.104,0,-5.08,-5.65,-4.51,-5.65,-4.51,2.5199000000000007,0.28,0.404,0.5,0.103,0.551,1,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,3.5,L
CHEMBL2,PRAZOSIN,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.525,0.103,0.0,0.299,0.237,0.5,0.58,0.0828,0.0,0.778,0.0297,0.0,0.628,0.0254,0.0,0.587,0.0917,0,0.158,0.243,1.0,0.825,0.0351,0,-4.77,-5.88,-3.65,-5.88,-3.65,1.7845999999999995,0.668,0.0666,0.0,0.186,0.25,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-1.0,L
CHEMBL2018096,IPRAGLIFLOZIN,OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,,0,0,,0,0,Sodium/glucose cotransporter 2 inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.507,0.165,0.0,0.585,0.113,0.0,0.00902,0.944,1.0,0.378,0.137,0.0,0.471,0.0606,0.0,0.972,0.00482,0,0.817,0.0312,0.0,0.137,0.204,1,-4.18,-4.72,-3.65,-4.72,-3.65,2.1461,0.805,0.0201,0.0,0.185,0.237,1,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,-4.0,L
CHEMBL2021430,DEXAMETHASONE SODIUM PHOSPHATE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.0507,0.599,1.0,0.985,0.00139,0.0,0.565,0.0857,0.0,0.532,0.0842,0.0,0.973,0.00167,0.0,0.411,0.142,0,0.863,0.012,0.0,0.307,0.128,0,-2.56,-3.44,-1.69,-3.44,-1.69,-5.243299999999994,0.664,0.052,0.0,0.212,0.2,0.5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.5,1.0,1.0,1.0,1.5,L
CHEMBL2023895,HYDROXYSTILBAMIDINE ISETHIONATE,N=C(N)c1ccc(/C=C/c2ccc(C(=N)N)cc2O)cc1.O=S(=O)(O)CCO.O=S(=O)(O)CCO,,0,0,,0,0,RNA inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.973,0.00332,0.0,0.977,0.0018,0.0,0.725,0.0504,0.0,0.882,0.0126,0.0,0.981,0.000777,0.0,0.937,0.0135,0,0.604,0.0505,0.0,0.868,0.0257,0,-0.457,-1.28,0.361,-1.28,0.361,-0.1362599999999987,0.815,0.0133,0.0,0.693,0.011,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,L
CHEMBL2028661,AZILSARTAN MEDOXOMIL,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,,3.0,,0,0,pathway_drug_candidates,3.0,0.319,0.2,0.0,0.878,0.0328,0.0,0.479,0.131,0.0,0.53,0.0839,0.0,0.0492,0.497,1.0,0.0831,0.369,1,0.977,0.00515,0.0,0.594,0.0683,0,-6.95,-7.59,-6.3,-7.59,-6.3,4.705220000000004,0.385,0.247,0.0,0.205,0.19,0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-6.5,L
CHEMBL2035187,PACRITINIB,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;RMTs methylate histone arginines",21,9,Tyrosine-protein kinase JAK2 inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,14.0,0.992,0.000875,0.0,0.282,0.254,0.5,0.219,0.322,0.5,0.0636,0.634,1.0,0.349,0.103,0.0,0.0287,0.549,1,0.642,0.0378,0.0,0.481,0.101,0,-5.38,-6.74,-4.02,-6.74,-4.02,4.466800000000004,0.807,0.0168,0.0,0.0861,0.539,1,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,0.0,1.0,3.5,L
CHEMBL2040682,CICLESONIDE,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.31,0.208,0.0,0.728,0.0721,0.0,0.891,0.011,0.0,0.526,0.0859,0.0,0.605,0.0365,0.0,0.539,0.0982,0,0.648,0.0448,0.0,0.61,0.0483,0,-5.56,-5.99,-5.12,-5.99,-5.12,4.703900000000005,0.288,0.335,0.5,0.04,0.838,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,5.0,L
CHEMBL2062257,BRIMONIDINE TARTRATE,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.908,0.0129,0.0,0.327,0.237,0.5,0.825,0.0178,0.0,0.978,0.00276,0.0,0.481,0.0691,0.0,0.0925,0.354,1,0.278,0.159,0.0,0.856,0.0337,0,-1.16,-2.0,-0.325,-2.0,-0.325,-0.3592000000000004,0.869,0.0128,0.0,0.159,0.313,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-3.0,L
CHEMBL2062264,PHENYLEPHRINE BITARTRATE,CNC[C@H](O)c1cccc(O)c1.O=C(O)C(O)C(O)C(=O)O,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.896,0.0124,0.0,0.645,0.0921,0.0,0.916,0.00493,0.0,0.99,0.00129,0.0,0.893,0.00449,0.0,0.904,0.0192,0,0.893,0.00987,0.0,0.12,0.266,1,-1.34,-2.87,0.186,-2.87,0.186,-1.4775999999999998,0.882,0.00786,0.0,0.567,0.025,0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,2.0,L
CHEMBL2062266,DIHYDROCODEINE BITARTRATE,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341.O=C(O)C(O)C(O)C(=O)O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.801,0.0255,0.0,0.131,0.468,1.0,0.844,0.0122,0.0,0.971,0.00418,0.0,0.733,0.0213,0.0,0.113,0.329,1,0.833,0.0174,0.0,0.912,0.0274,0,-0.793,-1.84,0.251,-1.84,0.251,-0.3974999999999984,0.651,0.0639,0.0,0.101,0.575,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-1.0,L
CHEMBL206253,NETUPITANT,Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,,0,0,,0,0,Neurokinin 1 receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.24,0.252,0.5,0.117,0.429,1.0,0.638,0.0672,0.0,0.0799,0.546,1.0,0.295,0.131,0.0,0.739,0.0439,0,0.944,0.00411,0.0,0.0488,0.289,1,-4.47,-4.87,-4.06,-4.87,-4.06,6.787020000000006,0.0122,0.974,1.0,0.0331,0.869,1,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-8.0,L
CHEMBL206815,APRATASTAT,CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)[C@H]1C(=O)NO,,0,0,R-HSA-1442490|Collagen degradation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.412,0.157,0.0,0.592,0.0888,0.0,0.479,0.117,0.0,0.834,0.0213,0.0,0.464,0.0684,0.0,0.749,0.0445,0,0.307,0.111,0.0,0.651,0.0554,0,-2.51,-2.97,-2.05,-2.97,-2.05,0.4512,0.406,0.275,0.5,0.442,0.0438,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,L
CHEMBL206834,BAFETINIB,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.819,0.0266,0.0,0.135,0.425,1.0,0.33,0.197,0.0,0.858,0.0137,0.0,0.477,0.0586,0.0,0.993,0.000358,0,0.72,0.0331,0.0,0.0836,0.234,1,-3.09,-4.14,-2.04,-4.14,-2.04,5.392620000000004,0.24,0.399,1.0,0.135,0.398,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,-0.5,L
CHEMBL20684,ABT-751,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.109,0.441,1.0,0.244,0.291,0.5,0.536,0.09,0.0,0.366,0.139,0.0,0.131,0.263,1.0,0.562,0.088,0,0.93,0.00717,0.0,0.821,0.0425,0,-3.06,-3.85,-2.27,-3.85,-2.27,3.340200000000001,0.5,0.109,0.0,0.221,0.228,0.5,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.5,3.0,1.0,1.0,-2.0,L
CHEMBL2068724,ACAMPROSATE CALCIUM,CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2],,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,Glutamate [NMDA] receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.977,0.00248,0.0,0.975,0.00502,0.0,0.952,0.00312,0.0,0.981,3.21e-05,0.0,0.604,0.0343,0.0,0.986,0.00183,0,0.609,0.051,0.0,0.957,0.000282,0,-0.759,-2.6,1.08,-2.6,1.08,-2.2651999999999957,0.551,0.068,0.0,0.494,0.0243,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,L
CHEMBL2068839,RISLENEMDAZ,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.106,0.468,1.0,0.309,0.215,0.5,0.469,0.113,0.0,0.112,0.477,1.0,0.89,0.0055,0.0,0.563,0.0905,0,0.46,0.0735,0.0,0.141,0.171,1,-3.81,-4.7,-2.92,-4.7,-2.92,3.1937200000000017,0.349,0.232,0.0,0.0777,0.444,1,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-5.0,L
CHEMBL207433,SB-705498,O=C(Nc1ccccc1Br)N[C@@H]1CCN(c2ccc(C(F)(F)F)cn2)C1,,0,0,R-HSA-3295583|TRP channels,1,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.298,0.213,0.5,0.421,0.178,0.0,0.0829,0.544,1.0,0.0491,0.663,1.0,0.0378,0.592,1.0,0.048,0.474,1,0.85,0.0189,0.0,0.579,0.093,0,-5.57,-6.12,-5.02,-6.12,-5.02,4.263300000000003,0.497,0.157,0.0,0.15,0.372,1,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-11.5,L
CHEMBL207538,BREXANOLONE,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.369,0.161,0.0,0.479,0.129,0.0,0.059,0.613,1.0,0.44,0.103,0.0,0.456,0.0728,0.0,0.461,0.118,0,0.433,0.0701,0.0,0.0223,0.331,1,-4.91,-5.61,-4.21,-5.61,-4.21,4.595200000000005,0.491,0.118,0.0,0.127,0.44,1,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,-5.5,L
CHEMBL2079587,STANOZOLOL,C[C@]12Cc3c[nH]nc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,2.0,Not yet recruiting,0,0,pathway_drug_candidates,2.0,0.424,0.144,0.0,0.287,0.269,0.5,0.52,0.103,0.0,0.22,0.257,0.5,0.796,0.0136,0.0,0.135,0.296,1,0.596,0.0537,0.0,0.104,0.233,1,-5.27,-5.72,-4.81,-5.72,-4.81,4.1181000000000045,0.525,0.117,0.0,0.701,0.0151,0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,-8.5,L
CHEMBL2079588,TELATINIB,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,2.0,Completed;Unknown status,0,0,pathway_drug_candidates,2.0,0.953,0.00492,0.0,0.568,0.104,0.0,0.876,0.00929,0.0,0.0858,0.527,1.0,0.0222,0.638,1.0,0.416,0.132,0,0.645,0.0367,0.0,0.196,0.161,0,-4.03,-4.6,-3.47,-4.6,-3.47,3.953400000000002,0.246,0.4,1.0,0.2,0.195,0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,-1.0,L
CHEMBL2095206,BOSUTINIB MONOHYDRATE,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.303,0.228,0.5,0.0121,0.841,1.0,0.321,0.198,0.0,0.966,0.00276,0.0,0.171,0.25,0.5,0.0739,0.412,1,0.391,0.071,0.0,0.158,0.175,1,-5.31,-6.1,-4.51,-6.1,-4.51,4.365680000000006,0.137,0.659,1.0,0.0329,0.885,1,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-8.0,L
CHEMBL2095208,COBICISTAT,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,CYP3A4,1,1,R-HSA-211981|Xenobiotics;R-HSA-5423646|Aflatoxin activation and detoxification,2,0,Cytochrome P450 3A inhibitor,4.0,Not yet recruiting,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.587,0.0775,0.0,0.202,0.35,0.5,0.189,0.315,1.0,0.261,0.219,0.5,0.804,0.00808,0.0,0.974,0.00343,0,0.94,0.00885,0.0,0.856,0.0147,0,-3.62,-4.19,-3.05,-4.19,-3.05,6.000700000000006,0.411,0.177,0.0,0.349,0.0748,0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,3.0,0.0,1.0,3.5,L
CHEMBL2096631,CLORAZEPATE DIPOTASSIUM,O=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-],,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.415,0.148,0.0,0.0431,0.654,1.0,0.15,0.414,1.0,0.142,0.374,1.0,0.0271,0.631,1.0,0.658,0.0688,0,0.772,0.0259,0.0,0.405,0.125,0,-3.98,-5.27,-2.69,-5.27,-2.69,-4.920799999999999,0.631,0.0614,0.0,0.0794,0.614,1,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,4.0,0.0,1.0,-4.5,L
CHEMBL2097081,NITROPRUSSIDE,,,0,0,R-HSA-445355|Smooth Muscle Contraction,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL2103736,FENOPROFEN CALCIUM,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2],PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.513,0.0962,0.0,0.292,0.26,0.5,0.419,0.132,0.0,0.442,0.107,0.0,0.919,0.00521,0.0,0.853,0.0263,0,0.789,0.0205,0.0,0.945,0.0176,0,-6.79,-7.31,-6.26,-7.31,-6.26,2.634400000000002,0.671,0.0674,0.0,0.163,0.354,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,7.0,H
CHEMBL2103738,LITHIUM CITRATE,O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+],,0,0,R-HSA-198323|AKT phosphorylates targets in the cytosol;R-HSA-381038|XBP1(S) activates chaperone genes;R-HSA-5674400|Constitutive Signaling by AKT1 E17K in Cancer;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9635465|Suppression of apoptosis;R-HSA-9683610|Maturation of nucleoprotein,6,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.946,0.00525,0.0,0.0102,0.835,1.0,0.022,0.847,1.0,0.881,0.0132,0.0,0.407,0.0763,0.0,0.00218,0.927,1,0.705,0.0323,0.0,0.786,0.0312,0,-1.05,-5.31,3.2,-5.31,2.14,-17.539400000000008,0.965,0.0011,0.0,0.299,0.0779,0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,-4.0,L
CHEMBL2103739,EMEDASTINE DIFUMARATE,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.977,0.00476,0.0,0.867,0.0294,0.0,0.936,0.006,0.0,0.935,0.00739,0.0,0.966,0.00203,0.0,0.0173,0.669,1,0.971,0.0062,0.0,0.795,0.0462,0,-1.17,-2.22,-0.127,-2.22,-0.127,1.6383000000000016,0.698,0.0603,0.0,0.242,0.214,0.5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.5,0.0,0.0,0.0,-1.0,L
CHEMBL2103743,TOFACITINIB CITRATE,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",28,13,,4.0,,0,0,pathway_drug_candidates,14.0,0.977,0.00425,0.0,0.492,0.152,0.0,0.931,0.00537,0.0,0.92,0.0102,0.0,0.113,0.339,1.0,0.00421,0.888,1,0.857,0.0167,0.0,0.831,0.0329,0,-0.829,-1.6,-0.0549,-1.6,-0.0549,0.2962800000000006,0.867,0.0196,0.0,0.272,0.139,0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,7.5,M
CHEMBL2103744,MORPHINE SULFATE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O.O.O.O.O.O=S(=O)(O)O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.973,0.00458,0.0,0.0169,0.769,1.0,0.00214,0.977,1.0,0.705,0.0448,0.0,0.859,0.0115,0.0,0.0172,0.673,1,0.89,0.0123,0.0,0.997,0.0165,0,-3.17,-6.79,0.44,-6.79,0.44,-2.3800999999999974,0.287,0.367,0.5,0.0475,0.874,1,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-2.5,L
CHEMBL2103792,AGATOLIMOD,Cc1cn([C@H]2C[C@H](OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome,5,0,,3.0,Terminated,0,0,pathway_drug_candidates,3.0,0.997,0.0021,0.0,0.997,0.00425,0.0,0.998,0.00265,0.0,0.995,0.00184,0.0,1.0,0.00184,0.0,1.0,0.000781,0,0.999,0.00273,0.0,0.997,0.0162,0,-28.6,-28.9,-28.3,-12.9,-12.9,-7.863120000000009,0.994,0.00613,0.0,0.022,0.999,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,L
CHEMBL2103793,AGATOLIMOD SODIUM,Cc1cn([C@H]2C[C@H](OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome,5,0,,3.0,Terminated,0,0,pathway_drug_candidates,3.0,0.000496,0.99,1.0,0.999,0.00142,0.0,0.999,0.000884,0.0,0.995,0.000616,0.0,0.999,0.000614,0.0,1.0,0.000261,0,0.997,0.000914,0.0,0.984,0.00541,0,-16.1,-16.4,-15.8,-12.9,-12.9,-91.3071199999986,0.971,0.00205,0.0,0.00736,0.994,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,-3.0,L
CHEMBL2103795,AZILSARTAN KAMEDOXOMIL,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[n-]2)cc1.[K+],,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,Type-1 angiotensin II receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.307,0.214,0.5,0.886,0.0305,0.0,0.478,0.13,0.0,0.543,0.0722,0.0,0.0484,0.496,1.0,0.134,0.299,1,0.976,0.00371,0.0,0.584,0.0597,0,-5.97,-6.73,-5.22,-6.73,-5.22,1.3383199999999995,0.367,0.244,0.0,0.194,0.187,{},1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,,2.0,1.0,1.0,-7.0,L
CHEMBL2103802,DAPAGLIFLOZIN PROPANEDIOL,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1.C[C@H](O)CO.O,,0,0,,0,0,Sodium/glucose cotransporter 2 inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.798,0.0327,0.0,0.843,0.039,0.0,0.00292,0.969,1.0,0.679,0.0523,0.0,0.36,0.0972,0.0,0.895,0.0153,0,0.387,0.111,0.0,0.302,0.111,0,-3.77,-4.34,-3.21,-4.34,-3.21,0.3791999999999993,0.849,0.0206,0.0,0.25,0.157,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-2.0,L
CHEMBL2103826,DAVUNETIDE,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.571,0.0846,0.0,0.984,0.00311,0.0,0.854,0.0081,0.0,0.576,0.0709,0.0,0.997,0.00135,0.0,0.999,0.000571,0,0.703,0.0338,0.0,0.95,0.0119,0,-1.1,-1.71,-0.479,-1.71,-0.479,-4.34050000000001,0.885,0.00806,0.0,0.503,0.0294,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,L
CHEMBL2103827,DROXIDOPA,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.447,0.122,0.0,0.565,0.102,0.0,0.0668,0.649,1.0,0.454,0.109,0.0,0.493,0.0557,0.0,0.551,0.1,0,0.0519,0.562,1.0,0.881,0.000488,0,-0.605,-1.41,0.199,-1.41,0.199,-0.4569000000000002,0.861,0.00733,0.0,0.744,0.00827,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,L
CHEMBL2103828,ELINOGREL,CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F,,0,0,R-HSA-418594|G alpha (i) signalling events,1,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.872,0.0128,0.0,0.823,0.0432,0.0,0.0229,0.836,1.0,0.197,0.275,1.0,0.141,0.284,1.0,0.997,0.000665,0,0.892,0.0119,0.0,0.856,0.0138,0,-6.77,-7.72,-5.82,-7.72,-5.82,3.0851000000000006,0.193,0.498,1.0,0.272,0.091,0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,0.0,1.0,-2.0,L
CHEMBL2103829,FAXELADOL,CN(C)C[C@@H]1CCCC[C@H]1c1cccc(O)c1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.607,0.0775,0.0,0.17,0.357,1.0,0.722,0.0439,0.0,0.54,0.0884,0.0,0.331,0.112,0.0,0.361,0.161,0,0.495,0.0596,0.0,0.392,0.127,0,-2.23,-3.45,-1.0,-3.45,-1.0,3.2276000000000016,0.409,0.202,0.0,0.23,0.155,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,2.0,L
CHEMBL2103831,NAPROXCINOD,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,3.0,,0,0,protein_drug_candidates;pathway_drug_candidates,9.0,0.147,0.368,1.0,0.354,0.213,0.5,0.356,0.166,0.0,0.0283,0.789,1.0,0.189,0.23,0.5,0.00976,0.767,1,0.897,0.0111,0.0,0.806,0.0283,0,-5.2,-6.07,-4.32,-6.07,-4.32,3.4836000000000027,0.25,0.393,1.0,0.215,0.161,0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,1.0,1.0,-3.0,L
CHEMBL2103849,UDENAFIL,CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1,,0,0,R-HSA-418457|cGMP effects;R-HSA-445355|Smooth Muscle Contraction;R-HSA-9013422|RHOBTB1 GTPase cycle,3,0,,3.0,Unknown status,0,0,pathway_drug_candidates,3.0,0.771,0.0262,0.0,0.751,0.0557,0.0,0.696,0.0377,0.0,0.134,0.416,1.0,0.525,0.0498,0.0,0.283,0.196,0,0.857,0.0136,0.0,0.473,0.109,0,-4.92,-5.56,-4.29,-5.56,-4.29,2.827500000000001,0.276,0.373,0.5,0.0697,0.647,1,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,L
CHEMBL2103851,AMUVATINIB,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.00565,0.879,1.0,0.0791,0.5,1.0,0.0524,0.639,1.0,0.0105,0.905,1.0,0.00235,0.921,1.0,0.0171,0.661,1,0.437,0.0677,0.0,0.167,0.194,1,-5.99,-6.65,-5.34,-6.65,-5.34,3.301400000000002,0.194,0.555,1.0,0.209,0.172,0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,1.0,1.0,-11.0,L
CHEMBL2103852,CROLIBULIN,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,1.0,Completed,0,0,pathway_drug_candidates,3.0,0.123,0.4,1.0,0.403,0.198,0.0,0.247,0.259,0.5,0.0892,0.545,1.0,0.0386,0.598,1.0,0.917,0.0163,0,0.364,0.103,0.0,0.127,0.225,1,-4.39,-5.33,-3.45,-5.33,-3.45,2.8488800000000003,0.18,0.592,1.0,0.263,0.149,0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,4.0,1.0,1.0,-4.5,L
CHEMBL2103854,OMADACYCLINE TOSYLATE,CN(C)c1cc(CNCC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O.Cc1ccc(S(=O)(=O)O)cc1,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.947,0.00495,0.0,0.492,0.146,0.0,0.856,0.0139,0.0,0.505,0.0901,0.0,0.787,0.0193,0.0,0.753,0.0468,0,0.887,0.0128,0.0,0.753,0.0383,0,-2.3,-2.93,-1.67,-2.93,-1.67,2.564020000000002,0.593,0.0749,0.0,0.419,0.0325,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.5,L
CHEMBL2103876,MAPRACORAT,Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,3.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.238,0.277,0.5,0.156,0.366,1.0,0.686,0.0598,0.0,0.244,0.232,0.5,0.501,0.0576,0.0,0.766,0.044,0,0.504,0.065,0.0,0.118,0.225,1,-4.47,-5.13,-3.8,-5.13,-3.8,5.690420000000004,0.16,0.599,1.0,0.0992,0.534,1,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-3.0,L
CHEMBL2103878,ODELEPRAN,NC(=O)c1ccc(Oc2ccc(CNCCC3CCOCC3)cc2F)nc1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.643,0.0655,0.0,0.396,0.212,0.5,0.154,0.392,1.0,0.518,0.0909,0.0,0.594,0.0372,0.0,0.0204,0.634,1,0.68,0.041,0.0,0.582,0.0635,0,-1.53,-2.49,-0.582,-2.49,-0.582,3.018200000000002,0.255,0.424,0.5,0.0864,0.57,1,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-3.5,L
CHEMBL2103881,DEXMECAMYLAMINE,CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C,,0,0,R-HSA-629587|Highly sodium permeable postsynaptic acetylcholine nicotinic receptors;R-HSA-629594|Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;R-HSA-629597|Highly calcium permeable nicotinic acetylcholine receptors,3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.491,0.106,0.0,0.362,0.206,0.5,0.478,0.111,0.0,0.467,0.0965,0.0,0.443,0.0674,0.0,0.351,0.166,0,0.487,0.0639,0.0,0.442,0.105,0,-2.22,-3.39,-1.05,-3.39,-1.05,2.4206000000000003,0.288,0.324,0.5,0.226,0.146,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.5,L
CHEMBL2104955,BECOCALCIDIOL,C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CC)CC[C@@H]23)C[C@H]1O,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.703,0.0459,0.0,0.445,0.167,0.0,0.153,0.391,1.0,0.587,0.08,0.0,0.43,0.0766,0.0,0.148,0.286,1,0.732,0.0296,0.0,0.168,0.166,{},-4.8,-5.62,-3.99,-5.62,-3.99,5.173500000000005,0.38,0.231,0.0,0.174,0.225,1,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-7.5,L
CHEMBL2104986,TEDATIOXETINE,Cc1ccc(Sc2ccccc2C2CCNCC2)cc1,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.093,0.483,1.0,0.274,0.276,0.5,0.174,0.375,1.0,0.21,0.273,0.5,0.301,0.128,0.0,0.624,0.0811,0,0.0949,0.381,1.0,0.124,0.203,1,-4.17,-5.32,-3.03,-5.32,-3.03,4.613220000000004,0.624,0.0591,0.0,0.083,0.646,1,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-10.5,L
CHEMBL2105107,INECALCITOL,C[C@H](CC#CC(C)(C)O)[C@H]1CC[C@@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,2.0,Unknown status,0,0,pathway_drug_candidates,2.0,0.627,0.0657,0.0,0.397,0.182,0.0,0.0744,0.586,1.0,0.536,0.0782,0.0,0.443,0.064,0.0,0.801,0.0336,0,0.387,0.0842,0.0,0.222,0.159,0,-4.06,-4.82,-3.31,-4.82,-3.31,4.7618000000000045,0.405,0.217,0.0,0.226,0.129,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-2.5,L
CHEMBL2105458,THENALIDINE,CN1CCC(N(Cc2cccs2)c2ccccc2)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.856,0.0157,0.0,0.0252,0.717,1.0,0.72,0.0429,0.0,0.235,0.258,0.5,0.19,0.205,0.5,0.711,0.0513,0,0.959,0.00615,0.0,0.249,0.15,0,-2.43,-3.15,-1.71,-3.15,-1.71,3.848900000000003,0.303,0.303,0.5,0.0234,0.943,1,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,0.0,1.0,0.0,L
CHEMBL2105527,TETRAZEPAM,CN1C(=O)CN=C(C2=CCCCC2)c2cc(Cl)ccc21,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.801,0.0294,0.0,0.159,0.366,1.0,0.464,0.119,0.0,0.248,0.239,0.5,0.0379,0.583,1.0,0.0868,0.364,1,0.397,0.0892,0.0,0.656,0.0759,0,-4.0,-4.62,-3.38,-4.62,-3.38,3.605900000000003,0.103,0.625,1.0,0.0647,0.767,1,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-7.5,L
CHEMBL2105629,VINFLUNINE DITARTRATE,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O,,0,0,,0,0,Tubulin inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.77,0.0335,0.0,0.00265,0.902,1.0,0.914,0.00386,0.0,0.996,0.000545,0.0,0.963,0.000545,0.0,0.68,0.067,0,0.951,0.00399,0.0,0.386,0.127,0,-4.43,-5.15,-3.71,-5.15,-3.71,0.8335000000000081,0.19,0.475,1.0,0.0322,0.823,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,-2.0,L
CHEMBL2105643,FOSBRETABULIN TROMETHAMINE,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.521,0.0919,0.0,0.682,0.0923,0.0,0.558,0.0866,0.0,0.748,0.0378,0.0,0.853,0.0078,0.0,0.9,0.0197,0,0.914,0.01,0.0,0.896,0.031,0,-2.45,-3.32,-1.57,-3.32,-1.57,1.0237000000000005,0.496,0.155,0.0,0.13,0.603,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,3.5,L
CHEMBL2105648,PALOVAROTENE,CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21,,0,0,R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-5362517|Signaling by Retinoic Acid;R-HSA-5617472|Activation of anterior HOX genes in hindbrain development during early embryogenesis,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.954,0.0037,0.0,0.156,0.407,1.0,0.19,0.314,1.0,0.402,0.134,0.0,0.6,0.0343,0.0,0.795,0.0368,0,0.661,0.0446,0.0,0.237,0.142,0,-6.3,-7.69,-4.92,-7.69,-4.92,6.149000000000006,0.701,0.0358,0.0,0.152,0.411,1,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-1.5,L
CHEMBL2105669,TEDIZOLID PHOSPHATE,Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](COP(=O)(O)O)OC4=O)cc3F)cn2)n1,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.69,0.0487,0.0,0.523,0.121,0.0,0.213,0.317,0.5,0.791,0.0256,0.0,0.711,0.0191,0.0,0.944,0.0122,0,0.873,0.0158,0.0,0.472,0.122,0,-2.25,-2.91,-1.58,-2.91,-1.58,1.5126999999999995,0.875,0.0139,0.0,0.151,0.388,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-1.5,L
CHEMBL2105682,EDOXABAN TOSYLATE,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,Coagulation factor X inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.751,0.0317,0.0,0.465,0.139,0.0,0.893,0.0077,0.0,0.219,0.241,0.5,0.828,0.0107,0.0,0.54,0.109,0,0.921,0.00795,0.0,0.815,0.0376,0,-1.81,-2.25,-1.37,-2.25,-1.37,2.5313200000000027,0.0206,0.921,1.0,0.24,0.158,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,4.5,L
CHEMBL2105683,NAPROXEN ETEMESIL,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,8.0,0.135,0.391,1.0,0.399,0.192,0.0,0.613,0.0719,0.0,0.0965,0.54,1.0,0.143,0.255,1.0,0.656,0.0676,0,0.858,0.0155,0.0,0.804,0.0449,0,-4.59,-5.57,-3.62,-5.57,-3.62,2.5397000000000007,0.415,0.235,0.0,0.2,0.237,0.5,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.5,3.0,1.0,1.0,1.0,L
CHEMBL2105705,LUNACALCIPOL,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)C/C=C/S(=O)(=O)C(C)(C)C)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.687,0.0447,0.0,0.317,0.242,0.5,0.173,0.384,1.0,0.651,0.0564,0.0,0.416,0.0777,0.0,0.505,0.108,0,0.78,0.0249,0.0,0.383,0.129,0,-3.75,-4.35,-3.16,-4.35,-3.16,5.800700000000008,0.421,0.17,0.0,0.149,0.281,1,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-2.0,L
CHEMBL2105708,PONATINIB HYDROCHLORIDE,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.959,0.00521,0.0,0.197,0.34,1.0,0.569,0.0697,0.0,0.831,0.0206,0.0,0.946,0.00349,0.0,0.799,0.0396,0,0.792,0.0259,0.0,0.0781,0.248,1,-2.32,-2.75,-1.9,-2.75,-1.9,4.877820000000005,0.108,0.722,1.0,0.0162,0.973,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.5,L
CHEMBL2105711,TOFOGLIFLOZIN,CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1.O,,0,0,,0,0,Sodium/glucose cotransporter 2 inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.654,0.0577,0.0,0.145,0.424,1.0,0.000999,0.982,1.0,0.0942,0.522,1.0,0.654,0.0281,0.0,0.871,0.0215,0,0.916,0.01,0.0,0.894,0.0122,0,-3.62,-4.81,-2.43,-4.81,-2.43,0.1718999999999994,0.926,0.00103,0.0,0.0806,0.536,1,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,0.0,1.0,-4.0,L
CHEMBL2105728,CRENOLANIB,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1,,0,0,R-HSA-5673001|RAF/MAP kinase cascade,1,0,,3.0,Recruiting,0,0,pathway_drug_candidates,3.0,0.715,0.0426,0.0,0.19,0.321,1.0,0.479,0.112,0.0,0.0801,0.574,1.0,0.141,0.248,1.0,0.0227,0.612,1,0.199,0.173,0.0,0.633,0.074,0,-5.19,-6.05,-4.33,-6.05,-4.33,3.916500000000001,0.262,0.426,0.5,0.251,0.165,0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,0.0,1.0,-7.5,L
CHEMBL2105738,GALETERONE,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3cnc4ccccc43)=CC[C@@H]12,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,3.0,Terminated,0,0,pathway_drug_candidates,3.0,0.37,0.151,0.0,0.208,0.326,0.5,0.121,0.457,1.0,0.268,0.217,0.5,0.398,0.0844,0.0,0.356,0.169,0,0.417,0.0746,0.0,0.923,0.0175,0,-5.69,-6.25,-5.14,-6.25,-5.14,5.810800000000006,0.527,0.11,0.0,0.0494,0.748,1,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,3.0,0.0,1.0,-3.5,L
CHEMBL2105749,SAMIDORPHAN L-MALATE,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3.O=C(O)C[C@H](O)C(=O)O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.954,0.00511,0.0,0.798,0.0449,0.0,0.528,0.0927,0.0,0.918,0.00771,0.0,0.97,0.00235,0.0,0.603,0.0819,0,0.898,0.00986,0.0,0.926,0.00183,0,-1.5,-2.25,-0.752,-2.25,-0.752,0.1600000000000005,0.739,0.0221,0.0,0.0909,0.485,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,5.5,L
CHEMBL2105754,TRELAGLIPTIN SUCCINATE,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O.O=C(O)CCC(=O)O,,0,0,,0,0,Dipeptidyl peptidase IV inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.939,0.00709,0.0,0.971,0.00449,0.0,0.817,0.0306,0.0,0.987,0.00194,0.0,0.41,0.0822,0.0,0.914,0.0154,0,0.925,0.0124,0.0,0.708,0.0548,0,-1.92,-2.47,-1.37,-2.47,-1.37,0.4693800000000018,0.956,0.00648,0.0,0.162,0.343,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-0.5,L
CHEMBL2105755,NALDEMEDINE,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.465,0.128,0.0,0.374,0.201,0.5,0.172,0.407,1.0,0.276,0.221,0.5,0.336,0.114,0.0,0.184,0.254,1,0.767,0.0271,0.0,0.913,0.00971,0,-5.22,-6.15,-4.29,-6.15,-4.29,3.4798000000000027,0.0623,0.768,1.0,0.0888,0.474,1,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-3.0,L
CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.644,0.0545,0.0,0.827,0.0363,0.0,0.615,0.0672,0.0,0.635,0.0565,0.0,0.0385,0.554,1.0,0.668,0.0648,0,0.163,0.238,1.0,0.448,0.101,0,-6.06,-6.86,-5.26,-6.86,-5.26,5.2352200000000035,0.0953,0.742,1.0,0.00857,0.995,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,-1.0,L
CHEMBL2105759,BARICITINIB,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,JAK1;JAK2,2,2,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",27,13,Tyrosine-protein kinase JAK1 inhibitor;Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor;Tyrosine-protein kinase JAK2 inhibitor,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,19.5,0.52,0.107,0.0,0.717,0.0711,0.0,0.821,0.0242,0.0,0.709,0.0415,0.0,0.0376,0.631,1.0,0.763,0.0417,0,0.416,0.0712,0.0,0.573,0.0918,0,-1.71,-2.23,-1.19,-2.23,-1.19,1.09568,0.235,0.51,1.0,0.25,0.157,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,21.0,H
CHEMBL2105760,BREXPIPRAZOLE,O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.658,0.0586,0.0,0.182,0.391,1.0,0.284,0.219,0.5,0.177,0.315,1.0,0.0814,0.392,1.0,0.0162,0.675,1,0.134,0.293,1.0,0.129,0.208,1,-5.4,-7.09,-3.71,-7.09,-3.71,4.724000000000004,0.471,0.172,0.0,0.152,0.271,1,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,4.0,0.0,1.0,-14.5,L
CHEMBL2105762,OMARIGLIPTIN,CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2,,0,0,,0,0,Dipeptidyl peptidase IV inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.255,0.241,0.5,0.237,0.291,0.5,0.672,0.0608,0.0,0.759,0.0305,0.0,0.844,0.0091,0.0,0.736,0.0502,0,0.365,0.104,0.0,0.371,0.146,0,-2.09,-2.68,-1.5,-2.68,-1.5,1.1421,0.635,0.0768,0.0,0.133,0.459,1,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,1.0,1.0,-4.5,L
CHEMBL2105842,CORTIVAZOL,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C=C(C)C4=Cc5c(cnn5-c5ccccc5)C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,4.0,0.714,0.0453,0.0,0.508,0.146,0.0,0.269,0.23,0.5,0.192,0.285,1.0,0.325,0.116,0.0,0.696,0.0573,0,0.363,0.107,0.0,0.0127,0.549,1,-5.71,-6.29,-5.12,-6.29,-5.12,4.300600000000004,0.143,0.676,1.0,0.0401,0.892,1,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,0.0,L
CHEMBL2106195,DEXMEDETOMIDINE HYDROCHLORIDE,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.0966,0.472,1.0,0.155,0.393,1.0,0.0975,0.523,1.0,0.0198,0.863,1.0,0.0681,0.436,1.0,0.674,0.0625,0,0.116,0.308,1.0,0.19,0.185,0.5,-3.16,-4.11,-2.21,-4.11,-2.21,3.600140000000003,0.503,0.124,0.0,0.0213,0.974,1,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,5.0,1.0,1.0,-7.0,L
CHEMBL2106798,NERAMEXANE MESYLATE,CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.449,0.114,0.0,0.81,0.0399,0.0,0.61,0.0681,0.0,0.779,0.0281,0.0,0.501,0.0547,0.0,0.0254,0.6,1,0.861,0.013,0.0,0.679,0.0395,0,-0.0723,-2.02,1.88,-2.02,1.88,2.4440999999999997,0.462,0.126,0.0,0.357,0.0491,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.0,L
CHEMBL2106829,METHAQUALONE HYDROCHLORIDE,Cc1ccccc1-n1c(C)nc2ccccc2c1=O.Cl,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.253,0.231,0.5,0.516,0.142,0.0,0.228,0.298,0.5,0.307,0.164,0.0,0.229,0.188,0.5,0.681,0.0638,0,0.17,0.222,1.0,0.417,0.117,0,-2.45,-3.34,-1.56,-3.34,-1.56,3.424340000000002,0.109,0.691,1.0,0.00485,0.969,1,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-6.5,L
CHEMBL2107067,TESTOSTERONE UNDECANOATE,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.645,0.0665,0.0,0.899,0.0161,0.0,0.818,0.0177,0.0,0.319,0.18,0.0,0.788,0.0145,0.0,0.225,0.23,0.5,0.942,0.00876,0.0,0.0376,0.382,1,-8.05,-11.3,-4.85,-11.3,-4.85,7.960900000000009,0.153,0.617,1.0,0.361,0.0585,0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,-4.0,L
CHEMBL2107339,ESMIRTAZAPINE MALEATE,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",7,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.943,0.00594,0.0,0.251,0.282,0.5,0.357,0.151,0.0,0.574,0.0738,0.0,0.835,0.0116,0.0,0.227,0.22,0.5,0.923,0.00776,0.0,0.762,0.046,0,-2.44,-3.53,-1.34,-3.53,-1.34,2.1907,0.539,0.11,0.0,0.148,0.399,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-3.5,L
CHEMBL2107360,PALIPERIDONE PALMITATE,CCCCCCCCCCCCCCCC(=O)OC1CCCn2c1nc(C)c(CCN1CCC(c3noc4cc(F)ccc34)CC1)c2=O,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.841,0.021,0.0,0.657,0.0748,0.0,0.781,0.0296,0.0,0.853,0.0196,0.0,0.598,0.0345,0.0,0.00651,0.823,1,0.977,0.00355,0.0,0.252,0.172,0.5,-7.37,-8.69,-6.05,-8.69,-6.05,9.113520000000005,0.0251,0.994,1.0,0.0414,0.868,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,-8.0,L
CHEMBL2107384,VICRIVIROC MALEATE,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C.O=C(O)/C=C\C(=O)O,,0,0,R-HSA-173107|Binding and entry of HIV virion;R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,4,2,,2.0,Completed,0,0,pathway_drug_candidates,6.0,0.515,0.106,0.0,0.809,0.0465,0.0,0.911,0.00741,0.0,0.979,0.00302,0.0,0.941,0.00302,0.0,0.172,0.267,1,0.948,0.00449,0.0,0.858,0.0172,0,-2.02,-2.62,-1.41,-2.62,-1.41,4.212540000000003,0.416,0.227,0.0,0.254,0.181,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,L
CHEMBL2107455,IGURATIMOD,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,3.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,9.0,0.522,0.101,0.0,0.397,0.216,0.5,0.412,0.15,0.0,0.216,0.25,0.5,0.0807,0.351,1.0,0.637,0.0719,0,0.348,0.0959,0.0,0.433,0.106,0,-4.45,-5.07,-3.83,-5.07,-3.83,2.5251,0.33,0.269,0.5,0.0913,0.529,1,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,4.0,L
CHEMBL2107546,BUCINDOLOL HYDROCHLORIDE,CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N.Cl,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.141,0.383,1.0,0.179,0.335,1.0,0.777,0.0347,0.0,0.471,0.0982,0.0,0.056,0.51,1.0,0.665,0.0625,0,0.815,0.0231,0.0,0.0702,0.269,1,-2.6,-3.64,-1.56,-3.64,-1.56,3.8119800000000024,0.0944,0.78,1.0,0.00682,0.97,1,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-3.5,L
CHEMBL2107729,ATACIGUAT,O=C(Nc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)s1,,0,0,R-HSA-445355|Smooth Muscle Contraction,1,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.647,0.0664,0.0,0.22,0.315,0.5,0.107,0.48,1.0,0.0113,0.874,1.0,0.0263,0.654,1.0,0.601,0.077,0,0.765,0.0341,0.0,0.617,0.0607,0,-7.52,-8.48,-6.55,-8.48,-6.55,4.1289000000000025,0.389,0.219,0.0,0.326,0.0949,0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,0.0,1.0,-3.5,L
CHEMBL2107759,MILATAXEL,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Unknown status,0,0,pathway_drug_candidates,4.0,0.583,0.0836,0.0,0.386,0.212,0.5,0.266,0.244,0.5,0.518,0.0906,0.0,0.614,0.0359,0.0,0.957,0.00932,0,0.794,0.0295,0.0,0.36,0.146,0,-5.0,-5.6,-4.4,-5.6,-4.4,4.063100000000002,0.0314,0.941,1.0,0.545,0.0262,0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,1.0,L
CHEMBL2107771,RALFINAMIDE,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.505,0.111,0.0,0.321,0.239,0.5,0.514,0.0891,0.0,0.499,0.0953,0.0,0.811,0.0127,0.0,0.228,0.227,0.5,0.508,0.0604,0.0,0.584,0.103,0,-3.24,-4.39,-2.1,-4.39,-2.1,2.3681,0.652,0.0783,0.0,0.217,0.229,0.5,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.5,1.0,0.0,0.0,-3.5,L
CHEMBL2107823,GANDOTINIB,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;RMTs methylate histone arginines",21,9,,2.0,"Active, not recruiting",0,0,pathway_drug_candidates,12.0,0.072,0.53,1.0,0.298,0.253,0.5,0.659,0.0604,0.0,0.306,0.186,0.0,0.015,0.734,1.0,0.944,0.011,0,0.268,0.109,0.0,0.883,0.0306,0,-3.05,-3.48,-2.62,-3.48,-2.62,4.028340000000003,0.27,0.34,0.5,0.13,0.414,1,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,6.0,L
CHEMBL2107830,EMPAGLIFLOZIN,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,,0,0,,0,0,Sodium/glucose cotransporter 2 inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.926,0.0107,0.0,0.876,0.0314,0.0,0.581,0.0673,0.0,0.24,0.234,0.5,0.53,0.0457,0.0,0.859,0.0221,0,0.379,0.119,0.0,0.359,0.129,0,-4.51,-5.02,-3.99,-5.02,-3.99,1.6133999999999993,0.689,0.0419,0.0,0.381,0.0674,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,-3.0,L
CHEMBL2107834,RIOCIGUAT,COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,,0,0,R-HSA-445355|Smooth Muscle Contraction,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.879,0.0132,0.0,0.575,0.106,0.0,0.686,0.0505,0.0,0.744,0.0448,0.0,0.0756,0.383,1.0,0.819,0.029,0,0.295,0.113,0.0,0.181,0.149,0,-3.81,-4.25,-3.36,-4.25,-3.36,2.442699999999999,0.309,0.345,0.5,0.112,0.501,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,2.5,L
CHEMBL2107842,ALBINTERFERON ALFA-2B,,,0,0,R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,5,2,,3.0,,0,0,pathway_drug_candidates,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,7.0,M
CHEMBL2107911,ONERCEPT,,TNF,1,1,R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,4,2,,3.0,Terminated,0,0,protein_drug_candidates;pathway_drug_candidates,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,9.0,M
CHEMBL2107979,PEXELIZUMAB,,C5,1,0,R-HSA-166665|Terminal pathway of complement;R-HSA-174577|Activation of C3 and C5;R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-977606|Regulation of Complement cascade,5,2,,3.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,9.0,M
CHEMBL2108080,PARNAPARIN SODIUM,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-8957275|Post-translational protein phosphorylation,4,0,,3.0,Terminated,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL2108147,STREPTOKINASE,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4,1,,4.0,,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL2108222,ALOXIPRIN,,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.0,H
CHEMBL2108250,ANISTREPLASE,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4,1,,4.0,,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL2108313,CONBERCEPT,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1234158|Regulation of gene expression by Hypoxia-inducible Factor;R-HSA-194138|Signaling by VEGF;R-HSA-194313|VEGF ligand-receptor interactions;R-HSA-195399|VEGF binds to VEGFR leading to receptor dimerization;R-HSA-4420097|VEGFA-VEGFR2 Pathway;R-HSA-5218921|VEGFR2 mediated cell proliferation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9679191|Potential therapeutics for SARS,10,2,,3.0,Terminated,0,0,pathway_drug_candidates,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,7.0,M
CHEMBL2108508,INTERFERON ALFA-2A,,,0,0,R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,5,2,,4.0,,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL2108589,CLAZAKIZUMAB,,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8957275|Post-translational protein phosphorylation,7,3,,2.0,Terminated,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL2108628,PACLITAXEL POLIGLUMEX,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,3.0,,0,0,pathway_drug_candidates,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,5.0,L
CHEMBL2108677,PEGINTERFERON BETA-1A,,,0,0,R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,5,2,,4.0,,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL2108718,SEMULOPARIN SODIUM,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-8957275|Post-translational protein phosphorylation,4,0,,3.0,Terminated,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL2108723,PEGINTERFERON LAMBDA-1A,,IL10RB,1,0,R-HSA-449836|Other interleukin signaling;R-HSA-6783783|Interleukin-10 signaling;R-HSA-8854691|Interleukin-20 family signaling,3,3,Interferon lambda receptor agonist,3.0,Completed,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,12.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,12.5,H
CHEMBL2108730,SARILUMAB,,IL6R,1,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9616222|Transcriptional regulation of granulopoiesis;R-HSA-9679191|Potential therapeutics for SARS,6,2,Interleukin-6 receptor alpha subunit antagonist,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_of_actions,11.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,12.5,H
CHEMBL2108739,PLACULUMAB,,TNF,1,1,R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,4,2,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL2108752,PEGAPTANIB OCTASODIUM,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1234158|Regulation of gene expression by Hypoxia-inducible Factor;R-HSA-194138|Signaling by VEGF;R-HSA-194313|VEGF ligand-receptor interactions;R-HSA-195399|VEGF binds to VEGFR leading to receptor dimerization;R-HSA-4420097|VEGFA-VEGFR2 Pathway;R-HSA-5218921|VEGFR2 mediated cell proliferation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9679191|Potential therapeutics for SARS,10,2,,3.0,Completed,0,0,pathway_drug_candidates,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,7.0,M
CHEMBL2108806,BEMIPARIN SODIUM,,SERPINC1,1,1,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-8957275|Post-translational protein phosphorylation,4,0,Antithrombin-III activator,3.0,Completed,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,6.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.5,L
CHEMBL2108887,AFELIMOMAB,,TNF,1,1,R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,4,2,,2.0,,0,0,protein_drug_candidates;pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL2109047,INTERFERON ALFA-N3,,,0,0,R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,5,2,,2.0,Completed,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL2109084,DESMOTEPLASE,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4,1,,3.0,Completed,0,0,pathway_drug_candidates,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,5.0,L
CHEMBL2109204,NADROPARIN CALCIUM,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-8957275|Post-translational protein phosphorylation,4,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL2109325,AMG-191,,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,1.0,Recruiting,0,0,pathway_drug_candidates,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.0,L
CHEMBL2109341,CCR5MAB004,,,0,0,R-HSA-173107|Binding and entry of HIV virion;R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,4,2,,1.0,Completed,0,0,pathway_drug_candidates,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,5.0,L
CHEMBL2109342,HGS-1025,,,0,0,R-HSA-173107|Binding and entry of HIV virion;R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,4,2,,1.0,Withdrawn,0,0,pathway_drug_candidates,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,5.0,L
CHEMBL2109343,LERONLIMAB,,CCR5,1,1,R-HSA-173107|Binding and entry of HIV virion;R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,4,2,C-C chemokine receptor type 5 antagonist,3.0,Suspended,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,10.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.5,H
CHEMBL2109430,GIMSILUMAB,,,0,0,"R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling",3,2,,2.0,Completed,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL2109433,OTILIMAB,,,0,0,"R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling",3,2,,3.0,Completed,0,0,pathway_drug_candidates,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,7.0,M
CHEMBL2109458,AMG-108,,,0,0,R-HSA-6783783|Interleukin-10 signaling;R-HSA-9020702|Interleukin-1 signaling;R-HSA-9679191|Potential therapeutics for SARS,3,2,,2.0,Withdrawn,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL2109470,PERAKIZUMAB,,,0,0,R-HSA-448424|Interleukin-17 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses,3,2,,1.0,Completed,0,0,pathway_drug_candidates,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,5.0,L
CHEMBL2109574,ASG-5ME,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,1.0,Completed,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL2109607,MEDI-8968,,,0,0,R-HSA-6783783|Interleukin-10 signaling;R-HSA-9020702|Interleukin-1 signaling;R-HSA-9679191|Potential therapeutics for SARS,3,2,,2.0,Completed,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL2109613,PF-04236921,,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8957275|Post-translational protein phosphorylation,7,3,,2.0,Completed,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL2109614,MEDI-5117,,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8957275|Post-translational protein phosphorylation,7,3,,1.0,Terminated,0,0,pathway_drug_candidates,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,7.0,M
CHEMBL2109615,MRA 003 US,,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8957275|Post-translational protein phosphorylation,7,3,,1.0,Completed,0,0,pathway_drug_candidates,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,7.0,M
CHEMBL2109636,VILOBELIMAB,,C5,1,0,R-HSA-166665|Terminal pathway of complement;R-HSA-174577|Activation of C3 and C5;R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-977606|Regulation of Complement cascade,5,2,,3.0,Recruiting,0,0,protein_drug_candidates;pathway_drug_candidates,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,9.0,M
CHEMBL2110372,RANITIDINE HYDROCHLORIDE,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.Cl,,0,0,R-HSA-418555|G alpha (s) signalling events,1,0,Histamine H2 receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.65,0.0656,0.0,0.145,0.378,1.0,0.27,0.235,0.5,0.245,0.228,0.5,0.724,0.0233,0.0,0.413,0.128,0,0.6,0.0523,0.0,0.911,0.00782,0,-1.6,-2.6,-0.598,-2.6,-0.598,1.8808,0.18,0.585,1.0,0.391,0.0638,0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,3.0,0.0,1.0,2.5,L
CHEMBL2110581,BEVASIRANIB,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1234158|Regulation of gene expression by Hypoxia-inducible Factor;R-HSA-194138|Signaling by VEGF;R-HSA-194313|VEGF ligand-receptor interactions;R-HSA-195399|VEGF binds to VEGFR leading to receptor dimerization;R-HSA-4420097|VEGFA-VEGFR2 Pathway;R-HSA-5218921|VEGFR2 mediated cell proliferation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9679191|Potential therapeutics for SARS,10,2,,3.0,Withdrawn,0,0,pathway_drug_candidates,7.0,0.999,0.000953,0.0,0.999,0.00194,0.0,0.989,0.00121,0.0,0.999,0.000838,0.0,0.999,0.000837,0.0,1.0,0.000355,0,0.998,0.00124,0.0,0.987,0.00737,0,-0.826,-1.13,-0.524,-1.13,-0.524,-25.635560000000194,0.976,0.00279,0.0,0.01,0.995,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,6.0,L
CHEMBL2110725,VINFLUNINE,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,Tubulin inhibitor,3.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,5.0,0.161,0.378,1.0,0.00521,0.866,1.0,0.546,0.0938,0.0,0.723,0.0384,0.0,0.778,0.0159,0.0,0.532,0.104,0,0.837,0.0157,0.0,0.0746,0.263,1,-5.87,-6.43,-5.32,-6.43,-5.32,5.078700000000006,0.0381,0.985,1.0,0.0742,0.77,1,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,-2.0,L
CHEMBL2110727,CENICRIVIROC,CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1,CCR2;CCR5,2,2,R-HSA-173107|Binding and entry of HIV virion;R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,4,2,C-C chemokine receptor type 2 antagonist;C-C chemokine receptor type 5 antagonist,3.0,Terminated,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,12.5,0.906,0.0101,0.0,0.694,0.0676,0.0,0.16,0.384,1.0,0.524,0.0828,0.0,0.0372,0.581,1.0,0.164,0.284,1,0.906,0.01,0.0,0.0249,0.286,1,-8.03,-8.88,-7.18,-8.88,-7.18,8.741700000000005,0.578,0.0939,0.0,0.209,0.187,0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,1.0,L
CHEMBL2110774,CHLORPHENOXAMINE,CN(C)CCOC(C)(c1ccccc1)c1ccc(Cl)cc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.155,0.347,1.0,0.0333,0.693,1.0,0.889,0.00707,0.0,0.334,0.155,0.0,0.182,0.253,0.5,0.0165,0.664,1,0.377,0.0853,0.0,0.202,0.138,0,-3.5,-4.22,-2.77,-4.22,-2.77,4.181700000000004,0.216,0.452,1.0,0.0845,0.606,1,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-5.5,L
CHEMBL2110954,NERAMEXANE,CC1(C)CC(C)(C)CC(C)(N)C1,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.244,0.257,0.5,0.235,0.295,0.5,0.384,0.154,0.0,0.272,0.201,0.5,0.421,0.0783,0.0,0.233,0.227,0.5,0.746,0.0321,0.0,0.432,0.115,0,-2.1,-4.34,0.139,-4.34,0.139,2.940100000000001,0.483,0.136,0.0,0.268,0.114,0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,3.0,1.0,1.0,-7.5,L
CHEMBL2111286,RANITIDINE BISMUTH CITRATE,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Bi+3],,0,0,R-HSA-418555|G alpha (s) signalling events,1,0,Histamine H2 receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.972,0.00304,0.0,0.147,0.401,1.0,0.395,0.133,0.0,0.821,0.0198,0.0,0.904,0.00374,0.0,0.0104,0.754,1,0.87,0.0151,0.0,0.973,0.00462,0,-4.41,-5.71,-3.11,-5.71,-3.11,-4.174399999999994,0.73,0.0268,0.0,0.918,0.00198,0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-5.0,L
CHEMBL211456,EPHEDRINE,CN[C@@H](C)[C@H](O)c1ccccc1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.461,0.115,0.0,0.012,0.796,1.0,0.39,0.144,0.0,0.159,0.328,1.0,0.0744,0.466,1.0,0.197,0.248,1,0.614,0.0469,0.0,0.811,0.0229,0,-0.815,-2.17,0.535,-2.17,0.535,1.3279,0.634,0.0691,0.0,0.271,0.0945,0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,3.0,0.0,1.0,-4.0,L
CHEMBL21333,PRANLUKAST,O=C(Nc1cccc2c(=O)cc(-c3nnn[nH]3)oc12)c1ccc(OCCCCc2ccccc2)cc1,,0,0,R-HSA-416476|G alpha (q) signalling events;R-HSA-9679191|Potential therapeutics for SARS,2,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.844,0.0194,0.0,0.517,0.143,0.0,0.0566,0.648,1.0,0.119,0.402,1.0,0.0231,0.694,1.0,0.634,0.0713,0,0.856,0.0174,0.0,0.0863,0.245,1,-6.05,-7.35,-4.75,-7.35,-4.75,4.627100000000003,0.469,0.135,0.0,0.214,0.182,0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,3.0,0.0,1.0,-4.5,L
CHEMBL2146063,CHLORTETRACYCLINE HYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12.Cl,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.765,0.0321,0.0,0.78,0.0502,0.0,0.322,0.193,0.0,0.538,0.0849,0.0,0.411,0.0848,0.0,0.595,0.0837,0,0.754,0.0291,0.0,0.702,0.0498,0,-2.42,-3.42,-1.42,-3.42,-1.42,0.8608000000000005,0.781,0.0189,0.0,0.143,0.361,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-1.0,L
CHEMBL2146102,EPHEDRINE HYDROCHLORIDE,CN[C@@H](C)[C@H](O)c1ccccc1.Cl,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.514,0.0963,0.0,0.0182,0.767,1.0,0.486,0.118,0.0,0.152,0.352,1.0,0.0804,0.45,1.0,0.17,0.264,1,0.617,0.0493,0.0,0.827,0.0373,0,-0.115,-1.62,1.39,-1.62,1.39,1.7496999999999998,0.713,0.0568,0.0,0.0507,0.903,1,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,-4.0,L
CHEMBL2146123,METHACYCLINE HYDROCHLORIDE,C=C1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12.Cl,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.84,0.016,0.0,0.754,0.0597,0.0,0.0451,0.649,1.0,0.295,0.18,0.0,0.513,0.0429,0.0,0.537,0.096,0,0.399,0.0798,0.0,0.48,0.114,0,-2.45,-3.16,-1.75,-3.16,-1.75,-0.0160999999999992,0.941,0.000355,0.0,0.0526,0.77,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-2.5,L
CHEMBL2147777,TENELIGLIPTIN,Cc1cc(N2CCN([C@@H]3CN[C@H](C(=O)N4CCSC4)C3)CC2)n(-c2ccccc2)n1,,0,0,,0,0,Dipeptidyl peptidase IV inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.385,0.16,0.0,0.415,0.17,0.0,0.246,0.256,0.5,0.0409,0.692,1.0,0.27,0.154,0.0,0.0646,0.413,1,0.529,0.0652,0.0,0.203,0.16,0,-3.42,-3.98,-2.86,-3.98,-2.86,1.5661200000000006,0.243,0.37,1.0,0.162,0.315,1,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,0.0,1.0,-6.0,L
CHEMBL214796,NGD-8243,FC(F)(F)c1ccc(Nc2ncnc3cc(-c4ncccc4C(F)(F)F)ccc23)cc1,,0,0,R-HSA-3295583|TRP channels,1,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.663,0.0605,0.0,0.204,0.38,0.5,0.609,0.0718,0.0,0.0716,0.578,1.0,0.00511,0.835,1.0,0.46,0.131,0,0.506,0.0566,0.0,0.156,0.222,1,-3.66,-4.3,-3.02,-4.3,-3.02,6.473000000000002,0.112,0.753,1.0,0.148,0.367,1,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-2.5,L
CHEMBL2159122,ELUXADOLINE,COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2ncc(-c3ccccc3)[nH]2)cc1C(=O)O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.596,0.0884,0.0,0.00793,0.846,1.0,0.584,0.087,0.0,0.661,0.052,0.0,0.161,0.253,0.5,0.991,0.00204,0,0.343,0.0979,0.0,0.823,0.0329,0,-2.69,-3.42,-1.95,-3.42,-1.95,4.159040000000003,0.37,0.248,0.0,0.173,0.308,1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,3.0,L
CHEMBL217092,SARACATINIB,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.475,0.123,0.0,0.0586,0.593,1.0,0.766,0.0365,0.0,0.24,0.241,0.5,0.185,0.206,0.5,0.54,0.0912,0,0.796,0.0202,0.0,0.147,0.205,1,-3.95,-4.99,-2.91,-4.99,-2.91,3.9395000000000024,0.0979,0.763,1.0,0.135,0.495,1,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-1.5,L
CHEMBL2178573,ILACIRNON,Cc1cnc(C(=O)c2ncnc3[nH]ccc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1,,0,0,R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.0649,0.542,1.0,0.49,0.159,0.0,0.641,0.0633,0.0,0.753,0.0343,0.0,0.0565,0.507,1.0,0.181,0.256,1,0.821,0.0192,0.0,0.538,0.104,0,-4.32,-4.88,-3.77,-4.88,-3.77,4.365320000000002,0.101,0.765,1.0,0.219,0.17,0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,1.0,1.0,-6.0,L
CHEMBL217899,TOFIMILAST,CCc1nn(C2CCCC2)c2c1CCn1c(-c3cccs3)nnc1-2,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.0387,0.665,1.0,0.0504,0.589,1.0,0.377,0.146,0.0,0.138,0.422,1.0,0.106,0.326,1.0,0.71,0.053,0,0.211,0.175,0.0,0.503,0.12,0,-2.84,-3.62,-2.05,-3.62,-2.05,4.1037000000000035,0.266,0.299,0.5,0.149,0.416,1,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-5.0,L
CHEMBL2179529,AZD1446,O=C(c1ccc(Cl)o1)N1CC2CNCC2C1,,0,0,R-HSA-629587|Highly sodium permeable postsynaptic acetylcholine nicotinic receptors;R-HSA-629594|Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;R-HSA-629597|Highly calcium permeable nicotinic acetylcholine receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.543,0.102,0.0,0.168,0.369,1.0,0.215,0.296,0.5,0.435,0.112,0.0,0.407,0.0805,0.0,0.037,0.514,1,0.327,0.107,0.0,0.188,0.172,0.5,-2.02,-2.98,-1.07,-2.98,-1.07,1.2244,0.577,0.0828,0.0,0.269,0.122,0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,-6.5,L
CHEMBL2180604,TAK-593,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1,,0,0,R-HSA-5673001|RAF/MAP kinase cascade,1,0,,1.0,Completed,0,0,pathway_drug_candidates,1.0,0.807,0.0314,0.0,0.276,0.254,0.5,0.864,0.0149,0.0,0.775,0.0297,0.0,0.366,0.0939,0.0,0.992,0.00214,0,0.132,0.312,1.0,0.323,0.148,0,-5.08,-5.64,-4.52,-5.64,-4.52,3.4727400000000017,0.214,0.485,1.0,0.176,0.254,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,-3.0,L
CHEMBL2204263,JNJ-41443532,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3cncs3)CC2)C1,,0,0,R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.249,0.263,0.5,0.374,0.184,0.0,0.298,0.213,0.5,0.203,0.289,0.5,0.936,0.00366,0.0,0.603,0.0838,0,0.691,0.0277,0.0,0.722,0.0417,0,-3.95,-4.37,-3.53,-4.37,-3.53,2.522500000000001,0.608,0.0658,0.0,0.155,0.305,1,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,1.0,1.0,-1.5,L
CHEMBL2206196,PAROMOMYCIN SULFATE,NC[C@@H]1O[C@H](O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O.O=S(=O)(O)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.972,0.00251,0.0,0.864,0.0273,0.0,0.909,0.00777,0.0,0.948,0.00327,0.0,0.98,0.00113,0.0,0.968,0.00548,0,0.576,0.0526,0.0,0.958,0.0005,0,1.29,0.713,1.86,0.713,1.86,-9.514500000000016,0.961,0.000189,0.0,0.912,0.000215,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,L
CHEMBL22108,DIMETHINDENE,CC(C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,2.0,,0,0,pathway_drug_candidates,2.0,0.462,0.12,0.0,0.0357,0.678,1.0,0.0664,0.605,1.0,0.0946,0.502,1.0,0.435,0.068,0.0,0.35,0.161,0,0.5,0.0551,0.0,0.518,0.0909,0,-3.61,-4.59,-2.62,-4.59,-2.62,4.146700000000004,0.278,0.402,0.5,0.248,0.116,0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,0.0,1.0,-2.0,L
CHEMBL221722,FAVIPIRAVIR,NC(=O)c1nc(F)cnc1O,,0,0,,0,0,RNA-directed RNA polymerase inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.507,0.0984,0.0,0.109,0.43,1.0,0.135,0.434,1.0,0.28,0.196,0.0,0.534,0.0532,0.0,0.17,0.264,1,0.339,0.108,0.0,0.502,0.101,0,-1.19,-2.03,-0.349,-2.03,-0.349,-0.5798000000000002,0.614,0.0772,0.0,0.237,0.14,0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,-8.0,L
CHEMBL2218877,ERYTHROMYCIN ESTOLATE,CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C.CCCCCCCCCCCCOS(=O)(=O)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.717,0.0378,0.0,0.987,0.00257,0.0,0.926,0.00622,0.0,0.669,0.0536,0.0,0.961,0.00325,0.0,0.333,0.175,0,0.99,0.00165,0.0,0.564,0.0569,0,-1.49,-1.99,-1.0,-1.99,-1.0,6.47320000000001,0.062,0.836,1.0,0.494,0.0366,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,L
CHEMBL2218894,FLUVASTATIN SODIUM,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)[O-])c(-c2ccc(F)cc2)c2ccccc21.[Na+],,0,0,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,HMG-CoA reductase inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.661,0.0469,0.0,0.972,0.011,0.0,0.0896,0.534,1.0,0.506,0.0894,0.0,0.843,0.0101,0.0,0.666,0.0679,0,0.827,0.0198,0.0,0.44,0.127,0,-2.22,-2.72,-1.72,-2.72,-1.72,0.2973999999999999,0.642,0.0801,0.0,0.0814,0.656,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,2.0,L
CHEMBL2219414,ERAVACYCLINE DIHYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12.Cl.Cl,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.957,0.00571,0.0,0.872,0.0289,0.0,0.333,0.206,0.5,0.752,0.0404,0.0,0.576,0.0403,0.0,0.923,0.0139,0,0.83,0.0202,0.0,0.943,0.00647,0,-2.29,-3.01,-1.57,-3.01,-1.57,1.1375999999999995,0.953,0.00245,0.0,0.00879,0.978,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-1.5,L
CHEMBL2219416,NALOXEGOL OXALATE,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5.O=C(O)C(=O)O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.993,0.00226,0.0,0.381,0.215,0.5,0.87,0.0121,0.0,0.86,0.0181,0.0,0.972,0.00199,0.0,0.0905,0.372,1,0.969,0.00455,0.0,0.553,0.093,0,-1.42,-2.79,-0.0517,-2.79,-0.0517,1.019100000000008,0.63,0.0888,0.0,0.0494,0.878,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,L
CHEMBL2219418,NALOXEGOL,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,Terminated,0,0,pathway_drug_candidates,6.0,0.99,0.0017,0.0,0.358,0.219,0.5,0.899,0.00677,0.0,0.858,0.0154,0.0,0.952,0.00256,0.0,0.0921,0.372,1,0.966,0.00222,0.0,0.338,0.145,0,-0.563,-1.53,0.4,-1.53,0.4,1.8635000000000028,0.258,0.273,0.5,0.0307,0.905,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,L
CHEMBL2219425,ARIPIPRAZOLE LAUROXIL,CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.725,0.0388,0.0,0.689,0.0785,0.0,0.15,0.372,1.0,0.15,0.374,1.0,0.456,0.0757,0.0,0.00172,0.941,1,0.965,0.00273,0.0,0.0947,0.252,1,-7.79,-8.95,-6.64,-8.95,-6.64,8.675400000000007,0.0143,0.995,1.0,0.0339,0.906,1,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-10.0,L
CHEMBL221959,TOFACITINIB,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",28,13,,3.0,Recruiting,1,0,known_drugs;pathway_drug_candidates,14.5,0.607,0.0594,0.0,0.396,0.192,0.0,0.868,0.0148,0.0,0.437,0.112,0.0,0.0431,0.509,1.0,0.214,0.217,{},0.544,0.0599,0.0,0.265,0.157,0,-1.2,-1.92,-0.49,-1.92,-0.49,1.5447799999999996,0.238,0.456,1.0,0.188,0.232,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,15.0,H
CHEMBL2220442,FLUVASTATIN,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,,0,0,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.875,0.0111,0.0,0.658,0.0795,0.0,0.0653,0.596,1.0,0.456,0.0998,0.0,0.62,0.0333,0.0,0.485,0.113,0,0.824,0.0177,0.0,0.425,0.114,0,-3.2,-3.72,-2.69,-3.72,-2.69,4.628100000000003,0.615,0.0754,0.0,0.115,0.366,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,L
CHEMBL222559,TIPRANAVIR,CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1,,0,0,,0,0,Human immunodeficiency virus type 1 protease inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.282,0.239,0.5,0.486,0.152,0.0,0.0258,0.796,1.0,0.197,0.282,1.0,0.17,0.239,0.5,0.95,0.0101,0,0.96,0.00688,0.0,0.275,0.135,0,-7.23,-7.69,-6.78,-7.69,-6.78,7.325500000000007,0.0674,0.698,1.0,0.0547,0.707,1,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,4.0,1.0,1.0,-8.0,L
CHEMBL223360,LINIFANIB,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,,0,0,R-HSA-5673001|RAF/MAP kinase cascade,1,0,,3.0,Terminated,0,0,pathway_drug_candidates,3.0,0.104,0.477,1.0,0.5,0.155,0.0,0.0146,0.889,1.0,0.199,0.269,1.0,0.0876,0.368,1.0,0.633,0.0762,0,0.79,0.03,0.0,0.235,0.149,0,-5.54,-6.54,-4.54,-6.54,-4.54,4.903620000000003,0.6,0.0636,0.0,0.111,0.481,1,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-6.5,L
CHEMBL227529,ALOGLIPTIN BENZOATE,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O.O=C(O)c1ccccc1,,0,0,,0,0,Dipeptidyl peptidase IV inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.713,0.0417,0.0,0.894,0.0152,0.0,0.604,0.0697,0.0,0.966,0.00231,0.0,0.0427,0.549,1.0,0.986,0.00325,0,0.872,0.013,0.0,0.776,0.0204,0,-2.11,-2.58,-1.65,-2.58,-1.65,1.7792800000000006,0.758,0.0184,0.0,0.141,0.381,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-1.5,L
CHEMBL23,DILTIAZEM,,,0,0,,0,0,,,,1,0,known_drugs,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL2304041,SAGOPILONE,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.168,0.361,1.0,0.651,0.0864,0.0,0.0791,0.584,1.0,0.494,0.0942,0.0,0.277,0.151,0.0,0.654,0.0668,0,0.733,0.0349,0.0,0.456,0.122,0,-4.83,-5.21,-4.45,-5.21,-4.45,5.456120000000006,0.182,0.593,1.0,0.151,0.282,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,-2.0,L
CHEMBL2311030,ERGOLOID MESYLATES,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.00551,0.86,1.0,0.997,0.000938,0.0,0.022,0.845,1.0,0.323,0.172,0.0,0.997,0.000406,0.0,0.0987,0.36,1,0.991,0.000604,0.0,0.00412,0.9,1,-5.88,-6.19,-5.57,-6.19,-5.57,7.904899999999989,0.00758,0.994,1.0,0.916,0.00153,0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,2.0,1.0,1.0,-8.0,L
CHEMBL2316582,OLVEREMBATINIB,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,3.0,Recruiting,0,0,pathway_drug_candidates,3.0,0.948,0.0065,0.0,0.273,0.288,0.5,0.658,0.0637,0.0,0.967,0.00358,0.0,0.951,0.00356,0.0,0.879,0.0215,0,0.788,0.0276,0.0,0.078,0.286,1,-3.64,-4.02,-3.25,-4.02,-3.25,4.684620000000004,0.129,0.623,1.0,0.156,0.366,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.5,L
CHEMBL231779,APIXABAN,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,F10,1,1,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,Coagulation factor X inhibitor,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.406,0.144,0.0,0.688,0.0771,0.0,0.0994,0.492,1.0,0.248,0.227,0.5,0.604,0.0387,0.0,0.314,0.185,0,0.188,0.204,1.0,0.711,0.0674,0,-4.03,-4.83,-3.23,-4.83,-3.23,2.699600000000001,0.063,0.893,1.0,0.154,0.364,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,0.0,1.0,4.0,L
CHEMBL2346976,AZD3514,CC(=O)N1CCN(CCOc2ccc(C3CCN(C4=Nn5c(nnc5C(F)(F)F)CC4)CC3)cc2)CC1,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,1.0,Completed,0,0,pathway_drug_candidates,1.0,0.945,0.00553,0.0,0.849,0.031,0.0,0.0601,0.653,1.0,0.823,0.0231,0.0,0.939,0.00271,0.0,0.125,0.311,1,0.337,0.098,0.0,0.188,0.184,0.5,-1.96,-2.69,-1.22,-2.69,-1.22,2.8272000000000013,0.351,0.27,0.5,0.26,0.151,0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,-6.0,L
CHEMBL2348780,VAMOROLONE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)CO,,0,0,,0,0,Glucocorticoid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.568,0.088,0.0,0.451,0.139,0.0,0.68,0.0479,0.0,0.365,0.142,0.0,0.549,0.043,0.0,0.633,0.0769,0,0.481,0.0735,0.0,0.0887,0.219,1,-3.45,-4.55,-2.35,-4.55,-2.35,2.752900000000001,0.391,0.193,0.0,0.438,0.029,0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,-1.5,L
CHEMBL2358147,CARPHENAZINE MALEATE,CCC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.993,0.00163,0.0,0.647,0.0751,0.0,0.934,0.00514,0.0,0.988,0.0025,0.0,0.982,0.00143,0.0,0.00395,0.894,1,0.956,0.0085,0.0,0.819,0.0409,0,-3.85,-5.36,-2.33,-5.36,-2.33,3.3056,0.537,0.14,0.0,0.0556,0.836,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-6.0,L
CHEMBL2359966,QUININE SULFATE,C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.O.O.O=S(=O)(O)O,,0,0,,0,0,Ferriprotoporphyrin IX inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.767,0.0338,0.0,0.0104,0.846,1.0,0.709,0.0382,0.0,0.872,0.0136,0.0,0.762,0.0158,0.0,0.0354,0.522,1,0.93,0.00912,0.0,0.00793,0.582,1,-3.59,-4.48,-2.71,-4.48,-2.71,4.044200000000004,0.0966,0.742,1.0,0.377,0.0513,0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,-6.5,L
CHEMBL2364574,DOXYCYCLINE CALCIUM,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2],,0,0,R-HSA-1442490|Collagen degradation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases;R-HSA-210991|Basigin interactions;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6798695|Neutrophil degranulation,7,1,Matrix metalloproteinase 13 inhibitor | Matrix metalloproteinase 7 inhibitor | Matrix metalloproteinase 8 inhibitor | Matrix metalloproteinase-1 inhibitor,0.5,Terminated,0,0,pathway_drug_candidates;mechanism_drug_candidate,2.0,0.963,0.00451,0.0,0.887,0.0166,0.0,0.0308,0.83,1.0,0.274,0.209,0.5,0.847,0.00716,0.0,0.437,0.13,0,0.216,0.181,0.0,0.706,0.0537,0,-3.75,-4.35,-3.15,-4.35,-3.15,-2.339999999999989,0.994,0.00605,0.0,0.477,0.0352,0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,-1.5,L
CHEMBL2364605,CEBRANOPADOL,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,3.0,Not yet recruiting,0,0,pathway_drug_candidates,5.0,0.434,0.136,0.0,0.0935,0.526,1.0,0.522,0.0986,0.0,0.231,0.255,0.5,0.431,0.0706,0.0,0.317,0.18,0,0.372,0.086,0.0,0.359,0.151,0,-5.53,-6.03,-5.03,-6.03,-5.03,5.106100000000005,0.291,0.393,0.5,0.063,0.871,1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-0.5,L
CHEMBL2364609,ESKETAMINE HYDROCHLORIDE,CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.422,0.142,0.0,0.468,0.161,0.0,0.345,0.158,0.0,0.315,0.162,0.0,0.381,0.0918,0.0,0.278,0.196,0,0.655,0.0429,0.0,0.795,0.0369,0,-0.189,-1.09,0.715,-1.09,0.715,3.3196000000000025,0.407,0.235,0.0,0.0245,0.975,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,3.5,L
CHEMBL2364618,MAVATREP,CC(C)(O)c1ccccc1-c1ccc2[nH]c(/C=C/c3ccc(C(F)(F)F)cc3)nc2c1,,0,0,R-HSA-3295583|TRP channels,1,0,,1.0,Completed,0,0,pathway_drug_candidates,1.0,0.0399,0.661,1.0,0.0136,0.81,1.0,0.184,0.366,1.0,0.194,0.285,1.0,0.0177,0.718,1.0,0.629,0.0723,0,0.795,0.0225,0.0,0.442,0.124,0,-5.98,-6.54,-5.42,-6.54,-5.42,6.646500000000005,0.635,0.0791,0.0,0.194,0.227,1,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,5.0,1.0,1.0,-8.5,L
CHEMBL2364619,METHYLSAMIDORPHAN,C[N@+]1(CC2CC2)CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.78,0.0285,0.0,0.817,0.0429,0.0,0.416,0.138,0.0,0.803,0.0218,0.0,0.815,0.0132,0.0,0.658,0.0661,0,0.775,0.0261,0.0,0.671,0.0507,0,-1.13,-1.92,-0.335,-1.92,-0.335,1.398,0.273,0.394,0.5,0.184,0.239,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,4.0,L
CHEMBL2364623,PLAZOMICIN SULFATE,CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CCN)OC[C@]1(C)O.O=S(=O)(O)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.996,0.00119,0.0,0.839,0.0371,0.0,0.945,0.00458,0.0,0.922,0.00749,0.0,0.986,0.00105,0.0,0.877,0.0213,0,0.538,0.0509,0.0,0.978,0.00922,0,2.76,2.2,3.32,2.14,2.14,-6.013900000000013,0.673,0.0392,0.0,0.443,0.0565,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,L
CHEMBL2364653,ANIFROLUMAB,,,0,0,R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,5,2,,4.0,,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL2364655,EVOLOCUMAB,,,0,0,,0,0,Subtilisin/kexin type 9 inhibitor,,,1,1,known_drugs;mechanism_of_actions,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL2364968,ERGOLOID,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.0004,0.941,1.0,0.906,0.016,0.0,0.00346,0.967,1.0,0.00225,0.96,1.0,0.986,0.000495,0.0,0.91,0.0134,0,0.962,0.00392,0.0,0.00503,0.985,1,-11.1,-11.5,-10.8,-11.5,-10.8,9.888900000000003,0.00925,0.995,1.0,0.891,0.00188,0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,3.0,1.0,1.0,-6.0,L
CHEMBL2368861,BUPRENORPHINE HYDROCHLORIDE,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5.Cl,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.236,0.269,0.5,0.122,0.441,1.0,0.49,0.106,0.0,0.515,0.0782,0.0,0.624,0.0332,0.0,0.0984,0.331,1,0.727,0.0318,0.0,0.537,0.104,0,-3.71,-4.65,-2.77,-4.65,-2.77,4.835600000000006,0.225,0.464,1.0,0.0253,0.98,1,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,-3.5,L
CHEMBL237500,LINAGLIPTIN,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,DPP4,1,1,,0,0,Dipeptidyl peptidase IV inhibitor,,,1,1,known_drugs;mechanism_drug_candidate;mechanism_of_actions,3.5,0.051,0.57,1.0,0.646,0.089,0.0,0.0744,0.57,1.0,0.129,0.404,1.0,0.152,0.28,1.0,0.839,0.0263,0,0.177,0.215,1.0,0.554,0.0845,0,-3.34,-3.81,-2.88,-3.81,-2.88,1.1474199999999997,0.419,0.21,0.0,0.174,0.287,1,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,4.0,1.0,1.0,-5.0,L
CHEMBL238465,SOFINICLINE,Clc1cc(N2C[C@@H]3CN[C@@H]3C2)cnc1Cl,,0,0,R-HSA-629587|Highly sodium permeable postsynaptic acetylcholine nicotinic receptors;R-HSA-629594|Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;R-HSA-629597|Highly calcium permeable nicotinic acetylcholine receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.435,0.129,0.0,0.133,0.434,1.0,0.233,0.267,0.5,0.279,0.197,0.0,0.137,0.27,1.0,0.00581,0.842,1,0.153,0.262,1.0,0.224,0.166,0,-4.01,-4.76,-3.27,-4.76,-3.27,1.7963999999999998,0.432,0.209,0.0,0.277,0.108,0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,3.0,0.0,1.0,-10.0,L
CHEMBL2424780,VESATOLIMOD,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-168181|Toll Like Receptor 7/8 (TLR7/8) Cascade;R-HSA-5686938|Regulation of TLR by endogenous ligand;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9692916|SARS-CoV-1 activates/modulates innate immune responses;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome;R-HSA-9824856|Defective regulation of TLR7 by endogenous ligand;R-HSA-9833110|RSV-host interactions,11,0,,2.0,"Active, not recruiting",0,0,pathway_drug_candidates,2.0,0.608,0.0746,0.0,0.1,0.477,1.0,0.217,0.288,0.5,0.815,0.0227,0.0,0.158,0.254,1.0,0.408,0.136,0,0.543,0.0496,0.0,0.959,0.00166,0,-3.17,-3.67,-2.67,-3.67,-2.67,2.7922,0.649,0.0471,0.0,0.182,0.18,{},0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,,3.0,0.0,1.0,-1.5,L
CHEMBL2443262,OLICERIDINE,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.549,0.0928,0.0,0.199,0.339,1.0,0.831,0.0217,0.0,0.252,0.234,0.5,0.151,0.258,1.0,0.972,0.00641,0,0.396,0.0862,0.0,0.773,0.0387,0,-1.02,-1.76,-0.275,-1.76,-0.275,4.692600000000004,0.308,0.293,0.5,0.117,0.478,1,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,3.0,0.0,1.0,1.5,L
CHEMBL24441,BETAHISTINE,CNCCc1ccccn1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.738,0.0349,0.0,0.931,0.0139,0.0,0.92,0.00558,0.0,0.95,0.00388,0.0,0.631,0.0296,0.0,0.748,0.0489,0,0.617,0.0392,0.0,0.909,0.0341,0,0.954,-0.416,2.32,-0.416,2.14,0.8434999999999999,0.7,0.052,0.0,0.121,0.449,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,3.5,L
CHEMBL2448612,ERGOTAMINE TARTRATE,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.53,0.103,0.0,0.193,0.35,1.0,0.761,0.0282,0.0,0.957,0.00572,0.0,0.711,0.0218,0.0,0.846,0.0279,0,0.985,0.00213,0.0,0.0466,0.286,1,-6.59,-7.15,-6.04,-7.15,-6.04,1.859000000000016,0.127,0.656,1.0,0.777,0.00946,0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.5,L
CHEMBL24778,SILODOSIN,C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.842,0.0317,0.0,0.544,0.129,0.0,0.418,0.146,0.0,0.529,0.0867,0.0,0.306,0.143,0.0,0.0156,0.678,1,0.286,0.115,0.0,0.978,0.0185,0,-1.58,-2.24,-0.917,-2.24,-0.917,3.0711000000000013,0.0793,0.907,1.0,0.141,0.421,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,L
CHEMBL25,ASPIRIN,CC(=O)Oc1ccccc1C(=O)O,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,Completed,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,11.5,0.885,0.0141,0.0,0.511,0.13,0.0,0.136,0.44,1.0,0.801,0.0274,0.0,0.676,0.0252,0.0,0.518,0.101,0,0.516,0.0519,0.0,0.21,0.166,0,-1.71,-2.16,-1.26,-2.16,-1.26,1.3101,0.751,0.0306,0.0,0.691,0.0185,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,11.5,H
CHEMBL254328,ABIRATERONE,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0497,0.612,1.0,0.244,0.288,0.5,0.276,0.251,0.5,0.958,0.00479,0.0,0.434,0.0786,0.0,0.0457,0.477,1,0.572,0.0469,0.0,0.952,0.0139,0,-4.19,-4.78,-3.6,-4.78,-3.6,5.398600000000005,0.489,0.137,0.0,0.0445,0.881,1,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-9.5,L
CHEMBL255863,NILOTINIB,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,3.0,"Active, not recruiting",0,0,pathway_drug_candidates,3.0,0.0179,0.75,1.0,0.593,0.101,0.0,0.136,0.429,1.0,0.946,0.00392,0.0,0.158,0.272,1.0,0.815,0.0285,0,0.629,0.0536,0.0,0.166,0.242,1,-3.52,-4.16,-2.89,-4.16,-2.89,6.355840000000005,0.156,0.65,1.0,0.147,0.398,1,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-3.5,L
CHEMBL256907,MARAVIROC,Cc1nnc(C(C)C)n1[C@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,,0,0,,0,0,C-C chemokine receptor type 5 antagonist,,,0,0,mechanism_drug_candidate,0.0,0.571,0.0702,0.0,0.113,0.452,1.0,0.576,0.0776,0.0,0.646,0.0531,0.0,0.974,0.00155,0.0,0.732,0.0493,0,0.742,0.0294,0.0,0.255,0.165,0,-3.44,-3.94,-2.93,-3.94,-2.93,5.950920000000006,0.229,0.484,1.0,0.145,0.377,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,-1.5,L
CHEMBL261244,REGRELOR DISODIUM,CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])[O-])[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21.[Na+].[Na+],,0,0,R-HSA-418594|G alpha (i) signalling events,1,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.336,0.196,0.0,0.984,0.0044,0.0,0.917,0.00583,0.0,0.731,0.0426,0.0,0.892,0.00726,0.0,0.998,0.000354,0,0.942,0.0092,0.0,0.912,0.0168,0,-2.77,-3.35,-2.19,-3.35,-2.19,-5.458099999999996,0.896,0.00989,0.0,0.0356,0.898,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.5,L
CHEMBL261772,MECLOCYCLINE SULFOSALICYLATE,C=C1c2c(Cl)ccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12.O=C(O)c1cc(S(=O)(=O)O)ccc1O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.986,0.00278,0.0,0.896,0.0131,0.0,0.145,0.392,1.0,0.81,0.0228,0.0,0.814,0.0131,0.0,0.815,0.0324,0,0.885,0.01,0.0,0.927,0.00262,0,-2.55,-4.06,-1.04,-4.06,-1.04,0.5526000000000006,0.964,0.000993,0.0,0.864,0.00113,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-2.0,L
CHEMBL269732,TACROLIMUS ANHYDROUS,,,0,0,,0,0,,,,1,0,known_drugs,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL270190,ALVIMOPAN,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.519,0.0923,0.0,0.295,0.262,0.5,0.657,0.0642,0.0,0.739,0.0372,0.0,0.815,0.0114,0.0,0.471,0.118,0,0.984,0.00584,0.0,0.609,0.0817,0,-3.32,-3.98,-2.65,-3.98,-2.65,3.051400000000001,0.433,0.185,0.0,0.147,0.428,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,4.0,L
CHEMBL274654,ORANTINIB,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O,,0,0,R-HSA-5673001|RAF/MAP kinase cascade,1,0,,3.0,Terminated,0,0,pathway_drug_candidates,3.0,0.547,0.0865,0.0,0.888,0.0218,0.0,0.2,0.303,0.5,0.0555,0.663,1.0,0.206,0.2,0.5,0.805,0.0362,0,0.414,0.0857,0.0,0.368,0.14,0,-3.68,-4.59,-2.77,-4.59,-2.77,3.141440000000001,0.576,0.0851,0.0,0.225,0.206,0.5,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.5,3.0,0.0,1.0,-1.0,L
CHEMBL276711,SEMAXANIB,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.0944,0.464,1.0,0.623,0.0945,0.0,0.07,0.58,1.0,0.00381,0.934,1.0,0.0584,0.462,1.0,0.592,0.0773,0,0.219,0.163,0.0,0.241,0.143,0,-3.82,-4.73,-2.92,-4.73,-2.92,3.1242400000000004,0.126,0.613,1.0,0.252,0.122,0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,1.0,1.0,-2.5,L
CHEMBL277474,ANTIPYRINE,Cc1cc(=O)n(-c2ccccc2)n1C,,0,0,R-HSA-140180|COX reactions;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX),2,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.528,0.104,0.0,0.359,0.209,0.5,0.417,0.136,0.0,0.459,0.102,0.0,0.322,0.116,0.0,0.252,0.209,0,0.609,0.0467,0.0,0.841,0.0316,0,-0.749,-1.68,0.177,-1.68,0.177,1.48442,0.32,0.283,0.5,0.0931,0.645,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,3.0,L
CHEMBL27810,CELIPROLOL,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.802,0.0293,0.0,0.185,0.323,1.0,0.88,0.0107,0.0,0.615,0.059,0.0,0.937,0.00424,0.0,0.84,0.0254,0,0.572,0.0541,0.0,0.483,0.0845,0,-2.08,-2.77,-1.39,-2.77,-1.39,2.8907000000000007,0.203,0.496,1.0,0.0636,0.765,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,4.0,L
CHEMBL278398,PHENINDAMINE,CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.12,0.464,1.0,0.0556,0.593,1.0,0.353,0.191,0.0,0.141,0.375,1.0,0.129,0.311,1.0,0.0312,0.541,1,0.26,0.141,0.0,0.093,0.213,1,-3.91,-4.76,-3.06,-4.76,-3.06,3.9212000000000033,0.481,0.113,0.0,0.108,0.43,1,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-9.0,L
CHEMBL279785,MARIMASTAT,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,,0,0,R-HSA-1442490|Collagen degradation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases;R-HSA-210991|Basigin interactions;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,6,1,,3.0,Completed,0,0,pathway_drug_candidates,5.0,0.318,0.204,0.0,0.594,0.0991,0.0,0.0862,0.557,1.0,0.347,0.15,0.0,0.584,0.0386,0.0,0.724,0.0509,0,0.346,0.0957,0.0,0.657,0.0671,0,0.826,-0.0882,1.74,-0.0882,1.74,-0.208099999999999,0.398,0.221,0.0,0.293,0.11,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,3.0,L
CHEMBL282042,SAQUINAVIR MESYLATE,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1.CS(=O)(=O)O,,0,0,,0,0,Human immunodeficiency virus type 1 protease inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.0999,0.466,1.0,0.49,0.159,0.0,0.33,0.185,0.0,0.494,0.097,0.0,0.449,0.0636,0.0,0.00773,0.808,1,0.951,0.0119,0.0,0.0477,0.297,1,-1.68,-2.28,-1.09,-2.28,-1.09,2.5964000000000036,0.213,0.502,1.0,0.442,0.0261,0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,-7.5,L
CHEMBL282052,METHAQUALONE,Cc1ccccc1-n1c(C)nc2ccccc2c1=O,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.215,0.28,0.5,0.385,0.181,0.0,0.173,0.373,1.0,0.308,0.164,0.0,0.214,0.198,0.5,0.711,0.0578,0,0.17,0.222,1.0,0.416,0.116,0,-3.13,-3.94,-2.31,-3.94,-2.31,3.0025400000000015,0.0665,0.805,1.0,0.104,0.451,1,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-6.5,L
CHEMBL284121,ILX23-7553,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)CC#CC(C)(C)O)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,1.0,Completed,0,0,pathway_drug_candidates,1.0,0.65,0.0545,0.0,0.442,0.153,0.0,0.112,0.477,1.0,0.606,0.0607,0.0,0.399,0.0799,0.0,0.773,0.0394,0,0.538,0.0503,0.0,0.254,0.157,0,-3.4,-4.05,-2.75,-4.05,-2.75,4.848000000000006,0.421,0.159,0.0,0.172,0.217,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-2.0,L
CHEMBL285674,ESTAZOLAM,Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.306,0.203,0.0,0.16,0.389,1.0,0.355,0.173,0.0,0.149,0.4,1.0,0.00863,0.824,1.0,0.17,0.265,1,0.77,0.026,0.0,0.232,0.145,0,-4.4,-5.4,-3.4,-5.4,-3.4,3.2717000000000027,0.147,0.619,1.0,0.105,0.493,1,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-9.0,L
CHEMBL288441,BOSUTINIB,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,3.0,"Active, not recruiting",0,0,pathway_drug_candidates,3.0,0.304,0.231,0.5,0.0315,0.704,1.0,0.668,0.0593,0.0,0.96,0.00374,0.0,0.164,0.26,0.5,0.0613,0.462,1,0.393,0.0724,0.0,0.168,0.184,1,-4.77,-5.44,-4.11,-5.44,-4.11,5.190380000000005,0.156,0.662,1.0,0.0446,0.864,1,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-10.0,L
CHEMBL289351,FOSBRETABULIN DISODIUM,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+],,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.011,0.779,1.0,0.987,0.00172,0.0,0.595,0.0703,0.0,0.682,0.0468,0.0,0.876,0.00502,0.0,0.872,0.0217,0,0.873,0.0138,0.0,0.771,0.0349,0,-2.88,-4.18,-1.58,-4.18,-1.58,-3.893099999999996,0.494,0.138,0.0,0.0466,0.87,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,-0.5,L
CHEMBL294199,CAPSAICIN,COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,,0,0,R-HSA-3295583|TRP channels,1,0,Vanilloid receptor opener,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.0794,0.523,1.0,0.359,0.217,0.5,0.185,0.357,1.0,0.435,0.107,0.0,0.0165,0.737,1.0,0.85,0.0263,0,0.159,0.25,1.0,0.454,0.13,0,-2.83,-4.12,-1.53,-4.12,-1.53,3.789600000000003,0.276,0.403,0.5,0.263,0.129,0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,1.0,1.0,-5.0,L
CHEMBL296419,ASTEMIZOLE,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.421,0.138,0.0,0.0319,0.684,1.0,0.417,0.136,0.0,0.239,0.249,0.5,0.917,0.00556,0.0,0.00058,0.982,1,0.165,0.343,1.0,0.0348,0.389,1,-5.72,-6.57,-4.86,-6.57,-4.86,5.351300000000005,0.064,0.851,1.0,0.699,0.013,0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,-8.0,L
CHEMBL296913,PARECOXIB SODIUM,CCC(=O)[N-]S(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1.[Na+],PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.142,0.392,1.0,0.969,0.00566,0.0,0.449,0.12,0.0,0.387,0.129,0.0,0.698,0.0164,0.0,0.381,0.146,0,0.905,0.01,0.0,0.616,0.0405,0,-3.2,-4.13,-2.26,-4.13,-2.26,1.3200199999999995,0.557,0.0975,0.0,0.193,0.179,{},0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,,1.0,1.0,1.0,6.5,L
CHEMBL299400,BUTORPHANOL TARTRATE,O=C(O)C(O)C(O)C(=O)O.Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.765,0.0339,0.0,0.128,0.433,1.0,0.893,0.0073,0.0,0.982,0.00294,0.0,0.78,0.0179,0.0,0.755,0.0426,0,0.932,0.0107,0.0,0.911,0.0353,0,-2.69,-3.52,-1.86,-3.52,-1.86,1.2429999999999992,0.689,0.0419,0.0,0.0992,0.562,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,4.5,L
CHEMBL3,NICOTINE,CN1CCC[C@H]1c1cccnc1,CHRNB2,1,1,R-HSA-629587|Highly sodium permeable postsynaptic acetylcholine nicotinic receptors;R-HSA-629594|Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;R-HSA-629597|Highly calcium permeable nicotinic acetylcholine receptors,3,0,Neuronal acetylcholine receptor; alpha4/beta2 agonist,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.224,0.283,0.5,0.449,0.163,0.0,0.367,0.175,0.0,0.191,0.299,1.0,0.231,0.175,0.5,0.157,0.282,1,0.64,0.0395,0.0,0.439,0.121,0,0.632,-0.166,1.43,-0.166,1.43,1.8483,0.425,0.174,0.0,0.112,0.437,1,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,1.0,1.0,-1.5,L
CHEMBL30,CIMETIDINE,CN/C(=N\CCSCc1nc[nH]c1C)NC#N,,0,0,R-HSA-418555|G alpha (s) signalling events,1,0,Histamine H2 receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.296,0.213,0.5,0.696,0.0707,0.0,0.531,0.0842,0.0,0.138,0.388,1.0,0.0468,0.5,1.0,0.446,0.117,0,0.441,0.0759,0.0,0.411,0.119,0,-1.63,-2.45,-0.804,-2.45,-0.804,0.5974,0.625,0.0737,0.0,0.79,0.00661,0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,1.0,1.0,-1.5,L
CHEMBL30219,METHOHEXITAL SODIUM,C=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+],,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.145,0.385,1.0,0.962,0.0115,0.0,0.151,0.39,1.0,0.384,0.147,0.0,0.723,0.0221,0.0,0.718,0.0462,0,0.759,0.0265,0.0,0.464,0.119,0,-0.766,-1.74,0.211,-1.74,0.211,-2.682699999999996,0.381,0.224,0.0,0.0462,0.857,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-5.0,L
CHEMBL3039504,NINTEDANIB ESYLATE,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,,0,0,R-HSA-5673001|RAF/MAP kinase cascade,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.461,0.131,0.0,0.606,0.0778,0.0,0.474,0.113,0.0,0.576,0.0767,0.0,0.786,0.0145,0.0,0.711,0.0534,0,0.475,0.0757,0.0,0.857,0.0239,0,-2.14,-2.69,-1.58,-2.69,-1.58,3.5100000000000025,0.0312,0.938,1.0,0.157,0.358,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,4.5,L
CHEMBL3039507,SOTAGLIFLOZIN,CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,,0,0,,0,0,Sodium/glucose cotransporter 2 inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.608,0.0607,0.0,0.855,0.0341,0.0,0.0262,0.777,1.0,0.503,0.0942,0.0,0.126,0.307,1.0,0.455,0.12,0,0.22,0.197,0.5,0.0958,0.253,1,-5.67,-6.17,-5.18,-6.17,-5.18,3.172600000000002,0.649,0.0743,0.0,0.441,0.0357,0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,-7.5,L
CHEMBL3039508,NALDEMEDINE TOSYLATE,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1.Cc1ccc(S(=O)(=O)O)cc1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.674,0.0545,0.0,0.283,0.237,0.5,0.376,0.177,0.0,0.416,0.142,0.0,0.484,0.0532,0.0,0.496,0.103,0,0.846,0.0139,0.0,0.954,0.0163,0,-3.91,-4.6,-3.22,-4.6,-3.22,4.721520000000004,0.0746,0.863,1.0,0.172,0.289,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,4.5,L
CHEMBL3039511,BEVENOPRAN,COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(C(N)=O)cn1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,3.0,Terminated,0,0,pathway_drug_candidates,5.0,0.899,0.019,0.0,0.0633,0.572,1.0,0.632,0.0609,0.0,0.335,0.162,0.0,0.222,0.179,0.5,0.00673,0.829,1,0.549,0.0582,0.0,0.662,0.0432,0,-2.48,-3.11,-1.85,-3.11,-1.85,2.2827,0.452,0.195,0.0,0.0833,0.638,1,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-2.5,L
CHEMBL3039547,PEXASTIMOGENE DEVACIREPVEC,,,0,0,"R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling",3,2,,3.0,Completed,0,0,pathway_drug_candidates,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,7.0,M
CHEMBL3039596,FOSINOPRIL SODIUM,CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)[O-])C(C)C.[Na+],,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,Angiotensin-converting enzyme inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.219,0.292,0.5,0.968,0.00793,0.0,0.902,0.0034,0.0,0.835,0.0217,0.0,0.901,0.00557,0.0,0.907,0.0151,0,0.954,0.00988,0.0,0.459,0.0963,0,-2.72,-3.14,-2.29,-3.14,-2.29,1.7906000000000024,0.564,0.0722,0.0,0.105,0.509,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,2.5,L
CHEMBL3039598,FOSINOPRIL,CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.618,0.0694,0.0,0.724,0.0664,0.0,0.894,0.00752,0.0,0.806,0.0267,0.0,0.687,0.0245,0.0,0.822,0.0308,0,0.957,0.0126,0.0,0.477,0.112,0,-3.76,-4.2,-3.33,-4.2,-3.33,6.121300000000007,0.598,0.0782,0.0,0.176,0.294,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,4.0,L
CHEMBL305660,EBASTINE,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,3.0,Recruiting,0,0,pathway_drug_candidates,3.0,0.497,0.111,0.0,0.117,0.452,1.0,0.117,0.426,1.0,0.739,0.0307,0.0,0.691,0.021,0.0,0.00289,0.906,1,0.982,0.00108,0.0,0.41,0.12,0,-5.99,-7.11,-4.87,-7.11,-4.87,7.217600000000008,0.0558,0.838,1.0,0.701,0.0149,0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,-6.0,L
CHEMBL3113974,TRANIMILAST,CS(=O)(=O)Nc1ccc(C(=O)O[C@@H](Cc2c(Cl)c[n+]([O-])cc2Cl)c2ccc(OC(F)F)c(OCC3CC3)c2)cc1OCC1CC1,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,3.0,Recruiting,0,0,pathway_drug_candidates,3.0,0.663,0.0444,0.0,0.121,0.414,1.0,0.768,0.0391,0.0,0.881,0.0155,0.0,0.0476,0.569,1.0,0.0131,0.718,1,0.471,0.0596,0.0,0.646,0.0606,0,-6.8,-7.3,-6.3,-7.3,-6.3,6.318100000000006,0.0486,0.905,1.0,0.0311,0.888,1,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-6.0,L
CHEMBL312448,XYLOMETAZOLINE,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.774,0.0398,0.0,0.264,0.264,0.5,0.558,0.0873,0.0,0.408,0.123,0.0,0.436,0.0799,0.0,0.205,0.239,1,0.861,0.0154,0.0,0.784,0.0439,0,-3.94,-4.55,-3.34,-4.55,-3.34,3.1451400000000014,0.421,0.177,0.0,0.271,0.116,0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-3.0,L
CHEMBL3137308,PEFICITINIB,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",28,13,,3.0,,0,0,pathway_drug_candidates,13.0,0.792,0.0269,0.0,0.416,0.183,0.0,0.611,0.0725,0.0,0.785,0.0279,0.0,0.278,0.151,0.0,0.604,0.0859,0,0.338,0.0988,0.0,0.582,0.0479,0,-2.89,-3.43,-2.34,-3.43,-2.34,2.0133,0.165,0.572,1.0,0.166,0.266,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,14.0,H
CHEMBL3137310,BENZHYDROCODONE HYDROCHLORIDE,COc1ccc2c3c1O[C@H]1C(OC(=O)c4ccccc4)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341.Cl,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.614,0.0646,0.0,0.0723,0.539,1.0,0.612,0.0738,0.0,0.102,0.475,1.0,0.128,0.29,1.0,0.437,0.129,0,0.764,0.0285,0.0,0.838,0.0463,0,-3.11,-3.65,-2.57,-3.65,-2.57,4.136800000000004,0.141,0.664,1.0,0.0244,1.0,1,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,3.5,L
CHEMBL3137313,AXELOPRAN,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)CO)c1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.703,0.0636,0.0,0.411,0.179,0.0,0.0855,0.553,1.0,0.13,0.382,1.0,0.717,0.0216,0.0,0.822,0.0332,0,0.783,0.0242,0.0,0.741,0.0487,0,-2.8,-3.42,-2.18,-3.42,-2.18,2.258,0.523,0.114,0.0,0.0919,0.499,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,1.5,L
CHEMBL3137316,FOSDAGROCORAT,Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,4.0,0.959,0.00455,0.0,0.152,0.402,1.0,0.825,0.0196,0.0,0.63,0.0651,0.0,0.418,0.0768,0.0,0.178,0.264,1,0.986,0.00115,0.0,0.258,0.139,0,-5.31,-5.89,-4.74,-5.89,-4.74,6.279520000000007,0.423,0.188,0.0,0.0851,0.509,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-5.5,L
CHEMBL313971,ZUCAPSAICIN,COc1cc(CNC(=O)CCCC/C=C\C(C)C)ccc1O,,0,0,R-HSA-3295583|TRP channels,1,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.078,0.521,1.0,0.358,0.214,0.5,0.183,0.355,1.0,0.433,0.105,0.0,0.0151,0.735,1.0,0.85,0.0256,0,0.156,0.247,1.0,0.438,0.116,0,-2.83,-4.12,-1.53,-4.12,-1.53,3.789600000000003,0.246,0.397,1.0,0.244,0.123,0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,1.0,1.0,-4.5,L
CHEMBL314437,MEPTAZINOL,CCC1(c2cccc(O)c2)CCCCN(C)C1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.424,0.145,0.0,0.214,0.314,0.5,0.505,0.11,0.0,0.469,0.0989,0.0,0.45,0.0666,0.0,0.667,0.0638,0,0.569,0.0482,0.0,0.166,0.191,1,-1.61,-2.48,-0.735,-2.48,-0.735,3.1557000000000013,0.38,0.269,0.5,0.231,0.199,0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,3.5,L
CHEMBL317094,IMIDAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,Angiotensin-converting enzyme inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.647,0.0525,0.0,0.455,0.166,0.0,0.217,0.284,0.5,0.245,0.219,0.5,0.48,0.0578,0.0,0.765,0.0437,0,0.875,0.0128,0.0,0.639,0.0572,0,-0.986,-1.53,-0.442,-1.53,-0.442,0.8762000000000008,0.777,0.0216,0.0,0.167,0.283,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,3.5,L
CHEMBL3181947,BROMFENAC SODIUM,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+],PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.262,0.239,0.5,0.984,0.000175,0.0,0.0163,0.866,1.0,0.022,0.834,1.0,0.873,0.00435,0.0,0.874,0.0237,0,0.954,0.00648,0.0,0.809,0.0195,0,-4.79,-5.66,-3.93,-5.66,-3.93,-5.356699999999995,0.695,0.036,0.0,0.0134,0.912,1,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,2.0,L
CHEMBL3183075,NIZATIDINE,CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1,,0,0,R-HSA-418555|G alpha (s) signalling events,1,0,Histamine H2 receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.491,0.109,0.0,0.362,0.209,0.5,0.441,0.127,0.0,0.192,0.289,1.0,0.427,0.0719,0.0,0.466,0.127,0,0.306,0.117,0.0,0.809,0.0495,0,-1.86,-2.73,-0.993,-2.73,-0.993,1.3224999999999998,0.351,0.343,0.5,0.421,0.0496,0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,2.0,L
CHEMBL3183409,APALUTAMIDE,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Androgen Receptor antagonist,4.0,"Active, not recruiting",0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.455,0.113,0.0,0.801,0.0426,0.0,0.215,0.282,0.5,0.168,0.326,1.0,0.0899,0.409,1.0,0.896,0.0201,0,0.839,0.0194,0.0,0.258,0.162,0,-3.86,-4.36,-3.36,-4.36,-3.36,3.5315800000000026,0.15,0.627,1.0,0.195,0.187,{},0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,,3.0,0.0,1.0,1.5,L
CHEMBL3184512,CLINDAMYCIN PHOSPHATE,CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](OP(=O)(O)O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.715,0.0465,0.0,0.397,0.201,0.5,0.695,0.0464,0.0,0.463,0.102,0.0,0.8,0.0161,0.0,0.23,0.227,0.5,0.887,0.0128,0.0,0.0975,0.227,1,-1.29,-1.72,-0.854,-1.72,-0.854,0.5064999999999993,0.721,0.0358,0.0,0.693,0.0124,0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,-7.5,L
CHEMBL3184791,STREPTOMYCIN SULFATE,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O.CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.998,0.000195,0.0,0.988,0.000396,0.0,0.99,0.000246,0.0,0.986,0.000172,0.0,0.997,0.000171,0.0,0.941,0.0101,0,0.862,0.0114,0.0,0.958,0.00151,0,6.88,6.49,7.27,2.14,2.14,-18.28059999999997,0.963,0.000571,0.0,0.927,0.000645,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,L
CHEMBL3187812,ILEPATRIL,CC(=O)S[C@H](C(=O)N[C@H]1Cc2ccccc2[C@H]2CCC[C@@H](C(=O)O)N2C1=O)C(C)C,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.222,0.304,0.5,0.731,0.0567,0.0,0.219,0.294,0.5,0.4,0.128,0.0,0.7,0.017,0.0,0.614,0.0772,0,0.332,0.089,0.0,0.39,0.131,0,-3.08,-3.68,-2.47,-3.68,-2.47,2.5386000000000006,0.686,0.039,0.0,0.303,0.109,0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,1.0,1.0,-0.5,L
CHEMBL3188034,TRIPROLIDINE HYDROCHLORIDE,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1.Cl.O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.28,0.203,0.0,0.114,0.488,1.0,0.538,0.0867,0.0,0.448,0.102,0.0,0.299,0.14,0.0,0.00566,0.838,1,0.711,0.0323,0.0,0.79,0.0214,0,-1.4,-3.22,0.421,-3.22,0.421,3.5146200000000034,0.72,0.0367,0.0,0.00346,0.993,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-2.5,L
CHEMBL3188576,DIHYDROSTREPTOMYCIN SULFATE,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O.CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)CO)O[C@@H](CO)[C@H](O)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.999,0.000984,0.0,0.969,0.00446,0.0,0.911,0.00433,0.0,0.977,0.00301,0.0,0.997,0.000864,0.0,0.595,0.0913,0,0.425,0.065,0.0,0.966,0.00761,0,5.38,4.74,6.02,2.14,2.14,-17.85511999999997,0.976,0.00288,0.0,0.896,0.0073,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,L
CHEMBL3188993,QUETIAPINE FUMARATE,O=C(O)/C=C/C(=O)O.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.954,0.00716,0.0,0.666,0.0861,0.0,0.642,0.0738,0.0,0.919,0.0106,0.0,0.996,0.002,0.0,0.206,0.233,1,0.566,0.0651,0.0,0.0203,0.735,1,-4.32,-5.12,-3.51,-5.12,-3.51,5.423800000000009,0.752,0.0422,0.0,0.049,0.899,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,-9.5,L
CHEMBL321582,BUCINDOLOL,CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.106,0.452,1.0,0.152,0.388,1.0,0.722,0.043,0.0,0.463,0.101,0.0,0.0554,0.517,1.0,0.692,0.0576,0,0.816,0.0238,0.0,0.0745,0.273,1,-3.25,-4.21,-2.29,-4.21,-2.29,3.3901800000000017,0.0798,0.85,1.0,0.166,0.302,1,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-3.5,L
CHEMBL3219616,CP-866087,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3(O)Cc4ccccc4C3)C[C@@H]21,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.0139,0.743,1.0,0.731,0.0694,0.0,0.472,0.108,0.0,0.571,0.0751,0.0,0.319,0.117,0.0,0.00352,0.897,1,0.779,0.0208,0.0,0.49,0.0853,0,-4.91,-5.79,-4.04,-5.79,-4.04,2.7974000000000014,0.121,0.629,1.0,0.103,0.429,1,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,-4.5,L
CHEMBL3264610,SEVITERONEL,CC(C)[C@](O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1c[nH]nn1,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.371,0.151,0.0,0.189,0.357,1.0,0.111,0.485,1.0,0.0842,0.574,1.0,0.292,0.146,0.0,0.0223,0.627,1,0.344,0.109,0.0,0.671,0.0511,0,-4.62,-5.12,-4.11,-5.12,-4.11,4.052600000000003,0.417,0.169,0.0,0.182,0.224,1,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,0.0,1.0,-8.5,L
CHEMBL3301582,POLATUZUMAB VEDOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,4.0,,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL3301585,PINATUZUMAB VEDOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,1.0,Completed,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL3301589,ENFORTUMAB VEDOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,4.0,,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL3301600,SPEBRUTINIB BESYLATE,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1.O=S(=O)(O)c1ccccc1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,4.0,0.854,0.018,0.0,0.0563,0.608,1.0,0.133,0.417,1.0,0.271,0.201,0.5,0.398,0.0843,0.0,0.666,0.0626,0,0.465,0.0569,0.0,0.117,0.252,1,-1.87,-2.57,-1.18,-2.57,-1.18,5.185900000000004,0.0763,0.867,1.0,0.313,0.088,0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,3.0,0.0,1.0,0.0,L
CHEMBL3301606,SOLCITINIB,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-449836|Other interleukin signaling;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,19,11,,2.0,Completed,0,0,pathway_drug_candidates,12.0,0.68,0.0556,0.0,0.9,0.0261,0.0,0.472,0.123,0.0,0.924,0.00813,0.0,0.447,0.0637,0.0,0.231,0.221,0.5,0.661,0.0407,0.0,0.436,0.128,0,-4.43,-5.1,-3.76,-5.1,-3.76,3.2268000000000017,0.45,0.191,0.0,0.21,0.181,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.5,L
CHEMBL3301607,FILGOTINIB,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",28,13,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,14.0,0.807,0.0276,0.0,0.883,0.0312,0.0,0.609,0.0595,0.0,0.838,0.02,0.0,0.555,0.0424,0.0,0.684,0.0666,0,0.894,0.0106,0.0,0.77,0.0533,0,-3.43,-4.25,-2.6,-4.25,-2.6,1.9752,0.421,0.212,0.0,0.171,0.278,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,13.5,H
CHEMBL3301625,SPEBRUTINIB,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,4.0,0.655,0.062,0.0,0.516,0.148,0.0,0.0612,0.612,1.0,0.351,0.148,0.0,0.232,0.183,0.5,0.886,0.0235,0,0.123,0.34,1.0,0.074,0.272,1,-3.45,-4.15,-2.75,-4.15,-2.75,4.252600000000002,0.0778,0.817,1.0,0.251,0.173,0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,-0.5,L
CHEMBL3306803,LUMATEPERONE,CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.603,0.0756,0.0,0.00879,0.834,1.0,0.233,0.273,0.5,0.183,0.319,1.0,0.579,0.0396,0.0,0.000212,0.995,1,0.568,0.0541,0.0,0.0103,0.603,1,-4.55,-5.64,-3.46,-5.64,-3.46,3.916500000000003,0.244,0.457,1.0,0.088,0.591,1,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-10.0,L
CHEMBL332750,TETOMILAST,CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.16,0.346,1.0,0.689,0.0664,0.0,0.268,0.244,0.5,0.0573,0.597,1.0,0.676,0.0234,0.0,0.842,0.0272,0,0.372,0.105,0.0,0.729,0.0644,0,-4.16,-5.06,-3.25,-5.06,-3.25,4.367700000000004,0.477,0.167,0.0,0.137,0.39,1,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-4.5,L
CHEMBL334966,CANGRELOR,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O,,0,0,R-HSA-418594|G alpha (i) signalling events,1,0,,3.0,Recruiting,0,0,pathway_drug_candidates,3.0,0.938,0.00688,0.0,0.304,0.232,0.5,0.178,0.344,1.0,0.39,0.136,0.0,0.945,0.00389,0.0,0.992,0.00256,0,0.76,0.0313,0.0,0.91,0.0249,0,-1.51,-1.95,-1.06,-1.95,-1.06,2.8505000000000034,0.826,0.0201,0.0,0.0714,0.789,1,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,1.0,L
CHEMBL33986,BUTORPHANOL,Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.343,0.175,0.0,0.141,0.399,1.0,0.703,0.0418,0.0,0.497,0.0903,0.0,0.464,0.06,0.0,0.665,0.0605,0,0.828,0.0161,0.0,0.767,0.0484,0,-3.14,-3.87,-2.41,-3.87,-2.41,3.3656000000000015,0.431,0.175,0.0,0.103,0.529,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,4.0,L
CHEMBL341812,IBUFENAC,CC(C)Cc1ccc(CC(=O)O)cc1,,0,0,,0,0,Cyclooxygenase inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.544,0.0877,0.0,0.426,0.175,0.0,0.167,0.365,1.0,0.134,0.4,1.0,0.424,0.0704,0.0,0.369,0.149,0,0.528,0.0602,0.0,0.557,0.102,0,-2.43,-3.87,-0.992,-3.87,-0.992,2.5122,0.936,0.00295,0.0,0.441,0.0317,0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,-2.5,L
CHEMBL3542265,LY2452473,CC(C)OC(=O)N[C@H]1Cc2c(n(Cc3ccccn3)c3ccc(C#N)cc23)C1,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.307,0.209,0.0,0.594,0.0966,0.0,0.0915,0.507,1.0,0.288,0.179,0.0,0.0361,0.643,1.0,0.741,0.0468,0,0.223,0.159,0.0,0.452,0.104,0,-4.09,-4.82,-3.35,-4.82,-3.35,3.558080000000002,0.271,0.286,0.5,0.0763,0.581,1,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-2.5,L
CHEMBL3544909,CALCIFEDIOL,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12.O,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Vitamin D receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.682,0.0512,0.0,0.316,0.24,0.5,0.206,0.311,0.5,0.753,0.0386,0.0,0.548,0.0513,0.0,0.891,0.0218,0,0.409,0.0971,0.0,0.163,0.188,1,-4.99,-5.52,-4.46,-5.52,-4.46,5.909200000000008,0.26,0.414,0.5,0.102,0.615,1,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-2.5,L
CHEMBL3544917,RAPASTINEL,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,3.0,Terminated,0,0,pathway_drug_candidates,3.0,0.595,0.0704,0.0,0.848,0.0365,0.0,0.0339,0.725,1.0,0.236,0.24,0.5,0.792,0.0158,0.0,0.892,0.0181,0,0.735,0.0346,0.0,0.223,0.158,0,0.571,0.0688,1.07,0.0688,1.07,-2.972599999999994,0.735,0.0241,0.0,0.471,0.0313,0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,0.0,L
CHEMBL3544945,SAR-113945,,,0,0,"R-HSA-112409|MAP3K8 (TPL2)-dependent MAPK1/3 activation;R-HSA-1169091|Activation of NF-kappaB in B cells;R-HSA-1236974|ER-Phagosome pathway;R-HSA-168638|NOD1/2 Signaling Pathway;R-HSA-168927|TICAM1, RIP1-mediated IKK complex recruitment;R-HSA-1810476|RIP-mediated NFkB activation via ZBP1;R-HSA-202424|Downstream TCR signaling;R-HSA-209543|p75NTR recruits signalling complexes;R-HSA-209560|NF-kB is activated and signals survival;R-HSA-2871837|FCERI mediated NF-kB activation;R-HSA-2871837|NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10;R-HSA-445989|TAK1-dependent IKK and NF-kappa-B activation;R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-5602636|IKBKB deficiency causes SCID;R-HSA-5603027|IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR);R-HSA-5603029|IkBA variant leads to EDA-ID;R-HSA-5607764|CLEC7A (Dectin-1) signaling;R-HSA-9020702|Interleukin-1 signaling;R-HSA-933542|TRAF6 mediated NF-kB activation;R-HSA-937039|IRAK1 recruits IKK complex;R-HSA-937041|IKK complex recruitment mediated by RIP1;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-975144|IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation;R-HSA-9758274|Regulation of NF-kappa B signaling;R-HSA-9833482|PKR-mediated signaling;R-HSA-9860276|SLC15A4:TASL-dependent IRF5 activation;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells;R-HSA-9909505|Modulation of host responses by IFN-stimulated genes",29,5,,2.0,Completed,0,0,pathway_drug_candidates,12.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,12.0,H
CHEMBL3544953,SAF312,,,0,0,R-HSA-3295583|TRP channels,1,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL3544974,ASENAPINE MALEATE,CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\C(=O)O,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.937,0.00714,0.0,0.28,0.277,0.5,0.853,0.0137,0.0,0.784,0.0288,0.0,0.306,0.131,0.0,0.00351,0.895,1,0.885,0.0125,0.0,0.257,0.168,0,-2.07,-3.7,-0.451,-3.7,-0.451,3.9703000000000017,0.303,0.334,0.5,0.112,0.536,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-7.0,L
CHEMBL3544984,TRADIPITANT,,,0,0,,0,0,Neurokinin 1 receptor antagonist,,,1,1,known_drugs;mechanism_of_actions,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL3544985,DASABUVIR SODIUM MONOHYDRATE,COc1c(-c2ccc3cc(NS(C)(=O)=O)ccc3c2)cc(-n2ccc(=O)[n-]c2=O)cc1C(C)(C)C.O.[Na+],,0,0,,0,0,RNA-directed RNA polymerase inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.0184,0.761,1.0,0.941,0.0131,0.0,0.798,0.0328,0.0,0.709,0.0443,0.0,0.496,0.0538,0.0,0.178,0.266,1,0.843,0.018,0.0,0.62,0.0688,0,-7.35,-7.85,-6.85,-7.85,-6.85,-0.1679999999999998,0.694,0.0475,0.0,0.0795,0.493,1,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,-11.0,L
CHEMBL3544986,PERINDOPRIL ARGININE,CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC.N=C(N)NCCC[C@H](N)C(=O)O,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,Angiotensin-converting enzyme inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.876,0.0124,0.0,0.835,0.0375,0.0,0.888,0.00638,0.0,0.596,0.0634,0.0,0.955,0.0023,0.0,0.952,0.0087,0,0.0885,0.402,1.0,0.874,0.0203,0,0.0331,-0.401,0.467,-0.401,0.467,0.6021700000000052,0.921,0.00053,0.0,0.0532,0.743,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,3.5,L
CHEMBL3545039,AZD1386,Cc1cc(Cl)cc2c1N(Cc1cccc(C(F)(F)F)c1)C(=O)C21NC(=O)NC1=O,,0,0,R-HSA-3295583|TRP channels,1,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.022,0.718,1.0,0.28,0.246,0.5,0.403,0.159,0.0,0.36,0.145,0.0,0.257,0.182,0.5,0.696,0.0561,0,0.808,0.0214,0.0,0.802,0.0416,0,-4.56,-5.23,-3.88,-5.23,-3.88,3.2487200000000014,0.172,0.599,1.0,0.0685,0.788,1,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-4.0,L
CHEMBL3545046,GSK2849466,,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,1.0,Completed,0,0,pathway_drug_candidates,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.0,L
CHEMBL3545060,ERYTHROMYCIN GLUCEPTATE,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.939,0.00729,0.0,0.918,0.0197,0.0,0.862,0.0138,0.0,0.973,0.00426,0.0,0.977,0.00211,0.0,0.867,0.0227,0,0.933,0.00951,0.0,0.924,0.0186,0,-0.495,-1.04,0.0505,-1.04,0.0505,-2.3465999999999867,0.877,0.0142,0.0,0.785,0.012,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,L
CHEMBL3545085,XL-228,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,1.0,Terminated,0,0,pathway_drug_candidates,1.0,0.278,0.218,0.5,0.667,0.0727,0.0,0.42,0.138,0.0,0.499,0.0873,0.0,0.0586,0.468,1.0,0.106,0.325,1,0.538,0.0564,0.0,0.456,0.108,0,-3.89,-4.4,-3.37,-4.4,-3.37,3.296000000000001,0.349,0.226,0.0,0.172,0.268,1,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-9.0,L
CHEMBL3545092,CR 1447,,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL3545132,MIRVETUXIMAB SORAVTANSINE,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,4.0,,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL3545155,JI-101,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1,,0,0,R-HSA-5673001|RAF/MAP kinase cascade,1,0,,1.0,Completed,0,0,pathway_drug_candidates,1.0,0.343,0.172,0.0,0.268,0.297,0.5,0.739,0.04,0.0,0.207,0.279,0.5,0.0175,0.744,1.0,0.959,0.00771,0,0.411,0.086,0.0,0.585,0.0753,0,-5.17,-6.1,-4.23,-6.1,-4.23,5.081900000000004,0.645,0.0818,0.0,0.152,0.372,1,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,3.0,0.0,1.0,-5.5,L
CHEMBL3545157,TIDEGLUSIB,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,,0,0,R-HSA-198323|AKT phosphorylates targets in the cytosol;R-HSA-5674400|Constitutive Signaling by AKT1 E17K in Cancer;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9683610|Maturation of nucleoprotein,4,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.326,0.183,0.0,0.226,0.306,0.5,0.0767,0.583,1.0,0.0709,0.595,1.0,0.124,0.3,1.0,0.233,0.224,0.5,0.145,0.277,1.0,0.812,0.0258,0,-4.79,-5.51,-4.06,-5.51,-4.06,3.2622000000000018,0.709,0.0383,0.0,0.211,0.184,0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,0.0,1.0,-10.5,L
CHEMBL3545168,IMD-1041,,,0,0,"R-HSA-112409|MAP3K8 (TPL2)-dependent MAPK1/3 activation;R-HSA-1169091|Activation of NF-kappaB in B cells;R-HSA-1236974|ER-Phagosome pathway;R-HSA-168638|NOD1/2 Signaling Pathway;R-HSA-168927|TICAM1, RIP1-mediated IKK complex recruitment;R-HSA-1810476|RIP-mediated NFkB activation via ZBP1;R-HSA-202424|Downstream TCR signaling;R-HSA-209543|p75NTR recruits signalling complexes;R-HSA-209560|NF-kB is activated and signals survival;R-HSA-2871837|FCERI mediated NF-kB activation;R-HSA-2871837|NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10;R-HSA-445989|TAK1-dependent IKK and NF-kappa-B activation;R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-5602636|IKBKB deficiency causes SCID;R-HSA-5603027|IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR);R-HSA-5603029|IkBA variant leads to EDA-ID;R-HSA-5607764|CLEC7A (Dectin-1) signaling;R-HSA-9020702|Interleukin-1 signaling;R-HSA-933542|TRAF6 mediated NF-kB activation;R-HSA-937039|IRAK1 recruits IKK complex;R-HSA-937041|IKK complex recruitment mediated by RIP1;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-975144|IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation;R-HSA-9758274|Regulation of NF-kappa B signaling;R-HSA-9833482|PKR-mediated signaling;R-HSA-9860276|SLC15A4:TASL-dependent IRF5 activation;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells;R-HSA-9909505|Modulation of host responses by IFN-stimulated genes",29,5,,2.0,Unknown status,0,0,pathway_drug_candidates,12.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,12.0,H
CHEMBL3545174,GSK2881078,,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL3545189,LANADELUMAB,,,0,0,,0,0,Plasma kallikrein inhibitor,,,1,1,known_drugs;mechanism_of_actions,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL3545193,MSC-2364447,,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,1.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL3545215,BMS-911543,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;RMTs methylate histone arginines",21,9,,1.0,Terminated,0,0,pathway_drug_candidates,11.0,0.22,0.281,0.5,0.672,0.0773,0.0,0.824,0.0188,0.0,0.848,0.0152,0.0,0.0658,0.405,1.0,0.831,0.0265,0,0.447,0.0832,0.0,0.723,0.0492,0,-1.9,-2.39,-1.41,-2.39,-1.41,3.495420000000002,0.372,0.215,0.0,0.105,0.505,1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,6.5,L
CHEMBL3545221,AZD2423,,,0,0,R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL3545225,INCB-047986,,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-449836|Other interleukin signaling;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,19,11,,2.0,Terminated,0,0,pathway_drug_candidates,12.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,12.0,H
CHEMBL3545237,HE3235,C#C[C@]1(O)CCC2C3CCC4CC(O)CC[C@]4(C)C3CC[C@@]21C,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,1.0,Completed,0,0,pathway_drug_candidates,1.0,0.327,0.2,0.0,0.445,0.17,0.0,0.0349,0.729,1.0,0.133,0.424,1.0,0.171,0.242,0.5,0.306,0.18,0,0.568,0.0477,0.0,0.29,0.15,0,-6.1,-6.77,-5.44,-6.77,-5.44,3.7543000000000033,0.693,0.0498,0.0,0.0499,0.895,1,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,0.0,1.0,-4.5,L
CHEMBL3545241,AC-430,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;RMTs methylate histone arginines",21,9,,1.0,Completed,0,0,pathway_drug_candidates,11.0,0.29,0.23,0.5,0.0585,0.563,1.0,0.104,0.486,1.0,0.0315,0.785,1.0,0.171,0.252,0.5,0.309,0.168,0,0.899,0.0135,0.0,0.027,0.391,1,-3.65,-4.2,-3.11,-4.2,-3.11,3.625720000000001,0.214,0.477,1.0,0.096,0.492,1,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,5.0,1.0,1.0,4.5,L
CHEMBL3545252,DOCETAXEL,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,Tubulin inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.613,0.0695,0.0,0.0194,0.757,1.0,0.0116,0.934,1.0,0.764,0.031,0.0,0.52,0.0567,0.0,0.739,0.0477,0,0.27,0.135,0.0,0.161,0.198,1,-6.3,-7.68,-4.93,-7.68,-4.93,0.7855000000000025,0.139,0.693,1.0,0.62,0.0161,0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,2.0,L
CHEMBL3545259,VANUCIZUMAB,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1234158|Regulation of gene expression by Hypoxia-inducible Factor;R-HSA-194138|Signaling by VEGF;R-HSA-194313|VEGF ligand-receptor interactions;R-HSA-195399|VEGF binds to VEGFR leading to receptor dimerization;R-HSA-4420097|VEGFA-VEGFR2 Pathway;R-HSA-5218921|VEGFR2 mediated cell proliferation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9679191|Potential therapeutics for SARS,10,2,,2.0,Terminated,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL3545309,LEFAMULIN ACETATE,C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O.CC(=O)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.901,0.0145,0.0,0.725,0.069,0.0,0.37,0.168,0.0,0.806,0.0255,0.0,0.59,0.0373,0.0,0.534,0.0958,0,0.434,0.0826,0.0,0.564,0.102,0,-2.59,-3.02,-2.16,-3.02,-2.16,3.957700000000002,0.262,0.473,0.5,0.248,0.137,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,L
CHEMBL3545316,RINUCUMAB,,,0,0,R-HSA-5673001|RAF/MAP kinase cascade,1,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL3545328,XL-019,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;RMTs methylate histone arginines",21,9,,1.0,Terminated,0,0,pathway_drug_candidates,11.0,0.799,0.0313,0.0,0.976,0.00658,0.0,0.562,0.0779,0.0,0.787,0.0275,0.0,0.67,0.0253,0.0,0.708,0.0534,0,0.0685,0.499,1.0,0.739,0.0629,0,-3.67,-4.76,-2.58,-4.76,-2.58,3.4143000000000017,0.647,0.0878,0.0,0.261,0.152,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,M
CHEMBL3545333,MK-0773,,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL3545350,EVT-101,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.467,0.169,0.0,0.155,0.394,1.0,0.385,0.17,0.0,0.808,0.0275,0.0,0.497,0.0563,0.0,0.915,0.0194,0,0.411,0.079,0.0,0.222,0.176,0.5,-3.08,-3.66,-2.49,-3.66,-2.49,3.773520000000002,0.625,0.0876,0.0,0.173,0.333,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,-1.0,L
CHEMBL3545351,AV-101,Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,3.0,"Active, not recruiting",0,0,pathway_drug_candidates,3.0,0.399,0.151,0.0,0.624,0.0949,0.0,0.743,0.0375,0.0,0.493,0.0936,0.0,0.0576,0.483,1.0,0.744,0.047,0,0.745,0.0308,0.0,0.199,0.173,0.5,-2.95,-3.67,-2.22,-3.67,-2.22,0.9069,0.701,0.0404,0.0,0.296,0.0941,0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,L
CHEMBL3545372,SOFITUZUMAB VEDOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,1.0,Completed,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL3545391,ORG-34517,CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,4.0,0.0194,0.729,1.0,0.0244,0.749,1.0,0.0213,0.837,1.0,0.0542,0.676,1.0,0.358,0.0935,0.0,0.62,0.071,0,0.718,0.0341,0.0,0.144,0.24,1,-6.42,-7.06,-5.79,-7.06,-5.79,5.069200000000006,0.233,0.494,1.0,0.339,0.083,0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,4.0,1.0,1.0,-5.0,L
CHEMBL3545401,X-82,,,0,0,R-HSA-5673001|RAF/MAP kinase cascade,1,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL3545402,XL-820,,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL3545413,FLUMATINIB,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,3.0,Recruiting,0,0,pathway_drug_candidates,3.0,0.781,0.0384,0.0,0.324,0.194,0.0,0.473,0.115,0.0,0.928,0.00692,0.0,0.855,0.00798,0.0,0.919,0.0166,0,0.903,0.0103,0.0,0.166,0.231,1,-0.793,-1.3,-0.287,-1.3,-0.287,5.004120000000004,0.111,0.83,1.0,0.0944,0.67,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,2.0,L
CHEMBL3545427,CM-082,,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,3.0,Unknown status,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL3559672,RAUWOLFIA SERPENTINA,,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL3590187,CLASCOTERONE,CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Androgen Receptor antagonist,4.0,"Active, not recruiting",0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.415,0.142,0.0,0.602,0.0983,0.0,0.816,0.0211,0.0,0.423,0.118,0.0,0.854,0.00826,0.0,0.249,0.21,0,0.687,0.0393,0.0,0.573,0.0916,0,-5.13,-6.0,-4.25,-6.0,-4.25,3.7717000000000023,0.514,0.138,0.0,0.136,0.418,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.5,L
CHEMBL3622820,ITACITINIB,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-449836|Other interleukin signaling;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,19,11,,3.0,,0,0,pathway_drug_candidates,13.0,0.785,0.0344,0.0,0.71,0.0722,0.0,0.839,0.0156,0.0,0.934,0.0066,0.0,0.394,0.0773,0.0,0.228,0.229,0.5,0.734,0.0305,0.0,0.195,0.152,0,-3.84,-4.4,-3.28,-4.4,-3.28,3.6036800000000024,0.269,0.308,0.5,0.079,0.47,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,7.0,M
CHEMBL3622821,UPADACITINIB,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",28,13,,3.0,"Active, not recruiting;Completed;Enrolling by invitation",0,0,pathway_drug_candidates,13.0,0.173,0.334,1.0,0.171,0.361,1.0,0.589,0.0695,0.0,0.405,0.122,0.0,0.426,0.0793,0.0,0.193,0.247,1,0.87,0.0146,0.0,0.48,0.115,0,-3.45,-4.03,-2.86,-4.03,-2.86,2.9079000000000006,0.227,0.472,1.0,0.192,0.242,1,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,1.0,1.0,5.0,L
CHEMBL362558,LY-2090314,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2,,0,0,R-HSA-198323|AKT phosphorylates targets in the cytosol;R-HSA-381038|XBP1(S) activates chaperone genes;R-HSA-5674400|Constitutive Signaling by AKT1 E17K in Cancer;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9635465|Suppression of apoptosis;R-HSA-9683610|Maturation of nucleoprotein,6,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.164,0.333,1.0,0.591,0.107,0.0,0.437,0.122,0.0,0.706,0.0411,0.0,0.394,0.0869,0.0,0.456,0.118,0,0.455,0.0737,0.0,0.218,0.135,0,-3.96,-4.52,-3.39,-4.52,-3.39,3.416800000000002,0.146,0.719,1.0,0.183,0.251,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,-0.5,L
CHEMBL364804,GW-406381,CCOc1ccc(-c2nn3ncccc3c2-c2ccc(S(C)(=O)=O)cc2)cc1,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,3.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,9.0,0.368,0.168,0.0,0.666,0.089,0.0,0.76,0.0431,0.0,0.848,0.0203,0.0,0.256,0.168,0.5,0.0074,0.823,1,0.48,0.0795,0.0,0.516,0.103,0,-4.14,-4.89,-3.4,-4.89,-3.4,3.8655000000000026,0.367,0.314,0.5,0.0754,0.867,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.5,L
CHEMBL3655081,ABROCITINIB,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-449836|Other interleukin signaling;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,19,11,Tyrosine-protein kinase JAK1 inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,14.0,0.623,0.0678,0.0,0.309,0.232,0.5,0.915,0.00549,0.0,0.717,0.0349,0.0,0.172,0.261,0.5,0.281,0.187,0,0.206,0.16,0.0,0.49,0.0997,0,-2.72,-3.35,-2.1,-3.35,-2.1,1.2544999999999995,0.351,0.245,0.0,0.172,0.229,1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,11.5,M
CHEMBL3666807,VELSECORAT,C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,4.0,0.74,0.0305,0.0,0.787,0.0421,0.0,0.276,0.223,0.5,0.0703,0.55,1.0,0.697,0.0214,0.0,0.964,0.00682,0,0.0652,0.502,1.0,0.098,0.208,1,-6.25,-6.73,-5.77,-6.73,-5.77,4.595400000000003,0.0837,0.679,1.0,0.09,0.468,1,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-3.0,L
CHEMBL3678958,RUSERONTINIB,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,3.0,Recruiting,0,0,pathway_drug_candidates,3.0,0.707,0.0515,0.0,0.148,0.377,1.0,0.925,0.00495,0.0,0.686,0.0398,0.0,0.891,0.00451,0.0,0.506,0.103,0,0.476,0.072,0.0,0.535,0.0964,0,-2.33,-3.39,-1.28,-3.39,-1.28,4.041200000000003,0.0443,0.879,1.0,0.228,0.163,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,2.5,L
CHEMBL3702854,RILZABRUTINIB,CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,3.0,Recruiting,0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.71,0.0384,0.0,0.819,0.0432,0.0,0.252,0.261,0.5,0.22,0.242,0.5,0.402,0.0787,0.0,0.643,0.0652,0,0.262,0.139,0.0,0.49,0.0803,0,-6.8,-7.38,-6.22,-7.38,-6.22,4.4153800000000025,0.0106,0.916,1.0,0.0563,0.755,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,2.0,L
CHEMBL3707226,DEFIBROTIDE SODIUM,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4,1,,4.0,,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL3707228,PLOZALIZUMAB,,,0,0,R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,3,1,,2.0,Withdrawn,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL3707250,CP-601927,,,0,0,R-HSA-629587|Highly sodium permeable postsynaptic acetylcholine nicotinic receptors;R-HSA-629594|Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;R-HSA-629597|Highly calcium permeable nicotinic acetylcholine receptors,3,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL3707293,XEN-D0501,,,0,0,R-HSA-3295583|TRP channels,1,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL3707311,VAMOROLONE,,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL3707313,TRIFAROTENE,CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1,,0,0,R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-5362517|Signaling by Retinoic Acid;R-HSA-5617472|Activation of anterior HOX genes in hindbrain development during early embryogenesis,3,0,,4.0,Completed,0,0,pathway_drug_candidates,4.0,0.959,0.00461,0.0,0.908,0.0167,0.0,0.768,0.0382,0.0,0.959,0.00299,0.0,0.303,0.131,0.0,0.8,0.0358,0,0.955,0.00443,0.0,0.0406,0.29,1,-5.9,-7.28,-4.53,-7.28,-4.53,5.987600000000008,0.836,0.0135,0.0,0.21,0.237,0.5,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.5,0.0,0.0,1.0,-0.5,L
CHEMBL3707325,LENZILUMAB,,CSF2,1,0,"R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling",3,2,Granulocyte-macrophage colony-stimulating factor inhibitor,3.0,"Active, not recruiting",1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,10.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.5,H
CHEMBL3707330,ROLAPITANT HYDROCHLORIDE,C[C@@H](OC[C@@]1(c2ccccc2)CC[C@]2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.Cl.O,,0,0,,0,0,Neurokinin 1 receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.35,0.178,0.0,0.0381,0.685,1.0,0.315,0.203,0.5,0.0982,0.506,1.0,0.587,0.0383,0.0,0.356,0.157,0,0.919,0.00917,0.0,0.255,0.149,0,-4.12,-5.01,-3.24,-5.01,-3.24,5.326600000000006,0.424,0.16,0.0,0.00974,0.983,1,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,3.0,0.0,1.0,-6.5,L
CHEMBL3707348,ACALABRUTINIB,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,Tyrosine-protein kinase BTK inhibitor,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.798,0.0276,0.0,0.737,0.0533,0.0,0.117,0.458,1.0,0.812,0.0189,0.0,0.304,0.141,0.0,0.933,0.0148,0,0.529,0.0488,0.0,0.641,0.0436,0,-4.12,-4.73,-3.52,-4.73,-3.52,3.3126000000000015,0.0736,0.763,1.0,0.274,0.104,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,6.5,L
CHEMBL3707356,TIVANISIRAN,,,0,0,R-HSA-3295583|TRP channels,1,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL3707357,BROLUCIZUMAB,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1234158|Regulation of gene expression by Hypoxia-inducible Factor;R-HSA-194138|Signaling by VEGF;R-HSA-194313|VEGF ligand-receptor interactions;R-HSA-195399|VEGF binds to VEGFR leading to receptor dimerization;R-HSA-4420097|VEGFA-VEGFR2 Pathway;R-HSA-5218921|VEGFR2 mediated cell proliferation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9679191|Potential therapeutics for SARS,10,2,,4.0,Withdrawn,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL3707365,BEMIPARIN,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,,3.0,Unknown status,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL3707398,PAC-14028,,,0,0,R-HSA-3295583|TRP channels,1,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL3707400,INDANTADOL,,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL376140,TIGECYCLINE,CN(C)c1cc(NC(=O)CNC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.918,0.00784,0.0,0.61,0.11,0.0,0.701,0.0484,0.0,0.591,0.068,0.0,0.831,0.0133,0.0,0.733,0.0524,0,0.801,0.0214,0.0,0.972,0.0134,0,-3.57,-4.09,-3.06,-4.09,-3.06,0.5132000000000028,0.784,0.0265,0.0,0.372,0.0422,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,L
CHEMBL37676,APC-100,Cc1c(C)c2c(c(C)c1O)CCC(C)(C)O2,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,1.0,Unknown status,0,0,pathway_drug_candidates,1.0,0.11,0.47,1.0,0.522,0.12,0.0,0.478,0.11,0.0,0.417,0.116,0.0,0.314,0.129,0.0,0.274,0.198,0,0.747,0.0244,0.0,0.412,0.116,0,-4.23,-5.1,-3.36,-5.1,-3.36,3.4210600000000024,0.108,0.633,1.0,0.193,0.219,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,-3.0,L
CHEMBL378544,VINBLASTINE SULFATE,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,Tubulin inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.423,0.14,0.0,0.058,0.6,1.0,0.864,0.0116,0.0,0.769,0.0274,0.0,0.803,0.00806,0.0,0.133,0.303,1,0.924,0.00723,0.0,0.199,0.147,0,-3.75,-4.29,-3.22,-4.29,-3.22,3.3381000000000043,0.0112,0.927,1.0,0.157,0.365,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.5,L
CHEMBL38,TRETINOIN,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1,,0,0,R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-5362517|Signaling by Retinoic Acid;R-HSA-5617472|Activation of anterior HOX genes in hindbrain development during early embryogenesis,3,0,Retinoic acid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.875,0.0157,0.0,0.418,0.185,0.0,0.795,0.0306,0.0,0.597,0.0578,0.0,0.465,0.0619,0.0,0.305,0.178,0,0.251,0.157,0.0,0.672,0.074,0,-4.41,-5.78,-3.04,-5.78,-3.04,5.602600000000005,0.548,0.103,0.0,0.466,0.0397,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.5,L
CHEMBL3813873,PEXIDARTINIB,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0819,0.515,1.0,0.061,0.598,1.0,0.918,0.0103,0.0,0.16,0.339,1.0,0.112,0.323,1.0,0.875,0.0198,0,0.779,0.0313,0.0,0.442,0.129,0,-5.87,-6.48,-5.25,-6.48,-5.25,5.228000000000002,0.0734,0.87,1.0,0.148,0.458,1,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,4.0,1.0,1.0,-4.0,L
CHEMBL383322,RESIQUIMOD,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-168181|Toll Like Receptor 7/8 (TLR7/8) Cascade;R-HSA-5686938|Regulation of TLR by endogenous ligand;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9692916|SARS-CoV-1 activates/modulates innate immune responses;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome;R-HSA-9824856|Defective regulation of TLR7 by endogenous ligand;R-HSA-9833110|RSV-host interactions,11,0,,2.0,"Active, not recruiting",0,0,pathway_drug_candidates,2.0,0.232,0.262,0.5,0.248,0.291,0.5,0.156,0.36,1.0,0.162,0.342,1.0,0.138,0.283,1.0,0.167,0.277,1,0.44,0.0523,0.0,0.562,0.0646,0,-1.89,-2.59,-1.2,-2.59,-1.2,2.4741000000000013,0.426,0.22,0.0,0.152,0.399,1,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,5.0,1.0,1.0,-9.0,L
CHEMBL3833306,VANDORTUZUMAB VEDOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,1.0,Completed,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL3833307,SATRALIZUMAB,,IL6R,1,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9616222|Transcriptional regulation of granulopoiesis;R-HSA-9679191|Potential therapeutics for SARS,6,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.0,H
CHEMBL3833343,VOBARILIZUMAB,,IL6R,1,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9616222|Transcriptional regulation of granulopoiesis;R-HSA-9679191|Potential therapeutics for SARS,6,2,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL3833389,DEXTROMORAMIDE,C[C@@H](CC(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1)N1CCOCC1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.0509,0.621,1.0,0.265,0.275,0.5,0.202,0.311,0.5,0.117,0.481,1.0,0.703,0.0277,0.0,0.4,0.149,0,0.752,0.0302,0.0,0.804,0.0371,0,-3.04,-3.97,-2.11,-3.97,-2.11,3.7059000000000024,0.359,0.225,0.0,0.0761,0.712,1,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-1.0,L
CHEMBL3833393,EMICIZUMAB,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,,4.0,"Active, not recruiting",0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL384467,DEXAMETHASONE,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.331,0.186,0.0,0.493,0.128,0.0,0.424,0.136,0.0,0.456,0.105,0.0,0.639,0.0286,0.0,0.149,0.288,1,0.617,0.0505,0.0,0.188,0.167,0,-4.08,-5.1,-3.06,-5.1,-3.06,1.8957,0.545,0.113,0.0,0.701,0.019,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.5,L
CHEMBL386630,TESTOSTERONE,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.398,0.155,0.0,0.57,0.111,0.0,0.293,0.217,0.5,0.198,0.288,1.0,0.621,0.0331,0.0,0.133,0.301,1,0.537,0.0524,0.0,0.0201,0.442,1,-3.67,-4.76,-2.58,-4.76,-2.58,3.879200000000003,0.631,0.0636,0.0,0.72,0.0116,0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,-5.0,L
CHEMBL38827,LUMEFANTRINE,CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1,,0,0,,0,0,Ferriprotoporphyrin IX inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.0937,0.461,1.0,0.00725,0.857,1.0,0.69,0.0529,0.0,0.675,0.0464,0.0,0.004,0.912,1.0,0.0216,0.637,1,0.868,0.0149,0.0,0.0788,0.286,1,-7.11,-7.84,-6.37,-7.84,-6.37,9.151699999999998,0.111,0.733,1.0,0.0675,0.788,1,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-13.0,L
CHEMBL389621,HYDROCORTISONE,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.45,0.125,0.0,0.546,0.107,0.0,0.446,0.124,0.0,0.459,0.103,0.0,0.661,0.0269,0.0,0.152,0.273,1,0.525,0.0592,0.0,0.873,0.0299,0,-3.4,-4.39,-2.4,-4.39,-2.4,1.7815999999999996,0.636,0.0646,0.0,0.698,0.0129,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,L
CHEMBL3900409,BRENSOCATIB,,,0,0,,0,0,Dipeptidyl peptidase I inhibitor,,,1,1,known_drugs;mechanism_of_actions,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL3900554,BMS-986142,Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,4.0,0.196,0.308,1.0,0.653,0.0926,0.0,0.0213,0.839,1.0,0.933,0.00794,0.0,0.174,0.232,0.5,0.845,0.0288,0,0.22,0.158,0.0,0.639,0.0416,0,-4.48,-4.84,-4.12,-4.84,-4.12,4.399020000000004,0.212,0.409,1.0,0.133,0.344,1,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-2.0,L
CHEMBL393220,ATORVASTATIN CALCIUM,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2],,0,0,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,HMG-CoA reductase inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.179,0.322,1.0,0.454,0.138,0.0,0.0132,0.911,1.0,0.518,0.09,0.0,0.66,0.0214,0.0,0.882,0.02,0,0.992,0.00163,0.0,0.936,0.00965,0,-7.0,-7.32,-6.67,-7.32,-6.67,9.577000000000004,0.813,0.0179,0.0,0.0254,0.944,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-3.5,L
CHEMBL3936761,ZANUBRUTINIB,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,Tyrosine-protein kinase BTK inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.48,0.107,0.0,0.806,0.0421,0.0,0.179,0.347,1.0,0.0675,0.607,1.0,0.5,0.0589,0.0,0.316,0.184,0,0.487,0.0478,0.0,0.37,0.0945,0,-3.74,-4.89,-2.58,-4.89,-2.58,4.222600000000003,0.0404,0.872,1.0,0.0381,0.883,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,4.5,L
CHEMBL3948730,UMBRALISIB,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.558,0.0868,0.0,0.818,0.0424,0.0,0.148,0.41,1.0,0.147,0.394,1.0,0.306,0.131,0.0,0.79,0.0387,0,0.114,0.317,1.0,0.154,0.2,1,-6.9,-7.35,-6.46,-7.35,-6.46,6.662700000000005,0.263,0.443,0.5,0.141,0.373,1,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-4.5,L
CHEMBL395091,ESKETAMINE,CN[C@]1(c2ccccc2Cl)CCCCC1=O,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.374,0.172,0.0,0.343,0.209,0.5,0.287,0.206,0.5,0.328,0.161,0.0,0.366,0.0968,0.0,0.311,0.181,0,0.653,0.0408,0.0,0.781,0.0247,0,-0.906,-1.74,-0.0712,-1.74,-0.0712,2.897800000000001,0.284,0.316,0.5,0.109,0.436,1,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,2.0,L
CHEMBL39541,DOLASTATIN-10,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.0994,0.471,1.0,0.354,0.195,0.0,0.779,0.0339,0.0,0.241,0.25,0.5,0.851,0.00853,0.0,0.436,0.125,0,0.963,0.00632,0.0,0.212,0.188,0.5,-2.18,-2.63,-1.72,-2.63,-1.72,5.190400000000006,0.122,0.797,1.0,0.0893,0.625,1,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,-1.5,L
CHEMBL398435,TICAGRELOR,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,P2RY12,1,1,R-HSA-418594|G alpha (i) signalling events,1,0,Purinergic receptor P2Y12 negative allosteric modulator,4.0,Unknown status,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.725,0.0467,0.0,0.561,0.0972,0.0,0.0266,0.771,1.0,0.341,0.168,0.0,0.409,0.0827,0.0,0.544,0.0951,0,0.283,0.128,0.0,0.0789,0.248,1,-4.42,-4.86,-3.98,-4.86,-3.98,2.0136999999999996,0.0866,0.808,1.0,0.0803,0.67,1,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,6.0,L
CHEMBL398707,HYDROMORPHONE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.684,0.0488,0.0,0.155,0.386,1.0,0.292,0.22,0.5,0.247,0.239,0.5,0.481,0.0514,0.0,0.113,0.333,1,0.739,0.0318,0.0,0.935,0.0186,0,-2.28,-3.32,-1.24,-3.32,-1.24,1.6303,0.285,0.407,0.5,0.126,0.465,1,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,-2.5,L
CHEMBL3989406,ENALAPRILAT,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,Angiotensin-converting enzyme inhibitor,3.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,5.0,0.895,0.0101,0.0,0.19,0.345,1.0,0.115,0.46,1.0,0.646,0.0453,0.0,0.65,0.0281,0.0,0.971,0.00513,0,0.945,0.01,0.0,0.536,0.097,0,-2.09,-2.94,-1.23,-2.94,-1.23,-0.5232999999999988,0.924,0.000994,0.0,0.231,0.143,0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,1.5,L
CHEMBL3989408,IBUPROFEN SODIUM,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+],PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,3.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,9.0,0.322,0.186,0.0,0.908,0.0118,0.0,0.0363,0.703,1.0,0.664,0.048,0.0,0.937,0.00403,0.0,0.778,0.0417,0,0.566,0.0538,0.0,0.815,0.0355,0,-3.68,-4.77,-2.59,-4.77,-2.59,-2.906899999999997,0.935,0.00629,0.0,0.491,0.0314,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,6.5,L
CHEMBL3989410,INDOMETHACIN SODIUM,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+],PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,1.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,7.0,0.202,0.291,1.0,0.782,0.0496,0.0,0.0435,0.684,1.0,0.774,0.0268,0.0,0.346,0.0975,0.0,0.898,0.02,0,0.804,0.0223,0.0,0.463,0.113,0,-4.78,-5.59,-3.96,-5.59,-3.96,-2.877479999999999,0.572,0.0713,0.0,0.026,0.863,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,0.0,L
CHEMBL3989512,SOBLIDOTIN,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.107,0.468,1.0,0.157,0.392,1.0,0.768,0.0301,0.0,0.172,0.33,1.0,0.916,0.00379,0.0,0.325,0.179,0,0.986,0.00246,0.0,0.382,0.118,0,-2.53,-3.09,-1.98,-3.09,-1.98,3.992600000000007,0.113,0.641,1.0,0.121,0.383,1,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-0.5,L
CHEMBL3989519,DOXAPRAM HYDROCHLORIDE,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O.Cl.O,,0,0,R-HSA-1299316|TWIK-releated acid-sensitive K+ channel (TASK);R-HSA-5576886|Phase 4 - resting membrane potential,2,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.166,0.322,1.0,0.173,0.382,1.0,0.321,0.188,0.0,0.209,0.29,0.5,0.623,0.0355,0.0,0.473,0.116,0,0.444,0.0641,0.0,0.731,0.0494,0,-1.73,-3.57,0.123,-3.57,0.123,2.7704000000000018,0.276,0.35,0.5,0.0159,0.997,1,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,1.0,1.0,-1.0,L
CHEMBL3989555,MECLIZINE HYDROCHLORIDE,Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1.Cl.Cl.O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.15,0.363,1.0,0.0112,0.827,1.0,0.628,0.0677,0.0,0.808,0.0235,0.0,0.588,0.0417,0.0,0.0407,0.504,1,0.777,0.027,0.0,0.871,0.0468,0,-3.91,-5.25,-2.56,-5.25,-2.56,5.574520000000008,0.562,0.107,0.0,0.0252,1.0,1,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-7.0,L
CHEMBL3989562,TERAZOSIN HYDROCHLORIDE,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0879,0.519,1.0,0.117,0.435,1.0,0.0905,0.52,1.0,0.738,0.0392,0.0,0.568,0.0466,0.0,0.804,0.0393,0,0.222,0.171,0.0,0.811,0.0243,0,-2.15,-3.74,-0.558,-3.74,-0.558,-0.1708000000000003,0.304,0.269,0.5,0.00743,0.97,1,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-2.5,L
CHEMBL3989568,OXYTETRACYCLINE CALCIUM,CN(C)[C@@H]1C([O-])=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12.CN(C)[C@@H]1C([O-])=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12.[Ca+2],,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.938,0.00499,0.0,0.917,0.0126,0.0,0.0148,0.905,1.0,0.348,0.158,0.0,0.836,0.00545,0.0,0.662,0.0691,0,0.779,0.0208,0.0,0.764,0.0197,0,-3.39,-3.98,-2.8,-3.98,-2.8,-5.263399999999995,0.961,0.000328,0.0,0.584,0.0125,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-2.5,L
CHEMBL3989571,SPECTINOMYCIN HYDROCHLORIDE,CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@@]3(O)C(=O)C[C@@H](C)O[C@H]3O[C@@H]2[C@H]1O.Cl.Cl.O.O.O.O.O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.953,0.00657,0.0,0.0402,0.662,1.0,0.0236,0.867,1.0,0.747,0.0326,0.0,0.584,0.0357,0.0,0.581,0.086,0,0.495,0.0707,0.0,0.596,0.0602,0,-0.885,-2.86,1.09,-2.86,1.09,-6.205499999999992,0.763,0.0264,0.0,0.0682,0.811,1,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-3.0,L
CHEMBL3989676,OXYPHENBUTAZONE,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.618,0.0545,0.0,0.477,0.15,0.0,0.0416,0.719,1.0,0.0835,0.51,1.0,0.115,0.312,1.0,0.785,0.0389,0,0.0722,0.447,1.0,0.55,0.1,0,-4.17,-5.35,-2.99,-5.35,-2.99,2.668700000000001,0.283,0.377,0.5,0.628,0.0186,0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,3.0,0.0,1.0,3.0,L
CHEMBL3989677,HYDROCODONE BITARTRATE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O.O=C(O)C(O)C(O)C(=O)O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.849,0.0169,0.0,0.0128,0.801,1.0,0.47,0.108,0.0,0.967,0.00299,0.0,0.736,0.019,0.0,0.201,0.241,1,0.867,0.0124,0.0,0.922,0.00745,0,-2.15,-2.86,-1.45,-2.86,-1.45,-1.8386999999999971,0.547,0.113,0.0,0.0606,0.845,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-1.5,L
CHEMBL3989680,AXOMADOL,COc1cccc(C2(O)CC(O)CCC2CN(C)C)c1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.328,0.192,0.0,0.113,0.452,1.0,0.269,0.242,0.5,0.586,0.0694,0.0,0.785,0.0158,0.0,0.439,0.129,0,0.236,0.172,0.0,0.18,0.186,0.5,-1.98,-2.62,-1.33,-2.62,-1.33,1.6054,0.24,0.438,1.0,0.174,0.33,1,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,0.0,1.0,2.5,L
CHEMBL3989694,OLANZAPINE PAMOATE,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1.O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O,,0,0,,0,0,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.941,0.00634,0.0,0.629,0.104,0.0,0.251,0.262,0.5,0.867,0.0131,0.0,0.791,0.0109,0.0,0.111,0.311,1,0.714,0.0306,0.0,0.154,0.2,1,-3.92,-4.63,-3.2,-4.63,-3.2,7.0059200000000095,0.759,0.022,0.0,0.169,0.292,1,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,-9.0,L
CHEMBL3989716,PROPOXYPHENE NAPSYLATE,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.O.O=S(=O)(O)c1ccc2ccccc2c1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.112,0.455,1.0,0.0112,0.842,1.0,0.469,0.119,0.0,0.579,0.0794,0.0,0.56,0.0428,0.0,0.539,0.0955,0,0.99,0.00318,0.0,0.935,0.0188,0,-4.24,-6.13,-2.35,-6.13,-2.35,5.537300000000007,0.375,0.243,0.0,0.0884,0.752,1,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-1.5,L
CHEMBL3989724,FLURAZEPAM HYDROCHLORIDE,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl.Cl,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.577,0.0686,0.0,0.295,0.258,0.5,0.399,0.136,0.0,0.785,0.0314,0.0,0.0575,0.456,1.0,0.399,0.144,0,0.613,0.0434,0.0,0.4,0.115,0,-3.46,-4.14,-2.78,-4.14,-2.78,4.848500000000006,0.168,0.587,1.0,0.0159,0.997,1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-2.5,L
CHEMBL3989740,DOXYCYCLINE HYCLATE,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O,,0,0,R-HSA-1442490|Collagen degradation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases;R-HSA-210991|Basigin interactions;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6798695|Neutrophil degranulation,7,1,Bacterial 70S ribosome inhibitor | Matrix metalloproteinase 13 inhibitor | Matrix metalloproteinase 7 inhibitor | Matrix metalloproteinase 8 inhibitor | Matrix metalloproteinase-1 inhibitor,4.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.974,0.00327,0.0,0.875,0.0288,0.0,0.00984,0.929,1.0,0.234,0.241,0.5,0.899,0.00608,0.0,0.539,0.103,0,0.227,0.173,0.0,0.706,0.0442,0,-2.03,-2.6,-1.46,-2.6,-1.46,-0.6776999999999942,0.973,0.00243,0.0,0.00873,0.962,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,2.5,L
CHEMBL3989754,FLURBIPROFEN SODIUM,CC(C(=O)[O-])c1ccc(-c2ccccc2)c(F)c1.O.O.[Na+],,0,0,,0,0,Cyclooxygenase inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.187,0.331,1.0,0.843,0.032,0.0,0.0139,0.904,1.0,0.874,0.0138,0.0,0.906,0.00419,0.0,0.912,0.0145,0,0.75,0.0301,0.0,0.803,0.0463,0,-3.94,-4.77,-3.11,-4.77,-3.11,-2.2992999999999992,0.938,0.00326,0.0,0.153,0.39,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-5.5,L
CHEMBL3989768,LEVORPHANOL TARTRATE,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13.O.O.O=C(O)C(O)C(O)C(=O)O,,0,0,,0,0,Mu opioid receptor agonist,,,0,0,mechanism_drug_candidate,0.0,0.946,0.00583,0.0,0.00869,0.848,1.0,0.669,0.0505,0.0,0.985,0.000831,0.0,0.759,0.0169,0.0,0.689,0.0576,0,0.94,0.0092,0.0,0.911,0.00731,0,-3.11,-3.9,-2.32,-3.9,-2.32,-0.6916,0.689,0.0349,0.0,0.0858,0.655,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-2.5,L
CHEMBL3989803,DIPYRONE,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+],PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.504,0.119,0.0,0.941,0.0136,0.0,0.212,0.295,0.5,0.753,0.0327,0.0,0.963,0.00268,0.0,0.183,0.253,1,0.072,0.483,1.0,0.919,0.0142,0,0.909,-0.0938,1.91,-0.0938,1.91,-3.3973799999999974,0.398,0.23,0.0,0.12,0.438,1,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,L
CHEMBL3989824,THIOTHIXENE HYDROCHLORIDE,CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1.Cl.Cl.O.O,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.158,0.351,1.0,0.0106,0.824,1.0,0.685,0.0525,0.0,0.644,0.0516,0.0,0.483,0.059,0.0,0.00563,0.845,1,0.741,0.0304,0.0,0.0542,0.284,1,-3.19,-4.24,-2.14,-4.24,-2.14,2.6649000000000043,0.247,0.365,1.0,0.014,0.996,1,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,1.0,1.0,-9.0,L
CHEMBL3989826,OXYCODONE TEREPHTHALATE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.O=C(O)c1ccc(C(=O)O)cc1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.984,0.00326,0.0,0.759,0.0561,0.0,0.81,0.021,0.0,0.89,0.0104,0.0,0.946,0.00286,0.0,0.602,0.0766,0,0.905,0.00744,0.0,0.91,0.00637,0,-2.74,-3.18,-2.31,-3.18,-2.31,3.179400000000002,0.565,0.0881,0.0,0.021,0.934,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,5.0,L
CHEMBL3989829,NETILMICIN SULFATE,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O.CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,1.0,0.00198,0.0,0.869,0.0336,0.0,0.998,0.0025,0.0,0.981,0.00175,0.0,0.996,0.00174,0.0,0.451,0.128,0,0.982,0.00418,0.0,0.996,0.0153,0,6.2,5.66,6.74,2.14,2.14,-9.665399999999975,0.721,0.0487,0.0,0.97,0.00656,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,L
CHEMBL3989833,ZIPRASIDONE MESYLATE,CS(=O)(=O)O.O.O.O.O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.78,0.0374,0.0,0.244,0.299,0.5,0.0145,0.902,1.0,0.241,0.24,0.5,0.157,0.272,1.0,0.00257,0.928,1,0.827,0.0217,0.0,0.502,0.1,0,-4.45,-5.4,-3.51,-5.4,-3.51,0.8389000000000006,0.197,0.527,1.0,0.145,0.374,1,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,4.0,0.0,1.0,-9.0,L
CHEMBL3989862,PEFCALCITOL,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)OCC(=O)NCC(F)(F)C(F)(F)F)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.741,0.0439,0.0,0.566,0.124,0.0,0.0263,0.816,1.0,0.491,0.0953,0.0,0.774,0.0203,0.0,0.261,0.212,0,0.8,0.027,0.0,0.333,0.15,0,-4.54,-4.99,-4.08,-4.99,-4.08,4.766400000000005,0.345,0.303,0.5,0.125,0.476,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-1.5,L
CHEMBL3989869,UMBRALISIB TOSYLATE,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.703,0.0405,0.0,0.777,0.0549,0.0,0.304,0.207,0.5,0.233,0.25,0.5,0.337,0.11,0.0,0.923,0.0123,0,0.254,0.129,0.0,0.249,0.152,0,-5.53,-5.96,-5.1,-5.96,-5.1,7.904420000000008,0.187,0.593,1.0,0.167,0.24,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,0.0,L
CHEMBL3989872,APIMOSTINEL,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.403,0.15,0.0,0.419,0.161,0.0,0.0195,0.835,1.0,0.264,0.198,0.0,0.799,0.0151,0.0,0.945,0.00961,0,0.975,0.00661,0.0,0.427,0.124,0,-0.943,-1.37,-0.512,-1.37,-0.512,-1.3596999999999937,0.656,0.0432,0.0,0.239,0.142,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,L
CHEMBL3989919,FOSNETUPITANT CHLORIDE HYDROCHLORIDE,Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)(O)O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.Cl.[Cl-],,0,0,,0,0,Neurokinin 1 receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.684,0.042,0.0,0.104,0.414,1.0,0.629,0.0669,0.0,0.107,0.47,1.0,0.511,0.0518,0.0,0.735,0.0484,0,0.959,0.00394,0.0,0.266,0.137,0,-1.91,-2.38,-1.44,-2.38,-1.44,3.794420000000004,0.0913,0.762,1.0,0.00604,0.994,1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-1.0,L
CHEMBL3989920,PITAVASTATIN SODIUM,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Na+],,0,0,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,HMG-CoA reductase inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.69,0.0423,0.0,0.969,0.00899,0.0,0.0556,0.63,1.0,0.702,0.0446,0.0,0.842,0.0125,0.0,0.59,0.0907,0,0.796,0.0249,0.0,0.48,0.119,0,-2.87,-3.33,-2.4,-3.33,-2.4,0.1873999999999995,0.638,0.0556,0.0,0.0594,0.694,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,2.0,L
CHEMBL3989923,PITAVASTATIN MAGNESIUM,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Mg+2],,0,0,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,HMG-CoA reductase inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.966,0.00355,0.0,0.812,0.0442,0.0,0.0147,0.872,1.0,0.849,0.017,0.0,0.8,0.0149,0.0,0.562,0.084,0,0.906,0.00941,0.0,0.575,0.0935,0,-6.07,-6.42,-5.73,-6.42,-5.73,5.986000000000008,0.644,0.0637,0.0,0.0614,0.813,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-0.5,L
CHEMBL3989932,ANGIOTENSIN II ACETATE,CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.457,0.119,0.0,0.974,0.00648,0.0,0.732,0.0425,0.0,0.826,0.0189,0.0,1.0,0.00174,0.0,0.977,0.00573,0,0.919,0.0121,0.0,0.836,0.0342,0,-1.27,-1.83,-0.716,-1.83,-0.716,-1.0141300000000144,0.993,0.0058,0.0,0.464,0.0349,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,L
CHEMBL3989949,CENOBAMATE,NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.316,0.222,0.5,0.184,0.364,1.0,0.273,0.231,0.5,0.256,0.218,0.5,0.149,0.272,1.0,0.312,0.177,0,0.495,0.0746,0.0,0.224,0.169,0,-1.75,-2.61,-0.885,-2.61,-0.885,1.1630999999999994,0.664,0.0636,0.0,0.273,0.113,0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,5.0,1.0,1.0,-6.0,L
CHEMBL3989967,LOTAMILAST,CNc1nc(-c2cccc(NC(=O)c3ccc(C(=O)OC)cc3)c2)c2cc(OC)c(OC)cc2n1,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.558,0.0878,0.0,0.546,0.136,0.0,0.0209,0.833,1.0,0.644,0.0557,0.0,0.0277,0.651,1.0,0.292,0.19,0,0.6,0.0334,0.0,0.0748,0.273,1,-6.54,-7.24,-5.83,-7.24,-5.83,4.394600000000003,0.101,0.836,1.0,0.531,0.0322,0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,-2.0,L
CHEMBL3989968,DIFAMILAST,CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,3.0,"Active, not recruiting;Completed",0,0,pathway_drug_candidates,3.0,0.0481,0.595,1.0,0.177,0.378,1.0,0.0479,0.658,1.0,0.0206,0.836,1.0,0.0542,0.497,1.0,0.199,0.236,1,0.573,0.0424,0.0,0.813,0.0437,0,-5.12,-5.5,-4.74,-5.5,-4.74,5.058900000000005,0.153,0.631,1.0,0.085,0.667,1,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,5.0,1.0,1.0,-10.0,L
CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0966,0.456,1.0,0.105,0.489,1.0,0.928,0.00721,0.0,0.141,0.367,1.0,0.119,0.31,1.0,0.866,0.0208,0,0.779,0.0313,0.0,0.442,0.129,0,-5.18,-5.83,-4.53,-5.83,-4.53,5.6498000000000035,0.0949,0.821,1.0,0.0214,0.979,1,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,4.0,1.0,1.0,-4.0,L
CHEMBL3989986,RAVULIZUMAB,,C5,1,0,R-HSA-166665|Terminal pathway of complement;R-HSA-174577|Activation of C3 and C5;R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-977606|Regulation of Complement cascade,5,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.0,H
CHEMBL3989992,PEGILODECAKIN,,,0,0,R-HSA-449836|Other interleukin signaling;R-HSA-6783783|Interleukin-10 signaling;R-HSA-8854691|Interleukin-20 family signaling,3,3,,3.0,Completed,0,0,pathway_drug_candidates,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,9.0,M
CHEMBL3990000,TIBULIZUMAB,,,0,0,R-HSA-448424|Interleukin-17 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses,3,2,,2.0,Withdrawn,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL3990025,OLENDALIZUMAB,,C5,1,0,R-HSA-166665|Terminal pathway of complement;R-HSA-174577|Activation of C3 and C5;R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-977606|Regulation of Complement cascade,5,2,,2.0,Terminated,0,0,protein_drug_candidates;pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL3990032,TELISOTUZUMAB VEDOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,3.0,Withdrawn,0,0,pathway_drug_candidates,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,5.0,L
CHEMBL403989,TG100-801,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,,0,0,R-HSA-5673001|RAF/MAP kinase cascade,1,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.985,0.00478,0.0,0.233,0.308,0.5,0.102,0.501,1.0,0.0948,0.535,1.0,0.0795,0.423,1.0,0.785,0.0368,0,0.376,0.0906,0.0,0.336,0.122,0,-5.96,-7.39,-4.53,-7.39,-4.53,7.091020000000006,0.447,0.21,0.0,0.0496,0.899,1,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,4.0,0.0,1.0,-4.5,L
CHEMBL404108,LUMIRACOXIB,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.7,0.0429,0.0,0.66,0.0844,0.0,0.0444,0.711,1.0,0.523,0.0837,0.0,0.196,0.216,0.5,0.621,0.0724,0,0.234,0.144,0.0,0.626,0.0488,0,-2.84,-3.68,-1.99,-3.68,-1.99,4.158220000000002,0.595,0.0718,0.0,0.156,0.256,1,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,7.0,M
CHEMBL4065122,FENEBRUTINIB,C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,3.0,"Active, not recruiting",0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.916,0.0104,0.0,0.411,0.187,0.0,0.904,0.00852,0.0,0.334,0.16,0.0,0.246,0.152,0.0,0.261,0.213,0,0.743,0.0327,0.0,0.802,0.0333,0,-3.73,-4.16,-3.29,-4.16,-3.29,3.574200000000001,0.391,0.238,0.0,0.173,0.286,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,4.0,L
CHEMBL4066936,VERICIGUAT,COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N,,0,0,R-HSA-445355|Smooth Muscle Contraction,1,0,Soluble guanylate cyclase activator,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.618,0.0683,0.0,0.539,0.124,0.0,0.203,0.302,0.5,0.717,0.0407,0.0,0.111,0.354,1.0,0.885,0.0186,0,0.131,0.303,1.0,0.413,0.114,0,-5.1,-5.6,-4.61,-5.6,-4.61,2.557499999999999,0.313,0.257,0.5,0.14,0.369,1,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-2.0,L
CHEMBL4068611,RELACORILANT,Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,3.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.345,0.172,0.0,0.509,0.131,0.0,0.67,0.0627,0.0,0.352,0.153,0.0,0.283,0.156,0.0,0.505,0.111,0,0.741,0.0315,0.0,0.159,0.205,1,-3.65,-4.13,-3.17,-4.13,-3.17,4.062100000000003,0.0368,0.974,1.0,0.0739,0.756,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,4.5,L
CHEMBL4071161,TIRABRUTINIB,CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,Tyrosine-protein kinase BTK inhibitor,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,4.0,0.428,0.131,0.0,0.695,0.0863,0.0,0.324,0.187,0.0,0.111,0.489,1.0,0.497,0.0642,0.0,0.492,0.108,0,0.307,0.124,0.0,0.554,0.103,0,-5.07,-5.66,-4.47,-5.66,-4.47,2.7534,0.427,0.232,0.0,0.102,0.644,1,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,L
CHEMBL4072756,AZD-5423,COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,4.0,0.15,0.356,1.0,0.23,0.302,0.5,0.165,0.365,1.0,0.073,0.584,1.0,0.347,0.105,0.0,0.951,0.00772,0,0.271,0.139,0.0,0.0321,0.274,1,-5.79,-6.2,-5.38,-6.2,-5.38,5.360300000000003,6.48e-06,0.95,1.0,0.101,0.532,1,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,4.0,1.0,1.0,-5.0,L
CHEMBL4072833,EVOBRUTINIB,C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,3.0,Terminated,0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.0703,0.53,1.0,0.34,0.251,0.5,0.141,0.429,1.0,0.0158,0.894,1.0,0.122,0.317,1.0,0.17,0.259,1,0.552,0.0562,0.0,0.297,0.144,0,-3.89,-4.44,-3.33,-4.44,-3.33,4.354600000000003,0.128,0.645,1.0,0.0787,0.774,1,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,5.0,1.0,1.0,-5.5,L
CHEMBL408403,ANGIOTENSIN II,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.398,0.148,0.0,0.969,0.00626,0.0,0.743,0.0285,0.0,0.767,0.0253,0.0,0.998,0.000573,0.0,0.97,0.00524,0,0.909,0.012,0.0,0.814,0.0239,0,-1.8,-2.35,-1.26,-2.35,-1.26,-1.1050300000000128,0.971,0.00191,0.0,0.444,0.0306,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,L
CHEMBL4085457,RITLECITINIB,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,3.0,Recruiting,0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.358,0.164,0.0,0.339,0.218,0.5,0.822,0.0186,0.0,0.378,0.135,0.0,0.142,0.27,1.0,0.267,0.204,0,0.296,0.108,0.0,0.639,0.0386,0,-1.6,-2.28,-0.933,-2.28,-0.933,1.9352999999999991,0.242,0.368,1.0,0.0896,0.508,1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,0.0,1.0,4.5,L
CHEMBL409,BICALUTAMIDE,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,AR,1,1,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Androgen Receptor antagonist,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.382,0.167,0.0,0.93,0.00967,0.0,0.0255,0.832,1.0,0.0391,0.72,1.0,0.586,0.0373,0.0,0.888,0.0204,0,0.498,0.062,0.0,0.0849,0.254,1,-2.92,-3.4,-2.44,-3.4,-2.44,2.8795800000000007,0.202,0.503,1.0,0.227,0.209,0.5,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.5,2.0,0.0,1.0,6.5,L
CHEMBL41,FLUOXETINE,,,0,0,,0,0,,,,1,0,known_drugs,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL4105630,ZURANOLONE,C[C@@]1(O)CC[C@H]2[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](C(=O)Cn4cc(C#N)cn4)CC[C@@H]32)C1,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.252,0.258,0.5,0.63,0.0924,0.0,0.507,0.11,0.0,0.659,0.0529,0.0,0.153,0.262,1.0,0.427,0.132,0,0.494,0.0642,0.0,0.24,0.164,0,-5.01,-5.49,-4.53,-5.49,-4.53,4.3436800000000035,0.195,0.501,1.0,0.479,0.0337,0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,1.0,1.0,-5.0,L
CHEMBL4116008,CERDULATINIB,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-449836|Other interleukin signaling;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses,21,12,,2.0,Completed,0,0,pathway_drug_candidates,12.0,0.178,0.333,1.0,0.95,0.00696,0.0,0.787,0.0289,0.0,0.953,0.00622,0.0,0.574,0.0415,0.0,0.66,0.0653,0,0.239,0.161,0.0,0.824,0.0265,0,-3.48,-4.24,-2.72,-4.24,-2.72,1.3651000000000009,0.0982,0.792,1.0,0.273,0.125,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,10.0,M
CHEMBL4130229,VODOBATINIB,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,2.0,Recruiting,0,0,pathway_drug_candidates,2.0,0.411,0.18,0.0,0.367,0.172,0.0,0.486,0.115,0.0,0.902,0.01,0.0,0.434,0.0752,0.0,0.0174,0.666,1,0.156,0.217,1.0,0.199,0.145,0,-4.85,-5.39,-4.3,-5.39,-4.3,4.979640000000003,0.0267,0.905,1.0,0.042,0.811,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,-7.0,L
CHEMBL416146,ETORICOXIB,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.175,0.34,1.0,0.117,0.426,1.0,0.804,0.0325,0.0,0.85,0.0194,0.0,0.178,0.23,0.5,0.102,0.344,1,0.898,0.0113,0.0,0.555,0.0953,0,-4.0,-4.66,-3.34,-4.66,-3.34,4.175920000000004,0.308,0.368,0.5,0.0771,0.656,1,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-1.0,L
CHEMBL4163691,POSELTINIB,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,2.0,Terminated,0,0,protein_drug_candidates;pathway_drug_candidates,4.0,0.916,0.00925,0.0,0.914,0.0188,0.0,0.903,0.00859,0.0,0.294,0.199,0.0,0.765,0.0124,0.0,0.648,0.0675,0,0.748,0.0296,0.0,0.332,0.138,0,-5.36,-5.85,-4.87,-5.85,-4.87,4.635000000000003,0.196,0.539,1.0,0.132,0.407,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,2.0,L
CHEMBL419213,LISINOPRIL,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,Angiotensin-converting enzyme inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.938,0.00739,0.0,0.37,0.208,0.5,0.41,0.136,0.0,0.8,0.0226,0.0,0.86,0.00755,0.0,0.995,0.000478,0,0.939,0.0128,0.0,0.609,0.0854,0,-1.03,-1.87,-0.191,-1.87,-0.191,-0.4141999999999983,0.94,0.00376,0.0,0.241,0.167,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,4.0,L
CHEMBL42,CLOZAPINE,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.419,0.15,0.0,0.0325,0.694,1.0,0.841,0.0174,0.0,0.659,0.0442,0.0,0.0437,0.538,1.0,0.134,0.3,1,0.565,0.0578,0.0,0.0358,0.399,1,-4.44,-5.26,-3.61,-5.26,-3.61,3.7227000000000023,0.236,0.469,1.0,0.131,0.39,1,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-9.0,L
CHEMBL420,GUANABENZ,N=C(N)N/N=C/c1c(Cl)cccc1Cl,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,1.0,Terminated,0,0,pathway_drug_candidates,1.0,0.0672,0.559,1.0,0.245,0.296,0.5,0.682,0.052,0.0,0.247,0.242,0.5,0.045,0.548,1.0,0.288,0.188,0,0.174,0.216,1.0,0.503,0.111,0,-2.79,-3.76,-1.82,-3.76,-1.82,1.8103700000000005,0.661,0.0773,0.0,0.439,0.0395,0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,4.0,1.0,1.0,-7.5,L
CHEMBL4204794,AVAPRITINIB,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.499,0.11,0.0,0.724,0.0662,0.0,0.15,0.38,1.0,0.907,0.00939,0.0,0.508,0.0522,0.0,0.184,0.251,1,0.85,0.0155,0.0,0.231,0.158,0,-4.08,-4.71,-3.46,-4.71,-3.46,2.6077000000000004,0.0353,0.906,1.0,0.0844,0.695,1,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,-2.5,L
CHEMBL4208229,ASCIMINIB,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.964,0.00522,0.0,0.611,0.0972,0.0,0.1,0.517,1.0,0.763,0.0271,0.0,0.331,0.11,0.0,0.899,0.0151,0,0.12,0.333,1.0,0.25,0.144,0,-5.93,-6.31,-5.54,-6.31,-5.54,3.462900000000001,0.0869,0.812,1.0,0.282,0.123,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,L
CHEMBL4208954,AMIKACIN SULFATE,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.994,0.0015,0.0,0.925,0.0154,0.0,0.904,0.00806,0.0,0.946,0.0056,0.0,0.995,0.00132,0.0,0.887,0.0219,0,0.86,0.0115,0.0,0.971,0.0116,0,1.17,-0.239,2.57,-0.239,2.14,-9.729800000000017,0.984,0.00439,0.0,0.208,0.275,0.5,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.5,0.0,0.0,0.0,-1.0,L
CHEMBL421,SULFASALAZINE,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.962,0.00681,0.0,0.684,0.0708,0.0,0.386,0.139,0.0,0.473,0.0972,0.0,0.899,0.00597,0.0,0.915,0.0166,0,0.621,0.0439,0.0,0.974,0.015,0,-5.76,-6.95,-4.56,-6.95,-4.56,3.7016000000000018,0.666,0.0628,0.0,0.742,0.0145,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.5,H
CHEMBL4210847,PF-00489791,CCOCCn1nc(C(=O)NS(C)(=O)=O)c2nc(N(C)CC)nc(Nc3cc(C)ccn3)c21,,0,0,R-HSA-418457|cGMP effects;R-HSA-445355|Smooth Muscle Contraction;R-HSA-9013422|RHOBTB1 GTPase cycle,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.461,0.122,0.0,0.692,0.0749,0.0,0.768,0.042,0.0,0.422,0.122,0.0,0.2,0.207,0.5,0.791,0.0406,0,0.793,0.0147,0.0,0.709,0.0496,0,-2.15,-2.82,-1.48,-2.82,-1.48,1.4553200000000002,0.0651,0.912,1.0,0.0418,0.88,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,2.0,L
CHEMBL4216467,RIPRETINIB,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0774,0.498,1.0,0.82,0.0434,0.0,0.103,0.478,1.0,0.909,0.00916,0.0,0.0245,0.702,1.0,0.241,0.207,0,0.982,0.00087,0.0,0.468,0.118,0,-6.62,-7.57,-5.67,-7.57,-5.67,5.670700000000004,0.131,0.606,1.0,0.0954,0.609,1,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-3.0,L
CHEMBL425,OLSALAZINE,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,8.0,0.983,0.00382,0.0,0.808,0.0474,0.0,0.416,0.131,0.0,0.187,0.294,1.0,0.8,0.0173,0.0,0.613,0.0755,0,0.031,0.68,1.0,0.773,0.0484,0,-4.17,-5.21,-3.13,-5.21,-3.13,2.9096000000000006,0.982,0.00405,0.0,0.812,0.00461,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,3.0,L
CHEMBL426084,SAMIDORPHAN,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.454,0.114,0.0,0.658,0.086,0.0,0.268,0.241,0.5,0.675,0.0468,0.0,0.799,0.0115,0.0,0.432,0.132,0,0.756,0.025,0.0,0.761,0.0446,0,-2.88,-3.86,-1.9,-3.86,-1.9,1.2533999999999996,0.255,0.428,0.5,0.0734,0.624,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,2.5,L
CHEMBL4279455,LAROTAXEL,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,3.0,Completed,0,0,pathway_drug_candidates,5.0,0.624,0.069,0.0,0.137,0.404,1.0,0.482,0.113,0.0,0.755,0.0328,0.0,0.618,0.0359,0.0,0.724,0.0493,0,0.269,0.123,0.0,0.146,0.194,1,-6.02,-6.91,-5.12,-6.91,-5.12,4.469500000000004,0.0509,0.852,1.0,0.456,0.0305,0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,2.0,L
CHEMBL428647,PACLITAXEL,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,Tubulin inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.426,0.125,0.0,0.362,0.205,0.5,0.42,0.137,0.0,0.458,0.104,0.0,0.437,0.0736,0.0,0.826,0.0331,0,0.627,0.0554,0.0,0.0942,0.224,1,-6.18,-6.86,-5.49,-6.86,-5.49,3.735700000000003,0.176,0.574,1.0,0.702,0.0113,0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,3.0,L
CHEMBL429,LABETALOL,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.683,0.0515,0.0,0.0131,0.798,1.0,0.214,0.302,0.5,0.183,0.306,1.0,0.431,0.0719,0.0,0.16,0.266,1,0.938,0.0115,0.0,0.831,0.0305,0,-3.25,-4.0,-2.5,-4.0,-2.5,2.1353999999999997,0.817,0.0151,0.0,0.686,0.0171,0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,3.0,0.0,1.0,-4.5,L
CHEMBL4297091,CODEINE SULFATE,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.O.O.O.O=S(=O)(O)O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.906,0.00773,0.0,0.0373,0.659,1.0,0.0204,0.871,1.0,0.648,0.0517,0.0,0.75,0.0196,0.0,0.0096,0.768,1,0.876,0.0101,0.0,0.961,0.00312,0,-1.97,-2.66,-1.27,-2.66,-1.27,-0.1246999999999979,0.132,0.503,1.0,0.0167,0.921,1,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-0.5,L
CHEMBL4297147,HALOPERIDOL LACTATE,CC(O)C(=O)O.O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.94,0.007,0.0,0.0663,0.532,1.0,0.924,0.00575,0.0,0.829,0.0179,0.0,0.676,0.0232,0.0,0.00217,0.929,1,0.913,0.0107,0.0,0.00791,0.696,1,-3.11,-3.82,-2.4,-3.82,-2.4,3.8774000000000033,0.182,0.542,1.0,0.136,0.402,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,-6.5,L
CHEMBL4297163,MUPARFOSTAT,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1234158|Regulation of gene expression by Hypoxia-inducible Factor;R-HSA-194138|Signaling by VEGF;R-HSA-194313|VEGF ligand-receptor interactions;R-HSA-195399|VEGF binds to VEGFR leading to receptor dimerization;R-HSA-4420097|VEGFA-VEGFR2 Pathway;R-HSA-5218921|VEGFR2 mediated cell proliferation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9679191|Potential therapeutics for SARS,10,2,,3.0,Terminated,0,0,pathway_drug_candidates,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,7.0,M
CHEMBL4297185,DAROLUTAMIDE,CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Androgen Receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.188,0.299,1.0,0.682,0.0762,0.0,0.00682,0.961,1.0,0.166,0.362,1.0,0.0248,0.666,1.0,0.765,0.0462,0,0.38,0.0888,0.0,0.31,0.158,0,-3.07,-3.6,-2.54,-3.6,-2.54,2.6700799999999996,0.179,0.549,1.0,0.288,0.1,0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,4.0,1.0,1.0,-1.0,L
CHEMBL4297214,PRALICIGUAT,OC(CNc1nc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)ncc1F)(C(F)(F)F)C(F)(F)F,,0,0,R-HSA-445355|Smooth Muscle Contraction,1,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.141,0.373,1.0,0.162,0.362,1.0,0.0369,0.692,1.0,0.261,0.204,0.5,0.201,0.22,0.5,0.968,0.00661,0,0.49,0.063,0.0,0.126,0.203,1,-3.77,-4.26,-3.28,-4.26,-3.28,4.589200000000002,0.522,0.137,0.0,0.122,0.403,1,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,5.0,1.0,1.0,-7.0,L
CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;RMTs methylate histone arginines",21,9,Tyrosine-protein kinase JAK2 inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,14.0,0.237,0.256,0.5,0.526,0.126,0.0,0.115,0.464,1.0,0.93,0.00854,0.0,0.567,0.0363,0.0,0.278,0.193,0,0.741,0.0286,0.0,0.75,0.0468,0,-3.19,-4.06,-2.31,-4.06,-2.31,4.8425200000000075,0.326,0.253,0.5,0.0251,1.0,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,8.0,M
CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.971,0.00542,0.0,0.651,0.0826,0.0,0.13,0.431,1.0,0.78,0.0273,0.0,0.341,0.102,0.0,0.891,0.0184,0,0.12,0.334,1.0,0.251,0.146,0,-5.24,-5.64,-4.83,-5.64,-4.83,3.884700000000003,0.111,0.717,1.0,0.043,0.925,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,L
CHEMBL4297268,BMS-275183,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Terminated,0,0,pathway_drug_candidates,4.0,0.665,0.0545,0.0,0.243,0.308,0.5,0.47,0.104,0.0,0.847,0.0157,0.0,0.476,0.0595,0.0,0.667,0.0648,0,0.404,0.0901,0.0,0.49,0.0905,0,-4.33,-5.45,-3.21,-5.45,-3.21,3.723700000000003,0.0519,0.856,1.0,0.628,0.0106,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,2.0,L
CHEMBL4297287,HT-0712,COc1ccc([C@H]2CNC(=O)[C@H](Cc3cccc(C)c3)C2)cc1OC1CCCC1,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.353,0.174,0.0,0.354,0.209,0.5,0.215,0.301,0.5,0.0579,0.624,1.0,0.367,0.0959,0.0,0.00462,0.866,1,0.959,0.00722,0.0,0.549,0.0805,0,-3.8,-4.4,-3.19,-4.4,-3.19,4.7874200000000044,0.174,0.509,1.0,0.0446,0.836,1,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-6.5,L
CHEMBL4297296,KOS-1584,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.717,0.0442,0.0,0.663,0.0824,0.0,0.12,0.474,1.0,0.269,0.199,0.0,0.467,0.0591,0.0,0.649,0.0651,0,0.407,0.0785,0.0,0.09,0.239,1,-3.27,-3.8,-2.74,-3.8,-2.74,5.042320000000006,0.475,0.183,0.0,0.478,0.0374,0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,L
CHEMBL4297356,AZD-8848,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-168181|Toll Like Receptor 7/8 (TLR7/8) Cascade;R-HSA-5686938|Regulation of TLR by endogenous ligand;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9692916|SARS-CoV-1 activates/modulates innate immune responses;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome;R-HSA-9824856|Defective regulation of TLR7 by endogenous ligand;R-HSA-9833110|RSV-host interactions,11,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.72,0.033,0.0,0.818,0.0422,0.0,0.376,0.151,0.0,0.803,0.0258,0.0,0.945,0.00326,0.0,0.826,0.0332,0,0.96,0.00643,0.0,0.979,0.00981,0,-1.79,-2.5,-1.09,-2.5,-1.09,2.2108000000000017,0.225,0.457,1.0,0.0903,0.534,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,3.5,L
CHEMBL4297383,GSK-1521498,Fc1cc(-c2cccc(-c3nc[nH]n3)c2)cc(F)c1CNC1Cc2ccccc2C1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.184,0.333,1.0,0.492,0.144,0.0,0.435,0.122,0.0,0.864,0.0165,0.0,0.104,0.359,1.0,0.775,0.0443,0,0.461,0.0722,0.0,0.243,0.145,0,-6.13,-7.28,-4.98,-7.28,-4.98,4.673900000000002,0.487,0.137,0.0,0.155,0.308,1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-3.5,L
CHEMBL4297440,T-900607,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Unknown status,0,0,pathway_drug_candidates,4.0,0.28,0.229,0.5,0.311,0.206,0.5,0.00564,0.953,1.0,0.903,0.0121,0.0,0.756,0.0153,0.0,0.938,0.00966,0,0.77,0.0307,0.0,0.186,0.153,0,-3.44,-4.04,-2.84,-4.04,-2.84,2.6820999999999993,0.577,0.0899,0.0,0.183,0.232,1,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,1.0,1.0,-1.5,L
CHEMBL4297441,PACLITAXEL DOCOSAHEXAENOIC ACID,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,3.0,Completed,0,0,pathway_drug_candidates,5.0,0.801,0.0299,0.0,0.307,0.249,0.5,0.834,0.0115,0.0,0.596,0.0637,0.0,0.707,0.0219,0.0,0.917,0.0134,0,0.826,0.0199,0.0,0.102,0.203,1,-0.227,-0.557,0.103,-0.557,0.103,10.764499999999996,0.00993,0.995,1.0,0.558,0.0222,0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,3.0,L
CHEMBL4297447,TRV-120027,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.544,0.0828,0.0,0.987,0.00197,0.0,0.921,0.00431,0.0,0.954,0.003,0.0,0.999,0.000852,0.0,0.892,0.0222,0,0.802,0.0267,0.0,0.826,0.0264,0,0.0113,-0.454,0.477,-0.454,0.477,-1.9104300000000052,0.976,0.00284,0.0,0.472,0.0275,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,L
CHEMBL4297460,DOVRAMILAST,CCOc1cc([C@@H](CS(C)(=O)=O)N2Cc3cccc(NC(=O)C4CC4)c3C2=O)ccc1OC,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.262,0.249,0.5,0.289,0.26,0.5,0.53,0.083,0.0,0.923,0.00632,0.0,0.554,0.0491,0.0,0.764,0.0422,0,0.727,0.0317,0.0,0.14,0.235,1,-3.57,-4.07,-3.08,-4.07,-3.08,3.1841000000000017,0.242,0.375,1.0,0.125,0.386,1,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,-2.5,L
CHEMBL4297477,BREPOCITINIB,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-449836|Other interleukin signaling;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses,21,12,,3.0,Recruiting,0,0,pathway_drug_candidates,13.0,0.359,0.169,0.0,0.543,0.142,0.0,0.63,0.0654,0.0,0.603,0.0669,0.0,0.483,0.0594,0.0,0.0495,0.46,1,0.343,0.109,0.0,0.579,0.0702,0,-3.25,-3.92,-2.59,-3.92,-2.59,1.7884999999999995,0.269,0.387,0.5,0.155,0.362,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,7.5,M
CHEMBL4297492,GSK-2245035,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-168181|Toll Like Receptor 7/8 (TLR7/8) Cascade;R-HSA-5686938|Regulation of TLR by endogenous ligand;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9692916|SARS-CoV-1 activates/modulates innate immune responses;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome;R-HSA-9824856|Defective regulation of TLR7 by endogenous ligand;R-HSA-9833110|RSV-host interactions,11,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.47,0.124,0.0,0.636,0.0863,0.0,0.924,0.00593,0.0,0.92,0.0106,0.0,0.367,0.0972,0.0,0.958,0.00857,0,0.796,0.0252,0.0,0.816,0.0457,0,-1.66,-2.95,-0.366,-2.95,-0.366,2.9254000000000016,0.477,0.157,0.0,0.19,0.245,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,2.0,L
CHEMBL4297507,DELGOCITINIB,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",28,13,,3.0,Completed;Recruiting,0,0,pathway_drug_candidates,13.0,0.327,0.189,0.0,0.556,0.119,0.0,0.856,0.0156,0.0,0.682,0.0441,0.0,0.0186,0.7,1.0,0.201,0.247,1,0.366,0.0846,0.0,0.197,0.152,0,-3.25,-3.81,-2.69,-3.81,-2.69,1.2987799999999996,0.212,0.426,1.0,0.242,0.134,0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,8.0,M
CHEMBL4297520,OGLEMILAST,CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.0336,0.662,1.0,0.0105,0.824,1.0,0.0262,0.829,1.0,0.118,0.416,1.0,0.0405,0.557,1.0,0.697,0.0581,0,0.606,0.0538,0.0,0.46,0.111,0,-6.13,-6.63,-5.62,-6.63,-5.62,5.513000000000003,0.425,0.167,0.0,0.111,0.388,1,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,5.0,1.0,1.0,-7.5,L
CHEMBL4297524,RADOTINIB,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,3.0,"Active, not recruiting",0,0,pathway_drug_candidates,3.0,0.0414,0.661,1.0,0.121,0.414,1.0,0.182,0.351,1.0,0.746,0.033,0.0,0.23,0.167,0.5,0.89,0.0199,0,0.731,0.0395,0.0,0.159,0.225,1,-3.31,-4.3,-2.33,-4.3,-2.33,5.750840000000004,0.282,0.366,0.5,0.124,0.388,1,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-6.0,L
CHEMBL4297527,REVAMILAST,O=C(Nc1c(Cl)c[n+]([O-])cc1Cl)c1ccc(OC(F)F)c2oc3ccncc3c12,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.0475,0.618,1.0,0.0164,0.794,1.0,0.0255,0.81,1.0,0.13,0.403,1.0,0.0517,0.525,1.0,0.756,0.0436,0,0.328,0.105,0.0,0.292,0.169,0,-4.28,-4.87,-3.68,-4.87,-3.68,4.7749000000000015,0.263,0.443,0.5,0.211,0.207,0.5,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.5,5.0,1.0,1.0,-7.5,L
CHEMBL4297538,MK-0812,,,0,0,R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL4297564,COBITOLIMOD,,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome,5,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL4297572,ABBV-3373,,NR3C1;TNF,2,2,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",13,2,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.0,H
CHEMBL4297589,SELATOGREL,CCCCOC(=O)N1CCN(C(=O)[C@H](CP(=O)(O)O)NC(=O)c2cc(N3CC[C@H](OC)C3)nc(-c3ccccc3)n2)CC1,,0,0,R-HSA-418594|G alpha (i) signalling events,1,0,,3.0,Enrolling by invitation,0,0,pathway_drug_candidates,3.0,0.972,0.00469,0.0,0.883,0.0268,0.0,0.316,0.209,0.5,0.165,0.342,1.0,0.0248,0.702,1.0,0.984,0.00311,0,0.552,0.0491,0.0,0.16,0.187,1,-3.22,-3.57,-2.87,-3.57,-2.87,1.7257000000000005,0.262,0.496,0.5,0.162,0.314,1,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,-1.5,L
CHEMBL4297608,ELDECALCITOL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)[C@@H](OCCCO)[C@@H]1O,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.861,0.0186,0.0,0.843,0.0328,0.0,0.451,0.133,0.0,0.781,0.0314,0.0,0.763,0.0142,0.0,0.875,0.0201,0,0.437,0.08,0.0,0.173,0.172,0.5,-2.46,-2.85,-2.07,-2.85,-2.07,5.082200000000007,0.345,0.269,0.5,0.0917,0.615,1,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,L
CHEMBL4297616,OLINCIGUAT,NC(=O)[C@](O)(CNc1nc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)ncc1F)C(F)(F)F,,0,0,R-HSA-445355|Smooth Muscle Contraction,1,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.289,0.22,0.5,0.279,0.264,0.5,0.0384,0.704,1.0,0.332,0.155,0.0,0.18,0.236,0.5,0.955,0.00842,0,0.33,0.115,0.0,0.253,0.156,0,-2.42,-2.9,-1.94,-2.9,-1.94,2.5122,0.541,0.102,0.0,0.173,0.237,1,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,4.0,1.0,1.0,-4.5,L
CHEMBL4297631,TELRATOLIMOD,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-168181|Toll Like Receptor 7/8 (TLR7/8) Cascade;R-HSA-5686938|Regulation of TLR by endogenous ligand;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9692916|SARS-CoV-1 activates/modulates innate immune responses;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome;R-HSA-9824856|Defective regulation of TLR7 by endogenous ligand;R-HSA-9833110|RSV-host interactions,11,0,,1.0,"Active, not recruiting",0,0,pathway_drug_candidates,1.0,0.114,0.426,1.0,0.713,0.0655,0.0,0.382,0.169,0.0,0.0278,0.775,1.0,0.115,0.311,1.0,0.359,0.159,0,0.978,0.00072,0.0,0.526,0.0703,0,-6.36,-7.51,-5.2,-7.51,-5.2,9.095800000000006,0.00941,0.969,1.0,0.0314,0.832,1,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-6.0,L
CHEMBL4297632,OXYCODEGOL,COCCOCCOCCOCCOCCOCCO[C@H]1CCC2(O)[C@H]3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,3.0,Completed,0,0,pathway_drug_candidates,5.0,0.959,0.00369,0.0,0.488,0.156,0.0,0.901,0.00466,0.0,0.644,0.0525,0.0,0.931,0.00217,0.0,0.0329,0.535,1,0.956,0.00323,0.0,0.0981,0.198,1,0.633,0.000986,1.26,0.000986,1.26,1.593700000000004,0.361,0.249,0.0,0.026,0.871,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,-1.0,L
CHEMBL4297636,PLOCABULIN,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.909,0.0178,0.0,0.482,0.15,0.0,0.896,0.007,0.0,0.876,0.0135,0.0,0.71,0.0209,0.0,0.752,0.047,0,0.435,0.0773,0.0,0.549,0.109,0,-2.83,-3.37,-2.28,-3.37,-2.28,4.508000000000004,0.431,0.209,0.0,0.294,0.116,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,L
CHEMBL4297674,BRANEBRUTINIB,CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,1.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,3.0,0.137,0.412,1.0,0.21,0.308,0.5,0.0294,0.823,1.0,0.382,0.141,0.0,0.105,0.347,1.0,0.668,0.064,0,0.144,0.275,1.0,0.504,0.113,0,-2.76,-3.38,-2.15,-3.38,-2.15,2.1310400000000005,0.439,0.2,0.0,0.189,0.299,1,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,4.0,1.0,1.0,-5.5,L
CHEMBL4297680,1018 ISS,,TLR9,1,1,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome,5,0,Toll-like receptor 9 agonist,3.0,Terminated,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,6.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.5,L
CHEMBL4297684,ABICIPAR PEGOL,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1234158|Regulation of gene expression by Hypoxia-inducible Factor;R-HSA-194138|Signaling by VEGF;R-HSA-194313|VEGF ligand-receptor interactions;R-HSA-195399|VEGF binds to VEGFR leading to receptor dimerization;R-HSA-4420097|VEGFA-VEGFR2 Pathway;R-HSA-5218921|VEGFR2 mediated cell proliferation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9679191|Potential therapeutics for SARS,10,2,,3.0,,0,0,pathway_drug_candidates,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,7.0,M
CHEMBL4297686,IZOKIBEP,,,0,0,R-HSA-448424|Interleukin-17 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses,3,2,,3.0,"Active, not recruiting",0,0,pathway_drug_candidates,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,7.0,M
CHEMBL4297700,BIMEKIZUMAB,,,0,0,R-HSA-448424|Interleukin-17 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses,3,2,,4.0,,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL4297717,CD24FC,,,0,0,,0,0,Heat shock 70 kDa protein 1A/1B inhibitor;Heat shock protein HSP90 inhibitor;High mobility group protein B1 inhibitor;Sialic acid-binding Ig-like lectin 10 modulator,,,1,1,known_drugs;mechanism_of_actions,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL4297722,CEMDISIRAN,,C5,1,0,R-HSA-166665|Terminal pathway of complement;R-HSA-174577|Activation of C3 and C5;R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-977606|Regulation of Complement cascade,5,2,,3.0,Recruiting,0,0,protein_drug_candidates;pathway_drug_candidates,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,9.0,M
CHEMBL4297732,ZILTIVEKIMAB,,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8957275|Post-translational protein phosphorylation,7,3,,1.0,Completed,0,0,pathway_drug_candidates,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,7.0,M
CHEMBL4297736,PRALUZATAMAB RAVTANSINE,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL4297750,FARICIMAB,,,0,0,R-HSA-114608|Platelet degranulation;R-HSA-1234158|Regulation of gene expression by Hypoxia-inducible Factor;R-HSA-194138|Signaling by VEGF;R-HSA-194313|VEGF ligand-receptor interactions;R-HSA-195399|VEGF binds to VEGFR leading to receptor dimerization;R-HSA-4420097|VEGFA-VEGFR2 Pathway;R-HSA-5218921|VEGFR2 mediated cell proliferation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9679191|Potential therapeutics for SARS,10,2,,4.0,,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL4297754,FITUSIRAN,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-8957275|Post-translational protein phosphorylation,4,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL4297768,IDRABIOTAPARINUX SODIUM,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,,3.0,Terminated,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL4297776,LEFITOLIMOD,,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome,5,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL4297819,ROPEGINTERFERON ALFA-2B,,,0,0,R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,5,2,Interferon alpha/beta receptor positive modulator,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,9.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.5,M
CHEMBL4297838,TILSOTOLIMOD,,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome,5,0,,3.0,Terminated,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL4297841,TISOTUMAB VEDOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,4.0,,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL4297859,AZINTUXIZUMAB VEDOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,1.0,Terminated,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL4297863,REMTOLUMAB,,TNF,1,1,R-HSA-448424|Interleukin-17 signaling;R-HSA-5357905|Regulation of TNFR1 signaling;R-HSA-5357956|TNFR1-induced NF-kappa-B signaling pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses,6,3,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.0,H
CHEMBL4297865,ABIVERTINIB,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,3.0,Not yet recruiting,0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.833,0.031,0.0,0.96,0.00847,0.0,0.974,0.00373,0.0,0.922,0.00689,0.0,0.926,0.00473,0.0,0.104,0.324,1,0.601,0.0437,0.0,0.273,0.155,0,-4.87,-5.35,-4.4,-5.35,-4.4,4.5092000000000025,0.196,0.542,1.0,0.106,0.508,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,-2.0,L
CHEMBL4297866,ABIVERTINIB MALEATE,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1.O.O.O=C(O)/C=C\C(=O)O,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,3.0,Not yet recruiting,0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.982,0.00319,0.0,0.957,0.00401,0.0,0.972,0.00249,0.0,0.987,0.000663,0.0,0.994,0.000662,0.0,0.102,0.334,1,0.921,0.0105,0.0,0.768,0.0436,0,-5.16,-5.85,-4.46,-5.85,-4.46,2.5716,0.412,0.191,0.0,0.0838,0.677,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,-2.0,L
CHEMBL4297886,ASUNERCEPT,,,0,0,R-HSA-140534|Caspase activation via Death Receptors in the presence of ligand;R-HSA-3371378|Regulation by c-FLIP;R-HSA-5213460|RIPK1-mediated regulated necrosis;R-HSA-5218900|CASP8 activity is inhibited;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-69416|Dimerization of procaspase-8;R-HSA-75157|FasL/ CD95L signaling;R-HSA-8862803|Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models;R-HSA-9614657|FOXO-mediated transcription of cell death genes,9,1,Tumor necrosis factor ligand superfamily member 6 binding agent,3.0,Terminated,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,6.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.5,L
CHEMBL4297892,ANVATABART OPADOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Withdrawn,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL4297926,CJM-112,,,0,0,R-HSA-448424|Interleukin-17 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses,3,2,,2.0,Completed,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL4297928,NOMACOPAN,,C5,1,0,R-HSA-166665|Terminal pathway of complement;R-HSA-174577|Activation of C3 and C5;R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-977606|Regulation of Complement cascade,5,2,,3.0,Withdrawn,0,0,protein_drug_candidates;pathway_drug_candidates,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,9.0,M
CHEMBL4297935,RG-7841,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,1.0,Completed,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL4297938,LIFASTUZUMAB VEDOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Terminated,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL4297951,COAGULATION FACTOR X HUMAN,,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,,4.0,,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL4297993,EMD-1201081,,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome,5,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL4297994,TILSOTOLIMOD SODIUM,,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome,5,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL4297995,BAZLITORAN,,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-168181|Toll Like Receptor 7/8 (TLR7/8) Cascade;R-HSA-5686938|Regulation of TLR by endogenous ligand;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9692916|SARS-CoV-1 activates/modulates innate immune responses;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome;R-HSA-9824856|Defective regulation of TLR7 by endogenous ligand;R-HSA-9833110|RSV-host interactions,11,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,2.0,L
CHEMBL4298012,TESIDOLUMAB,,C5,1,0,R-HSA-166665|Terminal pathway of complement;R-HSA-174577|Activation of C3 and C5;R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-977606|Regulation of Complement cascade,5,2,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL4298023,M-1095,,,0,0,R-HSA-448424|Interleukin-17 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses,3,2,,3.0,Recruiting,0,0,pathway_drug_candidates,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,7.0,M
CHEMBL4298045,INDUSATUMAB VEDOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Terminated,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL4298086,POZELIMAB,,C5,1,0,R-HSA-166665|Terminal pathway of complement;R-HSA-174577|Activation of C3 and C5;R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-977606|Regulation of Complement cascade,5,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.0,H
CHEMBL4298098,TUSAMITAMAB RAVTANSINE,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,3.0,"Active, not recruiting",0,0,pathway_drug_candidates,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,5.0,L
CHEMBL4298101,LADIRATUZUMAB VEDOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Recruiting,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL4298102,VUNAKIZUMAB,,,0,0,R-HSA-448424|Interleukin-17 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses,3,2,,3.0,Not yet recruiting,0,0,pathway_drug_candidates,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,7.0,M
CHEMBL4298167,FILGOTINIB MALEATE,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",28,13,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,14.0,0.987,0.00437,0.0,0.973,0.00391,0.0,0.887,0.0101,0.0,0.978,0.00384,0.0,0.951,0.00383,0.0,0.617,0.0784,0,0.97,0.0057,0.0,0.942,0.0149,0,-3.06,-4.02,-2.1,-4.02,-2.1,1.6869999999999998,0.686,0.0556,0.0,0.17,0.285,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,13.5,H
CHEMBL4298207,ZILUCOPLAN,,C5,1,0,R-HSA-166665|Terminal pathway of complement;R-HSA-174577|Activation of C3 and C5;R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-977606|Regulation of Complement cascade,5,2,Complement C5 inhibitor,3.0,Completed,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_of_actions,10.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.5,H
CHEMBL4298209,BELANTAMAB MAFODOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,4.0,,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL429910,DAPAGLIFLOZIN,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,,0,0,,0,0,Sodium/glucose cotransporter 2 inhibitor,,,1,1,known_drugs;mechanism_drug_candidate;mechanism_of_actions,1.5,0.712,0.0369,0.0,0.914,0.0179,0.0,0.018,0.848,1.0,0.631,0.0581,0.0,0.267,0.16,0.0,0.813,0.0296,0,0.15,0.271,1.0,0.198,0.125,0,-4.91,-5.46,-4.37,-5.46,-4.37,1.8443999999999996,0.759,0.0221,0.0,0.256,0.122,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,-3.5,L
CHEMBL4303201,CATEQUENTINIB,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,3.0,Not yet recruiting;Recruiting,0,0,pathway_drug_candidates,3.0,0.16,0.338,1.0,0.149,0.404,1.0,0.429,0.142,0.0,0.751,0.0316,0.0,0.542,0.0476,0.0,0.549,0.0988,0,0.621,0.0484,0.0,0.133,0.193,1,-4.05,-4.69,-3.41,-4.69,-3.41,4.834620000000004,0.196,0.569,1.0,0.233,0.2,0.5,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.5,2.0,1.0,1.0,-4.0,L
CHEMBL4303389,NS-018,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;RMTs methylate histone arginines",21,9,,1.0,Completed,0,0,pathway_drug_candidates,11.0,0.0185,0.744,1.0,0.127,0.432,1.0,0.181,0.356,1.0,0.241,0.236,0.5,0.176,0.239,0.5,0.849,0.027,0,0.767,0.0293,0.0,0.0691,0.278,1,-2.84,-3.44,-2.25,-3.44,-2.25,4.327900000000002,0.0903,0.766,1.0,0.0938,0.597,1,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,5.0,1.0,1.0,4.5,L
CHEMBL43064,CINNARIZINE,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.441,0.136,0.0,0.0129,0.777,1.0,0.135,0.41,1.0,0.457,0.103,0.0,0.343,0.103,0.0,0.0291,0.55,1,0.727,0.0333,0.0,0.108,0.235,1,-4.55,-5.95,-3.14,-5.95,-3.14,5.1070000000000055,0.53,0.114,0.0,0.0622,0.81,1,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-7.5,L
CHEMBL431,SPIRAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.795,0.0301,0.0,0.61,0.101,0.0,0.41,0.134,0.0,0.28,0.197,0.0,0.347,0.107,0.0,0.819,0.0316,0,0.771,0.0281,0.0,0.56,0.1,0,-2.67,-3.1,-2.25,-3.1,-2.25,2.3908000000000005,0.748,0.0379,0.0,0.213,0.208,0.5,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.5,0.0,0.0,0.0,5.5,L
CHEMBL432162,TASOSARTAN,Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,,2.0,,0,0,pathway_drug_candidates,2.0,0.601,0.0783,0.0,0.768,0.06,0.0,0.861,0.0111,0.0,0.712,0.0474,0.0,0.209,0.2,0.5,0.119,0.318,1,0.945,0.00991,0.0,0.422,0.115,0,-3.92,-5.11,-2.72,-5.11,-2.72,3.4199400000000013,0.739,0.0365,0.0,0.116,0.44,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-5.0,L
CHEMBL434394,NEBIVOLOL,,,0,0,,0,0,,,,1,0,known_drugs,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL435298,ESFLURBIPROFEN,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,3.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,9.0,0.508,0.0936,0.0,0.44,0.168,0.0,0.0596,0.619,1.0,0.829,0.0201,0.0,0.669,0.0265,0.0,0.818,0.0335,0,0.75,0.0299,0.0,0.802,0.045,0,-4.18,-4.87,-3.5,-4.87,-3.5,3.6808000000000023,0.935,0.00275,0.0,0.263,0.137,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,5.5,L
CHEMBL435381,CIMICOXIB,COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,8.0,0.748,0.0315,0.0,0.487,0.175,0.0,0.0993,0.477,1.0,0.748,0.0309,0.0,0.692,0.0223,0.0,0.543,0.0958,0,0.481,0.0619,0.0,0.0963,0.206,1,-3.15,-3.79,-2.52,-3.79,-2.52,2.9878,0.589,0.0924,0.0,0.138,0.423,1,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,5.5,L
CHEMBL440498,CTS-1027,O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1,,0,0,R-HSA-1442490|Collagen degradation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases;R-HSA-6798695|Neutrophil degranulation,4,0,,2.0,Completed;Terminated,0,0,pathway_drug_candidates,2.0,0.344,0.176,0.0,0.812,0.0449,0.0,0.274,0.237,0.5,0.808,0.0227,0.0,0.807,0.0141,0.0,0.0946,0.352,1,0.577,0.0449,0.0,0.0888,0.228,1,-4.06,-4.56,-3.57,-4.56,-3.57,3.2082000000000015,0.0453,0.822,1.0,0.0663,0.596,1,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,-6.0,L
CHEMBL442,ERGOTAMINE,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.255,0.262,0.5,0.19,0.358,1.0,0.324,0.191,0.0,0.191,0.305,1.0,0.292,0.135,0.0,0.571,0.0972,0,0.938,0.0125,0.0,0.0627,0.31,1,-4.87,-5.63,-4.1,-5.63,-4.1,1.990800000000002,0.16,0.632,1.0,0.694,0.0195,0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,3.0,1.0,1.0,-2.5,L
CHEMBL4435170,DEUCRAVACITINIB,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-449836|Other interleukin signaling;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses,20,12,,4.0,Completed,0,0,pathway_drug_candidates,14.0,0.819,0.0268,0.0,0.328,0.237,0.5,0.89,0.00915,0.0,0.291,0.181,0.0,0.0481,0.555,1.0,0.688,0.0627,0,0.521,0.0541,0.0,0.325,0.15,0,-4.34,-4.8,-3.88,-4.8,-3.88,1.7324,0.666,0.0674,0.0,0.384,0.0605,0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,10.0,M
CHEMBL4457723,BMS-741672,CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](Nc3ncnc4ccc(C(F)(F)F)cc34)C2=O)[C@H](NS(C)(=O)=O)C1,,0,0,R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.0371,0.644,1.0,0.352,0.215,0.5,0.866,0.0169,0.0,0.216,0.26,0.5,0.386,0.0952,0.0,0.775,0.0427,0,0.858,0.0174,0.0,0.182,0.197,0.5,-2.52,-2.99,-2.05,-2.99,-2.05,2.8405000000000005,0.299,0.309,0.5,0.115,0.473,1,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,1.0,1.0,-2.5,L
CHEMBL4459585,ROPSACITINIB,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-449836|Other interleukin signaling;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses,20,12,,2.0,Completed,0,0,pathway_drug_candidates,12.0,0.198,0.303,1.0,0.253,0.291,0.5,0.353,0.173,0.0,0.0542,0.618,1.0,0.0235,0.671,1.0,0.642,0.0706,0,0.342,0.106,0.0,0.434,0.126,0,-1.61,-2.21,-1.0,-2.21,-1.0,2.5358600000000004,0.151,0.691,1.0,0.197,0.256,1,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,4.0,1.0,1.0,7.5,M
CHEMBL448,PENTOBARBITAL,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.488,0.105,0.0,0.68,0.0706,0.0,0.204,0.314,0.5,0.392,0.136,0.0,0.593,0.0381,0.0,0.693,0.0625,0,0.624,0.0424,0.0,0.822,0.0339,0,-2.64,-3.23,-2.04,-3.23,-2.04,1.1849999999999998,0.339,0.259,0.5,0.0846,0.427,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-1.5,L
CHEMBL450,METHARBITAL,CCC1(CC)C(=O)NC(=O)N(C)C1=O,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.595,0.0757,0.0,0.619,0.0938,0.0,0.197,0.327,1.0,0.376,0.142,0.0,0.538,0.0556,0.0,0.756,0.0527,0,0.533,0.0589,0.0,0.391,0.132,0,-2.42,-3.84,-1.0,-3.84,-1.0,0.5009999999999999,0.429,0.193,0.0,0.0897,0.528,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-2.0,L
CHEMBL451,CHLORDIAZEPOXIDE,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.342,0.187,0.0,0.0728,0.527,1.0,0.475,0.0936,0.0,0.113,0.444,1.0,0.00724,0.871,1.0,0.61,0.083,0,0.469,0.0714,0.0,0.256,0.168,0,-4.28,-5.08,-3.48,-5.08,-3.48,2.950700000000001,0.197,0.546,1.0,0.112,0.536,1,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,3.0,0.0,1.0,-3.5,L
CHEMBL451930,PLITIDEPSIN,CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O,,0,0,,0,0,Elongation factor 1-alpha 2 inhibitor,,,1,1,known_drugs;mechanism_drug_candidate;mechanism_of_actions,1.5,0.246,0.252,0.5,0.977,0.00559,0.0,0.5,0.101,0.0,0.533,0.0882,0.0,0.997,0.00136,0.0,0.954,0.0083,0,0.601,0.0323,0.0,0.0351,0.484,1,-2.14,-2.48,-1.8,-2.48,-1.8,2.5247000000000157,0.413,0.23,0.0,0.472,0.0294,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,-3.0,L
CHEMBL452,CLONAZEPAM,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.146,0.361,1.0,0.532,0.12,0.0,0.126,0.404,1.0,0.163,0.354,1.0,0.237,0.167,0.5,0.257,0.207,0,0.428,0.077,0.0,0.374,0.126,0,-4.6,-5.35,-3.86,-5.35,-3.86,3.037700000000001,0.374,0.237,0.0,0.119,0.487,1,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-8.5,L
CHEMBL454,BUTALBITAL,C=CCC1(CC(C)C)C(=O)NC(=O)NC1=O,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.443,0.139,0.0,0.682,0.0769,0.0,0.111,0.469,1.0,0.455,0.101,0.0,0.555,0.0461,0.0,0.961,0.00642,0,0.715,0.0305,0.0,0.773,0.039,0,-2.53,-3.8,-1.25,-3.8,-1.25,0.961,0.295,0.358,0.5,0.0146,0.95,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-2.0,L
CHEMBL4541964,ZATOLMILAST,O=C(O)Cc1ccc(Cc2cc(-c3cccc(Cl)c3)nc(C(F)(F)F)c2)cc1,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,3.0,Enrolling by invitation,0,0,pathway_drug_candidates,3.0,0.62,0.0575,0.0,0.149,0.401,1.0,0.032,0.785,1.0,0.000152,0.974,1.0,0.0131,0.768,1.0,0.842,0.0296,0,0.497,0.0592,0.0,0.314,0.124,0,-4.63,-5.62,-3.64,-5.62,-3.64,5.638700000000004,0.677,0.047,0.0,0.14,0.388,1,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,4.0,0.0,1.0,-3.5,L
CHEMBL454950,TETRACYCLINE HYDROCHLORIDE,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12.Cl,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.823,0.0177,0.0,0.766,0.0607,0.0,0.377,0.147,0.0,0.36,0.146,0.0,0.575,0.0327,0.0,0.619,0.0739,0,0.592,0.0534,0.0,0.604,0.0522,0,-2.14,-2.99,-1.29,-2.99,-1.29,0.207400000000001,0.865,0.00904,0.0,0.0838,0.537,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-1.0,L
CHEMBL4577523,GOLIDOCITINIB,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-449836|Other interleukin signaling;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9833109|Evasion by RSV of host interferon responses,19,11,,2.0,Recruiting,0,0,pathway_drug_candidates,12.0,0.669,0.0604,0.0,0.137,0.404,1.0,0.91,0.00379,0.0,0.86,0.0112,0.0,0.19,0.222,0.5,0.753,0.042,0,0.599,0.0453,0.0,0.252,0.136,0,-2.33,-2.91,-1.76,-2.91,-1.76,2.6850000000000005,0.249,0.437,1.0,0.0943,0.498,1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,0.0,1.0,11.0,M
CHEMBL459,METHYLDOPA,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.755,0.0369,0.0,0.395,0.191,0.0,0.468,0.11,0.0,0.604,0.0592,0.0,0.628,0.0227,0.0,0.625,0.0733,0,0.591,0.053,0.0,0.842,0.012,0,-0.914,-2.19,0.367,-2.19,0.367,0.4423000000000001,0.631,0.0543,0.0,0.851,0.00109,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.5,L
CHEMBL459324,DIACETYLMORPHINE,CC(=O)Oc1ccc2c3c1O[C@H]1[C@@H](OC(C)=O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,3.0,Completed,0,0,pathway_drug_candidates,5.0,0.896,0.00976,0.0,0.237,0.275,0.5,0.144,0.419,1.0,0.758,0.0267,0.0,0.633,0.031,0.0,0.203,0.231,1,0.497,0.0653,0.0,0.691,0.0753,0,-2.53,-3.76,-1.3,-3.76,-1.3,1.9886,0.245,0.432,1.0,0.126,0.484,1,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,0.0,1.0,-1.0,L
CHEMBL4594217,CANAGLIFLOZIN,Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,,0,0,,0,0,Sodium/glucose cotransporter 2 inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.759,0.0396,0.0,0.491,0.16,0.0,0.00656,0.955,1.0,0.207,0.266,0.5,0.601,0.0358,0.0,0.603,0.0752,0,0.832,0.0246,0.0,0.103,0.25,1,-3.55,-4.12,-2.97,-4.12,-2.97,2.1436200000000003,0.469,0.148,0.0,0.0828,0.771,1,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-3.5,L
CHEMBL4594254,SIMPINICLINE,C(=C/[C@H]1CCNC1)\c1cncnc1,,0,0,R-HSA-629587|Highly sodium permeable postsynaptic acetylcholine nicotinic receptors;R-HSA-629594|Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;R-HSA-629597|Highly calcium permeable nicotinic acetylcholine receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.301,0.201,0.0,0.0906,0.48,1.0,0.501,0.1,0.0,0.862,0.0129,0.0,0.205,0.197,0.5,0.301,0.193,0,0.365,0.086,0.0,0.207,0.16,0,-0.67,-1.84,0.503,-1.84,0.503,1.0993000000000002,0.667,0.0536,0.0,0.241,0.126,0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,0.0,L
CHEMBL4594275,GUSACITINIB,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",28,13,,2.0,Completed,0,0,pathway_drug_candidates,12.0,0.712,0.043,0.0,0.717,0.0624,0.0,0.0118,0.917,1.0,0.214,0.259,0.5,0.0612,0.439,1.0,0.108,0.335,1,0.506,0.0641,0.0,0.875,0.0116,0,-3.69,-4.39,-2.98,-4.39,-2.98,2.54788,0.165,0.647,1.0,0.142,0.39,1,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,3.0,0.0,1.0,5.0,L
CHEMBL4594287,ENSIFENTRINE,COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(CCNC(N)=O)c(=O)n1CC2,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,Phosphodiesterase 4 inhibitor,3.0,Completed;Recruiting,0,0,pathway_drug_candidates;mechanism_drug_candidate,3.0,0.305,0.207,0.0,0.537,0.14,0.0,0.245,0.269,0.5,0.498,0.0894,0.0,0.835,0.0112,0.0,0.579,0.0869,0,0.0717,0.505,1.0,0.255,0.146,0,-3.26,-4.0,-2.52,-4.0,-2.52,2.7160599999999997,0.58,0.0801,0.0,0.056,0.792,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-0.5,L
CHEMBL4594293,ACALABRUTINIB MALEATE,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12.O=C(O)/C=C\C(=O)O,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,Tyrosine-protein kinase BTK inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.992,0.00268,0.0,0.945,0.0104,0.0,0.587,0.0928,0.0,0.976,0.00343,0.0,0.815,0.012,0.0,0.914,0.0187,0,0.899,0.00828,0.0,0.904,0.0113,0,-3.7,-4.41,-2.98,-4.41,-2.98,3.024400000000001,0.275,0.351,0.5,0.281,0.11,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,L
CHEMBL4594301,REMIMAZOLAM BESYLATE,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21.O=S(=O)(O)c1ccccc1,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.916,0.00872,0.0,0.0318,0.651,1.0,0.803,0.0233,0.0,0.173,0.33,1.0,0.166,0.23,0.5,0.552,0.096,0,0.954,0.00818,0.0,0.36,0.115,0,-1.92,-3.17,-0.676,-3.17,-0.676,5.116820000000004,0.227,0.45,1.0,0.13,0.41,1,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-3.0,L
CHEMBL4594316,CROVALIMAB,,C5,1,0,R-HSA-166665|Terminal pathway of complement;R-HSA-174577|Activation of C3 and C5;R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-977606|Regulation of Complement cascade,5,2,,3.0,Withdrawn,0,0,protein_drug_candidates;pathway_drug_candidates,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,9.0,M
CHEMBL4594348,ELSUBRUTINIB,C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,2.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,4.0,0.144,0.345,1.0,0.139,0.405,1.0,0.549,0.0978,0.0,0.321,0.176,0.0,0.137,0.289,1.0,0.178,0.257,1,0.552,0.0549,0.0,0.522,0.0896,0,-2.13,-3.05,-1.22,-3.05,-1.22,2.1588000000000003,0.112,0.709,1.0,0.0704,0.611,1,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,3.0,1.0,1.0,-5.0,L
CHEMBL4594382,DEURUXOLITINIB PHOSPHATE,O=P(O)(O)O.[2H]C1([2H])C([C@@H](CC#N)n2cc(-c3ncnc4[nH]ccc34)cn2)C([2H])([2H])C([2H])([2H])C1([2H])[2H],,0,0,,0,0,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.495,0.1,0.0,0.291,0.265,0.5,0.836,0.0246,0.0,0.714,0.046,0.0,0.0481,0.542,1.0,0.785,0.0441,0,0.576,0.0477,0.0,0.57,0.113,0,-2.16,-3.04,-1.27,-3.04,-1.27,2.5377799999999997,0.479,0.178,0.0,0.24,0.165,0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,-2.5,L
CHEMBL4594402,ORP-101,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(OCCOc5ccc6c7c5O[C@H]5[C@@]8(OC)CC[C@@]9(C[C@@H]8[C@](C)(O)C(C)(C)C)[C@@H](C6)N(CC6CC6)CC[C@]759)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.561,0.0933,0.0,0.108,0.466,1.0,0.576,0.0838,0.0,0.631,0.0562,0.0,0.79,0.0155,0.0,0.000692,0.972,1,0.849,0.0166,0.0,0.186,0.183,0.5,-6.82,-7.18,-6.45,-7.18,-6.45,9.187600000000003,0.0302,0.952,1.0,0.0186,0.941,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,-5.0,L
CHEMBL4594417,PRUXELUTAMIDE,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2F)C(=S)N1c1ccc(CCCc2ncco2)nc1,AR,1,1,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Androgen Receptor antagonist,3.0,Withdrawn,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,6.5,0.455,0.13,0.0,0.686,0.0777,0.0,0.0228,0.83,1.0,0.529,0.0829,0.0,0.0531,0.463,1.0,0.591,0.0851,0,0.8,0.0245,0.0,0.419,0.126,0,-3.48,-3.91,-3.05,-3.91,-3.05,5.191180000000005,0.0481,0.887,1.0,0.287,0.107,0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,4.0,L
CHEMBL4594419,BMS-813160,CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O,,0,0,R-HSA-173107|Binding and entry of HIV virion;R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,4,2,,2.0,Terminated,0,0,pathway_drug_candidates,6.0,0.652,0.0614,0.0,0.771,0.0504,0.0,0.759,0.0282,0.0,0.667,0.0497,0.0,0.794,0.0122,0.0,0.91,0.0147,0,0.538,0.0531,0.0,0.765,0.0316,0,-3.31,-3.86,-2.76,-3.86,-2.76,2.2485,0.395,0.158,0.0,0.184,0.199,{},0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,,0.0,0.0,0.0,5.5,L
CHEMBL4594455,AGS-16C3F,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL4594518,LUTIKIZUMAB,,,0,0,R-HSA-448706|Interleukin-1 processing;R-HSA-5620971|Pyroptosis;R-HSA-5660668|CLEC7A/inflammasome pathway;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9020702|Interleukin-1 signaling;R-HSA-9660826|Purinergic signaling in leishmaniasis infection,7,4,,3.0,Recruiting,0,0,pathway_drug_candidates,11.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,11.0,H
CHEMBL4594542,EFLEPEDOCOKIN ALFA,,,0,0,R-HSA-449836|Other interleukin signaling;R-HSA-6783783|Interleukin-10 signaling;R-HSA-8854691|Interleukin-20 family signaling,3,3,,2.0,Terminated,0,0,pathway_drug_candidates,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,8.0,M
CHEMBL4596392,CRAVACITINIB,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,,0,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-449836|Other interleukin signaling;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses,20,12,,3.0,"Active, not recruiting",0,0,pathway_drug_candidates,13.0,0.834,0.0202,0.0,0.523,0.13,0.0,0.922,0.00551,0.0,0.36,0.145,0.0,0.0486,0.515,1.0,0.789,0.0366,0,0.629,0.0375,0.0,0.408,0.119,0,-3.43,-3.88,-2.99,-3.88,-2.99,1.7323999999999995,0.563,0.0914,0.0,0.362,0.0548,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,11.5,H
CHEMBL461522,METAMIZOLE,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,3.0,Recruiting;Unknown status,0,0,protein_drug_candidates;pathway_drug_candidates,9.0,0.78,0.0325,0.0,0.653,0.0804,0.0,0.453,0.123,0.0,0.672,0.051,0.0,0.845,0.00918,0.0,0.0433,0.486,1,0.0721,0.483,1.0,0.92,0.0149,0,0.484,-0.402,1.37,-0.402,1.37,0.7659199999999997,0.4,0.23,0.0,0.245,0.165,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.5,L
CHEMBL464,ETRETINATE,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C,,0,0,R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-5362517|Signaling by Retinoic Acid;R-HSA-5617472|Activation of anterior HOX genes in hindbrain development during early embryogenesis,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.386,0.156,0.0,0.0104,0.816,1.0,0.561,0.0842,0.0,0.15,0.376,1.0,0.231,0.186,0.5,0.341,0.162,0,0.47,0.0663,0.0,0.159,0.195,1,-4.64,-5.38,-3.9,-5.38,-3.9,5.645560000000007,0.0933,0.781,1.0,0.201,0.241,0.5,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.5,3.0,0.0,1.0,-2.0,L
CHEMBL4650276,SHR3680,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(OC[C@@H](O)CO)cc1,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,3.0,"Active, not recruiting",0,0,pathway_drug_candidates,3.0,0.465,0.111,0.0,0.946,0.00975,0.0,0.35,0.169,0.0,0.221,0.261,0.5,0.394,0.0812,0.0,0.948,0.0104,0,0.787,0.0222,0.0,0.322,0.131,0,-3.52,-4.1,-2.95,-4.1,-2.95,3.225780000000002,0.0391,0.903,1.0,0.243,0.145,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,2.5,L
CHEMBL4650293,APRUTUMAB IXADOTIN,,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,1.0,Terminated,0,0,pathway_drug_candidates,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,3.0,L
CHEMBL4650299,HEPARIN,,SERPINC1,1,1,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-8957275|Post-translational protein phosphorylation,4,0,Antithrombin-III activator,3.0,Completed,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,6.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.5,L
CHEMBL4650321,ORELABRUTINIB,C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,3.0,Recruiting,0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.515,0.0914,0.0,0.824,0.0346,0.0,0.123,0.426,1.0,0.000894,0.98,1.0,0.366,0.108,0.0,0.315,0.172,0,0.41,0.07,0.0,0.413,0.104,0,-3.67,-4.75,-2.59,-4.75,-2.59,4.531800000000003,0.0596,0.878,1.0,0.0755,0.741,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,2.5,L
CHEMBL4650322,RUNCACIGUAT,C[C@H]([C@H](C(=O)Nc1cc([C@@H](CC(=O)O)C2CC2)ccc1Cl)c1ccc(Cl)cc1)C(F)(F)F,,0,0,R-HSA-445355|Smooth Muscle Contraction,1,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.576,0.0736,0.0,0.0631,0.555,1.0,0.0701,0.602,1.0,0.192,0.297,1.0,0.241,0.179,0.5,0.83,0.0301,0,0.907,0.0101,0.0,0.634,0.088,0,-4.95,-5.33,-4.57,-5.33,-4.57,6.882400000000004,0.687,0.0405,0.0,0.232,0.159,0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,4.0,0.0,1.0,-4.5,L
CHEMBL4650323,TOLEBRUTINIB,C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccc32)C1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,3.0,Recruiting,0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.424,0.146,0.0,0.483,0.158,0.0,0.734,0.043,0.0,0.0574,0.658,1.0,0.591,0.0427,0.0,0.0992,0.331,1,0.54,0.0556,0.0,0.558,0.0747,0,-3.49,-4.09,-2.88,-4.09,-2.88,3.911200000000002,0.202,0.507,1.0,0.0375,0.883,1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,-0.5,L
CHEMBL4650333,SERALUTINIB,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,3.0,Not yet recruiting,0,0,pathway_drug_candidates,3.0,0.0162,0.741,1.0,0.156,0.4,1.0,0.0906,0.528,1.0,0.79,0.0298,0.0,0.205,0.213,0.5,0.824,0.0317,0,0.143,0.309,1.0,0.0408,0.413,1,-3.85,-4.2,-3.5,-4.2,-3.5,5.289620000000004,0.155,0.656,1.0,0.381,0.08,0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,4.0,1.0,1.0,-6.5,L
CHEMBL4650338,EDRALBRUTINIB,CC#CC(=O)N1CC[C@@H](n2cc(-c3ccc(Oc4c(F)cccc4F)cc3)c3c(N)n[nH]c(=O)c32)C1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,2.0,Recruiting,0,0,protein_drug_candidates;pathway_drug_candidates,4.0,0.0442,0.643,1.0,0.675,0.0766,0.0,0.00391,0.983,1.0,0.797,0.0269,0.0,0.641,0.0322,0.0,0.626,0.0763,0,0.253,0.18,0.0,0.25,0.132,0,-5.97,-6.35,-5.59,-6.35,-5.59,3.841000000000001,0.654,0.0713,0.0,0.127,0.526,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-2.5,L
CHEMBL4650343,IZENCITINIB,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",28,13,,2.0,Terminated,0,0,pathway_drug_candidates,12.0,0.276,0.228,0.5,0.622,0.109,0.0,0.801,0.0262,0.0,0.589,0.0729,0.0,0.312,0.121,0.0,0.547,0.0936,0,0.268,0.132,0.0,0.161,0.16,{},-3.48,-4.01,-2.94,-4.01,-2.94,3.725900000000001,0.24,0.393,1.0,0.167,0.239,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,9.5,M
CHEMBL4650406,LEVILIMAB,,IL6R,1,0,R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-9616222|Transcriptional regulation of granulopoiesis;R-HSA-9679191|Potential therapeutics for SARS,6,2,Interleukin-6 receptor alpha subunit inhibitor,3.0,"Active, not recruiting",1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_of_actions,10.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.5,H
CHEMBL4650485,PIRTOBRUTINIB,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,Tyrosine-protein kinase BTK inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.0698,0.535,1.0,0.432,0.189,0.0,0.0975,0.525,1.0,0.561,0.0801,0.0,0.773,0.0221,0.0,0.458,0.129,0,0.85,0.0249,0.0,0.898,0.0154,0,-2.83,-3.49,-2.16,-3.49,-2.16,3.432200000000001,0.0728,0.874,1.0,0.0586,0.82,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,2.5,L
CHEMBL4650501,PF-4136309,,,0,0,R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,3,1,,2.0,Terminated,0,0,pathway_drug_candidates,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,4.0,L
CHEMBL4650518,PLONMARLIMAB,,,0,0,"R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling",3,2,,2.0,Completed,0,0,pathway_drug_candidates,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,6.0,L
CHEMBL46618,OTAMIXABAN,COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.996,0.00117,0.0,0.979,0.00237,0.0,0.963,0.00302,0.0,0.974,0.00317,0.0,0.95,0.0021,0.0,0.956,0.00861,0,0.99,0.00153,0.0,0.247,0.151,0,-2.64,-3.16,-2.11,-3.16,-2.11,2.42127,0.51,0.117,0.0,0.253,0.133,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,2.5,L
CHEMBL466659,PENTAERYTHRITOL TETRANITRATE,O=[N+]([O-])OCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-],,0,0,R-HSA-445355|Smooth Muscle Contraction,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.631,0.0584,0.0,0.313,0.245,0.5,0.062,0.642,1.0,0.0199,0.844,1.0,0.596,0.0373,0.0,0.0371,0.527,1,0.581,0.0539,0.0,0.748,0.0458,0,-3.13,-5.25,-1.0,-5.25,-1.0,-1.1939999999999995,0.426,0.192,0.0,0.255,0.132,0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,3.0,0.0,1.0,-5.5,L
CHEMBL467084,LANICEMINE,N[C@@H](Cc1ccccn1)c1ccccc1,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.35,0.18,0.0,0.0425,0.61,1.0,0.752,0.0357,0.0,0.0823,0.517,1.0,0.129,0.28,1.0,0.506,0.095,0,0.304,0.132,0.0,0.589,0.049,0,-0.463,-1.56,0.634,-1.56,0.634,2.3241000000000005,0.535,0.107,0.0,0.154,0.268,1,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,-1.0,L
CHEMBL469,KETOROLAC,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.756,0.0343,0.0,0.385,0.19,0.0,0.421,0.14,0.0,0.266,0.201,0.5,0.258,0.156,0.0,0.684,0.0586,0,0.319,0.113,0.0,0.603,0.0859,0,-3.13,-3.95,-2.3,-3.95,-2.3,2.291,0.758,0.0254,0.0,0.706,0.0126,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,8.5,H
CHEMBL477772,PAZOPANIB,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,3.0,"Active, not recruiting",0,0,pathway_drug_candidates,3.0,0.517,0.112,0.0,0.757,0.0641,0.0,0.609,0.0675,0.0,0.675,0.0514,0.0,0.42,0.0758,0.0,0.592,0.089,0,0.361,0.0954,0.0,0.542,0.084,0,-2.64,-3.31,-1.98,-3.31,-1.98,3.1390400000000005,0.0981,0.754,1.0,0.176,0.271,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,3.5,L
CHEMBL479,THIORIDAZINE,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,,0,0,,0,0,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.717,0.0459,0.0,0.0174,0.769,1.0,0.352,0.181,0.0,0.284,0.185,0.0,0.1,0.372,1.0,0.00379,0.896,1,0.626,0.0535,0.0,0.179,0.166,0,-5.64,-6.45,-4.82,-6.45,-4.82,5.885600000000005,0.278,0.381,0.5,0.0835,0.691,1,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-10.5,L
CHEMBL4802159,ENPATORAN,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-168181|Toll Like Receptor 7/8 (TLR7/8) Cascade;R-HSA-5686938|Regulation of TLR by endogenous ligand;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9692916|SARS-CoV-1 activates/modulates innate immune responses;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome;R-HSA-9824856|Defective regulation of TLR7 by endogenous ligand;R-HSA-9833110|RSV-host interactions,11,0,,2.0,Recruiting,0,0,pathway_drug_candidates,2.0,0.102,0.436,1.0,0.318,0.235,0.5,0.344,0.182,0.0,0.433,0.108,0.0,0.0546,0.484,1.0,0.0767,0.376,1,0.188,0.19,1.0,0.109,0.189,1,-3.79,-4.42,-3.17,-4.42,-3.17,2.8223800000000008,0.209,0.45,1.0,0.203,0.182,0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,3.0,1.0,1.0,-10.0,L
CHEMBL4802163,NEZULCITINIB,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",28,13,,1.0,Completed,0,0,pathway_drug_candidates,11.0,0.642,0.0657,0.0,0.597,0.0987,0.0,0.302,0.214,0.5,0.338,0.164,0.0,0.473,0.0523,0.0,0.708,0.0527,0,0.891,0.0126,0.0,0.444,0.131,0,-3.49,-3.91,-3.07,-3.91,-3.07,3.7955000000000023,0.549,0.0889,0.0,0.239,0.149,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,9.0,H
CHEMBL482968,ENMD-2076,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.223,0.271,0.5,0.727,0.0553,0.0,0.637,0.0654,0.0,0.148,0.368,1.0,0.079,0.404,1.0,0.743,0.0479,0,0.797,0.0228,0.0,0.187,0.173,0.5,-4.6,-5.18,-4.03,-5.18,-4.03,3.1739200000000016,0.211,0.433,1.0,0.0676,0.67,1,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-5.0,L
CHEMBL483465,ELRAGLUSIB,Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc3c(cc21)OCO3,,0,0,R-HSA-198323|AKT phosphorylates targets in the cytosol;R-HSA-5674400|Constitutive Signaling by AKT1 E17K in Cancer;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9683610|Maturation of nucleoprotein,4,0,,2.0,"Active, not recruiting",0,0,pathway_drug_candidates,2.0,0.0422,0.624,1.0,0.106,0.438,1.0,0.581,0.0738,0.0,0.742,0.0309,0.0,0.0248,0.678,1.0,0.827,0.0317,0,0.174,0.231,1.0,0.161,0.196,1,-5.41,-6.01,-4.81,-6.01,-4.81,3.3595000000000015,0.302,0.384,0.5,0.187,0.214,1,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-8.5,L
CHEMBL484785,CRISABOROLE,N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,Phosphodiesterase 4 inhibitor,4.0,"Active, not recruiting",0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.0752,0.525,1.0,0.628,0.101,0.0,0.163,0.384,1.0,0.263,0.194,0.0,0.452,0.0758,0.0,0.00641,0.824,1,0.368,0.122,0.0,0.151,0.188,1,-4.46,-5.53,-3.38,-5.53,-3.38,1.5682799999999997,0.385,0.22,0.0,0.252,0.186,0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,1.0,1.0,-8.0,L
CHEMBL485,CODEINE,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,Unknown status,0,0,pathway_drug_candidates,6.0,0.614,0.0604,0.0,0.16,0.395,1.0,0.101,0.527,1.0,0.299,0.184,0.0,0.414,0.0787,0.0,0.0356,0.528,1,0.593,0.0454,0.0,0.846,0.0237,0,-1.51,-2.15,-0.869,-2.15,-0.869,1.5011,0.323,0.27,0.5,0.0697,0.692,1,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-1.0,L
CHEMBL485629,MK-0873,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.172,0.346,1.0,0.442,0.175,0.0,0.735,0.0307,0.0,0.884,0.0107,0.0,0.223,0.182,0.5,0.568,0.0895,0,0.178,0.201,1.0,0.43,0.132,0,-2.27,-2.77,-1.78,-2.77,-1.78,2.3111000000000006,0.229,0.414,1.0,0.253,0.122,0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,2.0,1.0,1.0,-3.0,L
CHEMBL491473,CEDIRANIB,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.459,0.123,0.0,0.0535,0.609,1.0,0.248,0.269,0.5,0.788,0.0257,0.0,0.555,0.047,0.0,0.0401,0.482,1,0.505,0.0588,0.0,0.193,0.169,0,-3.6,-4.31,-2.88,-4.31,-2.88,5.224220000000004,0.652,0.0568,0.0,0.0881,0.685,1,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-6.0,L
CHEMBL492399,VERUBULIN,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.118,0.452,1.0,0.0853,0.483,1.0,0.464,0.123,0.0,0.453,0.102,0.0,0.15,0.297,1.0,0.466,0.116,0,0.154,0.247,1.0,0.0335,0.312,1,-3.08,-3.74,-2.42,-3.74,-2.42,3.7147200000000025,0.104,0.772,1.0,0.242,0.154,0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,1.0,1.0,-3.5,L
CHEMBL495727,AT-9283,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells;RMTs methylate histone arginines",22,9,,2.0,Completed,0,0,pathway_drug_candidates,12.0,0.148,0.355,1.0,0.288,0.265,0.5,0.72,0.0369,0.0,0.382,0.131,0.0,0.131,0.307,1.0,0.955,0.00724,0,0.309,0.124,0.0,0.967,0.00885,0,-0.99,-1.41,-0.566,-1.41,-0.566,2.0690999999999997,0.958,0.00335,0.0,0.151,0.356,1,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,1.0,1.0,7.0,M
CHEMBL49642,INDIBULIN,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,1.0,Completed,0,0,pathway_drug_candidates,3.0,0.006,0.874,1.0,0.0029,0.918,1.0,0.114,0.511,1.0,0.00632,0.924,1.0,0.00456,0.897,1.0,0.151,0.279,1,0.409,0.0859,0.0,0.0971,0.216,1,-4.4,-4.9,-3.9,-4.9,-3.9,4.559400000000003,0.269,0.421,0.5,0.177,0.254,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,5.0,1.0,1.0,-12.5,L
CHEMBL497939,CYTISINICLINE,O=c1cccc2n1C[C@@H]1CNC[C@H]2C1,,0,0,R-HSA-629587|Highly sodium permeable postsynaptic acetylcholine nicotinic receptors;R-HSA-629594|Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;R-HSA-629597|Highly calcium permeable nicotinic acetylcholine receptors,3,0,,3.0,,0,0,pathway_drug_candidates,3.0,0.443,0.125,0.0,0.331,0.214,0.5,0.503,0.107,0.0,0.313,0.177,0.0,0.455,0.0679,0.0,0.512,0.108,0,0.358,0.0995,0.0,0.179,0.165,0,0.228,-0.52,0.975,-0.52,0.975,0.5549999999999999,0.509,0.105,0.0,0.234,0.152,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.5,L
CHEMBL501867,VINCRISTINE SULFATE,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,Tubulin inhibitor,3.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,5.0,0.194,0.308,1.0,0.0675,0.528,1.0,0.883,0.00887,0.0,0.781,0.0276,0.0,0.757,0.0179,0.0,0.234,0.219,0,0.905,0.00917,0.0,0.334,0.12,0,-4.09,-4.57,-3.62,-4.57,-3.62,2.8647000000000036,0.0158,0.913,1.0,0.138,0.414,1,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,1.0,1.0,0.5,L
CHEMBL502835,NINTEDANIB,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,,0,0,R-HSA-5673001|RAF/MAP kinase cascade,1,0,,3.0,,1,0,known_drugs;pathway_drug_candidates,4.5,0.188,0.315,1.0,0.308,0.215,0.5,0.236,0.287,0.5,0.22,0.253,0.5,0.535,0.0469,0.0,0.583,0.0922,0,0.318,0.126,0.0,0.558,0.112,0,-3.58,-4.24,-2.92,-4.24,-2.92,3.6159000000000026,0.0387,0.921,1.0,0.0618,0.87,1,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,4.0,1.0,1.0,-1.0,L
CHEMBL503,LOVASTATIN,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,,0,0,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,HMG-CoA reductase inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.0507,0.592,1.0,0.617,0.0782,0.0,0.427,0.13,0.0,0.471,0.0992,0.0,0.588,0.0381,0.0,0.299,0.179,0,0.455,0.0742,0.0,0.0281,0.355,1,-5.37,-7.04,-3.69,-7.04,-3.69,4.195500000000004,0.216,0.431,1.0,0.235,0.164,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,-1.0,L
CHEMBL504652,TC-2216,c1cncc(N2CCC3(CCCN3)C2)c1,,0,0,R-HSA-629587|Highly sodium permeable postsynaptic acetylcholine nicotinic receptors;R-HSA-629594|Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;R-HSA-629597|Highly calcium permeable nicotinic acetylcholine receptors,3,0,,1.0,Completed,0,0,pathway_drug_candidates,1.0,0.27,0.227,0.5,0.0296,0.689,1.0,0.365,0.176,0.0,0.202,0.288,0.5,0.524,0.0517,0.0,0.01,0.768,1,0.425,0.0721,0.0,0.53,0.107,0,-1.29,-2.21,-0.367,-2.21,-0.367,1.4139,0.538,0.111,0.0,0.257,0.115,0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,3.0,1.0,1.0,-9.0,L
CHEMBL505,CHLORPHENIRAMINE,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.763,0.0327,0.0,0.0334,0.681,1.0,0.502,0.103,0.0,0.759,0.0383,0.0,0.0961,0.361,1.0,0.205,0.235,1,0.873,0.0156,0.0,0.824,0.0356,0,-2.89,-3.71,-2.06,-3.71,-2.06,3.818600000000002,0.275,0.396,0.5,0.757,0.0153,0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,-4.0,L
CHEMBL509,MECLOFENAMIC ACID,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.505,0.107,0.0,0.539,0.128,0.0,0.047,0.681,1.0,0.711,0.0445,0.0,0.0319,0.661,1.0,0.852,0.0225,0,0.428,0.0725,0.0,0.886,0.0144,0,-4.73,-5.98,-3.49,-5.98,-3.49,4.743620000000003,0.731,0.0233,0.0,0.725,0.0102,0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,4.5,L
CHEMBL5095029,PF-04634817,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1,,0,0,R-HSA-173107|Binding and entry of HIV virion;R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,4,2,,2.0,Completed,0,0,pathway_drug_candidates,6.0,0.653,0.0606,0.0,0.129,0.415,1.0,0.985,0.00249,0.0,0.0763,0.538,1.0,0.5,0.0563,0.0,0.677,0.0607,0,0.709,0.0328,0.0,0.103,0.232,1,-3.77,-4.33,-3.21,-4.33,-3.21,2.8733000000000013,0.319,0.245,0.0,0.27,0.144,0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,2.5,L
CHEMBL5095049,PACRITINIB CITRATE,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;RMTs methylate histone arginines",21,9,Tyrosine-protein kinase JAK2 inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,14.0,1.0,0.00214,0.0,0.975,0.0068,0.0,0.345,0.186,0.0,0.0974,0.447,1.0,0.129,0.281,1.0,0.0332,0.544,1,0.694,0.0346,0.0,0.933,0.0166,0,-4.05,-5.68,-2.41,-5.68,-2.41,3.7163,0.995,0.00628,0.0,0.161,0.335,1,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,4.5,L
CHEMBL511,PYRILAMINE,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.18,0.33,1.0,0.114,0.443,1.0,0.477,0.109,0.0,0.456,0.103,0.0,0.734,0.0169,0.0,0.0563,0.445,1,0.653,0.0412,0.0,0.868,0.0269,0,-2.6,-3.38,-1.82,-3.38,-1.82,2.658400000000001,0.0769,0.842,1.0,0.707,0.0156,0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,2.0,1.0,1.0,-4.0,L
CHEMBL511115,CILOMILAST,COc1ccc([C@]2(C#N)CC[C@@H](C(=O)O)CC2)cc1OC1CCCC1,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.485,0.114,0.0,0.684,0.0677,0.0,0.613,0.0668,0.0,0.884,0.01,0.0,0.236,0.183,0.5,0.868,0.0229,0,0.767,0.026,0.0,0.352,0.145,0,-3.49,-4.45,-2.53,-4.45,-2.53,4.052780000000003,0.517,0.0941,0.0,0.254,0.114,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,L
CHEMBL511142,BUPRENORPHINE,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.205,0.3,1.0,0.0796,0.511,1.0,0.431,0.139,0.0,0.517,0.0829,0.0,0.603,0.0347,0.0,0.113,0.31,1,0.724,0.0293,0.0,0.52,0.0886,0,-4.32,-5.16,-3.48,-5.16,-3.48,4.413800000000004,0.128,0.559,1.0,0.0819,0.538,1,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,-4.0,L
CHEMBL512351,BETRIXABAN,COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)c1,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,Coagulation factor X inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.64,0.0623,0.0,0.108,0.455,1.0,0.458,0.123,0.0,0.21,0.278,0.5,0.428,0.076,0.0,0.053,0.469,1,0.824,0.0175,0.0,0.0653,0.255,1,-3.78,-4.46,-3.1,-4.46,-3.1,4.135170000000002,0.0801,0.818,1.0,0.24,0.15,0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,-3.5,L
CHEMBL513,CARMUSTINE,O=NN(CCCl)C(=O)NCCCl,,0,0,,0,0,RNA inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.443,0.125,0.0,0.497,0.137,0.0,0.411,0.136,0.0,0.461,0.102,0.0,0.224,0.184,0.5,0.624,0.0755,0,0.0293,0.747,1.0,0.843,0.0306,0,-1.9,-2.65,-1.14,-2.65,-1.14,1.157,0.638,0.0687,0.0,0.117,0.438,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-3.0,L
CHEMBL514800,APREMILAST,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,PDE4A,1,1,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,Phosphodiesterase 4 inhibitor,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.214,0.299,0.5,0.891,0.0204,0.0,0.625,0.0698,0.0,0.661,0.0484,0.0,0.64,0.0334,0.0,0.955,0.00737,0,0.724,0.037,0.0,0.534,0.0776,0,-2.88,-3.57,-2.2,-3.57,-2.2,2.4342000000000006,0.088,0.694,1.0,0.0788,0.598,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,6.5,L
CHEMBL515387,GOSOGLIPTIN,O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1,,0,0,,0,0,Dipeptidyl peptidase IV inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.698,0.0459,0.0,0.186,0.368,1.0,0.339,0.172,0.0,0.42,0.113,0.0,0.615,0.0339,0.0,0.0796,0.373,1,0.708,0.0392,0.0,0.0938,0.251,1,-2.84,-3.76,-1.91,-3.76,-1.91,0.1967000000000005,0.421,0.205,0.0,0.122,0.513,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,-8.0,L
CHEMBL515606,CILAZAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](C(=O)O)N2C1=O,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.666,0.0524,0.0,0.283,0.27,0.5,0.31,0.191,0.0,0.308,0.172,0.0,0.311,0.128,0.0,0.728,0.0504,0,0.284,0.11,0.0,0.602,0.0848,0,-1.42,-1.88,-0.949,-1.88,-0.949,1.5955,0.775,0.0178,0.0,0.218,0.202,0.5,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.5,1.0,0.0,0.0,5.0,L
CHEMBL516,CYPROHEPTADINE,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,1,0,known_drugs;pathway_drug_candidates,5.5,0.231,0.298,0.5,0.0113,0.8,1.0,0.277,0.228,0.5,0.462,0.101,0.0,0.421,0.075,0.0,0.27,0.191,0,0.573,0.0528,0.0,0.0121,0.445,1,-3.07,-3.65,-2.5,-3.65,-2.5,4.697900000000004,0.403,0.19,0.0,0.115,0.396,1,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-1.5,L
CHEMBL5170587,VK5211,N#Cc1ccc(N2CCC[C@@H]2[C@@H](O)C(F)(F)F)cc1C(F)(F)F,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.164,0.32,1.0,0.802,0.0363,0.0,0.00206,0.966,1.0,0.0443,0.693,1.0,0.0626,0.514,1.0,0.885,0.0212,0,0.836,0.0217,0.0,0.0723,0.242,1,-2.34,-2.93,-1.74,-2.93,-1.74,3.4690800000000017,0.305,0.27,0.5,0.16,0.254,1,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-6.0,L
CHEMBL521,IBUPROFEN,CC(C)Cc1ccc(C(C)C(=O)O)cc1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.658,0.0588,0.0,0.609,0.0921,0.0,0.246,0.273,0.5,0.543,0.0817,0.0,0.771,0.0141,0.0,0.563,0.0991,0,0.567,0.0545,0.0,0.819,0.0398,0,-3.87,-4.74,-2.99,-4.74,-2.99,3.073200000000001,0.944,0.00791,0.0,0.657,0.021,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,8.0,H
CHEMBL522892,DOVITINIB,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.544,0.0783,0.0,0.409,0.196,0.0,0.167,0.36,1.0,0.836,0.0162,0.0,0.528,0.0536,0.0,0.506,0.112,0,0.258,0.139,0.0,0.561,0.0864,0,-2.89,-3.43,-2.35,-3.43,-2.35,2.5445,0.268,0.318,0.5,0.164,0.256,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.5,L
CHEMBL524,METHOXAMINE,COc1ccc(OC)c(C(O)C(C)N)c1,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.142,0.396,1.0,0.36,0.215,0.5,0.311,0.191,0.0,0.516,0.0911,0.0,0.138,0.279,1.0,0.157,0.27,1,0.63,0.0414,0.0,0.785,0.0281,0,-1.42,-2.07,-0.771,-2.07,-0.771,1.0844,0.38,0.236,0.0,0.513,0.0281,0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,3.0,1.0,1.0,-6.0,L
CHEMBL526,PROPOFOL,CC(C)c1cccc(C(C)C)c1O,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.12,0.389,1.0,0.357,0.219,0.5,0.409,0.136,0.0,0.0222,0.821,1.0,0.17,0.235,0.5,0.506,0.11,0,0.442,0.0787,0.0,0.113,0.23,1,-3.54,-4.79,-2.29,-4.79,-2.29,3.6390000000000025,0.383,0.273,0.5,0.119,0.435,1,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-8.0,L
CHEMBL527,PIROXICAM,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.645,0.0574,0.0,0.667,0.0768,0.0,0.0598,0.604,1.0,0.619,0.0526,0.0,0.637,0.0321,0.0,0.386,0.141,0,0.768,0.032,0.0,0.818,0.0292,0,-4.2,-5.26,-3.14,-5.26,-3.14,1.5809999999999995,0.165,0.55,1.0,0.411,0.0368,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,8.5,H
CHEMBL52885,ENMD-981693,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21,,0,0,R-HSA-5673001|RAF/MAP kinase cascade,1,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.158,0.343,1.0,0.501,0.117,0.0,0.56,0.0787,0.0,0.831,0.0194,0.0,0.0278,0.64,1.0,0.866,0.0232,0,0.027,0.739,1.0,0.0867,0.208,1,-3.81,-4.33,-3.28,-4.33,-3.28,3.1454000000000013,0.0834,0.69,1.0,0.356,0.0487,0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,1.0,1.0,-4.5,L
CHEMBL529,AZITHROMYCIN,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.673,0.0529,0.0,0.447,0.184,0.0,0.686,0.042,0.0,0.683,0.041,0.0,0.775,0.0217,0.0,0.203,0.24,1,0.849,0.018,0.0,0.551,0.0595,0,-0.404,-1.2,0.394,-1.2,0.394,1.9007000000000056,0.406,0.205,0.0,0.709,0.00932,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,-5.0,L
CHEMBL5303393,VARENICLINE TARTRATE,O=C(O)C(O)C(O)C(=O)O.c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1,,0,0,R-HSA-629587|Highly sodium permeable postsynaptic acetylcholine nicotinic receptors;R-HSA-629594|Highly calcium permeable postsynaptic nicotinic acetylcholine receptors;R-HSA-629597|Highly calcium permeable nicotinic acetylcholine receptors,3,0,,3.0,Recruiting,0,0,pathway_drug_candidates,3.0,0.838,0.0212,0.0,0.113,0.461,1.0,0.757,0.036,0.0,0.959,0.00254,0.0,0.364,0.0893,0.0,0.711,0.0497,0,0.271,0.161,0.0,0.574,0.0789,0,0.569,-1.09,2.23,-1.09,2.14,-0.3187000000000002,0.681,0.0442,0.0,0.233,0.14,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,L
CHEMBL5314374,IDRAPARINUX SODIUM,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)[O-])[C@H]3OS(=O)(=O)[O-])[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)[O-])[C@H]1OS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.756,0.0433,0.0,1.0,0.00366,0.0,1.0,0.00227,0.0,0.99,0.00159,0.0,1.0,0.00158,0.0,0.962,0.00658,0,0.966,0.00394,0.0,0.777,0.0611,0,7.73,7.24,8.21,2.14,2.14,-39.74910000000014,0.989,0.00528,0.0,0.145,0.381,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,2.0,L
CHEMBL5314391,XL-999,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.577,0.0819,0.0,0.495,0.139,0.0,0.107,0.49,1.0,0.0868,0.525,1.0,0.83,0.0109,0.0,0.709,0.0446,0,0.131,0.301,1.0,0.0342,0.275,1,-5.07,-5.64,-4.5,-5.64,-4.5,4.664620000000004,0.254,0.336,0.5,0.14,0.384,1,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-6.5,L
CHEMBL5314393,LY2624803,CC(C)(CN1CCN(C2=Nc3ccccc3Oc3ccccc32)CC1)C(=O)O,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.729,0.0442,0.0,0.349,0.208,0.5,0.105,0.486,1.0,0.601,0.0603,0.0,0.609,0.0356,0.0,0.0357,0.532,1,0.271,0.152,0.0,0.0457,0.304,1,-4.64,-5.31,-3.98,-5.31,-3.98,3.599000000000001,0.577,0.0902,0.0,0.193,0.221,1,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-8.5,L
CHEMBL5314400,DWP05195,FC(F)(F)c1cccnc1-c1ccc(-c2nc3ccc(Br)cc3[nH]2)nc1,,0,0,R-HSA-3295583|TRP channels,1,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.168,0.334,1.0,0.527,0.125,0.0,0.479,0.122,0.0,0.677,0.0412,0.0,0.0974,0.378,1.0,0.555,0.0942,0,0.781,0.023,0.0,0.211,0.164,0,-4.13,-4.75,-3.52,-4.75,-3.52,5.468200000000002,0.376,0.215,0.0,0.172,0.257,1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-5.5,L
CHEMBL5314408,AZD-0424,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1,,0,0,"R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1,0,,1.0,Terminated,0,0,pathway_drug_candidates,1.0,0.809,0.0252,0.0,0.168,0.343,1.0,0.121,0.432,1.0,0.373,0.144,0.0,0.323,0.122,0.0,0.309,0.184,0,0.69,0.036,0.0,0.0496,0.279,1,-4.15,-4.65,-3.65,-4.65,-3.65,3.4806000000000017,0.0942,0.699,1.0,0.223,0.192,0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,-3.0,L
CHEMBL5314649,RITLECITINIB TOSYLATE,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C.Cc1ccc(S(=O)(=O)O)cc1,BTK,1,1,R-HSA-1236974|ER-Phagosome pathway;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-9679191|Potential therapeutics for SARS,4,0,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,6.0,0.578,0.0749,0.0,0.214,0.301,0.5,0.878,0.0114,0.0,0.521,0.0874,0.0,0.223,0.186,0.5,0.588,0.0852,0,0.589,0.0596,0.0,0.79,0.0419,0,-0.633,-1.22,-0.0498,-1.22,-0.0498,3.1770200000000006,0.213,0.53,1.0,0.168,0.32,1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,5.0,L
CHEMBL5314801,IDRAPARINUX,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)O)[C@H]3OS(=O)(=O)O)[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)O)[C@H]1OS(=O)(=O)O,,0,0,R-HSA-140837|Intrinsic Pathway of Fibrin Clot Formation;R-HSA-140875|Common Pathway of Fibrin Clot Formation,2,0,,3.0,Completed,0,0,pathway_drug_candidates,3.0,0.999,0.00101,0.0,0.637,0.101,0.0,0.999,0.00128,0.0,0.985,0.000889,0.0,0.996,0.000887,0.0,0.603,0.0849,0,0.965,0.00291,0.0,0.77,0.055,0,2.59,2.0,3.19,2.0,2.14,-7.717500000000026,0.976,0.00296,0.0,0.536,0.0235,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,L
CHEMBL5315048,ZILUCOPLAN SODIUM,,C5,1,0,R-HSA-166665|Terminal pathway of complement;R-HSA-174577|Activation of C3 and C5;R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-977606|Regulation of Complement cascade,5,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,10.0,H
CHEMBL5315049,SITAGLIPTIN FUMARATE,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O=C(O)/C=C\C(=O)O,,0,0,,0,0,Dipeptidyl peptidase IV inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.883,0.0169,0.0,0.782,0.0491,0.0,0.178,0.349,1.0,0.918,0.00947,0.0,0.888,0.00624,0.0,0.697,0.0544,0,0.842,0.0141,0.0,0.729,0.0361,0,-0.739,-1.45,-0.0235,-1.45,-0.0235,1.7282999999999995,0.517,0.11,0.0,0.124,0.424,1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-1.0,L
CHEMBL5315054,ERTUGLIFLOZIN PIDOLATE,CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1.O=C1CC[C@@H](C(=O)O)N1,,0,0,,0,0,Sodium/glucose cotransporter 2 inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.854,0.019,0.0,0.968,0.00886,0.0,0.00589,0.953,1.0,0.574,0.0757,0.0,0.557,0.0466,0.0,0.871,0.0216,0,0.283,0.157,0.0,0.619,0.0622,0,-4.49,-4.88,-4.1,-4.88,-4.1,0.7060999999999995,0.912,0.00925,0.0,0.21,0.26,0.5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.5,1.0,0.0,0.0,-3.5,L
CHEMBL5315055,NALMEFENE HYDROCHLORIDE DIHYDRATE,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl.O.O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.397,0.143,0.0,0.0327,0.69,1.0,0.0882,0.526,1.0,0.582,0.0789,0.0,0.708,0.0178,0.0,0.172,0.263,1,0.511,0.0551,0.0,0.802,0.034,0,-4.75,-7.27,-2.23,-7.27,-2.23,1.2849000000000008,0.298,0.27,0.5,0.00768,0.986,1,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-3.0,L
CHEMBL5315056,NALOXONE HYDROCHLORIDE DIHYDRATE,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl.O.O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.644,0.052,0.0,0.0263,0.707,1.0,0.182,0.335,1.0,0.649,0.0553,0.0,0.54,0.0467,0.0,0.308,0.184,0,0.777,0.0265,0.0,0.856,0.0343,0,-3.26,-4.86,-1.67,-4.86,-1.67,0.0737999999999997,0.278,0.363,0.5,0.0209,0.998,1,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,3.0,L
CHEMBL5315119,UPADACITINIB HEMIHYDRATE,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-449836|Other interleukin signaling;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-909733|Interferon alpha/beta signaling;R-HSA-912694|Regulation of IFNA/IFNB signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-9725370|Signaling by ALK fusions and activated point mutants;R-HSA-9833109|Evasion by RSV of host interferon responses;RMTs methylate histone arginines",28,13,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,14.0,0.112,0.443,1.0,0.0604,0.576,1.0,0.432,0.146,0.0,0.579,0.0704,0.0,0.654,0.0254,0.0,0.364,0.161,0,0.946,0.00592,0.0,0.556,0.0728,0,-4.98,-5.41,-4.56,-5.41,-4.56,4.991100000000006,0.0346,0.917,1.0,0.0733,0.523,1,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,8.0,M
CHEMBL532,ERYTHROMYCIN,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.484,0.114,0.0,0.754,0.0475,0.0,0.643,0.0526,0.0,0.81,0.0217,0.0,0.852,0.00769,0.0,0.332,0.168,0,0.824,0.0194,0.0,0.454,0.0867,0,-1.41,-2.14,-0.689,-2.14,-0.689,1.785600000000004,0.555,0.09,0.0,0.775,0.00885,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,L
CHEMBL53292,ISOXICAM,Cc1cc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)no1,,0,0,,0,0,Cyclooxygenase inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.586,0.0667,0.0,0.885,0.019,0.0,0.415,0.135,0.0,0.591,0.0543,0.0,0.633,0.0296,0.0,0.591,0.088,0,0.622,0.0409,0.0,0.738,0.0442,0,-3.47,-4.17,-2.77,-4.17,-2.77,1.48242,0.264,0.405,0.5,0.234,0.16,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.5,L
CHEMBL534,KETOTIFEN,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,1,0,known_drugs;pathway_drug_candidates,5.5,0.285,0.223,0.5,0.0469,0.629,1.0,0.195,0.325,1.0,0.276,0.194,0.0,0.444,0.0692,0.0,0.562,0.0953,0,0.715,0.0345,0.0,0.803,0.0439,0,-3.51,-4.0,-3.02,-4.0,-3.02,4.014400000000004,0.472,0.156,0.0,0.0982,0.573,1,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,0.5,L
CHEMBL535,SUNITINIB,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,4.0,Completed,0,0,pathway_drug_candidates,4.0,0.674,0.0594,0.0,0.515,0.135,0.0,0.586,0.0872,0.0,0.0863,0.487,1.0,0.48,0.0564,0.0,0.204,0.242,1,0.172,0.197,1.0,0.0838,0.233,1,-2.48,-3.09,-1.88,-3.09,-1.88,3.3349400000000013,0.114,0.778,1.0,0.0347,0.825,1,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,-4.5,L
CHEMBL535650,MEFLOQUINE HYDROCHLORIDE,Cl.OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1,,0,0,,0,0,Ferriprotoporphyrin IX inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.548,0.0865,0.0,0.0553,0.574,1.0,0.498,0.102,0.0,0.442,0.108,0.0,0.531,0.0513,0.0,0.258,0.212,0,0.793,0.027,0.0,0.053,0.377,1,-1.48,-2.04,-0.919,-2.04,-0.919,4.869700000000003,0.54,0.11,0.0,0.0248,0.992,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,-3.5,L
CHEMBL538943,VINORELBINE TARTRATE,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,Tubulin inhibitor,3.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,5.0,0.866,0.0128,0.0,0.00263,0.9,1.0,0.93,0.00381,0.0,0.996,0.000508,0.0,0.893,0.00478,0.0,0.544,0.0956,0,0.934,0.00553,0.0,0.483,0.127,0,-4.64,-5.26,-4.01,-5.26,-4.01,0.5084000000000097,0.209,0.359,1.0,0.082,0.514,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,3.0,L
CHEMBL539423,SPARSENTAN,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,Type-1 angiotensin II receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.232,0.289,0.5,0.882,0.0193,0.0,0.186,0.356,1.0,0.71,0.0415,0.0,0.614,0.0415,0.0,0.678,0.0635,0,0.975,0.00447,0.0,0.955,0.0076,0,-4.28,-4.71,-3.85,-4.71,-3.85,6.539440000000007,0.261,0.392,0.5,0.0227,0.927,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-3.5,L
CHEMBL54,HALOPERIDOL,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.605,0.0768,0.0,0.0459,0.614,1.0,0.911,0.00464,0.0,0.699,0.0493,0.0,0.436,0.0717,0.0,0.00341,0.901,1,0.783,0.0239,0.0,0.011,0.774,1,-4.34,-5.12,-3.56,-5.12,-3.56,4.425600000000004,0.0614,0.854,1.0,0.139,0.437,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,-8.0,L
CHEMBL547,ISOTRETINOIN,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,RARG,1,1,R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-5362517|Signaling by Retinoic Acid;R-HSA-5617472|Activation of anterior HOX genes in hindbrain development during early embryogenesis,3,0,Retinoic acid receptor agonist,4.0,Not yet recruiting,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.874,0.0135,0.0,0.416,0.181,0.0,0.794,0.0278,0.0,0.595,0.0558,0.0,0.463,0.0599,0.0,0.305,0.177,0,0.248,0.154,0.0,0.652,0.0568,0,-4.41,-5.78,-3.04,-5.78,-3.04,5.602600000000005,0.51,0.0965,0.0,0.443,0.0323,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,L
CHEMBL549344,CPG-52852,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O,,0,0,R-HSA-1679131|Trafficking and processing of endosomal TLR;R-HSA-168181|Toll Like Receptor 7/8 (TLR7/8) Cascade;R-HSA-5686938|Regulation of TLR by endogenous ligand;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9692916|SARS-CoV-1 activates/modulates innate immune responses;R-HSA-9705671|SARS-CoV-2 activates/modulates innate and adaptive immune responses;R-HSA-975110|TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling;R-HSA-975138|TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation;R-HSA-975155|MyD88 dependent cascade initiated on endosome;R-HSA-9824856|Defective regulation of TLR7 by endogenous ligand;R-HSA-9833110|RSV-host interactions,11,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.0748,0.549,1.0,0.0915,0.469,1.0,0.421,0.122,0.0,0.162,0.341,1.0,0.23,0.186,0.5,0.0408,0.498,1,0.258,0.135,0.0,0.747,0.0423,0,-3.19,-3.82,-2.56,-3.82,-2.56,2.0584999999999996,0.336,0.273,0.5,0.156,0.289,1,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,4.0,1.0,1.0,-9.5,L
CHEMBL551978,DROTAVERINE,CCOc1ccc(/C=C2\NCCc3cc(OCC)c(OCC)cc32)cc1OCC,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,3.0,,0,0,pathway_drug_candidates,3.0,0.0107,0.783,1.0,0.492,0.137,0.0,0.438,0.13,0.0,0.467,0.101,0.0,0.582,0.0357,0.0,0.307,0.184,0,0.874,0.0133,0.0,0.649,0.0597,0,-5.06,-5.79,-4.33,-5.79,-4.33,4.925200000000005,0.147,0.683,1.0,0.0928,0.536,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,-2.0,L
CHEMBL552212,LEXIBULIN,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Terminated,0,0,pathway_drug_candidates,4.0,0.00104,0.965,1.0,0.0213,0.77,1.0,0.726,0.0419,0.0,0.699,0.0356,0.0,0.132,0.3,1.0,0.883,0.0205,0,0.891,0.00988,0.0,0.443,0.134,0,-2.81,-3.39,-2.23,-3.39,-2.23,4.950320000000004,0.453,0.14,0.0,0.0784,0.694,1,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-3.0,L
CHEMBL553025,VINORELBINE,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.265,0.23,0.5,0.0049,0.865,1.0,0.63,0.0714,0.0,0.672,0.0475,0.0,0.538,0.0538,0.0,0.371,0.155,0,0.762,0.0276,0.0,0.121,0.211,1,-6.02,-6.51,-5.54,-6.51,-5.54,4.753600000000004,0.0271,0.965,1.0,0.118,0.413,1,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,-1.0,L
CHEMBL559180,ISOXSUPRINE HYDROCHLORIDE,CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1.Cl,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,1.0,Completed,0,0,pathway_drug_candidates,1.0,0.693,0.0479,0.0,0.0478,0.615,1.0,0.713,0.0514,0.0,0.226,0.251,0.5,0.0631,0.441,1.0,0.453,0.121,0,0.551,0.0913,0.0,0.884,0.0313,0,-1.02,-1.87,-0.163,-1.87,-0.163,3.2930000000000024,0.746,0.0368,0.0,0.0938,0.566,1,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,0.0,1.0,-2.5,L
CHEMBL562,GRISEOFULVIN,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O,,0,0,,0,0,Tubulin inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.281,0.223,0.5,0.0195,0.741,1.0,0.467,0.0971,0.0,0.528,0.087,0.0,0.145,0.271,1.0,0.354,0.161,0,0.602,0.0479,0.0,0.517,0.0858,0,-3.99,-4.86,-3.12,-4.86,-3.12,2.8103000000000007,0.185,0.525,1.0,0.36,0.0447,0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,3.0,1.0,1.0,-4.0,L
CHEMBL563,FLURBIPROFEN,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.509,0.095,0.0,0.441,0.171,0.0,0.0604,0.621,1.0,0.83,0.0213,0.0,0.67,0.0277,0.0,0.818,0.034,0,0.752,0.0317,0.0,0.814,0.0555,0,-4.18,-4.87,-3.5,-4.87,-3.5,3.6808000000000023,0.958,0.00674,0.0,0.277,0.141,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,6.5,H
CHEMBL566534,ARTEMETHER,CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3,,0,0,,0,0,Ferriprotoporphyrin IX inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.523,0.103,0.0,0.286,0.263,0.5,0.796,0.0283,0.0,0.669,0.0497,0.0,0.101,0.352,1.0,0.136,0.295,1,0.187,0.2,1.0,0.768,0.0225,0,-4.4,-5.19,-3.6,-5.19,-3.6,2.8408000000000015,0.368,0.251,0.5,0.233,0.151,0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,-11.0,L
CHEMBL568,OXAZEPAM,O=C1Nc2ccc(Cl)cc2C(c2ccccc2)=NC1O,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.326,0.207,0.0,0.0621,0.566,1.0,0.217,0.304,0.5,0.0717,0.583,1.0,0.0135,0.742,1.0,0.0557,0.425,1,0.774,0.0233,0.0,0.298,0.138,0,-3.84,-4.6,-3.07,-4.6,-3.07,2.4479,0.258,0.399,0.5,0.0596,0.708,1,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,4.0,0.0,1.0,-8.5,L
CHEMBL570015,GSK-256066,COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.188,0.314,1.0,0.945,0.0146,0.0,0.578,0.102,0.0,0.881,0.0106,0.0,0.711,0.0192,0.0,0.793,0.0376,0,0.887,0.0142,0.0,0.673,0.0744,0,-3.54,-3.93,-3.15,-3.93,-3.15,3.9289200000000033,0.0386,0.985,1.0,0.217,0.181,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,-0.5,L
CHEMBL571,KETOPROFEN,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.85,0.0202,0.0,0.49,0.147,0.0,0.238,0.252,0.5,0.0425,0.688,1.0,0.281,0.139,0.0,0.893,0.0198,0,0.872,0.0121,0.0,0.877,0.0244,0,-3.4,-4.1,-2.7,-4.1,-2.7,3.1057000000000015,0.872,0.00924,0.0,0.0959,0.47,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,7.0,M
CHEMBL572284,OMBRABULIN,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,3.0,Completed,0,0,pathway_drug_candidates,5.0,0.314,0.194,0.0,0.767,0.0528,0.0,0.349,0.195,0.0,0.486,0.0936,0.0,0.341,0.114,0.0,0.778,0.0442,0,0.202,0.212,0.5,0.627,0.0693,0,-4.14,-5.07,-3.22,-5.07,-3.22,2.1495,0.599,0.076,0.0,0.222,0.256,0.5,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.5,0.0,0.0,0.0,1.0,L
CHEMBL57242,AZILSARTAN,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1,AGTR1,1,1,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,Type-1 angiotensin II receptor antagonist,3.0,Completed,1,1,known_drugs;pathway_drug_candidates;mechanism_of_actions,6.5,0.701,0.0509,0.0,0.91,0.0191,0.0,0.699,0.0457,0.0,0.86,0.0168,0.0,0.159,0.269,1.0,0.382,0.15,0,0.976,0.00589,0.0,0.717,0.0444,0,-5.9,-6.63,-5.16,-6.63,-5.16,4.1918000000000015,0.933,0.0132,0.0,0.275,0.12,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,3.0,L
CHEMBL572881,MOTESANIB,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,3.0,Terminated,0,0,pathway_drug_candidates,3.0,0.0216,0.74,1.0,0.0117,0.814,1.0,0.0132,0.889,1.0,0.0428,0.694,1.0,0.00366,0.942,1.0,0.247,0.213,0,0.38,0.0987,0.0,0.358,0.141,0,-4.28,-5.55,-3.01,-5.55,-3.01,4.044100000000002,0.121,0.779,1.0,0.149,0.407,1,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,5.0,1.0,1.0,-4.0,L
CHEMBL576982,QUIZARTINIB,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,3.0,Completed;Withdrawn,0,0,pathway_drug_candidates,3.0,0.857,0.0194,0.0,0.982,0.00475,0.0,0.162,0.399,1.0,0.439,0.123,0.0,0.2,0.224,0.5,0.671,0.0613,0,0.81,0.0206,0.0,0.723,0.0558,0,-5.83,-6.61,-5.05,-6.61,-5.05,5.856500000000005,0.977,0.00685,0.0,0.0759,0.669,1,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,-2.5,L
CHEMBL577,ENALAPRILAT ANHYDROUS,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,,3.0,Completed,0,0,pathway_drug_candidates,5.0,0.868,0.014,0.0,0.65,0.0827,0.0,0.559,0.0917,0.0,0.576,0.0712,0.0,0.647,0.0315,0.0,0.964,0.00703,0,0.945,0.0103,0.0,0.538,0.099,0,-1.37,-2.03,-0.711,-2.03,-0.711,1.1261000000000003,0.928,0.00175,0.0,0.301,0.103,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,L
CHEMBL578,ENALAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,,4.0,,1,0,known_drugs;pathway_drug_candidates,7.5,0.753,0.039,0.0,0.66,0.089,0.0,0.477,0.111,0.0,0.459,0.102,0.0,0.45,0.0642,0.0,0.929,0.00952,0,0.808,0.0238,0.0,0.436,0.113,0,-1.36,-1.89,-0.822,-1.89,-0.822,1.6046,0.739,0.0319,0.0,0.217,0.186,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,8.5,M
CHEMBL580,LORAZEPAM,O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.239,0.283,0.5,0.186,0.342,1.0,0.179,0.351,1.0,0.0605,0.599,1.0,0.0373,0.561,1.0,0.23,0.217,0,0.722,0.0324,0.0,0.21,0.135,0,-3.81,-4.55,-3.07,-4.55,-3.07,3.1013000000000015,0.257,0.369,0.5,0.0556,0.698,1,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,5.0,1.0,1.0,-7.0,L
CHEMBL58510,CHLOROQUINE PHOSPHATE,CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=P(O)(O)O.O=P(O)(O)O,,0,0,,0,0,Ferriprotoporphyrin IX inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.91,0.00872,0.0,0.0613,0.582,1.0,0.973,0.000232,0.0,0.953,0.00338,0.0,0.107,0.337,1.0,0.0257,0.589,1,0.231,0.156,0.0,0.0668,0.228,1,-2.59,-3.54,-1.64,-3.54,-1.64,2.9534000000000047,0.295,0.335,0.5,0.0654,0.638,1,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-8.5,L
CHEMBL589583,DELAPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,,3.0,,0,0,pathway_drug_candidates,5.0,0.553,0.0934,0.0,0.363,0.222,0.5,0.471,0.124,0.0,0.23,0.238,0.5,0.441,0.068,0.0,0.77,0.0421,0,0.876,0.0121,0.0,0.549,0.0905,0,-2.97,-3.67,-2.27,-3.67,-2.27,2.6096000000000004,0.452,0.131,0.0,0.0845,0.575,1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,2.5,L
CHEMBL591501,PF-03049423,CCCOCCn1c(=O)c(N2CCN(CCO)CC2)nc2cnc(-c3ccc(OC)nc3)cc21,,0,0,R-HSA-418457|cGMP effects;R-HSA-445355|Smooth Muscle Contraction;R-HSA-9013422|RHOBTB1 GTPase cycle,3,0,,2.0,Terminated,0,0,pathway_drug_candidates,2.0,0.17,0.348,1.0,0.612,0.0993,0.0,0.291,0.223,0.5,0.963,0.00442,0.0,0.756,0.0172,0.0,0.87,0.0232,0,0.357,0.113,0.0,0.507,0.105,0,-2.5,-2.93,-2.08,-2.93,-2.08,1.4030000000000005,0.282,0.365,0.5,0.168,0.318,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,1.0,1.0,-2.5,L
CHEMBL592,LEVORPHANOL,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,0.5,"Active, not recruiting",0,0,pathway_drug_candidates,2.0,0.717,0.0424,0.0,0.0516,0.608,1.0,0.631,0.0581,0.0,0.536,0.0801,0.0,0.424,0.0693,0.0,0.512,0.103,0,0.844,0.0171,0.0,0.9,0.0352,0,-2.8,-3.42,-2.18,-3.42,-2.18,3.080400000000002,0.505,0.156,0.0,0.123,0.479,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,L
CHEMBL594,EMEDASTINE,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.215,0.295,0.5,0.168,0.352,1.0,0.551,0.0893,0.0,0.186,0.281,1.0,0.319,0.124,0.0,0.0256,0.587,1,0.776,0.0208,0.0,0.0875,0.199,1,-2.04,-3.0,-1.08,-3.0,-1.08,2.2146999999999997,0.209,0.443,1.0,0.219,0.206,0.5,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.5,3.0,1.0,1.0,-6.0,L
CHEMBL596,FENTANYL,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,OPRM1,1,1,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,9.5,0.946,0.00883,0.0,0.101,0.461,1.0,0.697,0.0466,0.0,0.723,0.0313,0.0,0.442,0.0688,0.0,0.00828,0.792,1,0.995,0.00037,0.0,0.0243,0.38,1,-4.02,-5.27,-2.77,-5.27,-2.77,4.136700000000004,0.229,0.412,1.0,0.0529,0.786,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,2.5,L
CHEMBL597,PHENTOLAMINE,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.508,0.111,0.0,0.00455,0.883,1.0,0.514,0.101,0.0,0.0928,0.513,1.0,0.377,0.1,0.0,0.349,0.168,0,0.14,0.242,1.0,0.0509,0.262,1,-2.43,-3.39,-1.47,-3.39,-1.47,2.840420000000001,0.455,0.124,0.0,0.0863,0.55,1,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-1.5,L
CHEMBL599,MELOXICAM,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.233,0.273,0.5,0.195,0.312,1.0,0.0831,0.542,1.0,0.373,0.135,0.0,0.531,0.045,0.0,0.205,0.241,1,0.44,0.0749,0.0,0.613,0.057,0,-2.23,-3.25,-1.21,-3.25,-1.21,1.95092,0.552,0.0927,0.0,0.385,0.0364,0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,3.0,1.0,1.0,-0.5,L
CHEMBL6,INDOMETHACIN,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,11.5,0.538,0.0894,0.0,0.497,0.127,0.0,0.417,0.136,0.0,0.709,0.0431,0.0,0.0992,0.363,1.0,0.776,0.0423,0,0.805,0.0227,0.0,0.465,0.115,0,-4.74,-5.4,-4.08,-5.4,-4.08,3.9273200000000026,0.577,0.072,0.0,0.104,0.445,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,9.0,H
CHEMBL603,ZAFIRLUKAST,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,,0,0,R-HSA-416476|G alpha (q) signalling events;R-HSA-9679191|Potential therapeutics for SARS,2,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.278,0.241,0.5,0.0131,0.813,1.0,0.618,0.0695,0.0,0.621,0.0646,0.0,0.157,0.276,1.0,0.739,0.0483,0,0.64,0.0481,0.0,0.502,0.106,0,-5.7,-6.22,-5.17,-6.22,-5.17,5.695920000000005,0.108,0.704,1.0,0.153,0.349,1,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-3.0,L
CHEMBL603469,LESTAURTINIB,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,,0,0,"R-HSA-1059683|Interleukin-6 signaling;R-HSA-110056|MAPK3 (ERK1) activation;R-HSA-112411|MAPK1 (ERK2) activation;R-HSA-1170546|Prolactin receptor signaling;R-HSA-1433557|Signaling by SCF-KIT;R-HSA-2586552|Signaling by Leptin;R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling;R-HSA-5673000|RAF activation;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6788467|IL-6-type cytokine receptor ligand interactions;R-HSA-6802946|Signaling by moderate kinase activity BRAF mutants;R-HSA-8854691|Interleukin-20 family signaling;R-HSA-8984722|Interleukin-35 Signalling;R-HSA-9020591|Interleukin-12 signaling;R-HSA-9020933|Interleukin-23 signaling;R-HSA-9020956|Interleukin-27 signaling;R-HSA-9674555|Signaling by CSF3 (G-CSF);R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9705462|Inactivation of CSF3 (G-CSF) signaling;RMTs methylate histone arginines",21,9,,3.0,"Active, not recruiting",0,0,pathway_drug_candidates,13.0,0.412,0.146,0.0,0.216,0.319,0.5,0.27,0.226,0.5,0.121,0.438,1.0,0.113,0.327,1.0,0.162,0.267,1,0.0898,0.385,1.0,0.237,0.168,0,-4.77,-5.44,-4.1,-5.44,-4.1,3.474400000000002,0.996,0.0064,0.0,0.225,0.197,0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,0.0,1.0,0.5,L
CHEMBL605525,DP001,C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@H]1O,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.722,0.0404,0.0,0.617,0.0944,0.0,0.284,0.226,0.5,0.583,0.0761,0.0,0.577,0.044,0.0,0.661,0.0637,0,0.47,0.0782,0.0,0.164,0.19,1,-3.71,-4.17,-3.26,-4.17,-3.26,5.704700000000007,0.336,0.3,0.5,0.141,0.464,1,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,-2.0,L
CHEMBL6067484,GENTAMICIN SULFATE,,,0,0,,0,0,Bacterial 70S ribosome inhibitor,,,0,0,mechanism_drug_candidate,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,0.0,L
CHEMBL6067972,VARENICLINE TARTRATE,O=C(O)[C@H](O)[C@@H](O)C(=O)O.c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1,,0,0,,0,0,Neuronal acetylcholine receptor; alpha4/beta2 agonist,,,0,0,mechanism_drug_candidate,0.0,0.838,0.022,0.0,0.113,0.463,1.0,0.758,0.0371,0.0,0.96,0.00329,0.0,0.364,0.09,0.0,0.711,0.05,0,0.273,0.163,0.0,0.581,0.0855,0,0.569,-1.09,2.23,-1.09,2.14,-0.3187000000000002,0.695,0.0467,0.0,0.241,0.143,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-2.0,L
CHEMBL6067995,BEROTRALSTAT HYDROCHLORIDE,Cl.Cl.N#Cc1cccc([C@@H](NCC2CC2)c2ccc(F)c(NC(=O)c3cc(C(F)(F)F)nn3-c3cccc(CN)c3)c2)c1,,0,0,,0,0,Plasma kallikrein inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.661,0.0534,0.0,0.821,0.0389,0.0,0.226,0.287,0.5,0.18,0.314,1.0,0.361,0.0981,0.0,0.16,0.276,1,0.468,0.0728,0.0,0.0404,0.29,1,-3.39,-3.87,-2.9,-3.87,-2.9,6.545480000000005,0.182,0.588,1.0,0.022,0.999,1,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-8.5,L
CHEMBL6068334,SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE,Cl.N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O,,0,0,,0,0,Dipeptidyl peptidase IV inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.348,0.178,0.0,0.187,0.348,1.0,0.0106,0.93,1.0,0.525,0.0874,0.0,0.449,0.0714,0.0,0.73,0.0489,0,0.33,0.095,0.0,0.254,0.148,0,-1.01,-1.78,-0.238,-1.78,-0.238,1.6136,0.326,0.26,0.5,0.00848,0.97,1,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-2.0,L
CHEMBL6068336,MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE,Cl.Cl.N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1.O,,0,0,,0,0,Tyrosine-protein kinase JAK1 inhibitor | Tyrosine-protein kinase JAK2 inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.938,0.00706,0.0,0.909,0.0168,0.0,0.329,0.2,0.5,0.912,0.0105,0.0,0.0996,0.403,1.0,0.717,0.0526,0,0.273,0.143,0.0,0.793,0.0357,0,-4.23,-5.54,-2.93,-5.54,-2.93,2.996080000000001,0.241,0.49,1.0,0.0229,0.995,1,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,0.0,1.0,-2.5,L
CHEMBL6068339,IRBESARTAN HYDROCHLORIDE,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1.Cl,,0,0,,0,0,Type-1 angiotensin II receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.596,0.0713,0.0,0.922,0.0136,0.0,0.887,0.01,0.0,0.854,0.0209,0.0,0.433,0.0678,0.0,0.49,0.11,0,0.97,0.00558,0.0,0.887,0.0236,0,-3.76,-5.18,-2.35,-5.18,-2.35,5.199200000000005,0.888,0.0125,0.0,0.0193,0.974,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-2.0,L
CHEMBL607,MEPERIDINE,CCOC(=O)C1(c2ccccc2)CCN(C)CC1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.584,0.0752,0.0,0.278,0.259,0.5,0.723,0.0426,0.0,0.225,0.271,0.5,0.243,0.175,0.5,0.919,0.0135,0,0.844,0.0138,0.0,0.156,0.176,1,-1.96,-2.67,-1.26,-2.67,-1.26,2.2131,0.279,0.331,0.5,0.0599,0.785,1,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,2.0,L
CHEMBL608533,MIDOSTAURIN,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,,0,0,R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.102,0.475,1.0,0.116,0.45,1.0,0.66,0.0565,0.0,0.0233,0.854,1.0,0.0755,0.452,1.0,0.476,0.112,0,0.303,0.114,0.0,0.17,0.194,1,-5.99,-6.66,-5.31,-6.66,-5.31,5.906800000000007,0.788,0.0272,0.0,0.11,0.529,1,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-6.5,L
CHEMBL61006,PHENYLPROPANOLAMINE,CC(N)C(O)c1ccccc1,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.423,0.137,0.0,0.358,0.199,0.0,0.422,0.135,0.0,0.439,0.106,0.0,0.126,0.28,1.0,0.177,0.254,1,0.582,0.0533,0.0,0.89,0.014,0,-0.789,-1.43,-0.143,-1.43,-0.143,1.0672,0.677,0.0409,0.0,0.462,0.0342,0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,-2.0,L
CHEMBL611,TERAZOSIN,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0714,0.559,1.0,0.416,0.172,0.0,0.409,0.147,0.0,0.708,0.0434,0.0,0.537,0.053,0.0,0.782,0.0434,0,0.224,0.173,0.0,0.821,0.0332,0,-2.09,-3.14,-1.03,-3.14,-1.03,1.0567999999999995,0.255,0.393,0.5,0.158,0.306,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.5,L
CHEMBL622,ETODOLAC,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.696,0.0448,0.0,0.436,0.158,0.0,0.428,0.128,0.0,0.198,0.295,1.0,0.529,0.0499,0.0,0.688,0.058,0,0.556,0.0568,0.0,0.671,0.082,0,-3.18,-3.83,-2.54,-3.83,-2.54,3.383000000000002,0.708,0.0487,0.0,0.0973,0.549,1,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,8.0,H
CHEMBL625,THIABENDAZOLE,c1ccc2[nH]c(-c3cscn3)nc2c1,,0,0,,0,0,Tubulin inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.108,0.447,1.0,0.121,0.45,1.0,0.42,0.144,0.0,0.0701,0.601,1.0,0.0627,0.458,1.0,0.682,0.0604,0,0.197,0.202,0.5,0.194,0.169,0,-3.73,-4.35,-3.1,-4.35,-3.1,2.6864,0.852,0.0245,0.0,0.353,0.0724,0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,4.0,1.0,1.0,-8.5,L
CHEMBL628,PENTOXIFYLLINE,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418457|cGMP effects;R-HSA-418555|G alpha (s) signalling events;R-HSA-445355|Smooth Muscle Contraction;R-HSA-9013422|RHOBTB1 GTPase cycle;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",6,0,"3',5'-cyclic phosphodiesterase inhibitor",4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.533,0.101,0.0,0.795,0.0468,0.0,0.759,0.0354,0.0,0.87,0.0118,0.0,0.0545,0.497,1.0,0.784,0.0336,0,0.887,0.0111,0.0,0.0322,0.358,1,-0.403,-1.02,0.214,-1.02,0.214,0.193,0.591,0.071,0.0,0.0629,0.814,1,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.5,L
CHEMBL63,ROLIPRAM,COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1,,0,0,"R-HSA-180024|DARPP-32 events;R-HSA-418555|G alpha (s) signalling events;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3,0,,2.0,Completed,0,0,pathway_drug_candidates,2.0,0.692,0.0548,0.0,0.402,0.188,0.0,0.227,0.287,0.5,0.217,0.253,0.5,0.0646,0.438,1.0,0.0134,0.726,1,0.741,0.027,0.0,0.191,0.179,0.5,-2.45,-3.44,-1.46,-3.44,-1.46,2.6201000000000008,0.379,0.256,0.5,0.113,0.439,1,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,-7.5,L
CHEMBL632,BETAMETHASONE,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.33,0.185,0.0,0.492,0.125,0.0,0.423,0.134,0.0,0.454,0.103,0.0,0.638,0.0271,0.0,0.149,0.287,1,0.614,0.0483,0.0,0.174,0.154,0,-4.08,-5.1,-3.06,-5.1,-3.06,1.8957,0.518,0.108,0.0,0.684,0.0135,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,L
CHEMBL635,PREDNISONE,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.73,0.0417,0.0,0.568,0.102,0.0,0.648,0.0571,0.0,0.391,0.131,0.0,0.616,0.0343,0.0,0.396,0.145,0,0.487,0.0622,0.0,0.689,0.0385,0,-3.37,-3.92,-2.82,-3.92,-2.82,1.7658,0.492,0.128,0.0,0.706,0.00838,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,M
CHEMBL639,AZELASTINE,CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.122,0.446,1.0,0.0727,0.531,1.0,0.394,0.135,0.0,0.26,0.202,0.5,0.122,0.31,1.0,0.00547,0.85,1,0.702,0.0422,0.0,0.102,0.231,1,-4.88,-5.53,-4.23,-5.53,-4.23,4.297500000000004,0.49,0.163,0.0,0.169,0.264,1,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-10.5,L
CHEMBL643,PROMETHAZINE,CC(CN1c2ccccc2Sc2ccccc21)N(C)C,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.315,0.205,0.0,0.0429,0.643,1.0,0.275,0.223,0.5,0.215,0.273,0.5,0.171,0.279,0.5,0.214,0.234,1,0.706,0.035,0.0,0.554,0.113,0,-3.75,-5.31,-2.2,-5.31,-2.2,4.239400000000003,0.416,0.224,0.0,0.126,0.461,1,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,4.0,0.0,1.0,-5.0,L
CHEMBL644,TRIMIPRAMINE,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,Unknown status,0,0,pathway_drug_candidates,4.0,0.154,0.36,1.0,0.0845,0.504,1.0,0.353,0.175,0.0,0.354,0.15,0.0,0.39,0.0863,0.0,0.54,0.102,0,0.218,0.168,0.0,0.463,0.0905,0,-4.4,-5.54,-3.26,-5.54,-3.26,4.121000000000003,0.236,0.459,1.0,0.0835,0.701,1,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,-1.0,L
CHEMBL646,TRIAZOLAM,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.237,0.268,0.5,0.446,0.165,0.0,0.458,0.111,0.0,0.2,0.291,0.5,0.0386,0.564,1.0,0.178,0.261,1,0.662,0.0346,0.0,0.169,0.158,{},-3.91,-4.84,-2.98,-4.84,-2.98,4.233520000000002,0.0763,0.835,1.0,0.0727,0.693,1,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-9.5,L
CHEMBL647,APRACLONIDINE,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.342,0.182,0.0,0.167,0.38,1.0,0.577,0.0794,0.0,0.513,0.0821,0.0,0.208,0.202,0.5,0.46,0.12,0,0.0951,0.353,1.0,0.463,0.128,0,-2.34,-3.13,-1.55,-3.13,-1.55,1.7558999999999998,0.543,0.0984,0.0,0.212,0.18,0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,0.0,1.0,-0.5,L
CHEMBL648,CYCLIZINE,CN1CCN(C(c2ccccc2)c2ccccc2)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.281,0.23,0.5,0.0147,0.77,1.0,0.673,0.0509,0.0,0.696,0.0418,0.0,0.76,0.016,0.0,0.378,0.149,0,0.593,0.0494,0.0,0.076,0.274,1,-2.07,-3.17,-0.975,-3.17,-0.975,3.0234000000000014,0.667,0.075,0.0,0.101,0.569,1,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-2.0,L
CHEMBL650,METHYLPREDNISOLONE,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,1,1,known_drugs;protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.588,0.0726,0.0,0.454,0.152,0.0,0.42,0.135,0.0,0.557,0.0765,0.0,0.457,0.0625,0.0,0.19,0.252,1,0.661,0.0422,0.0,0.0268,0.439,1,-3.39,-4.02,-2.75,-4.02,-2.75,1.8036,0.479,0.13,0.0,0.0833,0.613,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,2.0,L
CHEMBL651,METHADONE,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.0773,0.473,1.0,0.0638,0.575,1.0,0.189,0.318,1.0,0.0633,0.599,1.0,0.219,0.185,0.5,0.0816,0.372,1,0.87,0.0135,0.0,0.801,0.0515,0,-2.13,-2.86,-1.4,-2.86,-1.4,4.292000000000004,0.269,0.407,0.5,0.0438,0.909,1,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,5.0,1.0,1.0,-6.0,L
CHEMBL654,MIRTAZAPINE,CN1CCN2c3ncccc3Cc3ccccc3C2C1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,Serotonin 2a (5-HT2a) receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.423,0.149,0.0,0.0332,0.678,1.0,0.0593,0.617,1.0,0.088,0.525,1.0,0.272,0.147,0.0,0.282,0.192,0,0.748,0.0294,0.0,0.36,0.137,0,-2.88,-3.79,-1.97,-3.79,-1.97,2.4789000000000003,0.281,0.33,0.5,0.143,0.403,1,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,0.5,L
CHEMBL655,MIDAZOLAM,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.294,0.211,0.5,0.192,0.361,1.0,0.377,0.155,0.0,0.524,0.0857,0.0,0.0416,0.579,1.0,0.0363,0.534,1,0.226,0.175,0.0,0.043,0.396,1,-5.32,-5.97,-4.66,-5.97,-4.66,4.324220000000002,0.245,0.411,1.0,0.0631,0.867,1,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,1.0,1.0,-12.0,L
CHEMBL656,OXYCODONE,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.387,0.149,0.0,0.131,0.449,1.0,0.591,0.0729,0.0,0.319,0.164,0.0,0.487,0.0518,0.0,0.0715,0.393,1,0.721,0.0325,0.0,0.548,0.0794,0,-1.61,-2.14,-1.07,-2.14,-1.07,1.0481999999999998,0.279,0.341,0.5,0.0559,0.723,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,L
CHEMBL657,DIPHENHYDRAMINE,CN(C)CCOC(c1ccccc1)c1ccccc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.638,0.0617,0.0,0.0186,0.747,1.0,0.438,0.127,0.0,0.0918,0.489,1.0,0.711,0.021,0.0,0.281,0.19,0,0.58,0.0551,0.0,0.92,0.015,0,-2.74,-3.64,-1.84,-3.64,-1.84,3.3542000000000023,0.542,0.0982,0.0,0.0699,0.852,1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,1.0,L
CHEMBL658,SUFENTANIL,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,3.0,Completed,0,0,pathway_drug_candidates,5.0,0.782,0.0358,0.0,0.0531,0.558,1.0,0.899,0.00516,0.0,0.794,0.0261,0.0,0.132,0.273,1.0,0.0608,0.425,1,0.976,0.00374,0.0,0.0253,0.39,1,-3.51,-4.27,-2.76,-4.27,-2.76,4.214800000000004,0.068,0.802,1.0,0.0301,0.884,1,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-2.5,L
CHEMBL660,AMANTADINE,NC12CC3CC(CC(C3)C1)C2,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,4.0,,1,0,known_drugs;pathway_drug_candidates,5.5,0.343,0.178,0.0,0.36,0.206,0.5,0.421,0.134,0.0,0.457,0.101,0.0,0.52,0.0483,0.0,0.343,0.17,0,0.653,0.04,0.0,0.81,0.0295,0,-2.03,-2.94,-1.12,-2.94,-1.12,1.9139,0.363,0.275,0.5,0.277,0.106,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,5.0,L
CHEMBL661,ALPRAZOLAM,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.381,0.162,0.0,0.18,0.356,1.0,0.529,0.0843,0.0,0.222,0.259,0.5,0.0117,0.747,1.0,0.183,0.256,1,0.764,0.025,0.0,0.268,0.139,0,-3.89,-4.85,-2.94,-4.85,-2.94,3.5801200000000017,0.0551,0.842,1.0,0.0603,0.717,1,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-7.5,L
CHEMBL6622,ISOSORBIDE DINITRATE,O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-],,0,0,R-HSA-445355|Smooth Muscle Contraction,1,0,Soluble guanylate cyclase activator,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.546,0.0888,0.0,0.363,0.22,0.5,0.987,0.00284,0.0,0.46,0.103,0.0,0.422,0.0801,0.0,0.134,0.301,1,0.585,0.0555,0.0,0.794,0.0363,0,-2.49,-3.21,-1.77,-3.21,-1.77,-1.0622000000000005,0.507,0.135,0.0,0.302,0.105,0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-3.5,L
CHEMBL679,EPINEPHRINE,CNC[C@H](O)c1ccc(O)c(O)c1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.428,0.13,0.0,0.794,0.0451,0.0,0.562,0.0743,0.0,0.847,0.0185,0.0,0.611,0.0355,0.0,0.743,0.0496,0,0.345,0.101,0.0,0.11,0.191,1,-0.777,-1.74,0.184,-1.74,0.184,0.3506000000000001,0.699,0.0365,0.0,0.823,0.00491,0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,2.5,L
CHEMBL685,MEBENDAZOLE,COC(=O)Nc1nc2cc(C(=O)c3ccccc3)ccc2[nH]1,,0,0,,0,0,Tubulin inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.86,0.0193,0.0,0.36,0.207,0.5,0.366,0.189,0.0,0.106,0.457,1.0,0.0358,0.584,1.0,0.845,0.0235,0,0.0704,0.451,1.0,0.643,0.0733,0,-4.21,-5.63,-2.79,-5.63,-2.79,2.972200000000001,0.255,0.385,0.5,0.0868,0.531,1,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,-7.0,L
CHEMBL686,MEFENAMIC ACID,Cc1cccc(Nc2ccccc2C(=O)O)c1C,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.241,0.249,0.5,0.623,0.089,0.0,0.059,0.604,1.0,0.693,0.0408,0.0,0.0638,0.44,1.0,0.881,0.0214,0,0.245,0.129,0.0,0.413,0.123,0,-4.22,-4.92,-3.52,-4.92,-3.52,3.7452400000000017,0.695,0.0358,0.0,0.693,0.00825,0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,1.0,1.0,2.5,L
CHEMBL688,FENTANYL CITRATE,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,Mu opioid receptor agonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,6.0,0.995,0.0005,0.0,0.13,0.401,1.0,0.843,0.0145,0.0,0.958,0.00366,0.0,0.712,0.0197,0.0,0.00035,0.987,1,0.995,0.000653,0.0,0.187,0.164,0,-3.65,-5.0,-2.3,-5.0,-2.3,2.8882000000000003,0.845,0.00861,0.0,0.0822,0.544,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-0.5,L
CHEMBL690,PRAVASTATIN SODIUM,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21.[Na+],,0,0,R-HSA-191273|Cholesterol biosynthesis;R-HSA-1989781|PPARA activates gene expression;R-HSA-2426168|Activation of gene expression by SREBF (SREBP);R-HSA-9619665|EGR2 and SOX10-mediated initiation of Schwann cell myelination,4,0,HMG-CoA reductase inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.412,0.143,0.0,0.982,0.00761,0.0,0.177,0.336,1.0,0.793,0.0237,0.0,0.929,0.00329,0.0,0.812,0.0355,0,0.676,0.0336,0.0,0.794,0.029,0,-1.03,-1.6,-0.46,-1.6,-0.46,-1.8902999999999948,0.736,0.0288,0.0,0.591,0.0205,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,2.0,L
CHEMBL70,MORPHINE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,Completed,0,0,pathway_drug_candidates,6.0,0.785,0.0272,0.0,0.215,0.308,0.5,0.0716,0.591,1.0,0.333,0.159,0.0,0.483,0.0495,0.0,0.0513,0.467,1,0.597,0.0434,0.0,0.949,0.00243,0,-2.02,-3.52,-0.521,-3.52,-0.521,1.1981,0.373,0.212,0.0,0.104,0.465,1,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-1.5,L
CHEMBL704,MESALAMINE,Nc1ccc(O)c(C(=O)O)c1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.925,0.0085,0.0,0.554,0.134,0.0,0.53,0.097,0.0,0.0939,0.503,1.0,0.512,0.0492,0.0,0.803,0.0364,0,0.555,0.0573,0.0,0.554,0.113,0,-2.06,-3.08,-1.05,-3.08,-1.05,0.6726000000000001,0.918,0.0142,0.0,0.468,0.0523,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,8.0,H
CHEMBL70418,CLOBAZAM,CN1C(=O)CC(=O)N(c2ccccc2)c2cc(Cl)ccc21,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.795,0.0299,0.0,0.247,0.293,0.5,0.362,0.17,0.0,0.155,0.385,1.0,0.0337,0.627,1.0,0.367,0.149,0,0.956,0.00714,0.0,0.0911,0.269,1,-2.84,-3.57,-2.11,-3.57,-2.11,3.3712000000000018,0.114,0.716,1.0,0.0703,0.755,1,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-3.5,L
CHEMBL705,ALITRETINOIN,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,,0,0,R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-5362517|Signaling by Retinoic Acid;R-HSA-5617472|Activation of anterior HOX genes in hindbrain development during early embryogenesis,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.874,0.0142,0.0,0.417,0.182,0.0,0.794,0.0287,0.0,0.596,0.0565,0.0,0.464,0.0606,0.0,0.305,0.178,0,0.249,0.155,0.0,0.659,0.0625,0,-4.41,-5.78,-3.04,-5.78,-3.04,5.602600000000005,0.523,0.0987,0.0,0.451,0.0348,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.5,L
CHEMBL707,DOXAZOSIN,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,Unknown status,0,0,pathway_drug_candidates,4.0,0.0412,0.634,1.0,0.202,0.328,0.5,0.24,0.275,0.5,0.304,0.18,0.0,0.417,0.0778,0.0,0.514,0.108,0,0.157,0.27,1.0,0.706,0.0439,0,-4.35,-5.6,-3.1,-5.6,-3.1,1.717799999999999,0.0541,0.802,1.0,0.0852,0.555,1,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,3.0,1.0,1.0,-3.5,L
CHEMBL709,ALFUZOSIN,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.425,0.138,0.0,0.0813,0.545,1.0,0.839,0.0158,0.0,0.765,0.0367,0.0,0.433,0.0752,0.0,0.95,0.00967,0,0.275,0.112,0.0,0.905,0.012,0,-2.61,-3.66,-1.57,-3.66,-1.57,1.3507000000000002,0.297,0.261,0.5,0.153,0.324,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,2.5,L
CHEMBL71,CHLORPROMAZINE,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,,0,0,,0,0,D2-like dopamine receptor antagonist;D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist;Serotonin 2a (5-HT2a) receptor antagonist,,,1,1,known_drugs;mechanism_drug_candidate;mechanism_of_actions,1.5,0.536,0.0942,0.0,0.00721,0.84,1.0,0.792,0.0251,0.0,0.0878,0.53,1.0,0.0419,0.592,1.0,0.0303,0.565,1,0.517,0.0577,0.0,0.0354,0.446,1,-5.33,-6.08,-4.57,-6.08,-4.57,4.894400000000004,0.127,0.658,1.0,0.0791,0.778,1,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,3.0,0.0,1.0,-9.5,L
CHEMBL715,OLANZAPINE,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,,0,0,,0,0,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.442,0.139,0.0,0.139,0.413,1.0,0.529,0.105,0.0,0.51,0.0889,0.0,0.399,0.0877,0.0,0.458,0.109,0,0.685,0.0334,0.0,0.0212,0.443,1,-2.84,-3.56,-2.12,-3.56,-2.12,3.4392200000000033,0.51,0.128,0.0,0.126,0.439,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,-3.0,L
CHEMBL723,CARVEDILOL,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0558,0.598,1.0,0.0738,0.509,1.0,0.719,0.0424,0.0,0.148,0.358,1.0,0.055,0.551,1.0,0.00453,0.873,1,0.711,0.0326,0.0,0.899,0.00468,0,-4.23,-4.89,-3.57,-4.89,-3.57,3.738000000000002,0.00993,0.987,1.0,0.221,0.175,0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,1.0,1.0,-8.0,L
CHEMBL729,LOPINAVIR,Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,,0,0,,0,0,Human immunodeficiency virus type 1 protease inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.144,0.34,1.0,0.0333,0.69,1.0,0.0238,0.796,1.0,0.179,0.295,1.0,0.554,0.0381,0.0,0.0113,0.733,1,0.99,0.000941,0.0,0.587,0.0716,0,-5.34,-5.92,-4.76,-5.92,-4.76,4.328140000000003,0.114,0.714,1.0,0.17,0.27,1,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,4.0,1.0,1.0,-12.0,L
CHEMBL730,NITROGLYCERIN,O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],,0,0,R-HSA-445355|Smooth Muscle Contraction,1,0,Soluble guanylate cyclase activator,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.39,0.165,0.0,0.338,0.23,0.5,0.336,0.19,0.0,0.0447,0.73,1.0,0.458,0.0664,0.0,0.0522,0.44,1,0.342,0.107,0.0,0.664,0.0385,0,-2.26,-2.91,-1.61,-2.91,-1.61,-1.0200999999999996,0.492,0.115,0.0,0.279,0.0934,0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,-4.5,L
CHEMBL73451,MEQUITAZINE,c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.418,0.161,0.0,0.0321,0.689,1.0,0.42,0.136,0.0,0.458,0.102,0.0,0.438,0.0722,0.0,0.00455,0.874,1,0.587,0.0518,0.0,0.0381,0.41,1,-4.83,-6.81,-2.85,-6.81,-2.85,4.631100000000005,0.357,0.263,0.5,0.374,0.0587,0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,-6.5,L
CHEMBL738,THIOPENTAL SODIUM,CCCC(C)C1(CC)C(=O)[N-]C(=S)NC1=O.[Na+],,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.118,0.418,1.0,0.97,0.00891,0.0,0.15,0.379,1.0,0.22,0.254,0.5,0.728,0.0241,0.0,0.664,0.0716,0,0.497,0.0599,0.0,0.843,0.0434,0,-2.7,-3.27,-2.12,-3.27,-2.12,-0.8619999999999983,0.257,0.433,0.5,0.59,0.0226,0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,3.0,1.0,1.0,-6.5,L
CHEMBL742,KETAMINE,CNC1(c2ccccc2Cl)CCCCC1=O,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,3.0,"Active, not recruiting",0,0,pathway_drug_candidates,3.0,0.375,0.173,0.0,0.343,0.211,0.5,0.288,0.207,0.5,0.329,0.162,0.0,0.367,0.0976,0.0,0.311,0.181,0,0.654,0.042,0.0,0.789,0.0319,0,-0.906,-1.74,-0.0712,-1.74,-0.0712,2.897800000000001,0.3,0.319,0.5,0.118,0.439,1,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,1.0,L
CHEMBL753,PHENOXYBENZAMINE,CC(COc1ccccc1)N(CCCl)Cc1ccccc1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.519,0.109,0.0,0.102,0.468,1.0,0.619,0.0647,0.0,0.229,0.272,0.5,0.289,0.134,0.0,0.537,0.106,0,0.0672,0.495,1.0,0.586,0.0666,0,-4.28,-4.81,-3.74,-4.81,-3.74,4.194900000000003,0.246,0.445,1.0,0.697,0.0124,0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,-1.0,L
CHEMBL75435,DEXKETOPROFEN,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.85,0.0201,0.0,0.49,0.147,0.0,0.238,0.252,0.5,0.0424,0.688,1.0,0.281,0.138,0.0,0.893,0.0198,0,0.872,0.0119,0.0,0.876,0.0234,0,-3.4,-4.1,-2.7,-4.1,-2.7,3.1057000000000015,0.87,0.00885,0.0,0.0945,0.47,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,7.0,M
CHEMBL761,NAPHAZOLINE,c1ccc2c(CC3=NCCN3)cccc2c1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.461,0.121,0.0,0.271,0.271,0.5,0.536,0.0914,0.0,0.454,0.104,0.0,0.433,0.0732,0.0,0.428,0.133,0,0.143,0.295,1.0,0.284,0.155,0,-2.94,-3.71,-2.16,-3.71,-2.16,2.3840000000000003,0.539,0.122,0.0,0.245,0.127,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.5,L
CHEMBL762,OXYMETAZOLINE,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",8,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.541,0.0931,0.0,0.257,0.275,0.5,0.689,0.0573,0.0,0.487,0.0957,0.0,0.395,0.0869,0.0,0.424,0.134,0,0.799,0.0227,0.0,0.0351,0.436,1,-3.37,-4.19,-2.55,-4.19,-2.55,2.850740000000001,0.495,0.133,0.0,0.266,0.123,0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.5,L
CHEMBL76222,REBIMASTAT,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C,,0,0,R-HSA-1442490|Collagen degradation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases;R-HSA-210991|Basigin interactions;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs);R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-6798695|Neutrophil degranulation,7,1,,2.0,Completed,0,0,pathway_drug_candidates,4.0,0.115,0.447,1.0,0.884,0.0206,0.0,0.217,0.309,0.5,0.286,0.183,0.0,0.927,0.00461,0.0,0.355,0.166,0,0.596,0.0435,0.0,0.547,0.107,0,-0.768,-1.59,0.0493,-1.59,0.0493,1.155300000000002,0.298,0.318,0.5,0.245,0.171,0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,2.0,1.0,1.0,0.0,L
CHEMBL770,TOLAZOLINE,c1ccc(CC2=NCCN2)cc1,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-416476|G alpha (q) signalling events;R-HSA-418555|G alpha (s) signalling events;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (12/13) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",9,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.616,0.0724,0.0,0.0402,0.638,1.0,0.424,0.131,0.0,0.503,0.0915,0.0,0.38,0.0933,0.0,0.248,0.208,0,0.939,0.0132,0.0,0.444,0.116,0,-2.11,-2.87,-1.34,-2.87,-1.34,1.2308,0.74,0.0401,0.0,0.231,0.187,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,2.5,L
CHEMBL778,DEXMEDETOMIDINE,Cc1cccc([C@H](C)c2c[nH]cn2)c1C,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,3.0,Recruiting,0,0,pathway_drug_candidates,3.0,0.0752,0.538,1.0,0.112,0.47,1.0,0.0729,0.607,1.0,0.02,0.86,1.0,0.0619,0.44,1.0,0.695,0.0581,0,0.115,0.307,1.0,0.182,0.179,0.5,-3.75,-4.61,-2.89,-4.61,-2.89,3.1783400000000013,0.419,0.189,0.0,0.113,0.423,1,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,5.0,1.0,1.0,-7.0,L
CHEMBL779,TADALAFIL,CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O,,0,0,R-HSA-418457|cGMP effects;R-HSA-445355|Smooth Muscle Contraction;R-HSA-9013422|RHOBTB1 GTPase cycle,3,0,Phosphodiesterase 5A inhibitor,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.0277,0.688,1.0,0.0641,0.559,1.0,0.255,0.257,0.5,0.0155,0.881,1.0,0.547,0.0396,0.0,0.134,0.3,1,0.76,0.0271,0.0,0.62,0.0849,0,-3.57,-4.53,-2.6,-4.53,-2.6,2.2112999999999996,0.245,0.389,1.0,0.19,0.202,1,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,4.0,1.0,1.0,-6.0,L
CHEMBL787,MONTELUKAST,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,,0,0,R-HSA-416476|G alpha (q) signalling events;R-HSA-9679191|Potential therapeutics for SARS,2,0,,4.0,Unknown status,1,0,known_drugs;pathway_drug_candidates,5.5,0.868,0.0152,0.0,0.829,0.0457,0.0,0.815,0.0208,0.0,0.381,0.142,0.0,0.0328,0.643,1.0,0.619,0.0784,0,0.364,0.0884,0.0,0.435,0.127,0,-7.32,-7.7,-6.94,-7.7,-6.94,8.948000000000002,0.356,0.262,0.5,0.109,0.472,1,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,2.0,L
CHEMBL80,NALOXONE,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.56,0.0834,0.0,0.0978,0.481,1.0,0.602,0.0712,0.0,0.571,0.0667,0.0,0.518,0.0516,0.0,0.247,0.213,0,0.776,0.0259,0.0,0.852,0.0308,0,-3.15,-4.21,-2.09,-4.21,-2.09,1.3014,0.225,0.433,1.0,0.0666,0.748,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,6.0,L
CHEMBL803,CYTARABINE,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,,0,0,,0,0,RNA inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.762,0.0333,0.0,0.741,0.0552,0.0,0.356,0.187,0.0,0.712,0.0411,0.0,0.874,0.00461,0.0,0.823,0.0269,0,0.597,0.053,0.0,0.734,0.0406,0,-1.64,-2.58,-0.693,-2.58,-0.693,-2.563,0.966,0.0011,0.0,0.118,0.505,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,-1.0,L
CHEMBL806,FLUTAMIDE,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,,0,0,R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Androgen Receptor antagonist,4.0,,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.528,0.104,0.0,0.359,0.206,0.5,0.328,0.192,0.0,0.0668,0.63,1.0,0.0251,0.658,1.0,0.925,0.0155,0,0.43,0.0831,0.0,0.163,0.181,1,-2.97,-3.64,-2.3,-3.64,-2.3,3.2081000000000017,0.244,0.408,1.0,0.464,0.037,0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,0.0,1.0,0.5,L
CHEMBL807,MEMANTINE,CC12CC3CC(C)(C1)CC(N)(C3)C2,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",9,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.326,0.193,0.0,0.24,0.305,0.5,0.499,0.107,0.0,0.464,0.103,0.0,0.438,0.071,0.0,0.159,0.271,1,0.696,0.0404,0.0,0.553,0.0981,0,-1.77,-3.05,-0.49,-3.05,-0.49,2.6941000000000006,0.428,0.191,0.0,0.144,0.431,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-2.0,L
CHEMBL811,BROMPHENIRAMINE,CN(C)CCC(c1ccc(Br)cc1)c1ccccn1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.762,0.0305,0.0,0.0529,0.589,1.0,0.758,0.0431,0.0,0.554,0.0847,0.0,0.419,0.0771,0.0,0.342,0.167,0,0.879,0.0127,0.0,0.774,0.0377,0,-2.67,-3.76,-1.57,-3.76,-1.57,3.9277000000000024,0.347,0.275,0.5,0.696,0.0162,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,2.0,L
CHEMBL813,EPROSARTAN,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,,4.0,,1,0,known_drugs;pathway_drug_candidates,5.5,0.931,0.00877,0.0,0.941,0.0128,0.0,0.467,0.114,0.0,0.663,0.0495,0.0,0.825,0.00983,0.0,0.757,0.0428,0,0.95,0.00508,0.0,0.443,0.0867,0,-4.43,-5.24,-3.62,-5.24,-3.62,4.744400000000003,0.555,0.104,0.0,0.0404,0.739,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,3.0,L
CHEMBL814,FLUVOXAMINE,,,0,0,,0,0,,,,1,0,known_drugs,1.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,,0.0,0.0,0.0,1.5,L
CHEMBL82301,VICRIVIROC,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,,0,0,R-HSA-173107|Binding and entry of HIV virion;R-HSA-380108|Chemokine receptors bind chemokines;R-HSA-418594|G alpha (i) signalling events;R-HSA-6783783|Interleukin-10 signaling,4,2,,3.0,Completed,0,0,pathway_drug_candidates,7.0,0.035,0.693,1.0,0.364,0.224,0.5,0.713,0.047,0.0,0.848,0.0188,0.0,0.568,0.053,0.0,0.192,0.247,1,0.855,0.0184,0.0,0.56,0.0805,0,-2.39,-2.92,-1.86,-2.92,-1.86,4.500740000000004,0.154,0.615,1.0,0.238,0.184,0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,2.0,1.0,1.0,-2.5,L
CHEMBL829,METHYLPROMAZINE,CC(CN(C)C)CN1c2ccccc2Sc2ccccc21,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.487,0.105,0.0,0.0171,0.761,1.0,0.458,0.118,0.0,0.348,0.157,0.0,0.383,0.0975,0.0,0.358,0.166,0,0.493,0.0621,0.0,0.054,0.274,1,-4.51,-6.54,-2.49,-6.54,-2.49,4.487000000000004,0.26,0.404,0.5,0.0889,0.599,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,-0.5,L
CHEMBL831,LOXAPINE,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1,,0,0,,0,0,D2-like dopamine receptor antagonist | Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.762,0.0375,0.0,0.0404,0.668,1.0,0.752,0.0427,0.0,0.707,0.0394,0.0,0.0664,0.435,1.0,0.0767,0.377,1,0.474,0.0712,0.0,0.00798,0.686,1,-4.55,-5.22,-3.87,-5.22,-3.87,3.7714000000000025,0.137,0.638,1.0,0.0607,0.745,1,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-9.0,L
CHEMBL833,TICLOPIDINE,Clc1ccccc1CN1CCc2sccc2C1,,0,0,R-HSA-418594|G alpha (i) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.0459,0.61,1.0,0.0236,0.738,1.0,0.0692,0.563,1.0,0.0211,0.84,1.0,0.0574,0.456,1.0,0.747,0.0491,0,0.484,0.0686,0.0,0.496,0.124,0,-3.37,-3.88,-2.86,-3.88,-2.86,3.959800000000002,0.614,0.0751,0.0,0.153,0.4,1,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,5.0,1.0,1.0,-3.0,L
CHEMBL836,TAMSULOSIN,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,,0,0,R-HSA-390696|Adrenoceptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-418597|G alpha (12/13) signalling events,3,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.044,0.629,1.0,0.162,0.382,1.0,0.351,0.185,0.0,0.818,0.0235,0.0,0.569,0.0501,0.0,0.0176,0.673,1,0.816,0.0301,0.0,0.881,0.00844,0,-1.89,-2.49,-1.28,-2.49,-1.28,2.3409000000000004,0.0999,0.8,1.0,0.138,0.455,1,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,2.0,1.0,1.0,-3.5,L
CHEMBL838,BENAZEPRIL,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,,0,0,R-HSA-2022377|Metabolism of Angiotensinogen to Angiotensins,1,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.549,0.0949,0.0,0.521,0.128,0.0,0.164,0.397,1.0,0.191,0.299,1.0,0.286,0.147,0.0,0.952,0.00946,0,0.723,0.0316,0.0,0.594,0.0738,0,-2.96,-3.44,-2.48,-3.44,-2.48,2.5731,0.621,0.0705,0.0,0.0875,0.615,1,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,3.5,L
CHEMBL841,LOPERAMIDE,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,3.0,Completed,0,0,pathway_drug_candidates,5.0,0.338,0.185,0.0,0.0946,0.507,1.0,0.911,0.00584,0.0,0.153,0.361,1.0,0.498,0.0597,0.0,0.00539,0.854,1,0.942,0.00603,0.0,0.0298,0.422,1,-3.04,-3.54,-2.53,-3.54,-2.53,5.088000000000005,0.0773,0.86,1.0,0.377,0.0558,0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,-3.5,L
CHEMBL844,BRIMONIDINE,Brc1c(NC2=NCCN2)ccc2nccnc12,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.628,0.0712,0.0,0.361,0.219,0.5,0.451,0.118,0.0,0.46,0.101,0.0,0.185,0.251,0.5,0.0562,0.444,1,0.0794,0.416,1.0,0.642,0.0508,0,-1.91,-2.69,-1.12,-2.69,-1.12,1.7634,0.661,0.0689,0.0,0.167,0.284,1,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,-5.0,L
CHEMBL846,CALCITRIOL,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,,0,0,R-HSA-196791|Vitamin D (calciferol) metabolism;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors,3,0,Vitamin D receptor agonist,4.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.653,0.0548,0.0,0.695,0.074,0.0,0.312,0.206,0.5,0.694,0.0481,0.0,0.608,0.0363,0.0,0.858,0.0231,0,0.439,0.0906,0.0,0.173,0.197,0.5,-3.84,-4.33,-3.35,-4.33,-3.35,5.704700000000008,0.331,0.332,0.5,0.138,0.534,1,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,L
CHEMBL85,RISPERIDONE,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.62,0.0651,0.0,0.174,0.352,1.0,0.554,0.0884,0.0,0.674,0.0443,0.0,0.522,0.055,0.0,0.0048,0.87,1,0.416,0.0706,0.0,0.578,0.0694,0,-2.29,-3.34,-1.24,-3.34,-1.24,3.5904200000000026,0.207,0.512,1.0,0.0943,0.564,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,-5.5,L
CHEMBL855,TRIPROLIDINE,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.21,0.283,0.5,0.195,0.359,1.0,0.757,0.0354,0.0,0.41,0.117,0.0,0.277,0.155,0.0,0.00522,0.855,1,0.712,0.0335,0.0,0.798,0.0284,0,-1.53,-2.81,-0.242,-2.81,-0.242,3.917520000000003,0.694,0.05,0.0,0.0643,0.79,1,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-5.5,L
CHEMBL856,PRIMIDONE,CCC1(c2ccccc2)C(=O)NCNC1=O,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.169,0.351,1.0,0.14,0.415,1.0,0.183,0.348,1.0,0.101,0.493,1.0,0.436,0.0723,0.0,0.295,0.18,0,0.0721,0.484,1.0,0.373,0.138,0,-2.47,-3.31,-1.63,-3.31,-1.63,0.5378999999999999,0.319,0.319,0.5,0.0968,0.62,1,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,4.0,1.0,1.0,-9.0,L
CHEMBL862,GUANFACINE,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,,0,0,"R-HSA-390696|Adrenoceptors;R-HSA-392023|Adrenaline signalling through Alpha-2 adrenergic receptor;R-HSA-400042|Adrenaline,noradrenaline inhibits insulin secretion;R-HSA-418594|G alpha (i) signalling events;R-HSA-418597|G alpha (z) signalling events;R-HSA-5683826|Surfactant metabolism",6,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.293,0.218,0.5,0.269,0.273,0.5,0.227,0.282,0.5,0.275,0.195,0.0,0.0947,0.39,1.0,0.381,0.156,0,0.235,0.165,0.0,0.446,0.108,0,-3.11,-4.36,-1.86,-4.36,-1.86,1.5455700000000003,0.683,0.0373,0.0,0.285,0.123,0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,4.0,1.0,1.0,-2.5,L
CHEMBL864,CARBINOXAMINE,CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.686,0.0563,0.0,0.109,0.463,1.0,0.949,0.0049,0.0,0.605,0.0634,0.0,0.436,0.0719,0.0,0.84,0.0251,0,0.486,0.0704,0.0,0.905,0.0112,0,-2.03,-2.88,-1.17,-2.88,-1.17,3.4026000000000023,0.384,0.251,0.5,0.103,0.592,1,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,2.0,L
CHEMBL865,VALDECOXIB,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.401,0.155,0.0,0.305,0.237,0.5,0.236,0.256,0.5,0.456,0.102,0.0,0.447,0.0654,0.0,0.21,0.233,1,0.83,0.0177,0.0,0.24,0.124,0,-2.9,-3.67,-2.13,-3.67,-2.13,2.9644200000000005,0.594,0.079,0.0,0.104,0.369,1,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,2.0,0.0,1.0,2.5,L
CHEMBL877,TRANEXAMIC ACID,NC[C@H]1CC[C@H](C(=O)O)CC1,PLG,1,1,R-HSA-114608|Platelet degranulation;R-HSA-1474228|Degradation of the extracellular matrix;R-HSA-1592389|Activation of Matrix Metalloproteinases;R-HSA-381426|Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4,1,Plasminogen inhibitor,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,9.5,0.895,0.0121,0.0,0.583,0.121,0.0,0.691,0.0567,0.0,0.893,0.0127,0.0,0.81,0.0127,0.0,0.912,0.014,0,0.559,0.0556,0.0,0.814,0.0461,0,0.138,-0.623,0.899,-0.623,0.899,0.8361000000000001,0.814,0.021,0.0,0.224,0.186,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,M
CHEMBL895,NALBUPHINE,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,Unknown status,0,0,pathway_drug_candidates,6.0,0.429,0.131,0.0,0.166,0.385,1.0,0.427,0.136,0.0,0.448,0.111,0.0,0.635,0.0316,0.0,0.153,0.281,1,0.579,0.0423,0.0,0.931,0.0148,0,-3.0,-4.81,-1.19,-4.81,-1.19,1.7072999999999998,0.46,0.163,0.0,0.0958,0.543,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-0.5,L
CHEMBL896,HYDROXYZINE,OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.565,0.0777,0.0,0.0268,0.682,1.0,0.767,0.0363,0.0,0.636,0.0521,0.0,0.636,0.0317,0.0,0.0377,0.504,1,0.312,0.104,0.0,0.0389,0.393,1,-2.52,-3.58,-1.45,-3.58,-1.45,3.055900000000001,0.544,0.131,0.0,0.0976,0.57,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,-4.0,L
CHEMBL898,DIFLUNISAL,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.79,0.0346,0.0,0.367,0.221,0.5,0.117,0.463,1.0,0.459,0.102,0.0,0.548,0.0507,0.0,0.719,0.0492,0,0.721,0.0309,0.0,0.488,0.117,0,-4.61,-5.29,-3.93,-5.29,-3.93,3.035600000000001,0.886,0.0121,0.0,0.377,0.0701,0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,5.5,L
CHEMBL90,HISTAMINE,NCCc1c[nH]cn1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,3.0,Unknown status,0,0,pathway_drug_candidates,3.0,0.423,0.138,0.0,0.357,0.209,0.5,0.399,0.136,0.0,0.431,0.109,0.0,0.441,0.0701,0.0,0.816,0.0288,0,0.689,0.0357,0.0,0.392,0.146,0,0.822,-0.292,1.94,-0.292,1.94,-0.0891000000000003,0.886,0.0122,0.0,0.403,0.0422,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,L
CHEMBL900,ORPHENADRINE,Cc1ccccc1C(OCCN(C)C)c1ccccc1,,0,0,"R-HSA-3928662|EPHB-mediated forward signaling;R-HSA-416476|G alpha (q) signalling events;R-HSA-438066|Unblocking of NMDA receptors, glutamate binding and activation;R-HSA-442982|Ras activation upon Ca2+ influx through NMDA receptor;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-6794361|Neurexins and neuroligins;R-HSA-8849932|Synaptic adhesion-like molecules;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9617324|Negative regulation of NMDA receptor-mediated neuronal transmission;R-HSA-9620244|Long-term potentiation",10,0,,3.0,Unknown status,0,0,pathway_drug_candidates,3.0,0.424,0.139,0.0,0.0199,0.718,1.0,0.63,0.0706,0.0,0.17,0.334,1.0,0.685,0.0233,0.0,0.565,0.0921,0,0.618,0.0459,0.0,0.922,0.017,0,-2.42,-3.04,-1.81,-3.04,-1.81,3.662620000000003,0.424,0.231,0.0,0.0475,0.926,1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,2.0,0.0,1.0,0.0,L
CHEMBL902,FAMOTIDINE,NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1,HRH2,1,1,R-HSA-418555|G alpha (s) signalling events,1,0,Histamine H2 receptor antagonist,4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.277,0.243,0.5,0.0872,0.496,1.0,0.801,0.0296,0.0,0.572,0.0667,0.0,0.343,0.109,0.0,0.671,0.0637,0,0.161,0.239,1.0,0.416,0.125,0,-2.49,-3.2,-1.79,-3.2,-1.79,-0.7679999999999998,0.838,0.0187,0.0,0.0414,0.875,1,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,1.0,L
CHEMBL90555,VINCRISTINE,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.0979,0.461,1.0,0.0248,0.719,1.0,0.751,0.0389,0.0,0.666,0.0495,0.0,0.568,0.0441,0.0,0.522,0.106,0,0.805,0.0179,0.0,0.217,0.134,0,-4.88,-5.29,-4.46,-5.29,-4.46,3.5175000000000027,0.00443,0.922,1.0,0.0797,0.515,1,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,2.0,1.0,1.0,1.0,L
CHEMBL908,CHLORPROTHIXENE,CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21,,0,0,,0,0,Serotonin 2a (5-HT2a) receptor antagonist,,,0,0,mechanism_drug_candidate,0.0,0.49,0.122,0.0,0.0106,0.82,1.0,0.72,0.04,0.0,0.531,0.0781,0.0,0.00458,0.892,1.0,0.0152,0.689,1,0.438,0.0684,0.0,0.0209,0.5,1,-5.43,-6.07,-4.78,-6.07,-4.78,5.188000000000004,0.101,0.703,1.0,0.088,0.669,1,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,2.0,0.0,1.0,-10.0,L
CHEMBL91397,RUPATADINE,Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,3.0,Recruiting,0,0,pathway_drug_candidates,3.0,0.043,0.632,1.0,0.0675,0.561,1.0,0.0914,0.509,1.0,0.732,0.0384,0.0,0.605,0.0351,0.0,0.556,0.0894,0,0.773,0.0252,0.0,0.0723,0.281,1,-3.62,-4.15,-3.09,-4.15,-3.09,5.6349200000000055,0.056,0.878,1.0,0.382,0.0556,0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,3.0,1.0,1.0,-3.5,L
CHEMBL914,FEXOFENADINE,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.508,0.108,0.0,0.361,0.214,0.5,0.584,0.0763,0.0,0.729,0.0359,0.0,0.866,0.00588,0.0,0.152,0.281,1,0.949,0.00877,0.0,0.877,0.0331,0,-5.13,-6.38,-3.87,-6.38,-3.87,5.510500000000006,0.643,0.0661,0.0,0.853,0.00613,0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,-5.5,L
CHEMBL92,DOCETAXEL ANHYDROUS,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,3.0,Not yet recruiting,0,0,pathway_drug_candidates,5.0,0.522,0.0957,0.0,0.183,0.323,1.0,0.119,0.461,1.0,0.688,0.0455,0.0,0.496,0.0668,0.0,0.657,0.0693,0,0.271,0.136,0.0,0.167,0.203,1,-5.31,-6.28,-4.34,-6.28,-4.34,3.2596000000000025,0.15,0.695,1.0,0.711,0.0142,0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,1.0,L
CHEMBL931,HALOTHANE,FC(F)(F)C(Cl)Br,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator | Glycine receptor (alpha-1/beta) positive modulator | Potassium channel subfamily K member 10 opener | Potassium channel subfamily K member 18 opener | Potassium channel subfamily K member 2 opener | Potassium channel subfamily K member 3 opener | Potassium channel subfamily K member 9 opener,,,0,0,mechanism_drug_candidate,0.0,0.184,0.321,1.0,0.111,0.44,1.0,0.125,0.452,1.0,0.224,0.248,0.5,0.205,0.196,0.5,0.097,0.362,1,0.218,0.168,0.0,0.181,0.177,0.5,-1.95,-2.81,-1.08,-2.81,-1.08,2.5084999999999997,0.527,0.117,0.0,0.149,0.44,1,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,5.0,1.0,1.0,-12.0,L
CHEMBL932,DIPYRIDAMOLE,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,PDE5A,1,1,"R-HSA-180024|DARPP-32 events;R-HSA-418457|cGMP effects;R-HSA-418555|G alpha (s) signalling events;R-HSA-445355|Smooth Muscle Contraction;R-HSA-9013422|RHOBTB1 GTPase cycle;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",6,0,"3',5'-cyclic phosphodiesterase inhibitor;3',5'-cyclic phosphodiesterase inhibitor | Equilibrative nucleoside transporter 1 inhibitor;Equilibrative nucleoside transporter 1 inhibitor",4.0,,1,1,known_drugs;pathway_drug_candidates;mechanism_drug_candidate;mechanism_of_actions,7.5,0.912,0.0105,0.0,0.394,0.205,0.5,0.762,0.0318,0.0,0.91,0.0103,0.0,0.566,0.0456,0.0,0.233,0.223,0.5,0.158,0.249,1.0,0.0284,0.402,1,-1.61,-3.22,-0.00668,-3.22,-0.00668,-0.0175999999999973,0.176,0.584,1.0,0.098,0.515,1,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,L
CHEMBL93645,ACECLOFENAC,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,PTGS2,1,1,R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,9,2,,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates,10.0,0.59,0.0646,0.0,0.741,0.0566,0.0,0.0666,0.618,1.0,0.513,0.091,0.0,0.441,0.0704,0.0,0.807,0.0336,0,0.716,0.0317,0.0,0.988,0.00882,0,-3.3,-4.67,-1.92,-4.67,-1.92,3.907300000000002,0.259,0.405,0.5,0.637,0.0199,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,8.0,H
CHEMBL94081,ALCLOFENAC,C=CCOc1ccc(CC(=O)O)cc1Cl,,0,0,R-HSA-140180|COX reactions;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX),2,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.869,0.0147,0.0,0.707,0.0717,0.0,0.613,0.0662,0.0,0.75,0.0354,0.0,0.165,0.228,0.5,0.892,0.0218,0,0.536,0.0526,0.0,0.775,0.0476,0,-2.84,-3.81,-1.88,-3.81,-1.88,2.5319000000000003,0.716,0.0395,0.0,0.317,0.0852,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,2.5,L
CHEMBL941,IMATINIB,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,,0,0,"R-HSA-1433557|Signaling by SCF-KIT;R-HSA-5673001|RAF/MAP kinase cascade;R-HSA-8866910|TFAP2 (AP-2) family regulates transcription of growth factors and their receptors;R-HSA-9860927|Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",4,0,,3.0,"Active, not recruiting;Recruiting",1,0,known_drugs;pathway_drug_candidates,4.5,0.529,0.0989,0.0,0.32,0.218,0.5,0.611,0.0615,0.0,0.987,0.00207,0.0,0.588,0.0416,0.0,0.698,0.0663,0,0.892,0.0126,0.0,0.169,0.226,1,-0.515,-1.31,0.283,-1.31,0.283,4.590320000000004,0.159,0.725,1.0,0.0504,0.846,1,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,2.5,L
CHEMBL94454,MIZOLASTINE,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.652,0.0538,0.0,0.47,0.146,0.0,0.664,0.0571,0.0,0.338,0.159,0.0,0.776,0.0173,0.0,0.0061,0.83,1,0.722,0.0337,0.0,0.0445,0.265,1,-4.43,-5.05,-3.8,-5.05,-3.8,3.412200000000002,0.248,0.358,1.0,0.242,0.13,0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,-3.0,L
CHEMBL946,AZATADINE,CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.483,0.116,0.0,0.212,0.321,0.5,0.292,0.221,0.5,0.653,0.0596,0.0,0.83,0.0135,0.0,0.502,0.108,0,0.709,0.0361,0.0,0.0392,0.431,1,-2.94,-3.52,-2.36,-3.52,-2.36,3.707700000000002,0.284,0.384,0.5,0.375,0.0755,0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,0.0,1.0,0.0,L
CHEMBL94657,PATUPILONE,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,3.0,Completed,0,0,pathway_drug_candidates,5.0,0.581,0.0832,0.0,0.638,0.0894,0.0,0.218,0.292,0.5,0.308,0.181,0.0,0.541,0.044,0.0,0.632,0.0705,0,0.404,0.0846,0.0,0.0979,0.218,1,-3.94,-4.31,-3.57,-4.31,-3.57,4.477520000000005,0.382,0.278,0.5,0.457,0.0369,0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,2.0,L
CHEMBL956,SUPROFEN,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1,PTGS2,1,1,R-HSA-140180|COX reactions;R-HSA-2142770|Synthesis of 15-eicosatetraenoic acid derivatives;R-HSA-2162123|Synthesis of Prostaglandins (PG) and Thromboxanes (TX);R-HSA-6783783|Interleukin-10 signaling;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling;R-HSA-73614|Nicotinamide salvaging;R-HSA-9018677|Biosynthesis of DHA-derived SPMs;R-HSA-9018679|Biosynthesis of EPA-derived SPMs;R-HSA-9025094|Biosynthesis of DPAn-3 SPMs;R-HSA-9027604|Biosynthesis of electrophilic Omega-3 PUFA oxo-derivatives,10,2,Cyclooxygenase inhibitor,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,10.0,0.528,0.0854,0.0,0.502,0.146,0.0,0.202,0.299,0.5,0.519,0.088,0.0,0.66,0.0214,0.0,0.613,0.0772,0,0.766,0.0319,0.0,0.968,0.00019,0,-2.42,-3.61,-1.24,-3.61,-1.24,3.167200000000001,0.776,0.0144,0.0,0.244,0.121,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,8.0,H
CHEMBL960,LEFLUNOMIDE,Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,,0,0,,0,0,Dihydroorotate dehydrogenase inhibitor,,,1,1,known_drugs;mechanism_drug_candidate;mechanism_of_actions,1.5,0.0988,0.462,1.0,0.117,0.471,1.0,0.407,0.142,0.0,0.426,0.115,0.0,0.182,0.219,0.5,0.136,0.304,1,0.334,0.0974,0.0,0.776,0.0207,0,-3.73,-4.28,-3.19,-4.28,-3.19,3.2541200000000012,0.444,0.147,0.0,0.154,0.372,1,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,3.0,1.0,1.0,-9.5,L
CHEMBL96172,EPOTHILONE D,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1,,0,0,R-HSA-1445148|Translocation of SLC2A4 (GLUT4) to the plasma membrane;R-HSA-190840|Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane;R-HSA-190861|Gap junction assembly;R-HSA-2132295|MHC class II antigen presentation;R-HSA-2467813|Separation of Sister Chromatids;R-HSA-2500257|Resolution of Sister Chromatid Cohesion;R-HSA-2565942|Regulation of PLK1 Activity at G2/M Transition;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-380259|Loss of Nlp from mitotic centrosomes;R-HSA-380270|Recruitment of mitotic centrosome proteins and complexes;R-HSA-380284|Loss of proteins required for interphase microtubule organization from the centrosome;R-HSA-380320|Recruitment of NuMA to mitotic centrosomes;R-HSA-389957|Prefoldin mediated transfer of substrate to CCT/TriC;R-HSA-389960|Formation of tubulin folding intermediates by CCT/TriC;R-HSA-389977|Post-chaperonin tubulin folding pathway;R-HSA-437239|Recycling pathway of L1;R-HSA-5610787|Hedgehog 'off' state;R-HSA-5617833|Cilium Assembly;R-HSA-5620912|Anchoring of the basal body to the plasma membrane;R-HSA-5620924|Intraflagellar transport;R-HSA-5626467|RHO GTPases activate IQGAPs;R-HSA-5663220|RHO GTPases Activate Formins;R-HSA-6798695|Neutrophil degranulation;R-HSA-6807878|COPI-mediated anterograde transport;R-HSA-6811434|COPI-dependent Golgi-to-ER retrograde traffic;R-HSA-6811436|COPI-independent Golgi-to-ER retrograde traffic;R-HSA-68877|Mitotic Prometaphase;R-HSA-8852276|The role of GTSE1 in G2/M progression after G2 checkpoint;R-HSA-8854518|AURKA Activation by TPX2;R-HSA-8955332|Carboxyterminal post-translational modifications of tubulin;R-HSA-9609690|HCMV Early Events;R-HSA-9609736|Assembly and cell surface presentation of NMDA receptors;R-HSA-9619483|Activation of AMPK downstream of NMDARs;R-HSA-9646399|Aggrephagy;R-HSA-9648025|EML4 and NUDC in mitotic spindle formation;R-HSA-9668328|Sealing of the nuclear envelope (NE) by ESCRT-III;R-HSA-983189|Kinesins;R-HSA-9833482|PKR-mediated signaling,38,1,,2.0,Terminated,0,0,pathway_drug_candidates,4.0,0.613,0.0768,0.0,0.656,0.0814,0.0,0.0675,0.609,1.0,0.39,0.136,0.0,0.361,0.0941,0.0,0.695,0.0581,0,0.498,0.0556,0.0,0.075,0.244,1,-3.58,-4.02,-3.15,-4.02,-3.15,5.2663200000000066,0.418,0.26,0.5,0.467,0.0359,0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,L
CHEMBL963,OXYMORPHONE,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,,0,0,pathway_drug_candidates,6.0,0.638,0.0682,0.0,0.189,0.376,1.0,0.481,0.112,0.0,0.361,0.146,0.0,0.569,0.0385,0.0,0.124,0.317,1,0.718,0.0365,0.0,0.825,0.037,0,-2.11,-3.45,-0.774,-3.45,-0.774,0.7451999999999999,0.387,0.257,0.5,0.102,0.496,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,-1.0,L
CHEMBL967,TEMAZEPAM,CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.523,0.0837,0.0,0.177,0.355,1.0,0.375,0.159,0.0,0.147,0.345,1.0,0.0328,0.598,1.0,0.147,0.281,1,0.72,0.0295,0.0,0.56,0.0994,0,-2.85,-3.51,-2.19,-3.51,-2.19,2.4722,0.219,0.434,1.0,0.0574,0.792,1,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,3.0,0.0,1.0,-7.0,L
CHEMBL969,PRAZEPAM,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.24,0.271,0.5,0.229,0.29,0.5,0.214,0.289,0.5,0.141,0.374,1.0,0.0213,0.683,1.0,0.161,0.277,1,0.816,0.0223,0.0,0.656,0.0852,0,-5.03,-5.69,-4.38,-5.69,-4.38,3.934000000000003,0.101,0.693,1.0,0.0508,0.855,1,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,5.0,1.0,1.0,-12.0,L
CHEMBL970,HALAZEPAM,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC(F)(F)F,,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.134,0.368,1.0,0.202,0.333,0.5,0.155,0.385,1.0,0.0769,0.54,1.0,0.0179,0.737,1.0,0.29,0.188,0,0.82,0.0229,0.0,0.667,0.0886,0,-5.09,-5.72,-4.46,-5.72,-4.46,4.086300000000002,0.108,0.698,1.0,0.0435,0.884,1,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,5.0,1.0,1.0,-7.0,L
CHEMBL971,PENTOBARBITAL SODIUM,CCCC(C)C1(CC)C(=O)N=C([O-])NC1=O.[Na+],,0,0,,0,0,GABA-A receptor; anion channel positive allosteric modulator,,,0,0,mechanism_drug_candidate,0.0,0.249,0.277,0.5,0.943,0.0142,0.0,0.186,0.333,1.0,0.378,0.14,0.0,0.769,0.0147,0.0,0.772,0.0449,0,0.424,0.0776,0.0,0.606,0.0824,0,-0.782,-1.5,-0.0605,-1.5,-0.0605,-2.804299999999997,0.432,0.174,0.0,0.189,0.205,1,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,2.0,1.0,1.0,-5.0,L
CHEMBL973,TERIFLUNOMIDE,C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1,,0,0,,0,0,Dihydroorotate dehydrogenase inhibitor,,,0,0,mechanism_drug_candidate,0.0,0.351,0.158,0.0,0.2,0.356,0.5,0.131,0.448,1.0,0.279,0.184,0.0,0.0451,0.586,1.0,0.291,0.197,0,0.285,0.132,0.0,0.16,0.205,1,-3.02,-3.85,-2.19,-3.85,-2.19,2.99948,0.474,0.131,0.0,0.174,0.226,1,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,3.0,0.0,1.0,-4.5,L
CHEMBL977,HYDROCORTISONE HEMISUCCINATE ANHYDROUS,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,,3.0,Completed,0,0,protein_drug_candidates;pathway_drug_candidates,5.0,0.886,0.0143,0.0,0.889,0.0192,0.0,0.769,0.0273,0.0,0.703,0.0427,0.0,0.888,0.00724,0.0,0.633,0.0712,0,0.792,0.0283,0.0,0.838,0.0166,0,-3.83,-5.23,-2.44,-5.23,-2.44,2.1973,0.807,0.017,0.0,0.147,0.362,1,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,4.5,L
CHEMBL982,NALMEFENE,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-418594|G alpha (i) signalling events;R-HSA-6785807|Interleukin-4 and Interleukin-13 signaling,3,1,,4.0,Terminated,0,0,pathway_drug_candidates,6.0,0.31,0.201,0.0,0.116,0.442,1.0,0.385,0.149,0.0,0.511,0.0919,0.0,0.687,0.0201,0.0,0.133,0.301,1,0.511,0.0553,0.0,0.804,0.0353,0,-4.66,-6.14,-3.18,-6.14,-3.18,2.512500000000001,0.26,0.374,0.5,0.0864,0.559,1,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,-2.0,L
CHEMBL989,FLUOCINOLONE ACETONIDE,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,NR3C1,1,1,"Circadian Clock;R-HSA-3371497|HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand;R-HSA-383280|Nuclear Receptor transcription pathway;R-HSA-4090294|SUMOylation of intracellular receptors;R-HSA-8849473|PTK6 Expression;R-HSA-8939902|Regulation of RUNX2 expression and activity;R-HSA-9615017|FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes;R-HSA-9679191|Potential therapeutics for SARS;R-HSA-9768777|Regulation of NPAS4 gene transcription",9,0,Glucocorticoid receptor agonist,4.0,,0,0,protein_drug_candidates;pathway_drug_candidates;mechanism_drug_candidate,6.0,0.312,0.213,0.5,0.666,0.0826,0.0,0.52,0.0884,0.0,0.728,0.0368,0.0,0.628,0.0335,0.0,0.161,0.273,1,0.536,0.0595,0.0,0.972,0.0127,0,-5.34,-6.26,-4.43,-6.26,-4.43,2.366800000000001,0.57,0.105,0.0,0.043,0.887,1,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,-4.0,L
CHEMBL995,LOSARTAN POTASSIUM,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[n-]2)cc1.[K+],,0,0,R-HSA-375276|Peptide ligand-binding receptors;R-HSA-416476|G alpha (q) signalling events;R-HSA-8856825|Cargo recognition for clathrin-mediated endocytosis;R-HSA-8856828|Clathrin-mediated endocytosis,4,0,Type-1 angiotensin II receptor antagonist,4.0,Completed,0,0,pathway_drug_candidates;mechanism_drug_candidate,4.0,0.678,0.0513,0.0,0.942,0.0101,0.0,0.879,0.00781,0.0,0.759,0.0301,0.0,0.443,0.0695,0.0,0.885,0.0218,0,0.967,0.00331,0.0,0.767,0.0385,0,-3.69,-5.16,-2.22,-5.16,-2.22,0.8998999999999999,0.702,0.0323,0.0,0.655,0.0124,0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,L
CHEMBL998,LORATADINE,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,,0,0,R-HSA-416476|G alpha (q) signalling events,1,0,,4.0,,0,0,pathway_drug_candidates,4.0,0.515,0.105,0.0,0.361,0.206,0.5,0.0662,0.605,1.0,0.604,0.0604,0.0,0.431,0.071,0.0,0.381,0.151,0,0.26,0.123,0.0,0.00467,0.513,1,-4.07,-4.7,-3.45,-4.7,-3.45,4.887800000000005,0.0486,0.855,1.0,0.364,0.0544,0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,2.0,0.0,1.0,-1.0,L
